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Summary 
The  work  presented  in  this  thesis  has  explored  the  impact  of  cachexia  on  patients  with 
advanced  pancreatic  cancer.  This  thesis  has  also  explored  the  metabolic  changes  responsible  for 
cachexia  and  the  lack  of  response  of  cachectic  subjects  to  apparently  adequate  nutrition.  The 
effect  of  a  fish  oil-enriched  nutritional  supplement  on  the  syndrome  of  cachexia  was  also  studied. 
Particular  emphasis  was  placed  on  the  potential  role  of  the  inflammatory  response  in  mediating 
aspects  of  cachexia.  In  order  to  evaluate  this,  the  interaction  of  the  inflammatory  process  and 
progress  of  disease  was  examined.  The  significance  of  the  acute  phase  protein  response  and  its 
potential  to  contribute  to  cachexia  was  also  emphasised. 
Progressive  weight  loss  was  seen  in  patients  with  pancreatic  cancer  and  this  accelerated 
with  time.  The  plasma  concentration  of  a  variety  of  positive  and  negative  acute  phase  proteins 
were  increased  or  reduced  respectively  in  advanced  pancreatic  cancer  and  these  concentration 
changes  became  more  pronounced  with  progress  of  disease  (Chapter  8).  Weight  loss  and  progress 
of  the  acute  phase  protein  response  were  associated  with  a  deterioration  in  the  ability  of  patients 
to  perform  normal  tasks  (Chapter  3).  The  presence  of  an  acute  phase  protein  response  was  also 
associated  with  a  shortened  survival  (Chapter  5).  Cachexia  thus  appeared  to  influence  both 
morbidity  and  mortality  in  advanced  pancreatic  cancer. 
Mediators  of  the  process  of  cachexia  were  explored.  The  progressive  acute  phase  protein 
response  in  advanced  pancreatic  cancer  was  associated  with  increased  circulating  concentrations 
and  production  of  pro-inflammatory  cytokines,  particularly  interleukin  (IL)-6.  These  cytokines 
appear  to  have  a  role  in  mediating  the  acute  phase  protein  response  (Chapters  4  and  7).  The 
relevance  of  the  circulating  cytokine  concentrations  and  ex  vivo  cytokine  production  to  the  in  vivo 
situation,  however,  remains  unclear  as  levels  were  not  different  to  those  observed  in  controls. 
Differences  in  the  extent  of  cachexia  and  the  inflammatory  response  in  patients  with 
apparently  similar  tumours  suggest  that  systemic  production  of  cytokines  may  be  dependent  not 
only  on  tumour  phenotype  but  also  on  host  genotype.  This  was  investigated  by  studying  a  variety 
of  cytokine  gene  polymorphisms  which  may  influence  cytokine  production.  The  production  of 
interleukin-1  ß  ex  vivo  was  different  in  those  patients  with  different  IL-1(3  gene  polymorphisms 
and  thus  appeared  to  be  genetically  determined.  The  genotype  of  patients  for  an  IL-1ß  gene 
polymorphism  also  seemed  to  influence  the  presence  of  an  acute  phase  protein  response.  IL-1ß 
genotypes  associated  with  increased  cytokine  production  and  acute  phase  protein  concentrations Summary  ii 
were  also  associated  with  poor  patient  survival.  By  contrast,  no  evidence  was  found  that  two 
polymorphisms  of  the  tumour  necrosis  factor  (TNF)  gene  or  a  polymorphism  of  the  IL-I  receptor 
antagonist  gene  affected  ex  vivo  cytokine  production,  the  in  vivo  acute  phase  protein  response  or 
survival  (Chapter  5).  Thus,  IL-113  (which  can  stimulate  the  production  of  other  pro-inflammatory 
cytokines)  may  be  an  important  early  mediator  in  the  cachectic  process.  TNF  may  still  be 
important  but  the  polymorphisms  studied  may  not  be  relevant  to  this  disease. 
Advanced  pancreatic  cancer  patients  were  found  to  have  changes  in  the  circulating 
concentration  or  excretion  rates  of  various  additional  metabolic  mediators  which  may  contribute 
to  catabolism  and  weight  loss.  These  changes  included  a  low  circulating  insulin  concentration  and 
the  excretion  in  urine  of  proteolysis  inducing  factor,  a  novel  cancer-associated  catabolic  factor 
(Chapter  7).  A  complex  cascade  of  mediators  including  pro-inflammatory  cytokines,  tumour 
associated  cachectic  factors  and  neuroendocrine  hormones  thus  appear  to  be  involved  in  the 
development  of  cachexia  and  may  give  rise  to  an  acute  phase  protein  response. 
The  metabolic  mechanisms  underlying  cachexia  were  then  explored,  with  studies  in  the 
fasted  and  fed  state.  Cachectic  patients  had  an  increased  resting  energy  expenditure  in  comparison 
with  controls  in  association  with  changes  in  substrate  utilisation  and  nitrogen  excretion  reflecting 
the  weight  losing  state.  However,  there  was  no  increase  in  the  metabolic  cost  of  digesting  and 
absorbing  a  meal  to  explain  the  failure  of  conventional  nutrition  to  reverse  cachexia  (Chapter  9). 
The  acute  phase  protein  response  stimulated  by  mediators  of  cachexia  has  been  noted 
above  to  be  associated  with  poor  outcome,  however,  a  causative  role  has  not  been  demonstrated. 
It  has  been  suggested  that  production  of  hepatic  acute  phase  proteins  contributes  to  cachexia  by 
increasing  the  breakdown  of  lean  tissue  to  provide  amino  acids  for  their  synthesis.  In  addition,  the 
effect  of  feeding  on  such  protein  synthesis  in  cancer  patients  has  not  been  studied  previously.  The 
present  study  found  that  the  synthesis  of  negative  acute  phase  proteins  by  the  liver  continued 
unchanged  in  advanced  pancreatic  cancer  compared  with  controls  (despite  low  plasma 
concentrations)  in  both  the  fasting  and  fed  state.  Moreover,  there  was  a  substantial  increase  in  the 
production  of  positive  acute  phase  proteins  which  was  increased  still  further  in  the  fed  state  in 
cancer  patients  (but  not  in  healthy  controls)  (Chapter  10).  Thus  feeding  stimulated  further  the 
acute  phase  response.  Diversion  of  amino  acids  to  meet  increased  demand  for  hepatic  export 
protein  synthesis  on  feeding  may  in  part  explain  the  block  to  the  accretion  of  lean  tissue  in 
cachectic  subjects  provided  with  conventional  nutritional  supplementation.  This  may  also  provide 
a  mechanism  whereby  the  acute  phase  protein  response  is  associated  with  progressive  cachexia. Summary  111 
Eicosapentaenoic  acid,  a  component  of  fish  oil  has  been  suggested  to  modulate  aspects  of 
the  inflammatory  process,  specifically  to  downregulate  pro-inflammatory  cytokine  production, 
interfere  with  the  action  of  proteolysis  inducing  factor  and  to  influence  hepatic  export  protein 
production.  It  could,  therefore,  potentially  influence  the  process  of  cachexia.  Thus  the 
combination  of  a  nutritional  supplement  and  eicosapentaenoic  acid  was  given  to  patients  with 
advanced  pancreatic  cancer  to  assess  its  effect  on  the  ongoing  cachectic  process.  The 
administration  of  a  fish  oil-enriched  nutritional  supplement  providing  2g  eicosapentaenoic  acid 
and  around  600kcal  per  day  resulted  in  a  significant  change  in  the  metabolic  disposition  of 
patients  with  advanced  pancreatic  cancer.  Consumption  of  the  supplement  resulted  in  a  reversal 
of  weight  loss  and  a  gain  in  lean  body  mass  in  association  with  a  reversal  of  negative  nitrogen 
balance.  Performance  status  and  appetite  improved.  Production  of  interleukin-6  was  reduced  and 
the  acute  phase  protein  response  stabilised,  insulin  concentration  increased  and  proteolysis 
inducing  factor  excretion  fell  (Chapters  6,7  and  8).  These  changes  were  associated  with  a  rise  in 
energy  intake,  a  fall  in  relative  resting  energy  expenditure  and  a  normalisation  of  the  metabolic 
response  to  feeding  and  substrate  utilisation  (Chapters  6  and  9).  The  increase  in  acute  phase 
protein  synthesis  with  feeding  was  abolished  after  the  administration  of  the  fish  oil-enriched 
nutritional  supplement  (Chapter  10). 
The  progressive  nutritional  and  functional  deterioration  of  advanced  pancreatic  cancer 
patients  thus  seems  to  be  associated  with  broadly  pro-inflammatory  metabolic  mediators  and  a 
progressive  acute  phase  protein  response.  This  deterioration  may  in  part  be  resistant  to 
conventional  nutritional  supplementation  because  of  further  stimulation  of  acute  phase  protein 
production  by  feeding. 
The  provision  of  a  fish  oil-enriched  nutritional  supplement  normalises  the  metabolic 
milieu,  stabilises  the  acute  phase  protein  response  and  abolishes  the  stimulation  of  acute  phase 
protein  production  by  feeding.  One  explanation  to  account  for  the  effects  observed  after 
intervention  would  be  that  it  to  allows  dietary  amino  acids  to  be  used  for  lean  tissue  anabolism 
with  the  consequent  potential  for  quality  of  life  and  survival  benefit. 
These  studies  emphasise  that  by  further  investigation  of  the  mechanisms  and  mediators  of 
the  cachectic  process  more  rational  and  effective  nutritional  therapy  can  be  designed.  The  benefits 
noted  in  the  initial  studies  of  the  fish  oil-enriched  nutritional  supplement  are  currently  being 
subjected  to  a  randomised  controlled  trial. Chapter  1 
Introduction 
Pancreatic  Cancer 
Pancreatic  adenocarcinoma  is  the  fourth  leading  cause  of  cancer  death  in  the  Western 
world  with  an  incidence  of  about  10/100000  person-years  representing  about  2%  of  all  cancers 
and  5%  of  cancer  deaths  (Rosewicz  &  Weidenmann,  1997,  Landis  et  al,  1999).  Over  95%  of 
patients  will  die  of  their  disease.  The  5-year  survival  rate  is  1.3%  with  a  median  survival  of  4.1 
months  (Ahlgren,  1996).  More  than  80%  of  cancers  are  unresectable  at  diagnosis  and  even  in 
those  patients  suitable  for  surgical  resection  the  5-year  survival  rate  is  less  than  25%  in  the  best 
centres  (Neoptolemos  &  Kerr,  1995). 
Numerous  studies  of  radiotherapy  and  chemotherapeutic  agents  in  patients  with  pancreatic 
cancer  have  shown  little  benefit  and  significant  toxicity  (Thomas,  1996,  Schnall  &  MacDonald, 
1996).  Current  trials  of  combination  chemotherapy  and  radiotherapy  tend  to  concentrate  on 
patients  who  have  already  had  surgical  resection  (Neoptolemos  &  Kerr,  1995).  This  leaves  little 
in  the  way  of  treatment  options  for  the  vast  majority  of  patients  with  unresectable  disease.  New 
agents,  such  as  the  antimetabolite  gemcitabine,  are  currently  being  tested  in  patients  with 
advanced  pancreatic  cancer.  These  new  agents  have  shown  some  benefits  against  surrogate 
disease  markers  despite  little  objective  anti-tumour  activity  (Casper  et  al,  1994,  Rothenberg  et  al, 
1995,  Moore  et  al,  1995,  Carmichael  et  al,  1995,  Parsons  et  al,  1997).  A  recent  randomised 
controlled  trial  of  gemcitabine  versus  5-fluorouracil  in  patients  with  advanced  pancreatic  cancer 
has  suggested  a  survival  benefit  for  gemcitabine  but  only  improved  median  survival  from  4.4  to 
5.6  months  (Burns  et  al,  1997).  These  agents  retain  many  of  the  side  effects  of  traditional 
chemotherapeutic  agents  and  thus  their  place  in  improving  the  well-being  of  this  unfortunate 
group  of  patients  remains  unclear.  A  recent  study  in  non-small  cell  lung  cancer  suggested  that  the 
patients  would  require  a  survival  benefit  of  4.5  months  for  a  chemotherapeutic  regime  resulting  in 
mild  toxicity  or  of  9  months  for  severe  toxicity  to  choose  this  over  supportive  treatment  alone 
(Silvestri  et  al,  1998).  Current  chemotherapy  regimes  for  pancreatic  cancer  cannot  begin  to 
approach  this  level  of  effectiveness  and  thus  while  continuing  to  explore  the  possibilities  of 
cytotoxic  treatment  it  seems  important  to  study  the  mechanisms  and  mediators  of  decline  in 
patients  with  advanced  cancer  in  an  attempt  to  maximise  supportive  treatment  with  the  potential 
to  improve  quality  and  perhaps  length  of  life.  The  work  presented  in  this  thesis  concentrates  on 
cachexia,  the  syndrome  of  metabolic  changes  observed  in  advanced  cancer,  and  the  modulation  of 
the  metabolic  changes  of  cachexia  by  n-3  polyunsaturated  fatty  acids. Chapter  1 
Cancer  cachexia 
Importance  of  Cachexia 
2 
The  term  cachexia  is  derived  from  the  Greek  words  kakos,  meaning  "bad,  "  and  hexis, 
meaning  "condition.  "  The  syndrome  is  characterised  by  anorexia,  early  satiety,  changes  in  taste 
perception,  weight-loss,  weakness,  anaemia  and  oedema  (Fearon,  1992).  Cachexia  is  not 
exclusive  to  cancer  but  is  also  seen  in  a  variety  of  inflammatory  conditions  such  as  acquired 
immunodeficiency  syndrome  and  rheumatoid  arthritis  (Roubenoff  et  al,  1992,  Grunfeld  & 
Feingold,  1992). 
Patients  with  advanced  cancer  frequently  exhibit  progressive  weight-loss  and  this  is 
associated  with  a  shorter  survival  time  and  reduced  quality  of  life  and  indeed,  some  patients 
appear  to  die  of  such  severe  wasting.  Cancer  patients  with  weight-loss  live  approximately  half  as 
long  as  those  without  and  those  with  greater  weight-loss  appear  to  live  a  shorter  time  (DeWys  et 
al,  1980).  Those  cancer  patients  with  weight-loss  have  also  been  reported  to  have  a  reduced 
performance  status  and  quality  of  life  (DeWys  et  al,  1980,  Ovesen  et  al,  1993a,  O'Gorman  et  al, 
1998).  It  has  been  suggested  that  around  20%  of  all  cancer  patients  die  of  cachexia  making  it  the 
most  common  cause  of  death,  with  this  proportion  being  substantially  higher  in  particular 
malignancies  (Warren,  1935,  Inagaki  et  al,  1974).  Cancer  cachexia  is  seen  in  the  majority  of 
patients  with  advanced  cancer  of  the  stomach,  pancreas,  lung  and  colon  (DeWys  et  al,  1980). 
Other  tumours,  such  as  breast  cancer  and  haematological  malignancies,  are  rarely  associated  with 
cachexia.  Similarly,  patients  with  an  apparently  identical  primary  cancer  and  disease  stage  can 
vary  considerably  in  terms  of  the  development  of  cachexia  suggesting  variations  in  tumour 
phenotype  and  host  response  as  important  contributary  factors. 
A  recent  survey  of  patients  with  unresectable  pancreatic  cancer  found  that  85%  of  such 
patients  have  unintentionally  lost  weight  by  the  time  of  diagnosis  and  that  the  median  weight  loss 
close  to  the  time  of  death  was  almost  25%  (Wigmore  et  al,  1997a)  Clearly  in  a  proportion  of 
these  individuals  weight-loss  contributed  to  their  demise.  The  fundamental  difference  between 
the  weight-loss  observed  in  cachexia  and  that  seen  in,  for  example,  starvation,  is  the  lack  of 
reversibility  with  feeding  (Brennan,  1977,  Nixon  et  al,  1981).  This  seems  to  be  due  to  metabolic 
changes  in  cachexia,  produced  by  the  tumour  or  by  the  host  in  response  to  the  tumour,  which  have 
a  profound  effect  on  the  progress  of  the  disease,  the  symptoms  experienced  by  patients,  and 
ultimately  the  survival  of  patients.  Attempts  to  modulate  the  metabolic  response  to  cancer 
therefore  have  the  potential  to  improve  quality  and  length  of  life  and  should  form  a  part  of  the 
integrated  care  of  patients  with  advanced  cancer. Chapter  1 
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Many  of  the  metabolic  changes  seen  following  surgery,  trauma  or  sepsis  share  many 
features  of  cachexia  and  are  driven,  in  part,  by  similar  mediators. 
Anorexia 
Probably  the  majority  of  patients  with  pancreatic  cancer  have  an  inadequate  nutritional 
intake  which  contributes  substantially  to  weight  loss  (Perez  et  al,  1983,  Wigmore  et  al,  1997b). 
In  simple  starvation  patients  undergo  adaptations  to  reduce  energy  expenditure,  conserve  protein 
and  to  utilise  fatty  acids  and  ketone  bodies  derived  from  fat  as  an  energy  source  (Grande  et  al, 
1958,  Leibel  et  al,  1995).  It  has  been  suggested  that  in  cancer  cachexia  these  adaptations  are 
attenuated  or  absent  such  that  energy  expenditure  may  be  increased  and  protein  loss  continues 
(Brennan,  1977).  This  also  has  implications  for  the  pattern  of  weight  loss  in  patients  with  cancer 
cachexia  who  may  preserve  visceral  protein  while  muscle  protein  is  lost  preferentially 
(Heymsfield  &  McManus,  1985,  Fearon  &  Preston,  1990). 
Patients  with  cancer  cachexia  frequently  have  specific  problems  which  reduce  nutritional 
intake,  including  physical  obstruction  of  the  gastrointestinal  tract,  nausea,  constipation  and 
debility,  psychological  problems  including  depression  and  pain  and  the  side  effects  of  treatment 
with  opiates,  radiotherapy  and  chemotherapy.  Given  the  role  of  the  pancreas  in  producing 
digestive  enzymes,  malabsorption  may  be  particularly  seen  in  patients  with  pancreatic  cancer 
(Perez  et  al,  1983).  However,  even  if  these  factors  are  well  controlled,  those  with  cancer  cachexia 
often  describe  poor  appetite,  early  satiety,  changes  in  taste  and  classical  anorexia  (Fearon,  1992). 
These  symptoms  are  similar  to  those  seen  in  many  groups  of  patients  with  inflammatory  and 
infective  illnesses  and  appear  to  constitute  part  of  the  metabolic  response  to  the  cancer-bearing 
state. 
Hypermetabolism 
A  heterogeneous  picture  of  energy  expenditure  has  been  described  in  cancer  patients  with 
resting  energy  expenditure  varying  between  less  than  60%  and  more  than  150%  of  that  predicted 
(Bozetti  et  al,  1980,  MacFie  et  al,  1982,  Knox  et  al,  1983,  Dempsey  et  al,  1984,  Hansell  et  al, 
1986,  Hyltander  et  al,  1991,  Fredrix  et  al,  1991).  Longitudinal  studies  in  a  rat  model  of  cancer 
cachexia  has  suggested  that  the  animals  are  initially  hypermetabolic  before  passing  through  a 
relatively  normometabolic  period  to  a  preterminal  hypometabolic  phase  (Zyclicz  et  al,  1990) 
(figure  1.1).  Such  longitudinal  studies  have  not  been  performed  in  humans  but  this  pattern  would 
account  for  some  of  the  variation  in  the  results  observed.  Patients  with  cancer  in  sites Chapter  1 
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Figure  1.1.  Possible  pattern  of  change  in  resting  energy  expenditure  through  disease  course  in 
cancer  cachexia  (based  on  findings  of  Zyclicz  et  al,  1990). 
frequently  associated with  cachexia  (such  as  lung  and  pancreas)  have  more  often  been  described 
as  exhibiting  elevated  resting  energy  expenditure  (Fredrix  et  al,  1991,  Staal-van  den  Brekel  et  al, 
1994,  Falconer  et  al,  1994a).  In  models  of  inflammation  sharing  mediators  with  cachexia  it  has 
been  suggested  that  this  increased  energy  expenditure  may  be  due  to  the  induction  of 
mitochondrial  uncoupling  proteins  (Faggioni  et  al,  1998a).  However,  it  has  been  suggested  that, 
while  resting  energy  expenditure  is  increased,  total  energy  expenditure  may  be  unchanged  due  to 
a  fall  in  physical  activity  (Gibney  et  al,  1997)  (figure  1.2).  Thus  overall  energy  balance  may  be 
maintained  by  a  concomitant  reduction  in  activity,  however,  this  decreased  physical  activity  may 
reflect  a  reduced  quality  of  life. Chapter  1 
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Figure  1.2.  Energy  expenditure  in  cancer  patients.  While  basal  metabolic  rate  may  be 
increased,  dietary  thermogenesis  and  physical  activity  may  be  decreased  resulting  in  little 
difference  in  total  energy  expenditure  (based  on  findings  of  Gibney  et  al,  1997). 
Substrate  metabolism 
A  variety  of  changes  in  nutrient  metabolism  have  been  described  in  patients  with  cancer 
cachexia.  Such  patients  exhibit  relative  glucose  intolerance  and  insulin  resistance  with  an 
increased  rate  of  glucose  production  and  recycling  via  lactate  (the  Con  cycle)  (Rohdenburg  et  al, 
1919,  Waterhouse,  1974,  Holroyde  et  al,  1975,  Lundholm  et  al,  1978,  Chlebowski  et  al,  1982, 
Holroyde  et  al,  1984,  Eden  et  al,  1984,  Shaw  &  Wolfe,  1987,  Copeland  et  al,  1987).  These 
changes  may  become  more  pronounced  with  progress  of  the  disease  (Chlebowski  et  al,  1982, 
Shaw  &  Wolfe,  1987).  Most  solid  tumours  seem  to  obtain  their  energy  from  the  anaerobic 
metabolism  of  glucose  (Holm  et  al,  1995)  and  there  is  debate  as  to  what  extent  the  above  changes 
exist  to  supply  the  tumour  with  nutrients.  It  has  been  suggested  that  the  increased  glucose 
turnover  observed  in  cancer  has  an  energy  cost  of  up  to  260kcal  per  day  (Eden  et  al,  1984). 
Substantial  loss  of  adipose  tissue  is  observed  in  cancer  cachexia  (Heymsfield  & 
McManus,  1985,  Fearon  &  Preston,  1990)  with  significantly  elevated  fat  oxidation  rates  (Hansell 
et  al,  1986).  Despite  this,  lipolysis  rates  are  not  significantly  increased  in  cancer  cachexia  but 
rather  lipogenesis  appears  to  be  reduced  (Jeevanandam  et  al,  1986).  This  may  be  due  to  reduced 
levels  of  lipoprotein  lipase  in  weight-losing  cancer  patients  (Vlassara  et  al,  1986). 
Normal  Cachectic 
subject  cancer 
patient Chapter  1  6 
Whole  body  protein  turnover  has  been  found  to  be  increased  in  the  majority  of  advanced 
cancer  patients  compared  with  starved  normal  individuals  and  weight-losing  non-cancer  patients 
and  appears  to  increase  further  with  progression  of  disease  (Carmichael  et  al,  1980,  Jeevanandam 
et  al,  1984,  Fearon  et  al,  1988,  Melville  et  al,  1990).  The  energy  cost  of  this  increased  protein 
turnover  has  been  estimated  to  be  around  100kcal/day  (Fearon  et  al,  1988).  In  addition,  animal 
studies  have  suggested  that  the  tumour  itself  may  utilise  circulating  albumin  as  a  source  of  amino 
acids  for  growth  (Stehle  et  al,  1997)  although  it  is  not  clear  how  relevant  this  is  in  human  disease 
where  the  relative  size  of  the  tumour  is  much  smaller. 
The  effect  of  the  cancer-bearing  state  affects  different  aspects  of  protein  synthesis  in 
different  ways.  A  model  of  the  protein  synthetic  response  to  injury  using  stress  hormone  infusion 
produced  an  immediate  reduction  in  lymphocyte  protein  synthesis,  a  delayed  fall  in  muscle 
protein  synthesis  and  a  delayed  rise  in  albumin  synthesis  (McNurlan  et  al,  1996).  Loss  of  skeletal 
muscle  protein  is  a  prominent  feature  of  cachexia,  however,  skeletal  muscle  protein  breakdown 
rates  in  cancer  patients  have  not  been  found  to  be  different  from  controls.  There  is,  however,  a 
reduction  in  the  rate  of  muscle  protein  synthesis  (Emery  et  al,  1984,  Dworzak  et  al,  1998).  Thus 
in  relative  terms  muscle  protein  breakdown  is  increased.  In  a  rat  model  of  cachexia  it  has  been 
suggested  that  muscle  wasting  is  associated  with  an  activation  of  the  ATP-dependent  ubiquitin- 
mediated  proteolytic  pathway  with  no  effect  on  calcium  dependent  or  lysosomal  proteolytic 
systems  (Llovera  et  al,  1994,  Baracos  et  al,  1995,  Llovera  et  al,  1995,  Lecker  et  al,  1999).  The 
relevance  in  this  system  in  human  cachexia  remains  to  be  explored. 
The  balance  of  liver  export  proteins  is  altered  in  many  cancer  patients  such  that  while 
albumin  synthesis  remains  unchanged  while  fibrinogen  synthesis  rates  are  significantly  increased 
(Fearon  et  al,  1998,  Preston  et  al,  1998).  These  changes  occur  on  a  background  of  a  decrease  in 
the  circulating  concentration  of  albumin  and  an  increase  in  the  concentration  of  fibrinogen. 
The  acute  phase  protein  response 
These  latter  changes  reflect  aspects  of  the  acute  phase  protein  response,  a  reprioritisation 
of  liver  protein  synthesis  often  seen  in  trauma,  inflammation  and  infection  (Fleck  et  al,  1985, 
Baumann  &  Gauldie,  1994).  The  acute  phase  protein  response  is  characterised  by  a  fall  in  the 
concentration  of  negative  acute  phase  proteins  such  as  albumin  and  a  rise  in  positive  acute  phase 
proteins  including  C-reactive  protein  and  fibrinogen.  An  acute  phase  protein  response  may  be 
seen  in  a  significant  proportion  of  patients  with  cancer  of  the  pancreas,  lung,  kidney  and 
oesophagus  (Falconer  et  al,  1994a,  Staal-van  den  Brekel  et  al,  1995,  Blay  et  al,  1992,  Wayman  et 
al,  1997).  The  proportion  of  pancreatic  cancer  patients  exhibiting  an  acute  phase  response Chapter  1  7 
increases  with  disease  progression  (Falconer  et  al,  1994a).  An  acute  phase  response  has  been 
related  to  increased  weight-loss  in  lung  and  pancreatic  cancer  and  melanoma  (Staal-van  den 
Breckel  et  al,  1995,  Scott  et  al,  1996,  Wigmore  et  al,  1997b,  Harvie  et  al,  1998).  Moreover,  the 
presence  of  such  a  response  in  cancer  patients  is  strongly  associated  with  a  reduced  quality  of  life 
in  gastrointestinal  cancer  patients  (O'Gorman  et  al,  1998)  and  a  shortened  survival  in  renal, 
pancreatic  and  colorectal  cancer  (Blay  et  al,  1992,  Falconer  et  al,  1995,  Nielsen  et  al,  1998).  In 
pancreatic  cancer  those  with  an  acute  phase  protein  response  were  found  to  have  a  median 
survival  of  66  days  while  those  without  had  a  median  survival  of  222  days  (Falconer  et  al,  1995). 
During  an  inflammatory  response  there  are  altered  demands  for  amino  acids.  Primary 
sources  of  amino  acids  are  the  diet  and  structural  protein  (largely  skeletal  muscle),  with  potential 
contributions  from  the  gut  and  plasma  proteins.  The  cachectic  cancer  patient  may  have  an 
insufficient  nutritional  intake  to  provide  the  required  amino  acids  and  consequently  there  may  be 
relatively  increased  breakdown  of  skeletal  muscle  to  supply  sufficient  amino  acids.  This 
breakdown  may  be  further  exaggerated  as  there  is  an  imbalance  between  the  amino  acid 
composition  of  skeletal  muscle  and  acute  phase  proteins  (Reeds  et  al,  1994).  During 
inflammation,  the  acute  phase  proteins  represent  only  one  possible  destination  of  amino  acids, 
others  would  include  structural  proteins  including  muscle,  gluconeogenesis,  transport  proteins 
and  processes  such  as  repair  and  the  immune  response. 
In  general  the  acute  phase  protein  response  aids  tissue  repair,  blood  clotting,  the 
prevention  of  ongoing  tissue  damage  and  the  destruction  of  infective  organisms  (Baumann  & 
Gauldie,  1994).  The  value  of  the  acute  phase  protein  response  in  patients  with  cancer  is  not  clear 
and  it  may  be  that  it  occurs  simply  as  part  of  a  stereotyped  response  to  inflammation.  The  acute 
phase  protein  response  is  stimulated  at  least  in  part  by  pro-inflammatory  cytokines,  notably 
interleukin  (IL)-6  (Castell  et  al,  1990).  Some  tumour  cell  lines  produce  pro-inflammatory 
cytokines  (Wigmore  et  al,  1994)  and  it  is  conceivable  that  the  tumour  may  benefit  from  changes 
associated  with  the  acute  phase  response  such  as  altered  energy  substrate  metabolism  (Eden  et  al, 
1984,  Holroyde  et  al,  1975)  which  may  aid  its  nutrition.  Alternatively,  the  strong  association 
between  an  acute  phase  protein  response  and  survival  in  some  malignancies  (Falconer  et  al,  1995) 
may  be  due  to  a  link  between  pro-inflammatory  cytokine  production  and  the  phenotypic 
behaviour  of  the  tumour.  For  example,  IL-1  receptor  blockade  will  reduce  the  metastatic 
potential  of  melanoma  cells  in  vivo  (Vidal-Vanaclocha  et  al,  1994). 
It  would  appear  that  these  alterations  in  substrate  metabolism  are  designed  to  provide  a 
ready  supply  of  nutrients  and  proteins  for  host  defense  and  tissue  repair.  While  this  may  be 
beneficial  in  relatively  short  term  insults  such  as  infection  or  trauma,  in  the  cancer-bearing  patient Chapter  1  8 
it  seems  that  such  alterations  are  likely  to  exacerbate  weight  loss  and  may  preferentially  provide 
additional  nutrients  for  the  tumour. 
Mediators  of  cachexia 
It  has  been  suggested  that  a  tumour  constitutes  a  new  metabolically  active  organ  requiring 
its  own  sustenance  and  so  increasing  demand  for  nutrients  and  causing  weight  loss  if  these  are  not 
forthcoming.  However,  the  presence  and  severity  of  cachexia  often  correlates  poorly  with  the 
size  of  the  tumour,  it  is  often  seen  early  in  the  course  of  the  disease  and  manifestations  such  as 
alterations  in  appetite  and  nutrient  metabolism  cannot  easily  be  explained  by  this  hypothesis 
(Tisdale,  97).  Parabiotic  studies  in  rats  where  the  tumour-bearing  animal  induces  cachexia  in  the 
non-tumour-bearing  partner  suggest  circulating  mediators  are  more  likely  to  be  responsible 
(Norton  et  al,  1985).  Thus  it  appears  likely  that  the  metabolic  changes  seen  are  the  result  of 
mediators  produced  by  the  tumour  or  by  the  body  in  response  to  the  tumour  (figure  1.3). 
Potential  mediators  are  discussed  below. 
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Figure  1.3.  Theories  of  the  mechanisms  causing  cachexia. 
Metabolic  competition  seems  unlikely  as  human  tumours  are  a  fraction  of  the  weight  of  the  host 
and  wasting  begins  early  in  disease.  Anorexia  does  not  explain  all  features  of  disease  as  the 
metabolic  changes  differ  from  those  of  simple  starvation 
and  wasting  is  seen  even  with  apparently  adequate  intake.  Thus  mediator  induced  metabolic 
changes  seem  the  most  likely  explanation. Chapter  1 
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Serotinergic  activity  in  the  hypothalamus  suppresses  appetite.  Increased  levels  of  free 
tryptophan,  the  precursor  of  serotonin,  are  found  in  cancer  patients  and  correlate  with  reduced 
food  intake  (Cangiano  et  al,  1994).  Increased  levels  of  neuropeptide  Y  within  the  hypothalamus 
are  thought  to  stimulate  feeding,  however,  tumour-bearing  rats  are  refractory  to  the  effects  of  this 
agent  when  injected  into  this  region  (Chance  et  al,  1996).  The  role  of  such  neurotransmitters  in 
weight-loss  in  humans  has  yet  to  be  explored. 
C  okines 
Several  pro-inflammatory  cytokines,  including  tumour  necrosis  factor  a  (TNFa), 
interleukin-1  (IL-1),  interleukin-6  (IL-6),  interferon  gamma  (IFN  y)  and  ciliary  neurotrophic 
factor  (CNTF),  have  been  implicated  in  cachexia.  Pro-inflammatory  cytokines  have  been  shown 
to  be  produced  by  tumour  associated  macrophages  and  tumour  cells  (Errol  et  al,  1989,  Wigmore 
et  al,  1994). 
TNFct  suppresses  lipoprotein  lipase  activity  in  adipocytes  so  preventing  fat  storage  (Fried 
&  Zechner,  1989).  Administration  of  TNFa  leads  to  anorexia,  weight  loss,  an  acute  phase  protein 
response,  protein  and  fat  breakdown,  a  rise  in  levels  of  cortisol  and  glucagon  and  a  fall  in  insulin 
levels,  insulin  resistance,  anaemia,  fever  and  elevated  energy  expenditure  in  animals  (Tracey  et  al, 
1988,  Mahony  and  Tisdale,  1988,  Moldawer  et  al,  1988,  Charters  &  Grimble,  1989,  Goodman, 
1990,  Llovera  et  al,  1993,  Llovera  et  al,  1997)  and  humans  (Starnes  et  al,  1988,  Warren  et  al, 
1987,  Selby  et  al,  1987,  Michie  et  al,  1988).  However,  it  is  rare  to  detect  circulating  TNFa  in 
cancer  patients,  even  those  losing  weight  (Socher  et  al,  1988),  and  while  antibodies  to  TNF  may 
increase  food  intake  in  an  animal  model  of  cachexia,  they  do  not  abolish  weight-loss  (Gelin  et  al, 
1991,  Smith  and  Kluger,  1993).  It  has  also  been  suggested  that  the  pattern  of  weight-loss 
observed  in  experimental  animals  given  TNFa  differs  from  that  seen  in  cancer  cachexia  (Mahony 
et  al,  1988).  Production  of  TNFa  by  isolated  peripheral  blood  mononuclear  cells  has  been  shown 
to  be  elevated  in  weight-losing  pancreatic  cancer  patients  with  an  acute  phase  protein  response 
suggesting  that  local  rather  than  systemic  production  of  this  cytokine  may  be  more  important 
(Falconer  et  al,  1994a).  It  has  been  suggested  that  circulating  TNFa  concentrations  exhibit 
circadian  changes  with  substantially  increased  levels  being  found  in  cancer  patients  at  3am  while 
levels  may  be  undetectable  at  other  times  of  day  (Muc-Wierzgon  et  al,  1996).  TNFa  induces  the 
release  of  soluble  TNF  receptors  from  cells  and  while  circulating  TNFa  may  not  be  detected, 
increased  concentrations  of  these  soluble  TNF  receptors  may  be  found  in  circulation  and  appear 
to  have  some  correlation  with  disease  stage  (Aderka  et  al,  1991).  The  incubation  of  muscle  in  the Chapter  1  10 
presence  of  TNFa  does  not  result  in  protein  breakdown  suggesting  that  other  mediators  are 
involved  (Goodman,  1990). 
IL-6  probably  induces  directly  the  acute  phase  protein  response  (Morrone  et  al,  1988, 
Castell  et  al,  1990)  and  is  produced  by  some  cancer  cell  lines  (Wigmore  et  al,  1994). 
Administration  of  IL-6  produces  weight-loss,  increased  energy  expenditure  and  increased  cortisol 
and  glucagon  concentrations  in  human  subjects  (Stouthard  et  al,  1996).  Elevated  circulating 
concentrations  of  IL-6  have  been  found  to  be  associated  with  weight-loss  and  the  acute  phase 
protein  response  in  lymphoma,  lung  and  colorectal  cancer  patients  (Fearon  et  al,  1991,  Kurzrock 
et  al,  1993,  Scott  et  al,  1996).  Antibodies  to  IL-6  will  suppress  the  development  of  cachexia  in 
animals  to  some  extent  (Strassmann  et  al,  1992).  The  administration  of  IL-12  to  tumour  bearing 
mice  (Mon  et  al,  1996)  or  the  incorporation  of  the  IL-10  gene  into  an  IL-6-producing  mouse 
cancer  model  (Fujiki  et  al,  1997)  both  resulted  in  attenuated  cachexia  in  association  with  reduced 
serum  levels  of  IL-6.  Antibodies  to  IL-6  given  to  patients  with  AIDS-related  lymphoma  produced 
weight-gain  in  those  losing  weight  and  stabilised  levels  of  the  acute  phase  reactant,  C-reactive 
protein  (Emilie  et  al,  1994).  However,  different  clones  of  experimental  tumours  will  produce 
very  different  patterns  of  weight-loss  despite  producing  similar  levels  of  IL-6  suggesting  that  IL-6 
may  work  in  concert  with  other  mediators  (Soda  et  al,  1995).  Local  production  of  IL-6  may  be 
important  in  addition  to  circulating  levels  as  peripheral  blood  mononuclear  cell  IL-6  production 
has  been  shown  to  be  elevated  in  those  pancreatic  cancer  patients  with  an  acute  phase  protein 
response  (Falconer  et  al,  1994a). 
CNTF  is  a  member  of  the  IL-6  superfamily  and  will  produce  weight-loss,  protein 
breakdown,  fever  and  an  acute  phase  protein  response  in  animals  (Henderson  et  al,  1994,  Espat  et 
al,  1996). 
Similarly,  IL-1  will  produce  anorexia,  weight-loss,  a  fall  in  muscle  protein  synthesis  and 
increased  protein  breakdown  (Okusawa  et  al,  1988,  Hellerstein  et  al,  1989,  Moldawer  et  al,  1988, 
Ballmer  et  al,  1991).  IL-1  also  stimulates  production  of  IL-6  (Yasumoto  et  al,  1995).  The 
administration  of  anti-IL-1  antibodies  to  tumour  bearing  animals  will  reduce  weight-loss  and  IL-6 
production  (Gelin  et  al,  1991,  Oldenburg  et  al,  1993).  Administration  of  anti-IL-1  antibodies  in 
an  inflammatory  model  attenuates  the  acute  phase  protein  response  and  IL-6  production 
(Gershenwald  et  al,  1990).  Mice  lacking  a  functional  IL-1  receptor  exhibit  an  attenuated  acute 
phase  response  in  a  model  of  inflammation  (Solorzano  et  al,  1996)  (those  lacking  a  TNF  receptor 
shown  no  change  in  the  inflammatory  response). 
Chinese  hamster  ovary  tumour  cells  genetically  engineered  to  produce  murine  IFN  y 
produced  greater  cachexia  when  implanted  in  mice  than  the  native  tumour  alone.  However,  IFN  y Chapter  1  11 
injections  did  not  produce  cachexia  without  the  presence  of  tumour  cells  (Matthys  et  al,  1991). 
Antibodies  to  IFN  y  may  prevent  or  attenuate  cachexia  in  this  model  and  other  models  (Matthys  et 
al,  1991,  Langstein  et  al,  1991).  Conversely,  the  attenuation  of  cachexia  produced  by  IL-12 
causing  a  fall  in  IL-6  was  attributed  to  increased  production  of  IFN  y  (Mori  et  al,  1996)  and  the 
attenuation  of  cachexia  and  tumour  growth  by  IL-  12  in  sarcoma-bearing  mice  is  not  observed  in 
IFN  y  knockout  mice  (Cahlin  et  al,  1998). 
Thus,  a  variety  of  pro-inflammatory  cytokines  appear  to  play  a  major  role  in  aspects  of 
cachexia.  However,  it  is  becoming  increasingly  apparent  that  individual  cytokines  do  not  work 
alone  in  the  in  vivo  situation  and  that  a  complex  network  of  cytokines  in  combination  with  other 
factors  are  involved.  This  situation  is  further  complicated  by  the  fact  that  the  release  of  pro- 
inflammatory  cytokines  stimulates  the  production  of  antagonists  which  may  limit  the  extent  of 
their  action,  such  as  interleukin-1  receptor  antagonist  and  soluble  TNF  receptors  (Dinarello  & 
Wolff,  1993,  Aderka  et  al,  1998).  Indeed,  some  traditionally  pro-inflammatory  cytokines,  such  as 
IL-6,  have  been  described  as  having  antiinflammatory  effects  (Tilg  et  al,  1994). 
Prostaglandins 
Concentrations  of  prostaglandin  E2  have  been  found  to  be  elevated  in  animal  models  of 
cachexia  (Tessitore  et  al,  1993)  and  some  tumours  produce  this  prostaglandin  (Strelkov  et  al, 
1989).  Release  of  prostaglandins  is  a  major  step  in  the  signalling  pathway  leading  to  muscle 
protein  breakdown  in  normal  tissues  (Thomson  &  Palmer,  1998).  It  also  appears  that 
prostaglandins  may  mediate  the  actions  of  most  pro-inflammatory  cytokines  (Okusawa  et  al, 
1988,  Rothwell,  1992).  Specific  inhibitors  of  prostaglandin  synthesis  abolish  the  protein 
catabolic  effect  of  serum  from  mice  with  cancer  cachexia  (Smith  &  Tisdale,  1993).  They  will 
also  prevent  the  experimental  cachectic  effects  of  TNFa  (Kozak  et  al,  1997)  and  IL-1  (Hellerstein 
et  al,  1989,  Uehara  et  al,  1989).  They  will  block  many  of  the  pro-inflammatory  actions  of  TNFa 
in  animal  models  (Kettelhut  et  al,  1987)  although  other  studies  have  failed  to  find  any  effect  on 
TNF-induced  weight-loss  (Mahony  &  Tisdale,  1989).  Administration  of  prostaglandin  inhibitors 
appears  to  prevent  muscle  protein  breakdown  in  tumour-bearing  rats  although  they  do  not 
increase  food  intake.  However,  this  effect  is  only  seen  in  some  tumour  models  (Strelkov  et  al, 
1989).  It  is  likely  that  prostaglandins  have  a  role  to  play  in  the  network  of  mediators  of  cachexia. 
Prostaglandins  also  have  a  variety  of  other  effects  in  influencing  inflammation  and  blood  clotting 
which  are  discussed  below. Chapter  1 
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Infusion  of  hydrocortisone  or  cortisol,  glucagon  and  adrenaline  in  humans  will  produce 
features  of  cachexia  such  as  protein  loss,  an  acute  phase  protein  response,  increased  energy 
expenditure  and  glucose  intolerance  (Bessey  et  al,  1984,  Watters  et  al,  1986).  That  pro- 
inflammatory  cytokines  effect  levels  of  classical  hormones  such  as  cortisol,  insulin  and  glucagon 
has  already  been  touched  upon.  Changes  in  hormone  levels  and  target-organ  sensitivity  have 
been  described  in  both  animals  and  humans  with  cachexia.  Profound  changes  are  seen  in 
hormone  levels  in  experimental  tumour-bearing  animals  although  the  patterns  of  change  varied 
with  the  tumour  cell  line  implanted  (Besedovsky  et  al,  1985).  In  humans  with  cancer  elevated 
levels  of  cortisol  and  glucagon  have  been  observed  (Schaur  et  al,  1979,  Burt  et  al,  1983,  Holroyde 
et  al,  1984,  Knapp  et  al,  1991)  and  these  may  amplify  the  acute  phase  protein  response  (Baumann 
&  Gauldie,  1994). 
A  blunted  insulin  secretory  response  to  a  glucose  load  has  been  described  in  a  group  of 
patients  with  colorectal  cancer  (Holroyde  et  al,  1984).  In  addition,  insulin  resistance  in  terms  of 
glucose  metabolism  has  been  noted,  particularly  in  pancreatic  cancer,  although  this  appears  to  be 
unrelated  to  the  loss  of  pancreatic  tissue  and  seems  to  be  due  to  the  production  of  islet  amyloid 
polypeptide  (amylin)  by  the  surrounding  normal  pancreatic  tissue  (Schwarz  et  al,  1978,  Gullo  et 
al,  1993,  Permert  et  al,  1993,  Permert  et  al,  1994).  The  production  of  amylin  appears  to  be 
stimulated  by  the  presence  of  pancreatic  cancer  cells  although  the  signal  involved  has  not  been 
identified  (Ding  et  al,  1998).  Amylin  will  induce  anorexia  and  weight  loss  when  administered  to 
rats  (Arnelo  et  al,  1996).  However,  it  has  been  suggested  that  the  skeletal  muscle  anabolic  effects 
of  insulin  are  not  affected  in  cancer  (Newman  et  al,  1991).  Insulin  also  affects  the  synthesis  of 
hepatic  acute  phase  proteins,  increased  concentrations  causing  a  rise  in  albumin  synthetic  rate 
and  a  reduction  in  fibrinogen  synthetic  rate  (De  Feo  et  al,  1993). 
It  is  increasingly  being  recognised  in  cancer  patients  with  weight  loss  that  small  increases 
in  circulating  cortisol  and  falls  in  insulin  concentration  result  in  a  marked  increase  in  the 
cortisol:  insulin  ratio  and  that  this  may  contribute  to  the  catabolism  of  peripheral  tissues  (Fearon  et 
al,  1998). 
It  has  been  suggested  that  leptin,  the  hormone  produced  by  fat  which  suppresses  appetite 
and  increases  energy  expenditure  to  maintain  weight  stability  (Zhang  et  al,  1994),  may  be 
involved  in  cancer  cachexia  as  elevated  leptin  levels  are  seen  in  some  models  of  inflammation 
(Grunfeld  et  al,  1996,  Sarraf  et  al,  1997).  The  administration  of  TNFa  will  increase  leptin 
concentrations  (Zumbach  et  al,  1997)  and  the  presence  of  IL-1ß  also  appears  to  be  required  for 
leptin  production  in  inflammation  (Faggioni  et  al,  1998b).  However,  initial  clinical  studies  have Chapter  1  13 
found  that  levels  of  leptin  are  appropriately  low  in  weight-losing  cancer  patients  (Simons  et  al, 
1997). 
Tumour-specific  products 
Additional  potential  mediators  for  cachexia  have  recently  been  described.  A  24kd 
glycoprotein  proteolysis  inducing  factor  (PIF)  has  been  isolated  from  the  urine  of  weight-losing 
cancer  patients  but  not  those  losing  weight  due  to  other  causes  (Todorov  et  al,  1996a,  Todorov  et 
al,  1996b).  This  produces  protein  breakdown  in  experimental  animals  and  appears  distinct  from 
known  cytokines  (Cariuk  et  al,  1997).  A  mouse  tumour-derived  lipid  mobilising  factor  (LMF) 
has  also  been  described  (Harai  et  al,  1997)  and  this  has  been  recently  identified  in  the  urine  of 
weight-losing  cancer  patients  and  appears  to  be  associated  with  zinc  a-2  glycoprotein  (Harai  et  al, 
1998).  The  failure  of  pro-inflammatory  cytokines  such  as  IL-6  to  reliably  induce  cachexia  in 
animal  models  has  led  to  the  suggestion  that  tumour-derived  factors  such  as  PIF  may  act  as  co- 
factors  with  host-  or  tumour-derived  cytokines  to  produce  a  cachectic  state  (Fujiki  et  al,  1997). 
Management  of  cancer  cachexia 
Nutritional  approaches 
The  best  way  to  treat  cancer  cachexia  is  to  cure  the  cancer.  Unfortunately,  this  remains  a 
rare  achievement  among  adults  with  advanced  solid  tumours.  The  next  obvious  option  is  to 
increase  nutritional  intake  by  enteral  or  parenteral  means. 
Two  substantial  randomised  trials  have  examined  the  effect  of  enteral  feeding  in  patients 
with  advanced  cancer  undergoing  chemotherapy  (Evans  et  al,  1987,  Ovesen  et  al,  1993b).  Both 
studies  included  patients  with  a  variety  of  cancer  types  who  were  randomised,  to  receive 
nutritional  counselling  (to  raise  their  energy  and  protein  intake)  or  not.  Both  trials  included  over 
100  patients  and  over  a3  month  period  demonstrated  a  significant  increase  in  nutritional  intake  in 
the  intervention  group.  However,  this  did  not  produce  any  improvement  in  weight, 
anthropometric  measures,  response  rate,  survival  or  quality  of  life. 
Parenteral  nutrition  is  difficult  to  supply  over  long  periods  and  has  its  own  complications. 
A  number  of  trials  of  parenteral  nutrition  were  performed  in  cancer  patients  in  the  1980s  and,  in 
general,  showed  no  benefit  in  terms  of  nutritional  measures  and  an  increase  in  infective 
complications.  This  led  the  American  College  of  Physicians  to  publish  a  position  paper  in  1989 
(American  College  of  Physicians,  1989)  which  concluded  that  in  cancer  patients  "parenteral 
nutritional  support  was  associated  with  net  harm,  and  no  conditions  could  be  defined  in  which 
such  treatment  appeared  to  be  of  benefit.  "  Since  then  a  number  of  further  large  trials  of Chapter  1  14 
parenteral  nutrition  in  cancer,  particularly  in  the  perioperative  setting,  have  been  performed. 
These  studies  have  shown  a  significant  improvement  in  energy  intake  in  patients  administered 
parenteral  nutrition  but  no  improvement  in  nutritional  measures  or  functional  outcome.  Once 
again  there  were  increased  complications  and  a  trend  to  a  shorter  survival  duration  (Veterans 
Affairs  TPN  Cooperative  Study  Group,  1991,  Sandstrom  et  al,  1993,  Brennan  et  al,  1994).  It  has 
been  suggested  that  severely  malnourished  patients  may  derive  more  benefit,  however,  these 
conclusions  were  based  on  very  small  numbers  of  patients  within  much  larger  studies  (Veterans 
Affairs  TPN  Cooperative  Study  Group,  1991,  De  Cicco  et  al,  1993). 
In  examining  the  short  term  metabolic  effects  of  enteral  and  parenteral  nutrition,  the 
majority  of  studies  have  shown  a  suboptimal  response  to  feeding  in  cachectic  cancer  patients 
compared  with  those  with  benign  causes  of  weight  loss  (Nixon  et  al,  1981,  Shaw  et  al,  1987, 
Shaw  et  al,  1988,  Melville  et  al,  1990,  Shaw  et  al,  1991)  with  an  apparent  anabolic  response  only 
being  demonstrated  by  one  group  (Bennegärd  et  al,  1983,  Lindmark  et  al,  1986).  It  has  been 
suggested  that  some  cancer  patients  without  obvious  cachexia  exhibit  some  limitation  of 
anabolism  in  response  to  feeding  compared  with  benign  depleted  controls  (Melville  et  al,  1990) 
and  also  that  those  with  different  malignancies  may  exhibit  different  responses  to  feeding  (Shaw 
et  al,  1988).  Thus  there  appears  to  be  at  least  a  large  subgroup  of  cachectic  patients  who  do  not 
benefit  from  the  provision  of  apparently  adequate  nutrition. 
Pharmacological  approaches 
The  disappointing  results  of  conventional  nutritional  supplementation  in  cancer  patients 
has  led  to  the  suggestion  that  there  is  a  block  to  weight-gain  in  this  group  (Nixon  et  al,  1981) 
perhaps  related  to  the  metabolic  changes  described  previously.  This  has  led  to  attempts  to 
manipulate  the  metabolic  milieu  with  a  variety  of  pharmacological  agents  using  our  knowledge  of 
the  mediators  thought  to  be  involved  in  cachexia. 
Steroids  are  among  the  most  widely  used  agents  in  patients  with  cancer  cachexia. 
Prednisolone  at  a  dose  of  5mg  three  times  daily  (Willox  et  al,  1984)  and  dexamethasone  3-6mg 
daily  (Moertel  et  al,  1974)  have  been  shown  to  improve  appetite  to  a  greater  extent  than  placebo. 
Methylprednisolone  given  intravenously  at  a  dose  of  125mg  daily  will  improve  quality  of  life 
(Robustelli  della  Curia  et  al,  1989,  Popiela  et  al,  1989).  However,  steroids  will  not  affect  ongoing 
weight-loss,  symptomatic  benefits  are  often  short  lived  and  they  are  associated  with  a  number  of 
adverse  effects  including  water  retention,  proximal  myopathy  and  insulin  resistance.  Thus 
steroids  tend  to  be  used  in  the  pre-terminal  phases  of  a  patients'  illness  and  are  not  suitable  for 
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Serotonin  is  known  to  have  a  role  in  appetite  control.  However,  a  trial  of  the 
antiserotoninergic  cyproheptadine  demonstrated  no  obvious  benefits  in  weight  change  or 
symptoms  (Kardinal  et  al,  1990). 
Due  to  the  potential  role  of  the  inflammatory  state  and  eicosanoids  in  cachexia,  non- 
steroidal  anti-inflammatory  drugs  have  been  investigated  in  cancer  patients.  A  randomised  trial 
of  mixed  cancer  patients  receiving  indomethacin  50mg  twice  daily  or  placebo  produced  a 
stabilisation  of  performance  status  and  a  near  doubling  of  survival  in  the  indomethacin  group 
(Lundholm  et  al,  1994).  Ibuprofen  at  a  dose  of  400mg  three  times  daily  has  been  shown  to  reduce 
levels  of  acute  phase  proteins,  interleukin-6  and  cortisol  and  to  normalise  whole-body  protein 
kinetics  to  some  extent  in  cachectic  colorectal  cancer  patients  (McMillan  et  al,  1995,  Preston  et 
al,  1995).  Ibuprofen  will  also  reduce  levels  of  acute  phase  proteins  and  resting  energy 
expenditure  in  those  with  pancreatic  cancer  (Wigmore  et  al,  1995). 
The  effects  of  the  progestational  agents  megestrol  acetate  and  medroxyprogesterone 
acetate  on  weight-loss  in  cancer  have  been  studied  extensively  following  observations  of 
unwanted  weight-gain  in  patients  with  breast  cancer  using  these  agents.  Several  randomised  trials 
in  mixed  groups  of  weight-losing  cancer  patients  have  suggested  that  megestrol  acetate  will 
improve  appetite  and  stabilise  weight  (Loprinzi  et  al,  1990,  Bruera  et  al,  1990,  Filiu  et  al,  1992, 
Tchekmedyan  et  al,  1992)  although  not  all  groups  have  been  able  to  demonstrate  these  findings 
(McMillan  et  al,  1994a).  Doses  have  varied  from  240-1600mg  per  day.  In  one  trial  comparing  a 
dose  of  160  to  320mg/day,  little  difference  was  found  (Gebbia  et  al,  1996).  In  another  study 
which  compared  160,480,800  and  1280mg/  day  a  marginal  advantage  for  a  dose  of  800mg  per 
day  was  described  (Loprinzi  et  al,  1993a).  A  recent  crossover  study  of  480mg  megestrol  acetate 
per  day  for  10  days  in  84  patients  with  advanced  cancer  demonstrated  improved  appetite,  activity 
and  well  being  while  receiving  megestrol  (although  performance  status  continued  to  fall)  but  no 
changes  in  nutritional  parameters  and  it  was  thus  suggested  that  these  apparent  beneficial  effects 
of  megestrol  are  not  secondary  to  any  nutritional  improvement  (Bruera  et  al,  1998). 
Medroxyprogesterone  acetate  has  similarly  been  shown  to  increase  appetite  and  food  intake  with 
stabilisation  of  weight  at  a  dose  of  500mg  twice  daily  (Simons  et  al,  1996,  Simons  et  al,  1998) 
and  to  improve  appetite  and  some  negative  acute  phase  protein  concentrations  at  a  dose  of  100mg 
three  times  daily  (Downer  et  al,  1993).  These  agents  have  a  number  of  side  effects  including  an 
increased  incidence  of  venous  thrombosis  and  peripheral  oedema.  The  frequency  of  oedema  and 
the  fact  that  weight  gained  by  patients  taking  megestrol  acetate  tended  to  consist  of  fat  and  water 
(Loprinzi  et  al,  1993b,  Simons  et  al,  1998)  means  that  it  may  not  be  a  useful  drug  for  arresting  the 
loss  of  lean  tissue.  Of  more  concern  is  a  recent  trial  of  megestrol  acetate  in  patients  receiving Chapter  1  16 
chemotherapy  which  found  an  inferior  response  to  therapy  and  a  trend  to  poorer  survival 
(Rowland  et  al,  1996). 
A  new  approach  to  the  management  of  cachexia  has  been  to  combine  the  appetite 
stimulating  properties  of  a  progestational  agent  with  the  anti-inflammatory  properties  of  the  non- 
steroidal  anti-inflammatory  drugs  by  using  megestrol  acetate  and  ibuprofen  together.  Early  trials 
suggest  that  this  combination  may  stabilise  quality  of  life  and  weight  in  advanced  gastrointestinal 
cancer  patients  (McMillan  et  al,  1997,  Wigmore  et  al,  1997c,  McMillan  et  al,  1999). 
Pentoxifylline  has  been  shown  to  inhibit  the  production  of  TNFa  (Strieter  et  al,  1988), 
and  to  suppress  protein  breakdown  in  a  tumour-bearing  rat  model  of  cachexia  (Combaret  et  al, 
1998).  A  case  report  of  the  use  of  pentoxifylline  in  two  patients  with  advanced  cancer  suggested 
improvements  in  wellbeing  (Dezube  et  al,  1990).  However,  a  controlled  trial  of  pentoxifylline  in 
patients  with  cancer  cachexia  failed  to  demonstrate  any  benefit  in  terms  of  appetite  or  nutritional 
measures  compared  with  placebo  (Goldberg  et  al,  1995). 
Melatonin  has  also  been  suggested  to  influence  TNFa  production  leading  to  a  controlled 
but  non-randomised  study  of  20mg  melatonin  daily  given  in  the  evening  (Lissoni  et  al,  1996).  In 
patients  with  a  variety  of  metastatic  solid  tumours  weight  loss  continued  in  both  groups  but 
melatonin  appeared  to  produce  a  significant  slowing  of  this  weight  loss  compared  with  controls. 
There  was  a  progressive  rise  in  serum  TNFa  concentrations  in  control  subjects  while 
concentrations  fell  in  those  receiving  melatonin. 
Hydrazine  sulphate  inhibits  phosphoenolpyruvate  carboxykinase,  an  enzyme  responsible 
for  gluconeogenesis  from  lactate  (the  Cori  cycle),  to  some  degree.  It  was  hoped  that  interrupting 
this  process  would  normalise  some  aspects  of  carbohydrate  metabolism  in  cachexic  cancer 
patients  and  so  improve  nutritional  status.  Given  orally  at  a  dose  of  60mg  three  times  daily 
hydrazine  sulphate  has  been  shown  to  have  marginal  benefits  over  placebo  in  terms  of  appetite 
and  maintenence  of  weight  in  a  mixed  group  of  cancer  patients  (Chlebowski  et  al,  1987). 
However,  subsequent  studies  in  large  groups  of  colorectal  (Loprinzi  et  al,  1994a)  and  lung 
(Loprinzi  et  al,  1994b)  cancer  patients  have  shown  no  effect  on  weight-loss  with  trends  to  worse 
survival  and  quality  of  life  in  hydrazine  treated  patients. 
Manipulation  of  the  hormonal  environment  has  also  been  used  in  an  attempt  to  promote 
skeletal  muscle  anabolism.  The  administration  of  insulin  to  patients  with  cancer  may  reduce 
protein  breakdown  in  cachectic  cancer  patients,  however,  this  requires  careful  control  of  blood 
glucose  (Heslin  et  al,  1992).  In  addition,  effects  are  limited  by  an  increase  in  glucagon  secretion 
(Bartlett  et  al,  1994)  and  concerns  over  the  promotion  of  tumour  growth  by  insulin  (Moley  et  al, 
1988,  Beck  &  Tisdale,  1989).  Subsequent  animal  studies  have  suggested  that  the  combination  of Chapter  1  17 
insulin  with  somatostatin,  sometimes  with  the  addition  of  growth  hormone,  will  attenuate  weight- 
loss  with  an  apparent  gain  in  muscle  mass  without  an  obvious  increase  in  tumour  growth  rate 
(Bartlett  et  al,  1994,  Bartlett  et  al,  1995a).  It  has  also  been  shown  that  the  combination  of  insulin 
like  growth  factor-1  and  its  binding  protein-3  (IGF-1  /IGFBP-3)  will  stimulate  muscle  protein 
synthesis  in  undernourished  rats.  This  combination  will  reduce  the  rate  of  weight-loss  in  tumour 
bearing  mice  (Svanberg  et  al,  1998). 
Growth  hormone  will  improve  carcass  weight  in  cachectic  tumour-bearing  rats  (Bartlett  et 
al,  1995b).  Small  clinical  studies  of  growth  hormone  administration  suggest  it  may  improve 
nitrogen  balance  (Wolf  et  al,  1992,  Tayek  &  Brasel,  1995)  although  this  effect  may  not  be  seen  in 
more  malnourished  patients  (Tayek  &  Brasel,  1995).  The  administration  of  growth  hormone 
appears  not  to  influence  the  acute  phase  protein  response  in  trauma  patients  (Petersen  et  al,  1997). 
Concerns  also  remain  about  the  effects  of  growth  hormone  on  promoting  tumour  growth  (Akaza 
et  al,  1991). 
Other  agents  undergoing  studies  at  the  present  time  include  agents  which  may  modulate 
TNFa  concentrations  such  as  thalidomide  and  melotonin  and  ß2-adrenoceptor  agonists  which 
may  impair  protein  breakdown  (Lissom  et  al,  1996,  Gagnon  &  Bruera,  1998,  Haslett,  1998). 
While  progress  has  been  made  in  understanding  the  physiological  changes  in  cancer 
which  give  rise  to  cachexia  it  remains  a  significant  cause  of  morbidity  and  mortality  in  malignant 
disease.  The  metabolic  alterations  that  occur  in  these  patients  would  appear  to  prevent  the 
effective  use  of  additional  calories  supplied.  A  number  of  pharmacological  agents  have  shown 
promise  in  normalising  some  of  these  metabolic  changes.  The  n-3  polyunsaturated  fatty  acids, 
particularly  eicosapentaenoic  acid,  have  also  been  shown  to  have  the  potential  to  modulate  the 
inflammatory  process.  The  properties  and  potential  of  these  agents  are  discussed  below. 
n-3  polyunsaturated  fatty  acids 
Humans  are  unable  to  synthesise  fatty  acids  with  double  bonds  more  proximal  to  the 
methyl  end  than  the  ninth  carbon  atom.  Thus  there  are  two  families  of  essential  fatty  acids  -  those 
with  the  last  double  bond  six  and  three  atoms  from  this  position  (figure  1.4).  The  parent  of  the 
omega-  or  n-6  fatty  acids  is  linoleic  acid  (18:  2n-6)  (see  appendix  1).  This  is  found  in  many  plant 
seeds  and  is  elongated  and  desaturated  in  vivo  to  form  arachidonic  acid  (20:  4n-6).  The  parent  of 
the  n-3  family  is  alpha-linolenic  acid  (18:  3n-3),  which  is  found  associated  with  chloroplasts. 
Linseed,  rapeseed  and  soybean  oils  contain  some  but  the  richest  source,  particularly  of  the  longer 
chain  eicosapentaenoic  (20:  5n-3)  and  docosahexaenoic  (22:  6n-3)  acids  is  marine  algae  (Leaf  & Chapter  1  18 
Weber,  1988,  Simopoulos,  1991).  These  algae  form  the  lowest  level  of  the  marine  food  chain 
and  thus  n-3  fatty  acids  are  found  in  appreciable  quantities  in  many  marine  animals  where  the 
high  level  of  desaturation  may  help  keep  cell  membranes  fluid  in  the  cold  of  the  open  ocean 
(Nerdoy  &  Dyerberg,  1989). 
Interest  in  polyunsaturated  fatty  acids  in  human  disease  was  initially  stimulated  by 
observations  on  Greenland  Eskimos  in  the  1970's.  These  showed  that,  despite  a  similar  fat  and 
cholesterol  intake  to  those  in  Denmark,  diseases  such  as  coronary  heart  disease  and  cancer  were 
rare  (Neilsen  &  Hansen,  1980,  Anonymous,  1983).  The  major  dietary  difference  between  this 
population  and  those  with  a  higher  incidence  of  such  diseases  seemed  to  be  in  the  type  of  fat 
rather  than  the  quantity  consumed.  The  main  sources  of  fat  in  Greenland  Eskimos  were  fish, 
seals  and  whales  resulting  in  a  higher  consumption  of  n-3  fatty  acids  and  a  lower  intake  of  n-6 
and  saturated  fats  (Dyerberg  et  al,  1975,  Bang  et  al,  1976).  In  the  United  Kingdom  n-3  fatty  acids 
make  up  less  than  0.5%  of  the  fats  in  our  diet  resulting  in  levels  of  less  than  1%  in  the  body's 
lipid  pools  (Bull  et  al,  1983).  In  populations  such  as  Eskimos  with  a  high  intake  n-3  fatty  acids 
may  make  up  15%  of  cholesterol  esters  and  7%  of  phospholipids  (Dyerberg  et  al,  1975). 
n-6  fatty  acids  n-3  fatty  acids 
Linoleic  acid  18:  2  Alpha-linolenic  acid  18:  3 
Delta-6-desaturase 
Gamma-linolenic  acid  18:  3  Octadecatetraenoic  acid  18:  4 
Elongase 
Dihomogammalinolenic  acid  20:  3  Eicosatetraenoic  acid  20:  4 
Delta-5-desaturase 
Arachidonic  acid  20:  4  Eicosapentaenoic  acid  20:  5 
Elongase 
Docosatetraenoic  acid  22:  4  Stearidonic  acid  22:  5 
Delta-4-desaturase 
Docosapentaenoic  acid  22:  5  Docoshexaenoic  acid  22:  6 
Figure  1.4.  Essential  fatty  acid  metabolism  in  man. Chapter  1  19 
The  thrust  of  initial  research  was  in  the  cardiovascular  field  where  n-3  fatty  acids  have 
been  shown  to  decrease  blood  viscosity,  improve  the  lipid  profile  and  lower  blood  pressure  (Leaf 
&  Weber,  1988,  Simopoulos,  1991).  Advice  to  increase  the  amount  of  fish  in  the  diet  of  men 
who  had  recovered  from  myocardial  infarction  led  to  a  reduction  in  mortality  of  29%  at  2  years  in 
a  study  of  over  2000  patients  (Burr  et  al,  1989).  Since  then  research  has  expanded  into  many 
fields  representing  many  increasingly  prevalent  diseases,  especially  those  of  an  inflammatory 
nature.  Beneficial  effects  for  n-3  fatty  acids  have  now  been  described  in  inflammatory  bowel 
disease  (Lorenz  et  al,  1989,  Belluzi  et  al,  1996),  rheumatoid  arthritis  (Lau  et  al,  1993),  asthma 
(Arm  et  al,  1988),  atopic  dermatitis  (Bjorneboe  et  al,  1989),  psoriasis  (Bittiner  et  al,  1988), 
models  of  sepsis  (Johnson  et  al,  1993),  organ  transplantation  (van  der  Heide  et  al,  1993), 
schizophrenia  (Laugharne  et  al,  1996),  infant  problem  solving  (Willatts  et  al,  1998)  and  cancer.  It 
has  been  suggested  that  during  human  evolution  the  balance  of  n-3/n-6  fatty  acids  was  much 
higher  than  in  the  current  Western  diet  and  that  the  change  in  diet,  particularly  during  the  second 
half  of  the  20th  Century  has  contributed  to  the  changes  in  the  pattern  of  diseases  seen  over  this 
period  (Simopoulos,  1991,  Okuyama  et  al,  1997). 
Biological  effects  of  n-3  polyunsaturated  fatty  acids 
Polyunsaturated  fatty  acids  have  been  shown  to  have  a  myriad  of  biological  effects  at  the 
tissue,  cellular  and  molecular  levels,  many  of  which  are  crucial  in  regulating  the  inflammatory 
state.  The  20  carbon  polyunsaturated  fatty  acids  are  metabolised  into  eicosanoids  -  by 
cyclooxygenase  into  the  prostanoids  -  prostaglandins  and  thromboxanes,  and  by  5-lipoxygenase 
into  the  leukotrienes.  The  n-6  fatty  acid  arachidonic  acid  is  the  major  precursor  for  these 
substances  in  the  modem  diet  and  gives  rise  to  the  2-series  prostanoids  (such  as  thromboxane  A2 
and  prostglandin  E2  and  12)  and  the  4-series  leukotrienes  (Leukotriene  B4,  C4  etc). 
Eicosapentaenoic  acid  is  also  metabolised  by  these  enzymes  into  the  3-series  prostanoids  and  5- 
series  leukotrienes.  Eicosanoids  are  a  major  determinant  of  vascular  tone,  the  haemostatic  state 
and  the  inflammatory  state.  Thromboxane  A2  derived  from  arachidonic  acid  is  a  potent 
vasoconstrictor  and  platelet  aggregating  agent.  The  actions  of  thromboxane  A2  are 
counterbalanced  by  those  of  prostaglandin  I2  (prostacyclin)  which  is  vasodilatory  and 
antiaggregatory.  Eicosapentaenoic  acid  inhibits  the  production  of  thromboxane  A2  by 
cyclooxygenase  and  serves  as  a  substrate  for  Thromboxane  A3  (with  much  weaker  effects  than 
thromboxane  A2).  Eicosapentaenoic  acid  has  little  effect  on  the  production  of  prostaglandin  12 
while  also  giving  rise  to  prostaglandin  I3  which  has  similar  properties  (Knapp  et  al,  1986,  Fischer 
&  Weber,  1983).  The  4-series  leukotrienes  derived  from  arachidonic  acid  are  chemoattractive  to 
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circulating  neutrophils  and  monocytes  and  cause  smooth  muscle  contraction  and  vasodilatation. 
The  5-series  leukotrienes  from  eicosapentaenoic  acid,  particularly  leukotriene  B5,  are  less  active 
than  their  4-series  counterparts  and  compete  with  those  of  the  4-series  for  binding  sites  (Lee  et  al, 
1985).  Thus,  with  regard  to  eicosanoids,  n-3  polyunsaturated  fatty  acids  produce  a  more 
vasodilatory  state  with  less  platelet  aggregation  and  a  less  pro-inflammatory  environment. 
Contributing  to  this  anticoagulatory  balance  fish  oil  supplementation  has  been  shown  to  reduce 
plasma  concentrations  of  fibrinogen  (a  positive  acute  phase  protein)  in  healthy  volunteers  and 
hyperlipidaemic  subjects  (Hostmark  et  al,  1988,  Radack  et  al,  1989). 
Fish  oil  and  eicosapentaenoic  acid  supplementation  have  been  shown  by  a  number  of 
groups  to  reduce  production  of  the  pro-inflammatory  cytokines  interleukin-1,  interleukin-6  and 
tumour  necrosis  factor  by  mononuclear  cells  in  normal  volunteers  and  this  effect  is  maintained  for 
some  weeks  after  stopping  supplementation  (Endres  et  al,  1989,  Meydani  et  al,  1991,  Meydani  et 
al,  1993,  Cooper  et  al,  1993,  Caughey  et  al,  1996).  This  effect  has  also  been  shown  in  cancer 
patients  (Purasiri  et  al,  1994,  Wigmore  et  al,  1997d).  However,  another  group  using  apparently 
similar  techniques  and  n-3  fatty  acid  doses  have  found  prompt  rises  in  pro-inflammatory  cytokine 
production  (Demols  et  al,  1998).  Similar  contradictory  findings  have  been  reported  in  animal 
studies  and  it  remains  unclear  how  these  data  can  be  reconciled,  however,  it  is  likely  that  minor 
differences  in  culture  conditions,  particularly  the  source  of  serum  used  may  be  important 
(Locniskar  et  al,  1983). 
Fish  oil  and  eicosapentaenoic  acid  have  also  been  found  to  have  a  wide  variety  of  effects 
upon  leukocytes  in  terms  of  their  proportions  and  function.  Dietary  supplementation  with  n-3 
fatty  acids  has  been  reported  to  result  in  a  reduction  in  the  proportion  and  cytotoxicity  of  natural 
killer  and  lymphokine-activated  killer  cells  (Purasiri  et  al,  1995),  an  increase  in  the  proportion  of 
T  suppressor  to  T  helper  cells  (Meydani  et  al,  1993),  a  reduction  in  lymphocyte  proliferation  in 
response  to  aT  cell  mitogen  (Meydani  et  al,  1991,  Meydani  et  al,  1993)  and  a  reduction  in  the 
delayed  hypersensitivity  skin  response  (Meydani  et  al,  1993).  Neutrophil  adherence  to 
endothelium  is  inhibited  (Lee  et  al,  1985)  and  neutrophil  chemotactic  response  is  reduced  (Lee  et 
al,  1985,  Endres  et  al,  1989).  A  clue  to  the  mechanism  behind  some  of  these  changes  can  be 
gained  from  the  observation  that  activated  human  monocytes  cultured  in  vitro  both  with 
eicosapentaenoic  acid  and  docosahexaenoic  acid  show  decreased  expression  of  major 
histocompatability  complex  II  molecules  HLA-DR  and  -DP  and  of  intracellular  adhesion 
molecule-1  (Hughes  et  al,  1996). 
The  relevance  of  these  findings  in  the  clinical  situation  is  unclear.  While  beneficial 
effects  have  been  seen  in  terms  of  prolonged  graft  survival  following  renal  transplantation  in Chapter  1  21 
those  given  fish  oil  supplementation  (van  der  Heide  et  al,  1993),  there  have  been  no  reports  of 
adverse  effects  with  regard  to  immunosuppression.  A  recent  study  examined  the  immunological 
effects  of  eicosapentaenoic  acid  in  patients  receiving  total  parenteral  nutrition  after  major  surgery. 
This  suggested  that  while  circulating  interleukin-6  concentrations  were  reduced  in  those  receiving 
eicosapentaenoic  acid  these  subjects  showed  increased  lymphocyte  proliferation  and  natural  killer 
cell  activity  and  lower  glucagon  concentrations  than  those  receiving  standard  or  fat  free  parenteral 
nutrition  (Furukawa  et  al,  1999).  Thus  it  seems  that  eicosapentaenoic  acid  produces  a  subtle 
immunomodulation  rather  than  a  blanket  immunosuppression. 
Mechanisms  of  n-3  fatty  acid  actions 
The  precise  mechanisms  by  which  polyunsaturated  fatty  acids  exert  specific  effects 
remain  largely  unclear,  however,  they  have  been  shown  to  influence  virtually  every  stage  of 
signal  transduction  including  the  activity  of  a  number  of  receptors  and  enzymes  with  a 
fundamental  role  in  cellular  signalling  (figure  1.5).  When  agonists  stimulate  receptors  in  the  cell 
membrane  they  may  activate  adenylate  cyclase  or  a  phospholipase,  the  second  messenger 
products  of  which  (including  lipids  in  the  case  of  phospholipases)  influence  the  actions  of  cAMP- 
dependent  protein  kinase  and  protein  kinase  C  respectively.  n-3  fatty  acids  have  been  shown  to 
influence  the  effects  of  adenylate  cyclase,  probably  via  an  inhibitory  guanine  nucleotide-binding 
protein  (Alam  et  al,  1988,  Tisdale,  1993,  Price  &  Tisdale,  1998),  phospholipase  A2  (Ballou  & 
Cheung,  1985),  cAMP-dependent  protein  kinase  (Speizer  et  al,  1991)  and  protein  kinase  C 
(Speizer  et  al,  1991,  Holian  &  Nelson,  1992).  Other  enzymes  which  have  been  suggested  to  be 
inhibited  by  n-3  fatty  acids  include  matrix  metalloproteinases  involved  in  tumour  invasion  and 
metastasis  (Suzuki  et  al,  1997)  and  farnesyl  protein  transferase  involved  in  the  transforming 
activity  of  ras  oncoproteins  (Singh  et  al,  1998).  Eicosapentaenoic  acid  also  binds  to  membrane 
voltage-sensitive  sodium  channels  and  may  alter  the  conductance  of  the  channel  (Kang  &  Leaf, 
1996,  Xiao  et  al,  1998)  and  n-3  fatty  acids  bind  to  the  cytoplasmic  glucocorticoid  receptor  at  a 
site  different  from  the 
hormone  binding  site  and  markedly  reduce  its  affinity  for  the  hormone  (Vallette  et  al,  1991, 
Sumida  et  al,  1993). Chapter  1 
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Figure  1.5.  Potential  mechanisms  of  action  of  fatty  acids  in  metabolism. 
In  addition  to  eicosapentaenoic  acid  providing  an  alternative  substrate  for  the  synthesis  of 
eicosanoids  as  discussed  above,  fish  oil  supplementation  will  reduce  expression  of  inducible 
cyclooxygenase  (COX-2)  and  so  further  alter  eicosanoid  production  (Singh  et  al,  1997). 
With  n-3  fatty  acid  supplementation  an  accelerated  catabolism  of  leukotriene  B4  has  been 
demonstrated  in  addition  to  reduced  synthesis  (von  Schacky  et  al,  1993).  Peroxisome 
proliferator-activated  receptor  a  is  a  gene  transcription  factor  which  induces  the  breakdown  of 
leukotrienes  and  thus  has  a  role  in  limiting  the  duration  and  extent  of  inflammation. 
Eicosapentaenoic  acid,  docosahexaenoic  acid  and  leukotrienes  themselves  appear  to  increase  the 
activity  of  this  factor  (Keller  et  al,  1993,  Yu  et  al,  1995,  Devchand  et  al,  1996). 
The  production  of  pro-inflammatory  cytokines  and  acute  phase  proteins  is  controlled  to 
some  extent  by  the  transcription  factor  NF-KB  (Beauparlant  &  Hiscott,  1996).  Because  of  the 
effects  of  polyunsaturated  fatty  acids  on  cytokine  production  initial  studies  have  been  performed 
to  investigate  the  effects  of  these  molecules  upon  NF-KB  activation.  Some  polyunsaturated  fatty 
acids  appear  to  activate  NF-KB  but  so  far  n-3  fatty  acids  have  not  been  shown  to  have  a  major 
effect  on  this  pathway  in  vitro  (Camandola  et  al.  1996). Chapter  1 
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Through  its  effects  upon  eicosanoids,  cytokines  and  leukocytes  eicosapentaenoic  acid  and 
other  11-3  fatty  acids  have  broadly  anti-inflammatory  properties.  However,  few  adverse  effects 
have  been  noted  with  the  administration  of  such  agents.  Fish  oil  supplementation  has  been 
suggested  to  adversely  affect  glucose  metabolism  in  otherwise  well  patients  with  non-insulin- 
dependent  diabetes  mellitus  (Glauber  et  al,  1988,  Borkman  et  al,  1989).  However,  a  study  of 
patients  with  hypertension  given  4g  fish  oil  or  placebo  daily  for  16  weeks  specifically  addressed 
this  issue  and  showed  no  change  in  response  to  glucose  tolerance  test,  insulin  release  or  insulin 
sensitivity  in  those  given  fish  oil  and  no  difference  between  groups  (Toft  et  al,  1995). 
The  reported  effects  of  n-3  fatty  acids  in  prolonging  bleeding  time  and  inhibiting  platelet 
function  have  raised  concerns  about  excessive  bleeding  after  consuming  fish  oils  (van 
Houwelingen  et  al,  1987).  However,  only  one  study  has  found  this  to  be  a  clinically  significant 
problem  with  an  increased  rate  of  epistaxis  in  hyperlipidaemic  adolescents  given  fish  oil  (Clarke 
et  al,  1990).  In  addition  there  has  been  concern  that  the  immunomodulatory  effects  of  fish  oils 
may  result  in  unwanted  immunosuppression  (Meydani  et  al,  1991)  but  there  appear  to  have  been 
no  reports  of  clinical  problems  related  to  immune  modulation  by  n-3  fatty  acids.  The 
administration  of  Maxepa,  providing  around  1.8g  eicosapentaenoic  acid  daily,  for  over  7  years 
has  not  been  reported  to  produce  adverse  effects  (Saynor  &  Gillott,  1992). 
n-3  polyunsaturated  fatty  acids  and  cancer 
Early  work  using  polyunsaturated  fatty  acids  in  in  vitro  studies  of  cancer  demonstrated 
that  eicosapentaenoic  acid  and  other  polyunsaturated  fatty  acids  would  kill  or  inhibit  the  growth 
of  many  malignant  cell  lines  including  those  from  human  lung,  breast,  prostate  (Begin  et  al, 
1986),  pancreatic  (Falconer  et  al,  1994b),  melanoma  (McMillan  et  al,  1994b)  and  colorectal 
cancers  (Mengeaud  et  al,  1992).  These  effects  were  achieved  at  fatty  acid  concentrations  of  10- 
300µM.  The  mechanism  for  this  action  has  been  suggested  to  be  via  cell  cycle  arrest  and 
induction  of  apoptosis  (Lai  et  al,  1996,  Hawkins  et  al,  1998,  Latham  et  al,  1998).  The  addition  of 
inhibitors  of  prostaglandin  synthesis,  such  as  indomethacin,  has  been  found  to  have  no  effect  on 
this  cytotoxicity  in  some  models  (Begin  et  al,  1988,  Mengeaud  et  al,  1992)  while  others  have 
noted  blockade  of  the  this  tumour  growth  suppression  with  cyclooxygenase  and  lipoxygenase 
inhibitors  (Kumar  &  Das,  1997).  The  addition  of  the  antioxidants  vitamin  E,  superoxide 
dismutase  or  glutathione  peroxidase  and  the  saturated  fatty  acid  oleic  acid  inhibited  cell  death 
while  the  pro-oxidants  iron  and  copper  enhanced  it  (Begin  et  al,  1986,  Falconer  et  al,  1994b, 
Kumar  &  Das,  1997,  Hawkins  et  al,  1998).  It  appears  likely  that  the  cytotoxicity  of Chapter  1  24 
polyunsaturated  fatty  acids  occurs  via  effects  on  peroxidation  and  eicosanoids.  The  levels  of  an 
indirect  measure  of  lipid  peroxidation  have  not  been  reliably  associated  with  the  degree  of  cell 
death  suggesting  other  factors  may  be  involved  (Falconer  et  al,  1994b).  Recent  work  using  a 
mouse  tumour  model  has  suggested  that  eicosapentaenoic  acid  inhibits  translation  initiation, 
reducing  the  synthesis  and  expression  of  growth  regulatory  proteins,  causing  cell  cycle  arrest  in 
G1  (Palakurthi  et  al,  2000).  Cultured  leukaemia  cells  with  increased  docosahexaenoic  acid  in 
their  membranes  have  been  shown  to  be  resticted  in  their  ability  to  passively  pass  through  a  filter 
and  thus  it  may  be  that  reduced  cell  deformability  alters  the  growth  of  malignancies  (Zerouga  et 
al,  1997).  It  has  also  been  suggested  that  n-3  polyunsaturated  fatty  acids  will  increase  the 
sensitivity  of  tumours  to  cytotoxic  chemotherapeutic  agents,  including  adriamycin  in  cultured 
leukaemia  cells  (Guffy  et  al,  1984),  cisplatin  and  doxorubicin  in  cultured  ovarian  cancer  cell  lines 
(Plumb  et  al,  1993)  and  doxorubicin  in  lung  tumour  xenografts  in  a  mouse  model  (Hardman  et  al, 
2000). 
The  widespread  antineoplastic  effects  in  vitro  led  to  much  animal  work,  mostly  using 
tumours  implanted  into  immunocompromised  mice.  These  studies  suggested  that  the  growth 
rates  of  transplanted  human  prostate  (Karmali  et  al,  1987),  breast  (Pritchard  et  al,  1989,  Gonzalez 
et  al,  1991,  Gonzalez  et  al,  1993,  Rose  &  Connolly,  1993,  Rose  et  al,  1995,  Hardman  et  al,  1995, 
Senzaki  et  al,  1998),  colon  (Sakaguchi  et  al,  1990a,  Sakaguchi  et  al,  1990b,  Calder  et  al,  1998) 
and  lung  (de  Bravo  et  al,  1991,  Mxhle  et  al,  1995)  tumours  could  be  slowed  by  the  administration 
of  eicosapentaenoic  acid  or  fish  oil.  Reduced  rates  of  metastases  have  also  been  shown  (Rose  et 
al,  1995,  Connolly  &  Rose,  1996).  Doses  have  varied  from  about  2  to  20g  eicosapentaenoic 
acid/kg  given  with  the  diet  but  most  groups  started  the  experimental  diet  before  the  implantation 
of  tumours.  Again  the  anti-tumour  effects  seem  to  be  inhibited  by  antioxidants  (Gonzalez  et  al, 
1991,  Gonzalez  et  al,  1993)  and  enhanced  by  iron  (Gonzalez  et  al,  1991,  Hardman  et  al,  1995). 
Other  studies  have  shown  that  eicosapentaenoic  acid  increases  the  resistance  of  cultured 
cells  to  transformation  by  radiation  and  transfection  by  the  Harvey  ras  oncogene  in  vitro 
(Takahashi  et  al,  1992).  Studies  in  rats  administered  carcinogens  have  shown  that  those  fed 
higher  proportions  of  fish  oil  containing  eicosapentaenoic  acid  developed  fewer  tumours  and  had 
decreased  expression  of  H-ras  (in  contrast  to  the  findings  for  n-6  fatty  acids)  (Abou-El-Ela  et  al, 
1988,  Reddy  &  Sugie,  1988,  Karmali  et  al,  1989).  Recent  epidemiological  studies  have  shown 
that  increasing  consumption  of  fish  and  fish  oil  correlates  with  a  decreased  risk  of  colorectal  and 
breast  cancer  (Kaizer  et  al,  1989,  Sasaki  et  al,  1993,  Caygill  et  al,  1996). 
It  is  difficult  to  untangle  the  role  of  docosahexaenoic  acid,  the  other  common  long  chain 
n-3  fatty  acid,  in  these  findings.  This  is  normally  found  in  relatively  high  concentrations  in  the Chapter  1  25 
structural  lipids  of  the  brain  and  retina  in  humans  (Sardesai,  1992).  Many  of  the  experiments 
described  above  were  performed  using  mixtures  of  n-3  fatty  acids  containing  both 
eicosapentaenoic  acid  and  docosahexaenoic  acids.  Supplementation  of  docosahexaenoic  acid 
alone  in  normal  volunteers  results  in  increased  levels  of  both  docosahexaenoic  and 
eicosapentaenoic  acids  in  plasma  and  platelet  phospholipids  but  feeding  of  eicosapentaenoic  acid 
does  not  result  in  any  change  in  docosahexaenoic  acid  levels  suggesting  conversion  in  only  one 
direction  in  vivo  (von  Schacky  &  Weber,  1985,  Conquer  &  Holub,  1997).  In  studies  comparing 
the  two,  docosahexaenoic  acid  has  had  similar  and  in  some  cases  superior  effects  in  inhibiting  the 
growth  or  killing  of  tumour  cell  lines  in  vitro  (Begin  et  al,  1986,  Falconer  et  al,  1994b,  Mwhle  et 
al,  1995),  in  reducing  the  growth  rate  of  tumours  and  number  of  metastases  in  experimental 
tumours  in  mice  (Rose  et  al,  1995)  and  in  reducing  the  transformation  of  cultured  cells  by 
radiation  and  transfection  (Takahashi  et  al,  1995).  A  recent  study  has  suggested  that 
eicosapentaenoic  acid  and  docosahexaenoic  acid  will  both  inhibit  growth  of  an  experimental 
tumour  in  rats  but  by  slightly  different  means.  Eicosapentaenoic  acid  appears  to  inhibit  cell 
proliferation  while  docosahexaenoic  acid  induces  apoptosis  (Calviello  et  al,  1998). 
Work  on  the  anti-neoplastic  activity  of  n-3  fatty  acids  is  extending  slowly  into  the  human 
clinical  arena.  A  reduction  in  abnormal  proliferation  was  noted  in  rectal  mucosal  biopsies  of 
patients  with  sporadic  colorectal  adenomas  given  doses  of  fish  oil  providing  between  1.4g 
eicosapentaenoic  acid  and  1.1  g  docosahexaenoic  acid  daily  and  4.1  g  eicosapentaenoic  acid  and 
3.6g  docosahexaenoic  acid  daily  in  a  controlled  study  (Anti  et  al,  1994).  A  study  of  12  heavily 
pretreated  patients  with  metastatic  breast  cancer  given  fish  oil  capsules  providing  3.6g 
eicosapentaenoic  acid  and  2.4g  docosahexaenoic  acid  daily  found  a  partial  regression  in  one 
patient  and  disease  stabilisation  in  another  (Holroyde  et  al,  1988).  A  recent  controlled  study  of  60 
patients  with  advanced  solid  tumours  found  that  survival  was  significantly  prolonged  in  those 
receiving  fish  oil  capsules  providing  around  3g  eicosapentaenoic  acid  and  2.1g  docosahexaenoic 
acid  daily  (Gogos  et  al,  1998). 
n-3  polyunsaturated  fatty  acids  and  cancer  cachexia 
The  failure  of  conventional  nutritional  supplementation  to  affect  the  progress  of  cachexia 
and  studies  to  elucidate  the  mechanisms  of  cachexia  have  led  to  the  conclusion  that  there  is  a 
metabolic  block  to  the  accretion  of  lean  body  mass  in  cachectic  patients  (Nixon  et  al,  1981, 
Moldawer  &  Copeland,  1997).  Modulation  of  a  variety  of  metabolic  mediators,  such  as  pro- 
inflammatory  cytokines  and  eicosanoids  by  n-3  polyunsaturated  fatty  acids,  that  have  been 
demonstrated  in  healthy  volunteers  have  led  to  the  the  hypothesis  that  these  fatty  acids  may  down Chapter  1  26 
regulate  the  metabolic  response  to  cancer  and  so  allow  moderation  of  cachexia. 
A  mouse  colorectal  tumour  model  has  been  described  in  which  the  animals  consistently 
lose  weight  with  tumour  progression  (Bibby  et  al,  1987).  Despite  experimental  diets  not  being 
commenced  until  the  subcutaneously  implanted  tumours  were  palpable,  tumour  growth  rate  has 
been  reduced  and,  in  addition,  weight-loss  abolished  with  doses  of  about  2.5g  eicosapentaenoic 
acid/kg  given  with  diet  or  by  gavage  (Tisdale  &  Dhesi,  1990,  Tisdale  &  Beck,  1991,  Beck  et  al, 
1991,  Hudson  et  al,  1993,  Hudson  &  Tisdale,  1994).  It  has  been  suggested  that  this  effect  is  due 
to  impairment  of  the  end-organ  effects  of  proteolysis  inducing  factor  and  lipid  mobilising  factor 
probably  by  an  effect  upon  cell  signalling  (Smith  &  Tisdale,  1993,  Tisdale,  1996).  Similar 
attenuation  of  weight-loss  with  eicosapentaenoic  acid  has  also  been  shown  in  a  mouse  model 
using  lung  cancer  cells  transfected  with  interleukin-6  to  produce  cachexia  (Ohira  et  al,  1996). 
These  data  have  now  been  complemented  by  early  studies  in  human  cancer  cachexia.  A 
group  of  18  weight-losing  patients  with  advanced  pancreatic  cancer  have  been  given  an  oral  fish 
oil  preparation  providing  around  2.2g  eicosapentaenoic  acid  and  1.4g  docosahexanoic  acid  daily. 
Before  treatment  all  patients  were  losing  weight  at  a  median  rate  of  2.9kg  per  month.  Following 
3  months  supplementation  patients  had  a  median  weight  gain  of  0.2kg/month  with  less  than  half 
of  the  patients  continuing  to  lose  weight.  There  was  no  change  in  the  percentage  of  total  body 
water  over  the  time  of  the  study  suggesting  that  patients  were  not  simply  retaining  fluid.  This 
regimen  also  produced  a  fall  in  the  serum  C-reactive  protein  level  suggesting  that  some  of  the 
metabolic  abnormalities  of  pancreatic  cancer  could  be  reversed  resulting  in  the  stabilisation  of 
weight  (Wigmore  et  al,  1996). 
Subsequently  27  patients  with  unresectable  pancreatic  cancer  were  given  6g  per  day  of 
95%  pure  eicosapentaenoic  acid  orally  after  a4  week  dose  escalation  period.  Patients  were  losing 
a  median  of  2.0kg  per  month  at  baseline.  After  4  weeks  patients  had  a  median  weight  gain  of 
0.75kg  and  this  effect  remained  at  3  months  with  a  median  weight  gain  of  0.25kg  per  month. 
Again  there  was  no  change  in  the  percentage  total  body  water  over  the  course  of  the  study 
confirming  that  the  achievement  of  weight  stability  was  not  due  to  changes  in  hydration  (Barber 
et  al,  1997).  There  were  no  serious  side  effects  in  these  studies  and  median  survival  was 
approximately  7  months.  A  subgroup  of  these  patients  underwent  evaluation  of  the  effect  of  the 
eicosapentaenoic  acid  preparation  on  pro-inflammatory  cytokine  production  by  mononuclear  cells 
and  of  the  acute  phase  protein  response.  Interleukin-6  and  tumour  necrosis  factor  production  and 
C-reactive  protein  concentrations  were  found  to  be  down-regulated  (Wigmore  et  al,  1997d). Chapter  1 
Summary  and  aims  of  thesis 
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Advanced  cancer  is  often  associated  with  a  variety  of  metabolic  abnormalities  which 
result  in  the  syndrome  of  cachexia  causing  weight-loss  not  responsive  to  conventional  nutritional 
support.  By  creating  an  extra  demand  for  amino  acids  the  hepatic  acute  phase  response  may  be  a 
significant  facet  of  such  metabolic  change.  A  more  complete  understanding  of  the  mechanisms 
and  mediators  surrounding  cachexia  and  the  response  to  feeding  in  cachectic  patients  has  the 
potential  to  advance  the  treatment,  not  only  of  patients  with  cancer  but  also  for  those  with  a 
variety  of  inflammatory  conditions  associated  with  wasting.  A  treatment  for  patients  with 
cachexia  is  not  available  at  present  but  would  have  the  potential  to  improve  quality  and  length  of 
life  in  this  unfortunate  group.  Fish  oil  and  EPA  are  able  to  modulate  some  of  these  metabolic 
adaptations  and  may  arrest  weight-loss.  With  a  degree  of  metabolic  normalisation  produced  by 
fish  oil,  the  supply  of  additional  calories  and  protein  may  allow  weight-gain  in  cachectic  cancer 
patients  (figure  1.6). 
Cancer 
Metabolic  response 
1 
/\  Reduced  nutritional 
intake 
Cachexia  Additional 
Anti-inflammatory  agents  -  nutrients  - 
questionable  benefit  no  benefit 
Combination  -  anti-inflammatory  agents 
plus  additional  nutrients  - 
potential  benefit 
Figure  1.6.  Hypothesis  of  cause  of  cancer  cachexia  and  potential  action  of  agents  used  to  treat 
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The  work  presented  in  this  thesis  will  thus  explore  - 
1)  the  role  of  inflammation  in  mediating  cachexia  in  advanced  pancreatic  cancer 
Specifically,  the  relationship  of  acute  phase  response  and  weight  loss  to  performance 
status,  the  relationship  of  cytokines  to  the  acute  phase  response  and  the  relationship  of 
cytokine  genotype  to  inflammatory  state  and  survival. 
(Chapters  3,4  and  5) 
2)  the  role  of  other  mediators  such  as  insulin,  cortisol,  leptin  and  proteolysis-inducing  factor  in 
weight  losing  pancreatic  cancer  patients 
This  will  be  addressed  by  a  comparison  of  the  concentrations  of  neuroendocrine 
hormones  and  the  excretion  of  proteolysis-inducing  factor  in  addition  to  the 
concentration  of  acute  phase  proteins  and  cytokines  and  cytokine  production 
between  weight-losing  pancreatic  cancer  patients  and  a  group  of  healthy  controls. 
(Chapters  4,7  and  8) 
3)  the  role  of  acute  phase  protein  synthesis  as  a  cause  of  increased  demand  for  amino  acids  in  the 
fasted  and  fed  state 
The  synthesis  of  albumin  and  fibrinogen  in  the  fasted  and  fed  state  will  be  measured  in 
weight-losing  cancer  patients  and  healthy  controls.  (Chapter  10) 
4)  the  modulation  of  the  metabolic  alterations  in  cancer  following  the  administration  of  a  fish  oil- 
enriched  nutritional  supplement 
In  particular  the  effect  upon  weight,  body  composition,  dietary  intake,  resting  energy 
expenditure,  nitrogen  balance,  acute  phase  protein  concentrations,  cytokine  production  and 
concentrations,  leptin,  insulin  and  cortisol  concentrations  and  the  excretion  of  proteolysis 
inducing  factor,  albumin  and  fibrinogen  synthesis  and  metabolic  response  to  feeding  will  be 
examined  in  a  group  of  cachectic  pancreatic  cancer  patients.  (Chapters  6,7)  8,9  and  10) 
It  is  hoped  that  this  work  will  clarify  to  some  degree  the  relationship  of  the  inflammatory 
response  to  cancer  and  its  importance  to  the  nutritional  decline  and  poor  survival  of  patients  with 
pancreatic  cancer.  The  thesis  also  aims  to  explore  the  potential  of  n-3  polyunsaturated  fatty  acids 
to  modulate  the  inflammatory  metabolic  state  and  determine  whether  the  supply  of  additional 
nutrients  via  oral  dietary  supplementation  will  result  in  an  improvement  in  patients'  nutritional 
status. Chapter  2 
Methods 
Ethical  approval 
Protocols  for  the  studies  described  in  this  thesis  were  submitted  to  the  Lothian  Health 
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Orthopaedic  Surgery/Surgery  Research  Ethics  Sub-Committee  and  received  ethical  approval  under 
reference  1702/96/5/47  and  1702/97/5/32. 
Clinical  and  nutritional  assessment 
Anthropometry 
Height  was  measured  to  the  nearest  0.5cm  on  a  wall  mounted  stadiometer.  Remembered 
pre-illness  stable  weight  and  duration  of  weight-loss  were  recorded.  Subjects  were  weighed  either 
on  spring  balance  scales  (Seca,  Germany)  or  a  beam  scale  (Avery,  Birmingham,  U.  K.  )  without 
shoes  and  wearing  light  clothing.  The  same  scale  was  used  within  individual  studies.  Body  mass 
index  was  calculated  by  dividing  the  weight  in  kilograms  by  the  height  in  metres  squared. 
Percentage  weight  loss  was  calculated  by  dividing  the  difference  between  remembered  stable  weight 
and  current  weight  by  the  remembered  stable  weight  and  multiplying  by  100. 
Mid-upper  arm  circumference  (MUAC)  was  measured  to  the  nearest  0.25cm  half  way 
between  the  acromion  process  and  olecranon  process.  Triceps  skinfold  thickness  (TSF)  was 
measured  using  Harpenden  calipers  (John  Bull  British  Indicators  Ltd,  UK)  at  the  midarm  over  the 
mid  point  of  the  triceps  muscle.  Three  measurements  were  performed  and  the  mean  value  recorded. 
Midmuscle  circumference  (MAMC)  was  calculated  using  Jelliffe's  equation  (Jelliffe,  1966). 
MAMC  (cm)  =  MUAC  (cm)  -  (0.3142  *  TSF  (mm)) 
Body  composition  analysis 
Body  composition  was  measured  using  a  Xitron  4000B  multiple  frequency  bioelectrical 
impedence  analyser  (Xitron  Technologies,  San  Diego,  CA,  USA).  All  assessments  were  made  with 
the  subject  supine  and  limbs  apart.  Electrodes  were  placed  over  the  wrist  and  ankle  joints  and 
metacarpal  and  metatarsal  heads.  Repeat  measurements  were  performed  using  the  same  pair  of Chapter  2  30 
limbs.  Resistance  was  measured  at  200Hz.  Values  for  total  body  water  (TBW)  and  extracellular 
water  (ECW)  were  derived  using  equations  validated  in  a  similar  patient  group  (Hannan  et  al,  1995). 
TBW  (1)  =  (0.2391  *  (height  (cm)2  /  resistance  at  200Hz))  + 
(0.1889  *  weight  (kg))  +  (2.971  *sex)  +  5.464 
Sex  -  male  =  1,  female  =0 
ECW  (1)  =  (0.1782  *  (height2  /  resistance  at  5Hz))  +  (0.0688  *  weight)  +  3.771 
Lean  body  mass  was  calculated  from  total  body  water  assuming  that  lean  tissue  contains  73% 
water.  Body  cell  mass  was  calculated  from  intracellular  water  (total  body  water  minus  extracellular 
water)  assuming  that  cell  mass  contains  70%  water  (Shizgal,  1990).  Lean  body  mass  index  was 
calculated  by  dividing  the  lean  body  mass  in  kilograms  by  the  height  in  metres  squared. 
Performance  status  and  appetite 
Karnofsky  performance  status  was  noted  as  described  by  Karnofsky  (Karnofsky,  1948). 
100  Normal,  no  complaints. 
90  Able  to  carry  on  normal  activity;  minor  signs  or  symptoms  of  disease. 
80  Normal  activity  with  effort;  some  signs  or  symptoms  of  disease. 
70  Cares  for  self.  Unable  to  carry  on  normal  activity  or  to  do  active  work. 
60  Requires  occasional  assistance,  but  is  able  to  care  for  most  needs. 
50  Requires  considerable  assistance,  and  frequent  medical  care. 
40  Disabled;  requires  special  care  and  assistance. 
30  Severely  disabled;  hospitalisation  is  indicated  although  death  not  imminent. 
20  Very  sick;  hospitalisation  necessary;  active  supportive  treatment  necessary. 
10  Moribund,  fatal  processes  progressing  rapidly. 
0  Dead. 
Appetite  was  measured  on  a  numerical  rating  scale  between  0  and  10,  where  0  indicated 
absolutely  no  appetite  and  10  indicated  an  extremely  good  appetite  (Simons  et  al,  1996). Chapter  2 
Nutritional  intake 
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The  daily  dietary  intake  of  subjects  was  measured  based  on  the  mean  dietary  intake  recorded 
in  a3  day  food  diary  calculated  using  CompEat  4  software  (Nutrition  Systems,  London,  UK)  with 
the  assistance  of  Dr  Alison  Hinds  and  Rosemary  Richardson. 
Blood  and  culture  superpatent  assays 
Acute  phase  proteins 
These  were  assessed  from  venous  serum  samples  apart  from  fibrinogen  which  was  assessed 
from  a  plasma  sample.  Serum  and  plasma  were  collected  following  centrifugation  and  stored  at  - 
70°C  until  analysis. 
Most  C-reactive  protein  measurements  were  made  using  an  immunoturbidometric  assay 
(Abbott  Laboratories,  Maidenhead,  U.  K.  )  in  the  clinical  laboratory  of  the  Department  of 
Microbiology  at  the  Royal  Infirmary  of  Edinburgh.  Reported  limit  of  detection  of  this  assay  was  10 
mg/1. 
For  the  results  described  in  chapter  4,  C-reactive  protein  was  measured  by  ELISA  using 
rabbit  anti-human-CRP  antibody  and  peroxidase-conjugated  rabbit  anti-human-CRP  antibody 
(DAKO,  High  Wycombe,  U.  K.  ).  The  lower  limit  of  detection  was  lmg/l. 
For  the  results  described  in  chapter  8,  C-reactive  protein  was  measured  by 
immunoturbidometry  using  Tina-Quant  assay  kits  (Boehringer  Mannheim,  Germany)  on  a  Hitachi 
911  analyser  (Ealing,  UK)  in  the  clinical  laboratory  of  the  Department  of  Clinical  Chemistry  at  the 
University  of  Liverpool.  The  lower  limit  of  detection  was  5mg/l. 
Serum  albumin  was  measured  using  an  automated  bromocresyl  green  method  in  the  clinical 
laboratory  of  the  Department  of  Clinical  Chemistry  at  the  Royal  Infirmary  of  Edinburgh. 
a-1-antitrypsin,  a-1-acid  glycoprotein,  haptoglobin  and  ceruloplasniin,  prealbumin  and 
transferrin,  were  measured  by  immunoturbidometry  using  Tina-Quant  assay  kits  (Boehringer 
Mannheim,  Germany)  on  a  Hitachi  911  analyser  (Ealing,  UK). 
Fibrinogen  was  measured  by  assessing  clotting  time  in  the  presence  of  a  high  thrombin 
concentration  on  a  KC4A  Coagulometer  (Baxter  Healthcare,  Thetford,  UK)  in  the  clinical 
laboratories  of  the  Department  of  Haematology  at  the  Royal  Infirmary  of  Edinburgh. 
Coefficient  of  variation  of  all  automated  assays  was  3%  or  less. Chapter  2  32 
Serum  c  okines 
Serum  interleukin-  Iß  (IL-1  ß),  interleukin-6  (IL-6),  soluble  interleukin-6  receptor  (sIL-6R), 
soluble  tumour  necrosis  factor  receptor  55  (sTNF-R55  or  sTNF-RI),  soluble  tumour  necrosis  factor 
receptor  75  (sTNF-R75  or  sTNF-RII)  were  all  measured  by  indirect  ELISA  from  serum  stored  at  - 
70°C  until  analysis.  Samples  underwent  no  more  than  one  freeze/thaw  cycle  before  analysis. 
IL-1  ß  was  measured  using  commercial  kits  (Quantikine  High  Sensitivity,  R&D  Systems, 
Abingdon,  UK).  Limit  of  detection  was  0.2pg/ml. 
For  the  results  described  in  chapter  4,  IL-6  was  measured  using  a  monoclonal  anti-human-IL- 
6  antibody  and  peroxidase-conjugated  Fab  fragments  of  a  murine  monoclonal  anti-human-IL-6 
antibody  (CLB,  Amsterdam,  Netherlands).  The  lower  limit  of  detection  was  0.25pg/ml.  Otherwise 
IL-6  was  measured  by  a  similar  method  using  different  kits  (Quantikine,  R&D  Systems,  Abingdon, 
UK).  Limit  of  detection  was  0.5pg/ml. 
sIL-6R  was  measured  using  a  monoclonal  anti-human-sIL-6R  antibody  and  peroxidase- 
conjugated  Fab  fragments  of  a  murine  monoclonal  anti-human-sIL-6R  antibody  (CLB,  Amsterdam, 
Netherlands).  The  lower  limit  of  detection  was  4ng/ml.  For  the  results  described  in  chapter  4, 
sTNF-R55  and  sTNF-R75  were  measured  using  polyclonal  and  monoclonal  anti-sTNF-R55  and 
sTNF-R75  antibodies  kindly  provided  by  Dr  WA  Buurman,  University  of  Maastricht,  Netherlands 
(Leeuwenberg  et  al,  1994).  The  lower  limit  of  detection  for  sTNF-R55  was  190pg/ml  and  for  sTNF- 
R75  was  2ng/ml.  Otherwise,  sTNF-R55  and  sTNF-R75  were  measured  using  commercial  kits 
(Quantikine,  R&D  Systems,  Abingdon,  UK).  Limits  of  detection  were  0.156ng/ml  and  0.78ng/ml 
respectively. 
Coefficient  of  variation  for  assays  were  as  follows  across  the  concentration  range  studied- 
-1  ß  less  than  11.1  % 
IL-6  less  than  6.3% 
TNF  receptors  less  than  8.8%. 
Peripheral  blood  mononuclear  cell  cytokine  production 
Peripheral  blood  mononuclear  cells  (PBMCs)  were  separated  from  20mis  of  heparin  anti- 
coagulated  blood  on  a  hypaque  gradient  (Histopaque  1077,  Sigma,  Poole,  UK)  by  centrifuging  at 
1500rpm  for  30  minutes.  Cells  from  the  interface  were  removed  and  washed  three  times  in  cell 
culture  medium  (Roswell  Park  Memorial  Institute  (RPMI)  medium  1640,  Life  Technologies, 
Paisley,  UK)  with  Penicillin  (501U/ml),  streptomycin  (50µg/ml)  and  glutamine  (2mmol/1)  (Sigma) Chapter  2 
added.  Cells  were  resuspended,  counted  and  incubated  at  37°C  in  96-well,  flat-bottomed  tissue 
culture  plates  (Costar,  Cambridge,  Massachussets,  USA)  at  a  concentration  of  2x  105  per  well  in 
200µl  cell  culture  medium  with  10%  fetal  calf  serum  or  autologous  plasma  in  the  presence  or 
absence  of  10µg/ml  E.  coli  lipopolysaccharide  (Sigma).  Supernatants  from  PBMC  cultures  were 
removed  at  24  hours  and  stored  at  -70°C  for  subsequent  analysis. 
IL-1  P,  IL-6  and  TNF  concentrations  from  supernatants  were  measured  by  ELISA 
(Quantikine,  R&D  Systems,  Abingdon,  UK).  Limits  of  detection  were  195pg/ml,  240pg￿ml  and 
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13.9pg/ml  respectively  for  stimulated  cells  and  19.5pg/ml,  30pg/ml  and  13.9pg/ml  respectively  for 
unstimulated  cells. 
Coefficient  of  variation  for  assays  were  as  follows  across  the  concentration  range  studied- 
-1ß  less  than  7.1% 
IL-6  less  than  4.4% 
TNF  less  than  8.7%. 
Hormones 
All  samples  for  the  measurement  of  baseline  hormone  concentration  were  taken  at  Bam  after 
an  overnight  fast. 
Insulin  and  cortisol  concentrations  were  measured  by  radioimmunoassay  in  the  clinical 
laboratory  of  the  Department  of  Clinical  Chemistry  at  Glasgow  Royal  Infirmary.  Limit  of  detection 
of  insulin  was  0.7mU/l. 
Leptin  concentrations  were  measured  by  radioimmunoassay  (Linco  Research,  St  Charles, 
MO,  USA)  in  the  research  laboratories  of  Zeneca  Pharmaceuticals  in  Macclesfield.  Limit  of 
detection  was  <ing/ml. 
Coefficient  of  variation  for  assays  were  as  follows  across  the  concentration  range  studied- 
Insulin  less  than  10.5% 
Cortisol  less  than  10% 
Leptin  less  than  8.3%. 
Proteolysis  inducing  factor 
The  isolation  of  proteolysis  inducing  factor  (PIF)  was  performed  in  the  research  laboratory  of 
the  Department  of  Pharmaceutical  Sciences  at  Aston  University,  Birmingham  by  Professor  Michael 
Tisdale  and  Bill  Field.  Urine  was  treated  with  80%  (NH4)2SO4  overnight,  the  precipitated  protein Chapter  2 
was  recovered  by  centrifugation,  dialysed  against  water  and  concentrated.  An  immunoblot  was 
performed  using  a  monoclonal  antibody  to  PIF  secreted  by  a  hybridoma  prepared  from  MAC  16 
tumour-bearing  mouse  splenocytes  fused  with  a  mouse  myeloma  cell  line  (Todorov  et  al,  1996). 
Fatty  acid  analysis 
Fatty  acid  analysis  was  performed  in  the  research  laboratory  of  the  Department  of 
Pharmaceutical  Sciences  at  Aston  University,  Birmingham  by  Professor  Michael  Tisdale  and  Bill 
Field. 
EDTA-anticoagulated  venous  blood  samples  were  centrifuged  at  2500rpm  for  15  minutes 
and  the  plasma  removed  and  stored  at  -70°C  until  subsequent  analysis.  Lipids  were  isolated  and 
purified  by  the  method  of  Folch  (Folch  et  al,  1957) 
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Lipids  were  extracted  from  plasma  by  homogenising  in  20  volumes  of  chloroform:  methanol 
(2:  lv/v).  Fatty  acids  were  extracted  from  plasma  phospholipids  by  heating  at  100°C  for  45-60 
minutes  in  2.5m1  5%  sodium  hydroxide  in  50%  methanol  in  an  atmosphere  of  nitrogen.  The 
solution  contained  butylated  hydroxytoluene  as  an  antioxidant  and  margaric  acid  as  an  internal 
standard.  The  released  fatty  acids  were  methylated  by  heating  to  80°C  for  5  minutes  in  the  presence 
of  boron  trifluoride  in  methanol.  The  fatty  acid  methyl  esters  were  extracted  twice  with 
hexane:  chloroform  (4:  1)  and  analysed  using  a  Hewlett  Packard  5890  Series  II  gas  chromatograph 
with  a  narrow  bore  (0.25mm)  DB32  column  (J&W  Scientific,  Fisons,  UK)  and  a  flame  ionisation 
chamber  at  250°C.  The  temperature  programme  ran  for  28  minutes  with  an  initial  temperature  of 
180°C  with  a  5°C/minute  increase  to  220°C  which  was  maintained  for  15  minutes.  The  column  was 
run  with  helium  as  the  carrier  gas.  The  fatty  acids  were  identified  by  their  retention  times  based  on 
the  use  of  authentic  fatty  acid  methyl  ester  standards. 
Routine  haematology  and  clinical  chemistry  measurements 
Full  blood  count,  electrolytes,  urea,  glucose  and  liver  function  tests  were  measured  using 
standard  automated  techniques  in  the  clinical  laboratories  of  the  Departments  of  Haematology  and 
Clinical  Chemistry  at  the  Royal  Infirmary  of  Edinburgh. Chapter  2 
Cytoýkine_gene  polymorphism  eý  ing 
DNA  extraction 
DNA  was  extracted  from  1ml  samples  of  EDTA  anticoagulated  blood  using  a  Puregene 
DNA  isolation  kit  based  on  a  simple  salting  out  technique  (Miller  et  al,  1988)  (Gentra  systems, 
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North  Carolina,  USA).  Red  blood  cells  were  lysed  and  the  precipitate  retained  after  centrifugation. 
White  blood  cells  were  lysed  in  the  presence  of  a  DNA  preservative  using  an  anionic  detergent  to 
solubilise  the  cellular  components.  RNA  was  removed  with  an  RNAase  and  cytoplasmic  and 
nuclear  proteins  removed  by  precipitation  with  a  saturated  NaCI  solution.  After  centrifugation  the 
precipitate  was  discarded  and  DNA  isolated  from  the  supematent  by  precipitation  with  100% 
isopropanol.  After  centrifugation  the  precipitate  containing  the  genomic  DNA  was  washed  with 
70%  ethanol  and  dissolved  in  a  buffered  solution  containing  a  DNA  preservative. 
Cytokine  gene  polymorphism  genotyping  was  performed  with  the  assistance  of  Dr  Susan 
Lynch  and  Dr  James  Powell. Chapter  2 
TNFB  Ncol  polymorphism 
The  polymerase  chain  reaction  (PCR)  was  used  to  amplify  a  368bp  fragment  of  the  of  the 
TNFß  genomic  sequence  using  primers  upstream  5'  CCGTGCTTCGTGCTTTGGACTA  3'  and 
downstream  5'  AGAGGGGTGCATGCTTGGGTTC  3'  (Genosys,  Pampisford,  UK)  (Stuber  et  al, 
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1996).  The  following  PCR  protocol  was  used  -  95°C  for  3  minutes,  45  cycles  of  95°C  for  30s,  68°C 
for  40s,  74°C  for  48s;  and  74°C  for  6  minutes  using  reagents  supplied  by  Promega  (Southampton, 
UK)  on  a  Hybaid  Omn-E  thermal  cycler  (Teddington,  UK).  The  PCR  product  was  digested  directly 
with  lu  of  Ncol  restriction  enzyme  (Promega,  Madison,  Wisconsin,  USA)  at  37°C  for  4  hours. 
Restriction  enzyme  products  were  analysed  on  I%  NuSieve  agarose  (FMC  bioproducts,  Rockland, 
Maine,  USA)  or  6%  polyacrylamide  gels  (Biorad,  Hemel  Hempstead,  UK).  The  cleaved  product 
produced  bands  at  133  and  235bp  representing  the  allele  TNFB1  while  the  uncleaved  368bp  product 
represented  the  allele  TNFB2  (Figure  2.1). 
368  bp 
235  bp 
133  bp 
1J1  1/2  2/2  genotype 
Figure  2.1.6%  polyacrylamide  gel  showing  TNFB  genotyping.  368bp  fragment  of  TNF(3  gene  has 
been  amplified  by  PCR  and  digested  with  Ncol  restriction  enzyme.  Allele  1  is  cleaved  into  133  and 
235bp  fragments  while  allele  2  remains  uncleaved  at  368bp. Chapter  2 
TNF-308  G  to  A  substitution 
PCR  was  used  to  amplify  a  107bp  fragment  of  the  of  the  TNF  genomic  sequence  using 
primers  upstream  5'  AGGCAATAGGTTTTGAGGGCCAT  3'  and  downstream  5' 
TCCTCCCTGCTCCGATTCCG  C  3'  (Oswell)  (Wilson  et  a),  1992).  The  following  PCR  protocol 
was  used  -  94°C  for  3  minutes,  60°C  for  1  minute,  72°C  for  1  minute;  35  cycles  of  94°C  for  1 
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minute,  60°C  for  1  minute,  72°C  for  1  minute;  and  94°C  for  1  minute,  60°C  for  1  minute,  72°C  for  5 
minutes  using  reagents  supplied  by  Promega  (Southampton,  UK)  on  a  Hybaid  Omn-E  thermal  cycler 
(Teddington,  UK).  The  PCR  product  was  digested  directly  with  1u  of  Ncol  restriction  enzyme 
(Promega)  at  37°C  for  4  hours.  Restriction  enzyme  products  were  analysed  on  9%  polyacrylamide 
gels  (Biorad,  Hemel  Hempstead,  UK).  The  cleaved  product  produced  bands  at  87  and  20bp 
representing  the  TNF  1  allele  while  the  uncleaved  107bp  product  represented  the  TNF2  allele  (Figure 
2.2). 
107  bp 
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Figure  2.2.9%  polyacrylamide  gel  showing  TNF-308  genotyping.  1  07bp  fragment  of  TNF  gene 
has  been  amplified  by  PCR  and  digested  with  NcoI  restriction  enzyme.  Allele  1  is  cleaved  into  20 
and  87bp  fragments  while  allele  2  remains  uncleaved  at  107bp. Chapter  238 
IL-  I  polymorphism 
PCR  was  used  to  amplify  a  699bp  fragment  of  the  of  the  IL-1(3  genomic  sequence  using 
primers  upstream  5'  TGT  TCT  TAG  CCA  CCC  CAC  TC  3'  and  downstream  5'  ATC  GCT  CCA 
GCA  CTC  TTG  TT  3'  (Genosys,  Pampisford,  UK)  designed  on  the  basis  of  the  published  sequence 
(Clark  et  al,  1986)  using  the  Primer  3  program  (Rozen  &  Skaletsky,  1996).  The  following  PCR 
protocol  was  used  -3  cycles  of  97°C  for  1.5  minutes,  54°C  for  1.5  minutes,  74°C  for  1  minute;  32 
cycles  of  97°C  for  0.5  minutes,  54°C  for  0.5  minutes,  74°C  for  1.5  minutes;  and  72°C  for  10 
minutes  using  reagents  supplied  by  Promega  (Southampton,  UK)  on  a  Hybaid  Omn-E  thermal  cycler 
(Teddington,  UK).  The  PCR  product  was  digested  directly  with  0.5u  of  Taql  restriction  enzyme 
(Appligene,  Chester-le-Street,  UK)  at  65°C  for  4  hours.  Restriction  enzyme  products  were  analysed 
on  1%  NuSieve  agarose  (FMC  bioproducts,  Rockland,  Maine,  USA)  or  6%  polyacrylamide  gels 
(Biorad,  Hemel  Hempstead,  UK).  The  cleaved  product  produced  bands  at  524  and  175bp 
representing  allele  1  while  the  uncleaved  699bp  product  represented  allele  2  (Figure  2.3). 
Figure  2.3.6%polyacrylamide  gel  showing  interleukin-1  ß  genotyping.  699bp  fragment  of  IL-1  ß 
gene  has  been  amplified  by  PCR  and  digested  with  TaqI  restriction  enzyme.  Allele  1  is  cleaved  into 
175  and  524bp  fragments  while  allele  2  remains  uncleaved  at  699bp. Chapter  2 
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Interleukin-1  receptor  antagonist  variable  number  tandem  re  eat  polymorphism 
PCR  was  used  to  amplify  a  fragment  of  the  of  the  IL-  I  Ra  genomic  sequence  using  primers 
upstream  5'  CTC  AGC  AAC  ACT  CCT  AT  3'  and  downstream  5'  TCC  TGG  TCT  GCA  GGT  AA 
3'  (Oswell).  The  following  PCR  protocol  was  used  -  35  cycles  of  94°C  for  1  minute,  60°C  for  1 
minute,  72°C  for  1  minute;  and  72°C  for  5  minutes  using  reagents  supplied  by  Promega 
(Southampton,  UK)  on  a  Hybaid  Omn-E  thermal  cycler  (Teddington,  UK).  The  PCR  products  were 
analysed  on  6%  polyacrylamide  gels  (Biorad,  Hemel  Hempstead,  UK).  The  86  base  pair  variable 
number  tandem  repeat  resulted  in  bands  of  around  240bp  (allele  2,2  repeats),  325bp  (allele  4,3 
repeats),  410bp  (allele  1,4  repeats),  500bp  (allele  3,5  repeats)  and  595bp  (allele  5,6  repeats). 
Metabolic  assessment 
Nitrogen  balance 
The  daily  nitrogen  intake  of  subjects  was  calculated  using  CompEat  4  software  (Nutrition 
Systems,  London,  UK)  based  on  the  mean  dietary  intake  recorded  in  a3  day  food  diary  with  the 
assistance  of  Dr  Alison  Hinds  and  Rosemary  Richardson. 
Nitrogen  loss  was  determined  by  measurement  of  urinary  nitrogen  from  a  24  hour  urine 
collection  using  a  rapid  combustion  and  thermal  conductivity  cell  method  (Leco  FP-328,  St  Joseph, 
Michigan,  USA)  in  the  research  laboratory  of  the  Department  of  Nutrition  at  Queen  Margaret 
College  in  Edinburgh  with  the  assistance  of  Colin  Nicolson.  A  further  2g  per  day  was  added  for 
faecal  losses. 
Indirect  Calorimet 
Subjects  were  studied  after  an  overnight  fast  using  a  ventilated  hood  system  (Deltatrac  II, 
Datex,  Helsinki,  Finland).  They  rested  for  at  least  30  minutes  in  the  supine  position  prior  to 
measurement.  To  determine  resting  energy  expenditure  measurements  of  oxygen  consumption 
(V02)  and  carbon  dioxide  production  (VC02)  were  made  over  at  least  30  minutes  with  patients 
supine  in  a  thermoneutral  environment.  Measurements  for  the  initial  10  minutes  were  discarded  and 
the  remaining  values  averaged.  The  equipment  was  calibrated  before  each  measurement.  Precision 
was  checked  three-monthly  by  burning  methanol. 
Respiratory  quotient  (RQ)  was  calculated  by  dividing  oxygen  consumption  by  carbon 
dioxide  production. Chapter  2 
Energy  expenditure  (EE)  was  calculated  using  the  Weir  formula  (Weir,  1949). 
EE  =  0.5373  *  V02  *  (3.78  +  1.16  *  RQ)  -43.2 
Substrate  utilisation  was  calculated  from  oxygen  consumption  (and  carbon  dioxide 
production  and  urinary  nitrogen  excretion  (NM)  according  to  the  equations  of  Cosolazio 
(Consolazio  et  al,  1963). 
Carbohydrate  =  -2.91  *  V02+4.12*  VCO2  -  2.56  *  NM 
Fat  =1.69*V02+1.69*VCO2-1.94*NM 
Protein  =  6.25  *  NM 
Albumin  and  fibrin  en  synthesis 
Sam  ling  protocol 
Albumin  and  fibrinogen  were  measured  by  a  flooding  dose  technique  (Garlick  et  al,  1989). 
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The  study  protocol  is  presented  diagramatically  in  chapter  10,  figure  1.  Subjects  attended  at  Bam  on 
two  consecutive  days.  On  the  first  day  following  an  overnight  fast,  a  venous  catheter  was  inserted 
into  the  subject's  antecubital  fossa.  At  10am  subjects  received  an  intravenous  bolus  of  2H5-  or  2H8- 
labelled  phenylalanine  (3.5g  10  mole%  labelled  L-phenylalanine,  2%  in  saline,  CK  Gas  Products, 
Finchampstead,  UK)  over  approximately  5  minutes.  The  tracer  was  prepared  under  sterile 
conditions,  tested  for  sterility  and  absence  of  pyrogens,  and  administered  via  a  0.22µm  filter. 
Taking  care  to  flush  the  catheter  to  avoid  tracer  contamination,  1Oml  blood  samples  were  obtained 
before  and  20,40,60,80,100  and  120  minutes  after  the  start  of  the  tracer  infusion.  The  blood 
sample  taken  before  the  "flooding"  dose  was  analysed  for  baseline  albumin  and  fibrinogen 
concentrations,  2H5-  or  2H3-phenylalanine  enrichment  in  plasma  albumin  and  fibrinogen  and  in  the 
plasma  free  phenylalanine  pool.  Subsequent  samples  were  analysed  for  2H5-  or  2H8-phenylalanine 
enrichment  in  plasma  albumin  and  fibrinogen  and  in  the  plasma  free  phenylalanine  pool.  Subjects 
remained  fasting  throughout  this  period.  On  the  second  day,  again  following  an  overnight  fast  a 
venous  catheter  was  inserted  into  the  subject's  antecubital  fossa  and  subjects  received  a  meal  of  a 
balanced  whole  protein  liquid  nutritional  supplement  (Fortisip,  Nutricia,  Zoetermeer,  Holland) Chapter  2 
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providing  a  twelfth  of  the  subjects  estimated  energy  requirement  (measured  resting  energy 
expenditure  *  1.4)  (Hunter  et  al,  1995).  The  supplement  provided  13%  of  energy  from  protein,  48% 
from  carbohydrate  and  39%  from  fat,  similar  to  a  "typical"  British  diet.  Subjects  received  such  a 
feed  on  an  hourly  basis  until  the  end  of  the  study  period.  At  I  Oam  a  similar  flooding  dose  of 
phenylalanine  was  given  as  described  above  using  the  alternative  label  and  blood  samples  collected 
similarly. 
Sample  preparation  and  isotope  analysis 
The  study  protocol  required  the  measurement  of  labelled  phenylalanine  enrichment  in  the 
plasma  free  phenylalanine  pool  and  in  plasma  albumin  and  fibrinogen  (McMillan  et  al,  1996).  For 
free  phenylalanine  analysis,  1.5m1  plasma  samples  were  diluted  with  5ml  deionised  distilled  water 
with  250nmol  cycloleucine  added  as  an  internal  standard.  Diluted  samples  were  then  deproteinised 
by  ultrafiltration  (25000  molecular  weight  cut-off  Centrifree  cone,  Amicon,  Gloustershire,  UK), 
acidified  and  the  amino  acids  purified  by  cation  exchange.  2H5-  or  2H8-phenylalanine  enrichment 
was  measured  by  gas  chromatography  mass  spectrometry  (GC-MS)  as  its  tertbutyldimethylsilyl 
derivative  (Slater  et  al,  1995).  2H8-phenylalanine 
was  found  to  form  2H7-phenylalanine  over  time 
(around  53%  2H7-phenylalanine  by  120  minutes).  Both  isotopes  were  measured  in  the  appropriate 
samples. 
Albumin  was  extracted  from  lml  of  serum  by  differential  solubility  in  absolute  ethanol  from 
trichloroacetic  acid  (10%  weight/weight)  -precipitated  protein.  To  remove  traces  of  free 
phenylalanine,  the  ethanolic  albumin  solution  was  washed  three  times  with  5m1  deionised  distilled 
water  using  ultrafiltration.  Purified  albumin  was  then  hydrolysed  and  labelled  phenylalanine 
enrichment  measured  by  GC-MS  (Slater  et  al,  1995). 
Following  washing  of  the  plasma  three  times  in  an  ultrafiltration  cone  as  described  above, 
fibrinogen  was  removed  as  a  fibrin  clot.  Clotting  was  performed  by  diluting  1.5m1  of  plasma  to 
20m1  with  saline  and  0.5m1  calcium  chloride  (0.5molll).  Fifteen  units  of  human  albumin-free 
thrombin  (Sigma,  Poole,  UK)  was  then  added  and  after  10  minutes  the  fibrin  was  collected  on  an 
etched  glass  rod.  The  fibrin  was  then  hydrolysed  under  vacuum  at  145°C  for  4  hours  with  6  mot/l 
HCl  and  its  labelled  phenylalanine  enrichment  measured  as  described  above. 
Sample  preparation  was  performed  with  the  assistance  of  Dr  Donald  McMillan  and  Jason 
Donnelly.  GC-MS  was  performed  by  Dr  Tom  Preston. Chapter  2 
Calculations 
Plasma  volume  was  predicted  from  body  weight  and  height  (Retzlaff  et  al,  1969). 
Men  -  Plasma  volume  (ml)  =  (23.7  *  height  (cm))  +  (9.0  *  weight  (kg))  -  1709 
Women  -  Plasma  Volume  =  (40.5  *  height)  +  (8.4  *  weight)  -  4811 
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Fractional  synthesis  rates  of  albumin  and  fibrinogen  were  calculated  by  dividing  the  rate  of 
change  of  labelled  phenylalanine  enrichment  of  albumin  or  fibrinogen  by  the  area  under  the  curve  of 
precursor  enrichment  versus  time  (Ballmer  et  al,  1990).  Calculations  were  performed  with  the 
assistance  of  Dr  Tom  Preston. 
Statistical  analysis 
Statistical  analysis  was  carried  out  using  Statview  (Abacus  Concepts,  Inc,  Berkeley, 
California,  U.  S.  A.  ).  Data  were  largely  nonparametric  in  distribution  and  thus  nonparametric 
statistics  were  used. 
Data  are  presented  as  median  (interquartile  range)  unless  otherwise  stated. 
Paired  comparisons  between  individuals  at  two  time  points  were  made  using  the  Wilcoxon 
signed  rank  test. 
Comparisons  between  groups  involving  more  than  two  variables  were  made  using  the 
Kruskal  Wallis  test. 
Comparisons  between  control  and  patient  groups  were  made  using  the  Mann-Whitney  U  test. 
Categorical  variables  were  compared  by  the  Chi-squared  test. 
Correlation  was  assessed  using  Spearman's  rank  correlation  coefficient. 
Survival  was  analysed  using  the  Kaplan-Meier  technique  and  groups  compared  by  the  log 
rank  test. 
Results  were  considered  to  be  statistically  significant  with  ap  value  of  <0.05. Chapter  3 
Relationship  of  weight  loss  to  the  acute  phase  response  and 
performance  status 
Summary 
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Weight-loss  and  the  acute  phase  response  have  been  associated  with  poor  quality  of  life 
and  survival  in  advanced  pancreatic  cancer,  however,  little  information  is  available  on  changes 
in  these  factors  over  time  and  their  inter-relationships.  This  chapter  examined  changes  in 
weight,  Karnofsky  performance  status,  C-reactive  protein  (CRP)  and  serum  albumin  in  25 
patients  with  advanced  pancreatic  cancer  given  supportive  symptomatic  treatment  only. 
Patients  were  assessed  at  approximately  monthly  intervals  on  a  total  of  70  occasions  allowing 
assessment  of  changes  over  37  intervals.  Changes  were  assumed  to  occur  in  a  linear  pattern  and 
were  averaged  to  28  days. 
Overall,  patients  had  a  median  weight-loss  of  2.3kg/28  days.  Median  CRP  levels  rose  by 
15mg/1  and  serum  albumin  fell  by  lg/l  on  average  over  28  days.  Karnofsky  performance  status 
fell  by  4  points  every  28  days. 
The  nine  patients  assessed  close  to  death  were  compared  with  the  13  assessed  closer  to 
diagnosis.  The  increase  in  CRP  level  and  fall  in  weight  and  performance  status  was 
significantly  greater  within  eight  weeks  of  death  than  within  eight  weeks  of  diagnosis.  Only 
13%  of  patients  had  an  elevated  CRP  level  close  to  diagnosis  compared  with  100%  of  those 
close  to  death.  In  multivariate  analysis  Karnofsky  performance  status  was  significantly 
associated  with  percentage  weight  loss  and  CRP  levels. 
These  data  further  implicate  the  acute  phase  protein  response  as  being  associated  with  the 
progressive  weight-loss  seen  in  patients  with  advanced  pancreatic  cancer.  Changes  appear  to 
accelerate  close  to  death.  Moreover,  the  development  of  cachexia  is  associated  with  a  reduction 
in  patients'  functional  capacity. Chapter  3 
Introduction 
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Greater  knowledge  of  the  extent  and  relationship  of  changes  in  nutritional,  inflammatory 
and  fuctional  factors  is  important  for  understanding  the  natural  history  of  advanced  pancreatic 
cancer  and  so  for  assessing  the  effects  of  any  nutritional  therapy  and  thus  whether  therapy 
directed  at  reversing  the  weight-loss  observed  in  these  patients  might  have  the  potential  to 
influence  quality  of  life. 
No  attempt  has  been  made  previously  to  quantify  changes  in  nutritional  and  inflammatory 
markers  such  as  weight,  albumin  and  C-reactive  protein  (CRP)  from  month  to  month  in  patients 
with  advanced  pancreatic  cancer  and  to  relate  these  changes  to  one  another  or  to  consider  the 
effects  such  changes  may  have  on  the  functional  status  of  patients. 
It  has  been  shown  previously  that  the  presence  of  the  acute  phase  protein  response 
(APPR)  is  a  major  predictor  of  survival  in  those  with  advanced  pancreatic  cancer  and  that 
between  the  time  of  diagnosis  and  death  there  is  a  significant  rise  in  the  number  of  patients 
exhibiting  an  APPR  (as  defined  by  a  CRP  level  >  10mg/1)  and  a  fall  in  serum  albumin 
concentration  (Falconer  et  al,  1995).  Although  CRP  and  albumin  are  respectively  the  major 
positive  and  negative  acute  phase  proteins  in  man,  their  levels  also  vary  with  nutritional  status 
and  vascular  permeability  (Fleck  et  al,  1985,  Steel  &  Whitehead,  1994).  It  has  been  shown  that 
85%  of  patients  with  advanced  pancreatic  cancer  exhibit  weight-loss  at  diagnosis  and  that  this 
progresses  inexorably  until  death  (Wigmore  et  al,  1997).  The  functional  decline  of  patients 
with  advanced  cancer  has  an  important  effect  on  quality  of  life  in  these  patients  and  it  is  not 
clear  how  this  deterioration  relates  to  the  ongoing  cachectic  state  (Ovesen  et  al,  1993a). Chapter  3 
Patients  and  Methods 
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Twenty  five  patients  with  unresectable  pancreatic  cancer  diagnosed  by  histology  or 
unequivocal  radiological  findings  were  studied.  Patients  received  full  symptomatic  supportive 
care  over  the  period  of  the  study.  None  of  the  patients  received  chemotherapy  or  radiotherapy 
and  were  examined  at  least  4  weeks  after  surgical  intervention.  Patients  were  examined  on  a 
total  of  70  occasions  allowing  changes  over  37  individual  periods  to  be  assessed.  Patients  were 
reviewed  at  approximately  monthly  intervals  (median  28  days,  interquartile  range  16-35  days). 
Changes  in  nutrition-related  variables  were  transformed  to  give  a  calculated  change  over  28 
days.  At  the  time  of  assessment  no  patient  had  clinical  evidence  of  infection.  Two  patients 
developed  significant  ascites  between  assessments  and  their  weight  change  was  excluded  from 
analysis  thereafter. 
At  each  review  patients  were  weighed  on  a  beam  scale  and  Karnofsky  performance  status 
was  noted.  A  venous  blood  sample  was  taken  for  determination  of  CRP  and  albumin.  Total 
body  water  was  estimated  by  bioelectric  impedence  analysis. 
Further  details  of  methods  are  found  in  chapter  2. Chapter  3 
Results 
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Patient  characteristics  and  changes  in  weight,  CRP,  albumin  and  Karnofsky  performance 
status  are  presented  in  table  3.1.  Patients  had  a  median  age  of  64  (range  29-76).  10  patients  had 
UICC  stage  II  disease,  4  patients  stage  III  disease  and  11  patients  stage  4  disease. 
Overall,  patients  had  a  median  weight  change  of  -2.3kg  (-4.5--0.6)  per  28  day  period  with 
gains  in  weight  only  being  observed  on  three  of  35  occasions  (9%).  CRP  rose  by  a  median  of 
15mg/1(0-48)  while  albumin  fell  by  a  median  of  lg/1(-3-+l)  over  the  average  28  day  period. 
CRP  fell  on  only  three  of  37  occasions  (8%).  Karnofsky  performance  status  fell  by  a  median  of 
4  points  (-19-0)  over  28  days.  An  improvement  in  performance  status  was  not  observed  in  this 
group  of  patients. 
Table  3.1.  Characteristics  of  25  patients  with  advanced  pancreatic  cancer  and  of  13  patients 
assessed  close  to  diagnosis  and  9  patients  assessed  close  to  death  and  changes  in  weight,  C- 
reactive  protein  and  albumin  over  intervals  of  28  days. 
UICC  Stage 
Number  of  Age  234  Change  in  Change  in  Change  in  Change  in 
intervals  weight  CRP  Albumin  KPS 
All  patients  37  64  10  4  11  -2.3  15  -1  -4 
(29-76)  (-4.5--0.6)  (0-48)  (-3-+1)  (-19-0) 
Patients  close  to  13  70  427  -2.5  0  -1  0 
diagnosis  (51-76)  (-4.6--1.1)  (0-28)  (-3-+2)  (-4-0) 
Patients  close  to  9  55  a  234b  -5.6  c  69  d  -5  e  -20  f 
death  (29-76)  (-7.2--2.6)  (39-128)  (-7-0)  (-42--16) 
Values  are  median  with  interquartile  range  in  parentheses  except  for  age  where  values  are 
median  and  range. 
CRP  -  C-reactive  protein 
KPS  -  Karnofsky  performance  status 
UICC  -  Union  Internationale  Contre  le  Cancre 
a-  Age  of  patients  close  to  death  compared  with  those  close  to  diagnosis  p=0.08 
b-  Disease  stage  of  patients  close  to  death  compared  with  those  close  to  diagnosis  p=0.91 
c-  Change  in  weight  of  patients  close  to  death  compared  with  those  close  to  diagnosis  p=0.047 
d-  Change  in  CRP  of  patients  close  to  death  compared  with  those  close  to  diagnosis  p=0.0021 
e-  Change  in  albumin  of  patients  close  to  death  compared  with  those  close  to  diagnosis  p=0.27 
f-  Change  in  KPS  of  patients  close  to  death  compared  with  those  close  to  diagnosis  p=0.0045 Chapter  3  47 
Nine  patients  were  assessed  within  8  weeks  of  death  and  13  patients  were  assessed  within 
eight  weeks  of  diagnosis.  In  patients  close  to  death,  rate  of  weight-loss,  rise  in  CRP  and  fall  in 
Karnofsky  performance  status  were  significantly  greater  than  the  rates  close  to  the  time  of 
diagnosis  (p=0.047,0.0021  and  0.0045  respectively).  Although  albumin  fell  faster  close  to 
death  this  did  not  reach  statistical  significance  (p=0.27).  All  nine  patients  close  to  death  had  an 
elevated  CRP  while  only  two  of  13  patients  close  to  diagnosis  (15%)  did  so  (p<0.001). 
There  was  a  significant  correlation  between  Karnofsky  performance  status  and  both 
percentage  weight  loss  and  lean  body  mass  index  (p=0.0001  and  0.016  respectively)  (Figures 
3.1  and  3.2)  but  there  was  no  significant  corelation  between  Karnofsky  performance  status  and 
body  mass  index  (p=0.45)  (Figure  3.3).  There  were  also  significant  correlations  between 
Karnofsky  performance  status  and  both  CRP  and  albumin  (both  p=0.0001)  (Figure  3.4  and  3.5). 
There  was  a  significant  correlation  between  percentage  weight  loss  and  CRP  (p=0.038)  and  lean 
body  mass  index  and  CRP  (p=0.019)  (Figure  3.6).  However,  there  was  no  significant 
correlation  between  body  mass  index  and  CRP  (p=0.29).  Serum  albumin  concentration 
correlated  with  CRP  (p=0.0001)  and  with  percentage  weight  loss,  body  mass  index  and  lean 
body  mass  index  (p=0.0006,0.022  and  0.01  respectively). 
Multiple  regression  analysis  involving  the  factors  found  to  correlate  significantly  revealed 
associations  between  Karnofsky  performance  status  and  CRP  and  percentage  weight  loss 
(p=0.013  and  0.0002  respectively).  CRP  concentration  was  otherwise  related  only  to  albumin 
(p=0.013). Chapter  3 
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Figure  3.1.  Significant  correlation  between  Karnofsky  performance  statuc  and  percentage  weight  loss  (r=-0.50, 
p=0.0001). 
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Figure  3.2.  Significant  correlation  between  Karnofsky  performance  status  and  lean  body  mass  index  (r=0.33, 
p=0.016). Chapter  3 
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Figure  3.3.  Lack  of  significant  correlation  between  Karnofsky  performance  status  and  body  mass  index  (r=0.09, 
p=0.45). 
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Figure  3.4.  Significant  correlation  between  Karnofsky  performance  status  and  C-reactive  protein  (r=-0.62, 
p=0.0001). Chapter  3 
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Figure  3.5.  Significant  correlation  between  Karnofsky  performance  status  and  serum  albumin  (r_0.54, 
p=0.0001). 
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Figure  3.6.  Significant  correlation  between  C-reactive  protein  and  lean  body  mass  index  (r=-0.32,  p=0.019). Chapter  3 
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In  the  present  study  patients  with  advanced  pancreatic  cancer  lost  weight  at  a  median  rate 
of  2.3kg  over  each  28  day  period.  This  value  is  very  similar  to  that  reported  in  previous  studies 
of  pancreatic  cancer  patients  prior  to  nutritional  intervention  who  had  been  losing  weight  at  a 
rate  of  2.9kg/month  (Wigmore  et  al,  1996)  and  2.2kg/month  (Barber  et  al,  1997)  respectively. 
In  a  previous  study  in  which  the  natural  history  of  the  pattern  of  weight-loss  was  examined  in 
pancreatic  cancer  patients,  it  had  appeared  that  weight-loss  occurred  in  a  relatively  linear 
pattern  (Wigmore  et  al,  1997).  The  current  data  suggests  that  near  to  death  weight-loss  may  be 
accelerated.  This  may  reflect  a  pre-terminal  worsening  of  inanition  and  anorexia. 
The  progressive  increase  in  CRP  levels  and  fall  in  weight  over  time  is  similar  to  the 
pattern  observed  in  previous  studies  of  patients  with  pancreatic  (Falconer  et  al,  1995)  and  lung 
cancer  (Staal-van  den  Brekel  et  al,  1995).  Only  2  of  13  of  patients  (15%)  in  the  present  chapter 
had  an  elevation  of  CRP  around  the  time  of  diagnosis  (between  four  and  eight  weeks  after 
surgical  intervention  or  bile  duct  stenting)  whereas  all  nine  patients  sampled  within  8  weeks  of 
death  had  an  elevated  CRP  concentration.  Moreover,  the  rate  at  which  CRP  increased  seemed 
to  accelerate  with  time.  The  reason  for  the  progressive  increase  in  the  prevalence  and  intensity 
of  the  acute  phase  response  in  patients  with  advancing  disease  is  not  clear.  It  may  relate  to 
changes  in  tumour  production  of  pro-inflammatory  cytokines  (Wigmore  et  al,  1994)  or 
progressive  inflammation  around  the  enlarging  tumour  may  stimulate  increased  host  cytokine 
production. 
The  relationship  between  high  serum  CRP  levels  and  weight-loss  may  support  the  view 
that  in  the  face  of  reduced  food  intake,  the  demand  for  amino  acids  to  produce  acute  phase 
proteins  results  in  ongoing  skeletal  muscle  catabolism  and  thus  contributes  to  progressive 
weight-loss  (Reeds  et  al,  1994).  Alternatively,  both  the  APPR  and  muscle  breakdown  may  be 
driven  simultaneously  by  pro-inflammatory  cytokines  and  other  proteolytic  factors  (Todorov  et 
al,  1996,  Fujiki  et  a1,1997).  If  the  latter  hypothesis  is  correct  then  upstream  targetting  of 
increased  pro-inflammatory  cytokine  release  would  be  more  likely  to  result  in  therapeutic 
benefit  rather  than  targetting  the  acute  phase  response  itself. 
An  association  between  the  APPR  and  weight-loss  has  also  been  shown  in  non-small-cell 
lung  cancer  (Staal-van  der  Brekel  et  al,  1995)  and  between  APPR  and  disease  stage  in 
oesophageal  cancer  (Wayman  et  al,  1997).  Interestingly,  the  present  chapter  found  a 
relationship  between  the  level  of  the  acute  phase  response  and  lean  body  mass  index  but  not 
with  the  body  mass  index  suggesting  that  the  APPR  may  be  preferentially  driving  loss  of  lean 
tissue  rather  than  fat. Chapter  3  52 
Low  albumin  concentrations  were  significantly  associated  with  weight-loss  and  with 
increased  CRP  perhaps  reflecting  its  role  as  a  marker  of  nutritional  status  and  as  a  negative 
acute  phase  protein.  A  low  serum  albumin  concentration  was  also  associated  with  reduced 
performance  status  which  may  explain  the  previously  noted  association  between 
hypoalbuminaemia  and  reduced  survival  in  pancreatic  and  colorectal  cancer  patients  (Falconer 
1995,  Heys  et  al,  1998). 
The  functional  ability  of  patients  as  measured  by  Karnofsky  performance  status  was,  like 
CRP,  significantly  related  to  weight  loss  and  lean  body  mass  index  but  not  overall  body  mass 
index,  suggesting  that  it  is  lean  tissue  that  is  important  in  determining  function.  However,  in 
multivariate  analysis,  performance  status  was  related  to  CRP  and  percentage  weight-loss  alone. 
Thus  individual  patients  may  adapt  to  a  particular  weight  and  when  this  falls  (particularly  with 
loss  of  lean  tissue)  functional  ability  deteriorates  despite  the  fact  that  patients  may  remain 
relatively  overweight  in  terms  of  body  mass  index. 
This  chapter  attempted  to  quantify  the  changes  over  time  in  weight,  CRP,  albumin  and 
Karnofsky  performance  status  in  patients  with  advanced  pancreatic  cancer  and  has  shown  that 
the  rate  of  weight-loss,  rise  in  CRP  and  deterioration  in  functional  ability  accelerate  close  to 
death.  It  has  also  shown  that  CRP  levels  rise  and  performance  status  falls  with  loss  of  lean 
tissue.  These  findings  may  provide  a  benchmark  with  which  to  compare  changes  in  these 
factors  following  nutritional  or  anticancer  treatment  and  further  implicate  pro-inflammatory 
events  in  exacerbating  weight-loss  and  affecting  functional  ability  in  these  patients. 
The  next  chapter  will  examine  the  relationship  of  the  acute  phase  protein  response  to 
concentrations  of  pro-inflammatory  cytokines  in  cachectic  cancer  patients. Chapter  4 
Relationship  of  pro-inflammatory  cytokines  to  the  acute  phase 
protein  response 
Summary 
The  level  of  the  acute  phase  response  is  a  major  predictor  of  survival  in  patients  with 
advanced  pancreatic  cancer.  Moreover,  as  shown  in  Chapter  3,  the  acute  phase  response  also 
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relates  with  weight  loss  and  functional  ability.  This  chapter  examines  the  association  between 
the  acute  phase  protein  response,  as  determined  by  serum  C-reactive  protein  ,  and  serum  levels 
of  interleukin-6,  soluble  interleukin-6  receptor  and  the  soluble  tumour  necrosis  factor  receptors 
in  pancreatic  cancer  patients. 
Thirty-four  blood  samples  were  collected  from  13  patients  with  advanced  pancreatic 
cancer.  Samples  were  also  collected  from  6  healthy  subjects.  Levels  of  C-reactive  protein, 
interleukin-6,  soluble  interleukin-6  receptor,  soluble  tumour  necrosis  factor  receptor  55  and 
soluble  tumour  necrosis  factor  receptor  75  were  measured  by  indirect  ELISA. 
Serum  levels  of  C-reactive  protein,  interleukin-6  and  soluble  tumour  necrosis  factor 
receptor  55  and  75  were  significantly  higher  in  cancer  patients  than  in  controls.  Serum  soluble 
interleukin-6  receptor  levels  were  not  significantly  different  between  the  two  groups. 
In  cancer  patients,  a  significant  positive  association  was  found  between  the  level  of  the 
acute  phase  protein  response  and  serum  concentrations  of  interleukin-6,  soluble  tumour 
necrosis  factor  receptor  55  and  soluble  tumour  necrosis  factor  receptor  75.  No  association  was 
found  between  levels  of  soluble  interleukin-6  receptor  and  any  other  factor. 
In  vitro  work  has  suggested  that  pro-inflammatory  cytokines  stimulate  the  acute  phase 
protein  response.  This  chapter  suggests  that  in  vivo  there  is  a  direct  correlation  between  pro- 
inflammatory  cytokine  levels  and  concentrations  of  C-reactive  protein.  This  confirms  the  value 
of  the  acute  phase  response  as  a  marker  of  the  inflammatory  state  in  general  and  of  in  vivo  pro- 
inflammatory  cytokine  activity  in  particular  in  advanced  pancreatic  cancer  patients. Chapter  4 
introduction 
The  previous  chapter  has  shown  that  the  weight-loss  and  deterioration  in  functional 
ability  in  patients  with  advanced  pancreatic  cancer  patients  is  associated  with  a  hepatic  acute 
phase  protein  response  (APPR).  The  APPR  involves  a  reprioritisation  of  protein  synthesis 
within  the  liver  in  response  to  trauma  and  inflammation.  The  roles  of  the  APPR  include 
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limitation  of  tissue  damage,  isolation  and  destruction  of  infective  organisms  and  the  promotion 
of  repair  (Baumann  &  Gauldie,  1994).  However,  the  presence  of  an  APPR  as  measured  by  an 
elevated  serum  C-reactive  protein  (CRP)  level  is  strongly  associated  with  a  shorter  duration  of 
survival  in  patients  with  advanced  pancreatic  cancer  (Falconer  et  al,  1995).  Thus,  in  patients 
with  cancer  cachexia,  the  reprioritisation  of  protein  synthesis  associated  with  the  APPR  may 
lead  to  persisting  muscle  catabolism  and  wasting  which  is  detrimental  to  survival. 
Interleukin-6  (IL-6)  appears  to  have  a  major  role  in  inducing  the  APPR  (Heinrich  et  al, 
1990)  but  previously  a  relationship  between  serum  IL-6  levels  and  the  APPR  in  pancreatic 
cancer  patients  as  measured  by  an  elevated  C-reactive  protein  (CRP)  has  not  been 
demonstrated  (Falconer  et  al,  1994).  Tumour  necrosis  factor  a  (TNF(X)  will  also  produce  many 
of  the  features  of  cachexia  when  administered  to  humans  (Warren  et  al,  1987)  but  significant 
serum  levels  are  rarely  detected  in  cancer  (Falconer  et  al,  1994a).  However,  elevated 
production  of  IL-6  and  TNFa  by  peripheral  blood  mononuclear  cells  (PBMC)  isolated  from 
patients  with  an  APPR  suggests  that  local  production  of  these  cytokines  may  be  more 
important  to  regulation  of  the  APPR  than  serum  levels  (Falconer  et  al,  1994a). 
Of  additional  interest  in  the  context  of  the  APPR  and  cachexia  are  the  receptors  for 
TNFa  and  IL-6.  Two  receptors  for  TNF  of  55  and  75kD  have  been  described  (Hohman  et  al, 
1989).  Soluble  forms  of  these  receptors  -  sTNF-R55  and  sTNF-R75  -  appear  to  be  shed  from 
cells  in  response  to  TNF  release,  possibly  to  limit  the  activity  of  this  cytokine(Olsson  et  al, 
1993).  TNF  receptor  levels  are  associated  with  disease  severity  in  a  number  of  inflammatory 
conditions  Goldie  et  al,  1995,  Nakayama  et  al,  1996,  Yoshida  et  al,  1996).  In  contrast  to  many 
other  soluble  receptors,  it  has  been  shown  that  the  IL-6  signal  may  be  delivered  via  binding  to 
soluble  1L-6  receptor  (sIL-6R)  and  subsequent  interaction  of  this  complex  with  gp  130  on  the 
cell  surface  whether  or  not  membrane-bound  IL-6R  is  present  (Taga  et  al,  1989).  The  capacity 
of  the  cell  to  respond  to  IL-6  may  depend  not  only  on  cell  surface  IL-6R,  and  gp  130  expression 
but  also  the  level  of  sIL-6R,  at  least  in  vitro  (Mackiewicz  et  al,  1992,  Tamura  et  al,  1993, 
Modur  et  al,  1997).  Serum  levels  of  slL-6R  may  therefore  be  a  more  important  determinant  of 
the  response  to  IL-6  than  serum  levels  of  IL-6. Chapter  4 
The  aim  of  this  chapter  is  to  assess  the  relationship  between  serum  levels  of  IL-6,  sIL- 
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6R,  sTNF-R55  and  sTNF-R75  and  the  APPR  in  patients  with  advanced  pancreatic  cancer. Chapter  4 
Patients  and  Methods 
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After  local  ethical  committee  approval  13  patients  gave  written,  informed  consent  for  the 
collection  of  a  total  of  34  venous  blood  samples.  All  had  unequivocal  diagnosis  of 
unresectable  pancreatic  cancer  based  on  histological  or  operative  findings.  All  samples  were 
taken  at  least  14  days  after  surgery  or  biliary  drainage.  No  patient  had  clinical  evidence  of 
current  infection.  All  repeated  samples  were  taken  at  least  eight  days  apart.  After  gaining 
consent,  samples  were  also  obtained  from  6  healthy  control  subjects  with  no  active  medical 
conditions. 
Serum  was  stored  at  -70°C  until  batch  analysis  by  indirect  ELISA  for  IL-6,  sIL-6R, 
sTNF-R55,  sTNF-R75  and  CRP. 
Further  details  of  methods  are  found  in  Chapter  2. Chapter  4 
Results 
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Cancer  patients  had  a  median  age  of  67  years  (range  51-76).  Healthy  control  subjects 
had  a  median  age  of  54  years  (range  50-62)  (p=0.043  vs  patients).  Seven  cancer  patients  had 
stage  II  disease,  one  stage  III  and  five  stage  IV  (UICC  system).  The  data  for  CRP,  IL-6,  sTNF- 
R55,  sTNF-R75  and  sIL-6R  are  summarised  in  figure  4.1. 
Cancer  patients  had  significantly  higher  serum  levels  of  CRP  (healthy  control  -  <lmg/ml 
versus  cancer  patients  5.4mg/1(2.6-22.2),  p=0.001),  IL-6  (0.5  (<0.25-1.0)  vs  5.2pg/ml  (<0.25- 
11.5),  p=0.041),  sTNF-R55  (1.88ng/ml  (1.59-2.03)  vs  2.69ng/ml  (1.91-3.78),  p=0.022)  and 
sTNF-R75  (4.62ng/ml  (3.17-5.40)  vs  6.62  (4.12-8.94),  p=0.021),  however,  sIL-6R  levels  were 
not  significantly  different  (33.  Ong/ml  (17.5-39.5)  vs  40.  Ong/ml  (30.2-49.6),  p=0.093). 
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Figure  4.1.  Serum  levels  of  interleukin-6  (IL-6),  soluble  tumour  necrosis  factor  55  (sTNF-R55) 
and  75  (sTNF-R75),  C-reactive  protein  (CRP)  and  soluble  interleukin-6  receptor  (sIL-6R)  in 
cancer  patients  (open  circles)  and  healthy  controls  (closed  circles).  Medians  are  shown  by  a 
horizontal  line. Chapter  4  58 
There  was  no  significant  relationship  between  any  parameter  and  patient  disease  stage. 
There  was  no  significant  relationship  between  IL-6,  sIL-6R  or  sTNF-R55  and  age.  sTNF-R75 
significantly  increased  with  age  (p=0.03). 
There  was  a  significant  positive  correlation  between  serum  CRP  and  IL-6  (p=0.0004), 
sTNF-R55  (p=0.0008),  and  sTNF-R75  (p=0.0024).  There  was,  however,  no  significant 
correlation  between  CRP  and  sIL-6R  (p=0.34)  (Figure  4.2),  indeed  there  was  no  correlation 
between  sIL-6R  and  any  other  factor  assessed.  There  was  a  positive  correlation  between  IL-6 
and  sTNF-R55  and  sTNF-R75  (p=0.038  and  0.0074  respectively)  and  a  strong  positive 
correlation  between  the  two  TNF  receptors  (p=0.0003)  (Figure  4.3). 
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Figure  4.2a  Correlation  between  serum  CRP  and  Il-6  levels  in  pancreatic  cancer  patients 
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Figure  4.2b.  Correlation  between  serum  CRP  and  sTNF-R55  levels  in  pancreatic  cancer 
patients  (n=34)  (rho=0.59,  p=0.0008). 
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Figure  4.2c.  Correlation  between  serum  CRP  and  sTNF-R75  levels  in  pancreatic  cancer 
patients  (n=34)  (rho=0.53,  p=0.0024). Chapter  4 
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Figure  4.2d.  Lack  of  significant  correlation  between  serum  CRP  and  sIl-6R  levels  in 
pancreatic  cancer  patients  (n=32)  (rho=0.17,  p=0.34). 
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Figure  4.3.  Correlation  between  serum  sTNF-R55  and  sTNF-R75  levels  in  pancreatic  cancer 
patients  (n=34)  (rho=0.64,  p=0.0003). Chapter  4 
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This  chapter  has  demonstrated  that  patients  with  advanced  pancreatic  cancer  have  an 
acute  phase  protein  response,  as  shown  by  elevated  levels  of  CRP,  and  elevated  pro- 
inflammatory  cytokine  levels  with  elevated  levels  of  IL-6  and  the  TNF  receptors  compared 
with  healthy  controls.  sIL-6R  levels,  however,  were  not  significantly  elevated.  Previously, 
CRP  and  IL-6  levels  have  been  shown  to  be  elevated  in  a  similar  group  of  patients  (Falconer  et 
al,  1994a)  but  concentrations  of  receptors  of  TNF  and  IL-6  have  not  previously  been  examined. 
sIL-6R  have  been  found  to  be  elevated  compared  with  controls  in  patients  with  haematological 
malignancy  (Lavabre-Bertrand  et  al,  1995)  and  interstitial  lung  disease  (Yokoyama  et  al,  1995). 
The  present  chapter  also  examined  the  relationship  between  the  acute  phase  protein 
response  and  serum  IL-6,  sIL-6R,  sTNF-R55  and  sTNF-R75  levels  in  patients  with  advanced 
pancreatic  cancer  and  has  shown  that  while  IL-6,  sTNF-R55  and  sTNF-R75  levels  are 
significantly  positively  associated  with  the  level  of  the  acute  phase  response,  sIL-6R  is  not. 
This  would  suggest  that,  in  advanced  pancreatic  cancer,  serum  sIL-6R  may  not  be  important  in 
conducting  the  IL-6  signal.  The  IL-6  bound  to  sIL-6R  may  be  unavailable  for  the  induction  of 
signalling  via  gp  130  or  hepatocytes  may  be  refractory  to  this  mechanism  in  vivo.  In  addition, 
serum  levels  of  sIL-6R  may  not  accurately  reflect  relevant  tissue  levels.  However,  the  results 
of  the  present  study  suggest  that  sIL-6R  would  appear  to  be  a  poor  indicator  of  the 
inflammatory  response  in  pancreatic  cancer.  Studies  of  an  animal  model  of  autoimmune 
disease  have  suggested  the  presence  of  elevated  sIL-6R  levels  in  association  with  increasing 
levels  of  IL-6  (Suzuki  et  al,  1993)  and  a  weak  but  significant  association  was  shown  between 
sIL,  -6R  and  disease  stage  in  human  subjects  with  haematological  malignancy  (Lavabre- 
Bertrand  et  al,  1995).  However,  a  lack  of  association  between  serum  sIL-6R  and  CRP  was 
seen  in  patients  with  interstitial  lung  disease  (Yokoyama  et  al,  1995)  as  in  the  present  study. 
A  close  association  between  levels  of  sTNF-R55  and  sTNF-R75  has  previously  been 
shown  in  sarcoidosis  (Nakayama  et  al,  1996)  and  asthma  (Yoshida  et  al,  1996).  An  association 
between  TNF  receptor  levels  and  disease  severity  was  found  in  these  conditions  and  also  in 
cancer  (Aderka  et  al,  1991)  and  severe  sepsis  (Goldie  et  al,  1995)  although  no  such  association 
was  found  in  a  small  group  of  patients  with  mild  psoriasis  (Bonifati  et  al,  1995).  Whether  the 
high  levels  of  TNF  receptors  in  this  variety  of  inflammatory  conditions  represents  an  attempt 
by  the  body  to  limit  cytokine  effects  by  binding  TNFa  or  if  this  binding  serves  to  hold  TNFa 
in  the  circulation  resulting  in  sustained,  controlled  release  remains  to  be  elucidated.  It  also 
remains  to  be  seen  whether  assessment  of  the  levels  of  TNF  receptors  may  provide  a  more 
accurate  representation  of  TNFot  activity  than  TNFoc  itself. Chapter  4  62 
While  the  present  study  has  shown  significant  correlations  between  CRP  concentration 
and  IL-6  and  TNF  receptors  using  methods  appropriate  to  the  nonparametric  distribution  of 
the  data  there  were  outliers,  particularly  among  the  patients  with  a  relatively  low  serum  CRP. 
Clearly  the  acute  phase  protein  response  is  a  heterogeneous  process  involving  many  proteins 
in  addition  to  CRP.  It  may  be  that  the  concentration  of  another  protein  or  an  index  of  values 
for  several  proteins  will  provide  a  more  accurate  assessment  of  the  acute  phase  response  and, 
consequently,  a  better  correlation  with  other  inflammatory  mediators. 
An  association  between  the  acute  phase  response  and  serum  levels  of  IL-6  in  pancreatic 
cancer  patients  has  not  been  shown  in  the  past  although  increased  PBMC  IL-6  production  has 
been  seen  in  those  with  an  APPR  (Falconer  et  al,  1994a).  Others  have  found  a  relationship 
between  serum  IL-6  levels  and  survival  in  lymphoma  (Kurzrock  et  al,  1993)  and  weight  loss 
in  colon  cancer  (Preston  et  al,  1995).  Previous  studies  showing  the  presence  of  an  APPR  to 
be  a  strong  predictor  of  poor  survival  in  pancreatic  cancer  have  used  a  serum  CRP  level  of 
10mg/1  or  more  to  define  those  pateints  with  an  APPR  (Falconer  et  al,  1995).  The  use  of 
ELISA  techniques  in  the  current  study  rather  than  a  turbidometric  assay  has  allowed  us  to 
examine  the  relationship  of  inflammatory  mediators  to  CRP  levels  below  10mg/l.  This  data 
indicates  a  clear  association  between  IL-6  and  the  APPR.  It  remains  a  matter  of  conjecture 
whether  local  IL-6  production  in  the  liver  is  more  important  in  stimulating  the  APPR  than 
circulating  serum  levels.  It  would  appear  that  the  IL-6,  sTNF-R55  and  sTNF-R75  are 
associated  with  changes  in  CRP  even  at  relatively  low  levels  and  may  have  a  role  in 
determining  the  level  of  the  APPR  in  vivo  in  these  patients. 
The  use  of  multiple  samples  from  individual  patients  may  have  artificially  strengthened 
the  correlation  between  the  acute  phase  response  and  the  measured  cytokines.  This  method 
was  used  to  maximise  the  data  available.  Similar  findings  are  noted  in  an  overlapping  group 
of  patients  studied  in  Chapter  7  using  different  ELISA  kits. 
In  conclusion,  this  chapter  has  shown  that  the  level  of  the  APPR  is  significantly 
associated  with  serum  levels  of  IL-6,  sTNF-R55  and  sTNF-R75  in  patients  with  pancreatic 
cancer  but  there  is  no  such  association  with  sIL-6R.  This  suggests  that  sIL-6R  does  not  have  a 
significant  influence  on  the  magnitude  of  the  APPR  in  pancreatic  cancer.  In  vitro  work  has 
shown  that  pro-inflammatory  cytokines  stimulate  the  acute  phase  protein  response.  This 
chapter  suggests  that,  in  vivo,  with  the  direct  correlation  between  pro-inflammatory  cytokine 
levels  (particularly  IL-6)  and  concentrations  of  C-reactive  protein,  the  acute  phase  protein 
response  is  an  indicator  of  the  wider  inflammatory  state. 
The  next  chapter  examines  the  possible  influence  of  the  patient's  genotype  on  cytokine 
production,  the  APPR  and  survival. Chapter  5 
Relationship  of  cytokine  genotype  to  inflammatory  state  and 
survival 
Summary 
Polymorphisms  of  cytokine  genes  have  been  suggested  to  influence  the  severity  and 
outcome  of  a  number  of  conditions.  Pro-inflammatory  cytokines  contribute  to  the  cachexia 
associated  with  pancreatic  cancer  and  also  stimulate  the  acute  phase  response  which  has  been 
found  to  be  related  to  shortened  survival  in  such  patients.  This  chapter  examines  the  effect  of 
polymorphisms  of  the  interleukin  (IL)-1  P,  IL-1  receptor  antagonist  (IL-1  Ra)  and  tumour 
necrosis  factor  (TNF)  genes  upon  survival  of  patients  with  pancreatic  cancer. 
Genomic  DNA  was  obtained  from  64  patients  with  pancreatic  cancer  and  101  healthy 
controls.  Using  the  polymerase  chain  reaction  and  subsequent  endonuclease  digestion  the 
subject's  genotype  for  a  diallelic  polymorphism  of  the  interleukin-11  gene,  a  variable  repeat 
polymorphism  of  the  IL-1  Ra  gene  and  two  diallelic  polymorphisms  of  the  TNF  gene  (TNFB 
and  TNF-308)  were  determined. 
IL-1  ß  production  by  peripheral  blood  mononuclear  cells  was  measured  in  22  patients 
and  serum  concentrations  of  the  two  tumour  necrosis  factor  receptors  and  C-reactive  protein 
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were  measured  in  45  of  the  cancer  patients  with  no  evidence  of  infection  or  jaundice,  one  month 
after  surgical  intervention  and  survival  noted. 
Patients  homozygous  for  allele  2  of  the  I1-10  gene  had  significantly  shorter  survival 
than  other  groups  (p=0.0001).  These  patients  also  exhibited  substantially  higher  FL-lß 
production  (p=0.022)  (although  numbers  of  patients  were  small).  Possession  of  allele  2  was 
also  associated  with  significantly  shorter  survival  (median  144  vs  256  days,  p=0.034)  and 
significantly  higher  CRP  level  (p=0.0003). 
No  association  was  found  between  IL-1  Ra  genotype  and  the  inflammatory  state  or 
survival. 
There  was  no  association  between  either  TNF  genotype  and  concentrations  of  any  of  the 
measured  inflammatory  mediators.  While  those  with  an  elevated  C-reactive  protein 
concentration  had  significantly  poorer  survival,  there  was  no  association  between  either  TNF 
genotype  and  survival. 
The  possession  of  a  genotype  resulting  in  increased  IL-1ß  production  appears  to  be 
related  to  shortened  survival  and  increased  serum  CRP  level.  However,  no  association  was 
found  between  IL-1  Ra  genotype  or  two  TNF  genotypes  and  the  inflammatory  state  or  survival Chapter  5  64 
in  advanced  pancreatic  cancer.  This  may  reflect  the  role  of  IL-lß  in  the  genesis  of  local 
inflammation  as  a  cofactor  in  inducing  an  acute  phase  protein  response  and  cachexia  in  cancer. 
It  is  also  possible  that  this  polymorphism  may  reflect  a  particularly  aggressive  tumour 
phenotype  resulting  in  shortened  survival. Chapter  5 
Introduction 
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Previous  chapters  have  explored  the  relationship  between  the  inflammatory  state  and  the 
acute  phase  protein  response,  and  between  the  acute  phase  response  and  the  functional 
deterioration  of  patients  with  advanced  pancreatic  cancer.  As  discussed  previously,  the  acute 
phase  protein  response  is  modulated,  at  least  in  part,  by  pro-inflammatory  cytokines.  Many 
pro-inflammatory  cytokines,  including  interleukin  (IL)  -1,  IL-6,  interferon-y  and  tumour 
necrosis  factor  (TNF),  will  give  rise  to  aspects  of  cachexia  when  administered  in  animal  models 
(Mahony  &  Tisdale,  1988,  Gelin  et  al,  1991,  Hellerstein  et  al,  1989,  Matthys  et  al,  1991, 
Strassmann  et  al,  1992).  Interleukin-1  receptor  antagonist  (IL-1  Ra)  has  broadly 
antiinflammatory  actions  in  antagonising  the  action  of  IL-1  (Dinarello  &  Wolff,  1993). 
Although  production  of  these  cytokines  depends  on  a  variety  of  clinical  factors,  there  is 
increasing  evidence  that  genetic  factors  may  be  involved.  Variations  in  the  genes  coding  for  IL- 
113,1L-1Ra  and  TNF  have  been  found  to  affect  production  of  the  relevant  cytokines  (Pociot  et 
al,  1992,  Danis  et  al,  1995,  Stüber  et  al,  1996).  Coincidentally,  in  each  case  allele  2  has  been 
associated  with  increased  production  of  the  relevant  cytokine.  If  these  polymorphisms  were 
relevant  to  the  survival  of  patients  it  would  reinforce  the  relationship  between  the  inflammatory 
state  and  survival  in  pancreatic  cancer. 
It  remains  difficult  to  predict  survival  in  patients  with  advanced  pancreatic  cancer.  it  has 
previously  been  demonstrated  that  nutritional  and  inflammatory  factors  such  as  albumin  and  C- 
reactive  protein  (CRP)  are  of  major  importance  in  determining  survival  (Falconer  et  al,  1995). 
This  appears  to  be  due  to  their  relationship  to  the  progressive  nutritional  decline  seen  in  the 
majority  of  patients  with  advanced  pancreatic  cancer  (as  discussed  in  Chapter  3). 
Despite  progress  in  diagnosis  and  staging  pancreatic  cancer  still  has  a  dismal  prognosis 
(Ahlgren,  1996).  Surgical  resection  with  intent  to  cure  is  not  possible  in  80-90%  of  patients 
thus,  for  the  vast  majority  of  patients,  palliation  of  biliary  obstruction  is  the  main  goal  of 
surgery  (Rosewicz  &  Weidenmann,  1997). 
Operative  bypass  or  endoscopic  stenting  are  the  two  main  options  for  palliating  biliary 
obstruction  in  pancreatic  cancer.  It  has  been  suggested  that  surgical  bypass  is  associated  with 
longer  initial  hospital  stay  and  early  complications  while  late  blockage  of  endoscopic  stents 
results  in  late  complications  and  hospital  readmissions  (van  den  Bosch  et  al,  1994).  Thus, 
surgical  intervention  may  be  more  appropriate  for  those  with  a  longer  anticipated  survival 
whilst  endoscopic  stenting  may  be  more  suitable  for  those  with  shorter  survival.  Albumin  and 
CRP  are  sensitive  to  clinical  events  often  experienced  by  patients  around  the  time  of  diagnosis, Chapter  5  66 
such  as  jaundice,  cholangitis  and  surgery,  and  thus  they  are  of  limited  use  in  determining  the 
form  of  palliative  therapy  for  these  patients.  If  polymorphisms  of  cytokine  genes  were  related 
to  survival  they  would  offer  a  window  on  the  inflammatory  state  of  the  patient  independent  of 
their  clinical  condition  and  therefore  may  also  be  useful  in  guiding  palliative  intervention. 
This  chapter  examines  a  biallelic  TaqI  polymorphism  of  the  IL-1  P  gene,  a  variable 
repeat  polymorphism  of  the  IL-1  Ra  gene  and  two  polymorphisms  of  the  TNF  gene  in  patients 
with  advanced  pancreatic  cancer  and  related  this  to  CRP  concentration,  IL-1ß  production  or 
TNF  receptor  concentrations  and  survival. Chapter  5 
Methods 
SubLects 
After  informed  consent,  venous  blood  was  collected  for  IL-10  and  TNF  genotyping 
from  64  patients  with  a  diagnosis  of  unresectable  pancreatic  cancer  based  on  histological  or 
unequivocal  radiological  or  operative  findings.  Blood  was  also  collected  from  101  healthy 
volunteers  attending  the  Blood  Transfusion  Service  Plasmapheresis  Centre  in  Edinburgh. 
For  cancer  patients  survival  was  noted  from  time  of  histological  confirmation  of 
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pancreatic  adenocarcinoma  (80%)  or  of  unequivocal  radiological  or  operative  findings  in  those 
for  whom  histological  confirmation  was  not  obtained. 
DNA  was  extracted  from  plasma  samples  and  genotyping  performed  for  the  IL-1ß  TaqI 
polymorphism  (Pociot  et  al,  1992),  the  interleukin-1  receptor  antagonist  variable  number 
tandem  repeat  polymorphism  (Danis  et  al,  1995),  the  TNFB  Ncol  polymorphism  (Shimura  et 
al,  1994)  and  the  TNF-308  G  to  A  substitution  polymorphism  (Stüber  et  al,  1996). 
The  inflammatory  state  was  assessed  in  patients  without  evidence  of  infection  or 
jaundice  approximately  one  month  after  diagnosis,  surgery  or  endobiliary  stenting.  It  was 
possible  to  obtain  venous  blood  from  45  such  patients  for  the  measurement  of  serum  CRP  and 
TNF  receptor  concentrations  and  22  such  patients  for  measurement  of  peripheral  blood 
mononuclear  cell  (PBMC)  IL-1  ß  production. 
Further  details  of  methods  are  found  in  Chapter  2. Chapter  5 
Results 
Subject  characteristics  and  genotype 
Subject  characteristics  and  prevalence  of  genotypes  are  presented  in  table  5.1.  Thirty 
patients  had  UICC  stage  II  disease,  8  patients  stage  III  and  26  patients  stage  IV.  No  subject 
underwent  resectional  surgery  or  received  chemotherapy  or  radiotherapy.  There  was  no 
significant  difference  in  the  distribution  of  genotypes  between  pancreatic  cancer  patients  and 
healthy  controls. 
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Table  5.1.  Characteristics  and  genotype  of  64  patients  with  pancreatic  cancer  and  101  healthy 
subjects. 
Cancer  patients  Healthy  volunteers 
Age  64  (57-72)  42  (36-47) 
Gender  F:  30  M:  34  F:  32  M:  69 
EL-lß  genotype'  1/1  68%  55% 
1/2  25%  40% 
2/2  6%  5% 
Frequency  of  1  66%  67% 
IL-lRa  allelesb  2  30%  30% 
3  3%  2% 
4  1%  1% 
TNFB  genotype`  1/1  9%  16% 
1/2  56%  47% 
2/2  34%  38% 
TNF308  genotyped  1/1  56%  64% 
1/2  38%  31% 
2/2  6%  5% 
m-  male 
f-  female 
Comparison  by  Chi  squared  test  a-p=0.18 
b-  p=0.97 
c-  p=0.35 
d-  p=0.89 Chapter  5  69 
Acute  phase  protein  response  and  survival 
Survival  of  patients  with  advanced  pancreatic  cancer  stratified  by  the  presence  or 
absence  of  an  elevated  CRP  concentration  is  shown  in  figure  5.1.  Those  with  an  elevated  CRP 
concentration  had  a  significantly  shorter  survival  (Median  137  (interquartile  range  88-25  1)  days 
versus  243  (152-320)  days,  p=0.0073).  Disease  stage  was  not  a  significant  predictor  of  survival 
in  this  group  of  patients  (p=0.65). 
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Figure  5.1.  Kaplan  Meier  survival  curve  (from  diagnosis)  of  45  patients  with  advanced 
pancreatic  cancer  stratified  for  C-reactive  protein.  C-reactive  protein  <10mgl7  -  solid  line,  C- 
reactive  protein  >10mg/7  -dotted  line.  Comparison  by  log  rank  test  p=0.0073. 
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IL,  -1  ß  polymorphism,  cytokine  levels,  acute  phase  protein  response  and  survival 
IL-10  was  only  detectable  in  serum  from  only  two  patients  of  the  45  patients  in  whom  it 
was  measured.  One  patient  of  genotype  2/2  had  a  serum  level  of  7.24pg/ml  while  a  patient  of 
1/2  genotype  had  a  level  of  1.16pg/ml.  Both  patients  had  substantially  elevated  serum  CRP 
levels  at  151  and  53mg/l  respectively. 
IL-1  ß  production  by  PBMCs  from  the  22  cancer  patients  in  whom  it  was  measured 
according  to  their  IL-1  (3  genotype  is  presented  in  figure  5.2.  PBMC  IL-1  ß  production  by  those 
with  a  2/2  genotype  (median  9.7ng/ml  (range  7.9-11.5))  was  significantly  higher  than  those  with 
1/2  (2.2  (interquartile  range  1.5-2.7),  p=0.046)  or  1/1  (1.9  (1.4-2.6),  p=0.027)  genotype.  There 
was  no  significant  difference  between  PBMC  IL-1ß  production  between  1/2  and  1/1  genotype 
(p=0.72).  There  was  no  significant  relationship  between  PBMC  IL-1(3  production  and  CRP 
level  (r=0.28,  p=0.21). 
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Figure  5.2.  Endotoxin-stimulated  interleukin-10  production  by  peripheral  blood  mononuclear 
cells  from  22  patients  with  advanced  pancreatic  cancer  presented  by  IL-Iß  genotype. 
Horizontal  bar  represents  median  value.  Comparisons  between  groups  by  Mann  whitney  U 
test. 
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Serum  CRP  concentration  in  relation  to  IL-1  ß  genotype  of  cancer  patients  is  presented 
in  figure  5.3.  CRP  levels  from  those  with  the  2/2  (28mg/l  (20-130))  or  1/2  genotype  (31mg/l 
(13-72))  were  significantly  higher  than  those  with  the  1/1  genotype  (0mg/l  (0-10))  (p=0.015  and 
0.0042  respectively).  There  was  no  significant  difference  between  CRP  levels  from  those  with 
2/2  and  1/2  genotypes  (p=0.42). 
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Figure  5.3.  Serum  C-reactive  protein  concentrations  in  43  patients  with  advanced  pancreatic 
cancer  presented  by  IL-Iß  genotype.  Horizontal  bar  represents  median  value.  Comparisons 
between  groups  by  Mann  whitney  U  test. 
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Survival  of  patients  by  IL-1  ß  genotype  is  presented  in  figure  5.4.  Those  with  2/2 
genotype  (88days  (69-108))  had  significantly  shorter  survival  than  those  with  1/2  (173  days 
(107-269))  or  1/1  (243  days  (126-333))  genotype  (p=0.012  and  0.0001  respectively).  The 
difference  between  survival  of  those  with  1/1  and  1/2  genotype  is  not  statistically  significant 
(p=0.10).  All  4  censored  individuals  possess  the  1/1  genotype. 
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Figure  5.4.  Kaplan-Meier  survival  curve  (from  diagnosis)  of  64  patients  with  advanced 
pancreatic  cancer  presented  by  IL-10  genotype.  Median  survivals  -  1/1  genotype  243  days 
(solid  line),  1/2  173  days  (broken  line),  2/2  88  days  (dotted  line).  Comparison  by  log  rank  test  - 
Overall  p=0.0005,1/1  vs  112  p=0.010,1/1  vs  2/2  p=0.0001,1/2  vs  2/2  p=0.012. Chapter  5  73 
Those  possessing  allele  2  had  significantly  shorter  survival  (148  days  (85-245))  than 
those  who  did  not  (243  days  (126-333))  (p=0.043)  (figure  5.5). 
When  survival  by  IL-1  ß  genotype  was  split  by  disease  stage  genotype  remained  a 
significant  predictor  of  survival  in  those  with  stage  II  and  IV  disease  (p<0.03)  (patient  numbers 
were  insufficient  for  stage  III  disease. 
For  predicting  survival  at  six  months  the  possession  of  allele  2  has  a  sensitivity  of  48%, 
a  specificity  of  81%,  a  positive  predictive  value  of  65%,  a  negative  predictive  value  of  67%  and 
an  accuracy  of  67%. 
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Figure  5.5.  Kaplan-Meier  survival  curve  (from  diagnosis)  of  64  patients  with  advanced 
pancreatic  cancer  stratified  for  possession  of  IL-1P  allele  2.  Median  survivals  -  possesion  of 
allele  2-  148  days  (broken  line),  no  allele  2-  243  days  (solid  line).  Comparison  by  log  rank 
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IL-lRa  polymorphism,  cytokine  levels,  acute  phase  protein  response  and  survival 
There  was  no  obvious  relation  between  IL-  lRa  genotype  and  the  inflammatory 
response.  In  particular,  there  was  no  difference  between  CRP,  TNF-R  55  and  TNF-R75 
concentrations  in  patients  with  or  without  IL-1Ra  allele  2  (Figure  5.6).  There  was  no 
relationship  between  IL-1  Ra  genotype  and  survival  (p=0.17,  log  rank  test).  Similarly,  the 
posession  of  IL-1  Ra  allele  2  did  not  appear  to  influence  survival  (allele  2  present  median 
survival  265  (135-333)  days,  allele  2  absent  181  (85-254)  days,  p=0.24,  log  rank  test)  (Figure 
5.7). 
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Figure  5.6.  Serum  concentrations  of  soluble  tumour  necrosis  factor  receptor  (sTNF-R)  55  and 
75  and  C-reactive  protein  (CRP)  from  45  patients  with  advanced  pancreatic  cancer  presented 
by  IL-1  Ra  genotype.  Statistical  analysis  by  Mann  Whitney  U  test. Chapter  5 
.8 
> 
ü, 
.b 
a> > 
.4 
E 
U 
.2 
0 
0  400  800  1200  1600 
Time  (Days) 
Figure  5.7.  Kaplan  Meier  survival  curve  (from  diagnosis)  of  64  patients  with  advanced 
pancreatic  cancer  by  IL-1  Ra  genotype.  Allele  2  present  -  solid  line,  Allele  2  absent  -  dashed 
75 
line.  Comparison  by  log  rank  test  p=0.24. Chapter  5  76 
TNF  polymorphisms,  cytokine  levels,  acute  phase  protein  response  and  survival 
Serum  concentrations  of  TNF-R  55,  TNF-R75  and  CRP  are  shown  in  relation  to  TNF 
genotype  in  figure  5.8.  There  were  no  significant  differences  in  serum  concentrations  of  either 
TNF  receptor  or  CRP  between  TNFB  or  TNF308  genotypes.  In  addition,  there  was  no 
significant  difference  between  serum  concentrations  of  TNF-R55,  TNF-R75  and  CRP  between 
those  bearing  allele  2  of  either  polymorphism  and  those  with  allele  1. 
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Figure  5.8.  Serum  concentrations  of  soluble  tumour  necrosis  factor  receptor  (sTNF-R)  55  and 
75  and  C-reactive  protein  (CRP)  from  45  patients  with  advanced  pancreatic  cancer  presented 
by  TNFB  and  TNF-308  genotype.  Statistical  analysis  by  Kruskal  Wallis  test. Chapter  5  77 
Survival  of  the  64  pancreatic  cancer  patients  stratified  by  TNF  genotype  is  shown  in 
figures  5.9  and  5.10.  For  the  TNFB  polymorphism,  those  with  1/1  genotype  had  a  median 
survival  of  235  (122-266)  days,  1/2  -  202  (112-357)  days  and  2/2  -  256  (76-333)  days.  For  the 
TNF-308  polymorphism,  those  with  1/1  genotype  had  a  median  survival  of  202  (97-333)  days, 
1/2  -  227  (136-294)  days  and  2/2  -  82  (57-185)  days.  There  was  no  significant  relationship 
between  either  genotype  and  survival.  In  addition,  the  posession  of  the  TNFB2  or  TNF2 
genotype  made  no  difference  to  survival  (p=0.51  and  0.77  respectively). 
5  .8  > 
.> 
c 
.6 
> 
o 
.4 
E 
:3 
U 
0 
0  400  800  1200  1600 
Time  (Days) 
Figure  5.9.  Kaplan  Meier  survival  curve  (from  diagnosis)  of  64  patients  with  advanced 
pancreatic  cancer  by  TNFB  genotype.  1/1  -  solid  line,  1/2  -  dashed  line,  2/2  -  dotted  line. 
Comparison  by  log  rank  test  p=0.78. Chapter  5 
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Figure  5.10.  Kaplan  Meier  survival  curve  (from  diagnosis)  of  64  patients  with  advanced 
pancreatic  cancer  by  TNF-308  genotype.  11  -  solid  line,  1/2  -  dashed line,  2/2  -  dotted  line. 
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Comparison  by  log  rank  test  p=0.13. Chapter  5 
Discussion 
In  this  chapter  it  has  been  shown  that  IL-  I1  genotype  appears  to  be  important  in 
determining  IL-1  ß  production,  serum  CRP  level  and  survival  from  diagnosis  in  patients  with 
advanced  pancreatic  cancer.  However,  neither  of  the  TNF  genotypes  studied  or  the  IL-1  Ra 
genotype  significantly  influenced  the  inflammatory  state  or  survival. 
There  was  no  difference  in  the  frequency  distribution  of  IL-  I  (3  genotypes  between 
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normal  subjects  and  cancer  patients.  The  distribution  found  in  normal  subjects  is  very  similar  to 
that  described  in  other  European  populations  (Pociot  et  al,  1992,  Bioque  et  al,  1995,  Heresbach 
et  al,  1997).  There  was,  however,  a  trend  towards  fewer  cancer  patients  possessing  allele  2.  If 
possession  of  allele  2  shortens  survival  it  is  possible  that  some  patients  who  died  were  missed 
before  assessment,  thus  our  estimate  of  the  importance  of  allele  2  may  be  a  conservative  one. 
Distribution  of  the  IL,  -1  Ra  genotypes  was  almost  identical  between  patients  and  controls 
and  was  similar  to  that  reported  in  other  studies  (Blakemore  et  al,  1994,  Mansfield  et  al,  1994, 
Crusius  et  al,  1995,  Danis  et  al,  1995).  However,  a  number  of  studies  have  suggested  an 
increased  frequency  of  allele  2  in  those  with  conditions  in  which  inflammation  may  play  a  role 
such  as  systemic  lupus  erythematosis,  ulcerative  colitis  and  multiple  sclerosis  (Blakemore  et  al, 
1994,  Mansfield  et  al,  1994,  Crusius  et  al,  1995).  No  relationship  was  found  between  IL-1Ra 
genotype  and  the  inflammatory  state  in  the  present  study. 
Distribution  of  the  TNF  genotypes  was  also  similar  between  pancreatic  cancer  patients 
and  controls.  Frequencies  of  the  genotypes  were  also  similar  to  those  described  by  other  groups 
in  healthy  subjects  and  in  patients  with  inflammatory  and  malignant  diseases  (Shimura  et  al, 
1994,  O'Mahony  et  al,  1998,  Wilson  et  al,  1992,  Stuber  et  al,  1996,  Westendorp  et  al,  1997).  It 
has  been  suggested  that  the  TNFB2  heterozygote  is  less  common  in  patients  with  lung  cancer 
than  in  the  control  population  and  may  thus  protect  against  this  disease  (Shimura  et  al,  1994). 
The  present  study  provides  no  evidence  to  support  this  hypothesis  in  pancreatic  cancer. 
It  is  rare  to  detect  IL-1  in  the  serum  of  cancer  patients,  thus  measures  of  production  are 
used  for  gauging  levels  that  may  occur  in  the  relavent  tissue  compartments  (Moldawer  & 
Copeland,  1997).  Only  one  group  has  previously  studied  the  relationship  between  the  IL-1  ß 
polymorphism  examined  in  the  present  study  and  production  of  IL-1  ß  by  leukocytes  (Pociot  et 
al,  1992).  Examining  a  group  of  45  healthy  individuals  they  were  able  to  show  a  stepwise 
increase  in  IL-1(3  production  from  1/1  to  1/2  to  2/2  genotype.  While  numbers  in  the  present 
study  were  insufficient  to  confirm  this  relationship,  differences  between  the  2/2  genotype  and 
the  other  groups  were  significant  and  there  was  a  trend  in  agreement  with  this  previous  study 
(p=0.072  -  Kruskal-Wallis  test). Chapter  5  80 
The  relationship  between  IL-1(3  genotype  and  the  acute  phase  protein  response  has  not 
previously  been  examined.  It  is  known  that  the  administration  of  IL-1  a  or  ß  will  induce  an 
acute  phase  response  in  mice  (Moldawer  et  al,  1988)  and  that  the  administration  of  antibodies  to 
the  IL-1  receptor  will  attenuate  the  acute  phase  response  to  turpentine  abscess  in  mice 
(Gerschenwald  et  al,  1990).  It  is  thought  that  the  acute  phase  response  is  primarily  activated  by 
IL-6  (Castell  et  al,  1990)  but  it  has  been  suggested  that  blockade  of  IL-1  action  will  reduce  IL-6 
production  (Yasumoto  et  all,  1995).  It  is  thus  possible  that  with  increased  IL-1(3  production 
there  is  increased  IL-6  production  and  so  increased  stimulation  of  the  acute  phase  protein 
response.  In  the  present  study  we  failed  to  identify  any  simple  relationship  between  serum  CRP 
levels  and  IL-  13  production  although  numbers  were  small  and  IL-1(3  genotype  again  seemed  to 
be  important  with  those  possessing  allele  2  having  significantly  higher  CRP  levels  than  those 
without. 
TNFa  is  also  rarely  detected  in  serum  samples  from  patients  with  cancer 
(Falconer  et  al,  1994).  However,  the  two  TNF  receptors  are  shed  from  cells  in  response  to  TNF 
release  and  therefore  the  serum  concentration  of  soluble  TNF  receptors  may  provide  an  indirect 
measure  of  TNFa  release  (Olsson  et  a1,1993).  In  the  previous  chapter  it  was  demonstrated  that 
the  serum  concentrations  of  soluble  TNF  receptors  correlate  with  the  level  of  the  acute  phase 
protein  response  in  advanced  pancreatic  cancer.  However,  in  the  present  study  we  were  unable 
to  show  any  relationship  between  either  TNF  genotype  and  concentrations  of  the  two  TNF 
receptors.  In  addition  the  present  study  was  unable  to  show  a  relationship  between  either  TNF 
genotype  and  the  acute  phase  response  as  measured  by  serum  CRP  concentration.  A 
relationship  between  the  TNFB  genotype  and  serum  TNFa  concentration  was  found  in  septic 
patients  (Stuber  et  al,  1996)  and  between  the  TNF-308  genotype  and  TNFa  production  by 
lymphoid  cell  lines  (Abraham  et  al,  1993).  However,  others  have  found  no  relationship 
between  TNF-308  genotype  and  TNFa  production  by  cultured  blood  cells  (Westendorp  et  al, 
1997).  It  may  be  that  serum  concentrations  of  the  TNF  receptors  and  CRP  are  an  inadequate 
measure  of  TNFa  production  or  that  the  polymorphisms  studied  are  not  sufficiently 
discriminatory  of  the  propensity  to  produce  this  cytokine. 
The  possession  of  IL-lRa  allele  2  has  been  associated  with  increased  production  of  IL- 
1Ra  and  decreased  production  of  IL-1  a  (Danis  et  al,  1995).  However,  it  has  also  been 
associated  with  an  increased  susceptibility  to  a  variety  of  inflammatory  conditions  (Blakemore 
et  al,  1994,  Mansfield  et  al,  1994,  Crusius  et  al,  1995)  with  a  suggestion  of  increased  disease 
severity  in  systemic  lupus  erythematosis  (Blakemore  et  al,  1994).  The  present  study  found  no 
association  between  this  genotype  and  the  inflammatory  state  as  measured  by  CRP  or  the  TNF Chapter  5 
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receptors.  The  production  of  IL-  l  Ra  itself  was  not  measured.  The  role  of  IL-1  Ra  in  mediating 
the  action  of  IL-1  in  cancer  remains  unclear  but  it  would  appear  that  the  possession  of  allele  2  is 
not  an  adverse  factor  in  pancreatic  cancer. 
The  administration  of  pro-inflammatory  cytokines,  including  IL-1,  IL-6,  interferon-a 
and  TNF,  produces  features  of  cachexia  in  experimental  models  (Mahony  &  Tisdale,  1988, 
Gelin  et  al,  1991,  Hellerstein  et  a1,1989,  Matthys  et  al,  1991,  Strassmann  et  al,  1992).  These 
agents  all  induce  an  acute  phase  response  and  it  has  been  suggested  that  the  need  for  amino 
acids  to  manufacture  acute  phase  reactants  in  the  absence  of  adequate  nutritional  intake 
contributes  to  breakdown  of  skeletal  muscle  (Reeds  et  al,  1994)  and  so  the  weight  loss  of 
cachexia.  It  has  previously  been  shown  that  the  presence  of  an  acute  phase  response  is 
associated  with  nutritional  decline  and  poor  survival  in  pancreatic  cancer  (Falconer  et  al,  1994, 
Falconer  et  al,  1995,  Wigmore  et  al,  1997  and  preceding  chapters).  In  this  chapter  it  has  been 
shown  that  EL-1  ß  genotype  is  related  to  survival.  The  stepwise  decrease  in  median  survival 
between  the  1/1,1/2  and  2/2  genotypes  may  be  related  to  the  apparent  increase  in  IL-lß 
production  associated  with  these  genotypes  and  would  therefore  be  compatible  with  the 
hypothesis  that  a  more  marked  pro-inflammatory  state  is  detrimental  to  survival  in  pancreatic 
cancer,  perhaps  due  to  cytokine-mediated  nutritional  decline.  Alternatively,  it  has  been 
suggested  that  pro-inflammatory  cytokines  will  promote  tumour  growth  in  animal  models 
(Gelin  et  al,  1991).  Blockade  of  the  IL-1  receptor  has  been  shown  to  reduce  liver  metastasis  in 
a  melanoma  model  (Vidal-Vanaclocha  et  al,  1994)  perhaps  due  to  an  H_-1  induced  increase  in 
endothelial  receptor  expression  (Vidal-Vanaclocha  et  al,  1996).  Therefore,  IL-1  may  accelerate 
tumour  progression  accounting  for  the  shortened  survival  of  the  2/2  genotype  group. 
The  work  presented  in  this  chapter  has  demonstrated  that  advanced  pancreatic  cancer 
patients  with  an  elevated  CRP  concentration,  despite  having  no  evidence  of  infection  or 
jaundice,  have  a  significantly  shorter  survival  than  those  without.  However,  despite  the 
apparent  importance  of  the  inflammatory  state,  the  present  study  found  no  association  between 
survival  and  either  TNF  polymorphism.  Those  with  the  2/2  genotype  for  the  TNF-308 
polymorphism  had  an  almost  significantly  shorter  survival  than  the  other  two  groups  (p=0.054) 
but  this  genotype  was  only  seen  in  6%  of  patients  making  it  of  little  practical  value.  Previous 
studies  of  the  TNFB  polymorphism  in  cancer  have  suggested  that  two  different  genotypes,  1/2 
and  1/1,  are  associated  with  poor  survival  in  lung  and  oesophageal  cancer  respectively  (Shimura 
et  al,  1994,  O'Mahony  et  al,  1998).  Although  no  measurement  of  the  inflammatory  state  was 
made  in  the  cancer  patient  groups  in  these  studies,  these  genotypes  have  been  associated  with 
significantly  lower  TNFa  concentrations  in  septic  patients  (Stüber  et  al,  1996).  This  would Chapter  5  82 
appear  to  conflict  with  the  observation  that  elevated  pro-inflammatory  cytokine  levels  are 
associated  with  a  worse  outcome  in  cancer  (Falconer  et  al,  1994a,  Falconer  et  al,  1995).  It  may 
be  that  pro-inflammatory  cytokines  other  than  TNFa  are  of  more  importance  in  determining 
outcome  in  cancer  patients,  that  the  cytokines  of  importance  vary  between  different 
malignancies  or  that  the  polymorphisms  studied  are  of  limited  importance  in  this  patient  group. 
The  very  poor  survival  of  patients  with  IL-1  ß  2/2  genotype  is  clinically  of  limited  value 
due  to  the  low  prevalence  of  this  genotype.  However,  the  possession  of  allele  2  was  also  a 
significant  predictor  of  survival.  This  was  present  in  a  third  of  the  cancer  patients  in  the  present 
study  and  almost  a  half  of  the  population  as  a  whole  thus  it  may  be  a  valuable  clinical  tool  for 
predicting  survival.  It  has  been  suggested  that  endoscopic  palliation  of  jaundice  is  appropriate 
in  those  patients  with  a  life  expectancy  of  6  months  or  less  (Rosewicz  &  Weidenmann,  1997, 
van  den  Bosch  et  al,  1994).  Existing  measures  of  the  inflammatory  state  such  as  CRP  are 
sensitive  to  surgery,  infection  and  jaundice  while  EL-1P  genotype  is  not.  Using  this  method  to 
predict  6  month  survival  had  an  accuracy  of  67%  in  the  current  study,  suggesting  that  it  may  be 
useful  in  guiding  palliative  biliary  drainage  in  these  patients.  It  may  also  be  useful  in  predicting 
patients  who  may  benefit  from  therapy  for  cachexia  targeted  at  the  inflammatory  state. 
In  conclusion,  this  chapter  confirms  the  association  between  the  inflammatory  state  and 
shortened  survival  in  pancreatic  cancer.  The  IL-1(3  genotype  is  related  to  IL-1(3  production  and 
the  level  of  the  acute  phase  protein  response  (although  numbers  of  patients  were  small)  and  also 
affects  survival  in  patients  with  advanced  pancreatic  cancer.  However,  genotypes  resulting 
from  a  polymorphism  of  the  IL-1Ra  gene  and  two  polymorphisms  of  the  TNF  gene  were  not 
found  to  be  associated  with  outcome  or  the  inflammatory  state  in  such  patients. 
The  next  chapters  examine  the  potential  of  eicosapentaenoic  acid  to  influence  the 
inflammatory  state  and  associated  metabolic  abnormalities  associated  with  cachexia  in  patients 
with  advanced  pancreatic  cancer. Chapter  6  83 
Nutritional  effects  of  an  oral  nutritional  supplement  enriched  with 
fish  oil  in  pancreatic  cancer  patients 
Summary 
Previous  studies  have  suggested  that  administration  of  oral  eicosapentaenoic  acid  (EPA) 
will  down-regulate  inflammatory  mediators  of  weight  loss  and  thus  may  stabilise  weight  in 
patients  with  advanced  pancreatic  cancer.  The  aim  of  this  chapter  is  to  determine  if  a 
combination  of  EPA  with  a  conventional  oral  nutritional  supplement  could  produce  weight  gain 
in  these  patients. 
20  patients  with  unresectable  pancreatic  adenocarcinoma  were  asked  to  consume  2  cans  of 
a  fish  oil-enriched  nutritional  supplement  per  day  in  addition  to  their  normal  food  intake.  Each 
can  contained  3l0kcal,  16.  lg  protein  and  1.09g  EPA.  Patients  were  assessed  for  weight,  body 
composition,  dietary  intake,  resting  energy  expenditure  (REE)  and  performance  status. 
Patients  consumed  a  median  of  1.9  cans  per  day.  All  patients  were  losing  weight  at 
baseline  at  a  median  rate  of  2.9kg  per  month.  After  administration  of  the  fish  oil-enriched 
supplement,  patients  had  significant  weight-gain  at  both  three  (median  lkg,  p=0.024)  and  seven 
weeks  (median  2kg,  p=0.033).  Dietary  intake  increased  significantly  by  almost  400kcal  per  day 
(p=0.002).  REE  per  kg  body  weight  and  per  kg  lean  body  mass  fell  significantly.  Performance 
status  and  appetite  were  significantly  improved  at  3  weeks. 
In  contrast  to  previous  studies  of  oral  conventional  nutritional  supplements  in  weight- 
losing  cancer  patients,  this  study  suggests  that  an  EPA-enriched  supplement  may  reverse 
cachexia  in  advanced  pancreatic  cancer. Chapter  6  84 
Introduction 
As  described  in  Chapter  3,  pancreatic  cancer  is  almost  inevitably  associated  with 
progressive  nutritional  decline.  Weight-loss  in  patients  with  gastrointestinal  cancer  is  often 
refractory  to  therapeutic  intervention  and  is  associated  with  a  shorter  survival  time  and  a  reduced 
quality  of  life  (DeWys  et  al,  1980,  Ovesen  et  al,  1993a).  The  provision  of  conventional  oral 
nutritional  supplements  may  increase  overall  dietary  intake  but  this  does  not  generally  lead  to 
any  benefit  in  terms  of  nutritional  status  (Evans  et  al,  1987,  Ovesen  et  al,  1993b).  Consequently 
it  has  been  suggested  that  the  metabolic  processes  which  contribute  to  weight-loss  in  patients 
with  cancer  may  also  block  the  accretion  of  lean  tissue  (Moldawer  &  Copeland,  1997). 
The  association  between  pro-inflammatory  cytokine  production,  the  acute  phase  protein 
response,  weight  loss  and  survival  explored  in  the  preceding  chapters  permits  speculation  that 
agents  capable  of  down-regulating  pro-inflammatory  cytokine  production  or  the  acute  phase 
response  may  affect  the  progress  of  cachexia.  Attempts  to  manipulate  the  inflammatory 
response  in  cancer  patients  using  non-steroidal  anti-inflammatory  drugs  with  the  intention  of 
improving  nutritional  status  have  been  made  previously  with  promising  results  (McMillan  et  al, 
1997,  McMillan  et  al,  1999). 
The  n-3  polyunsaturated  fatty  acids,  eicosapentaenoic  acid  (EPA)  and  docosahexaenoic 
acid  (DHA),  are  immunomodulatory  and  have  been  shown  to  suppress  endotoxin-induced 
production  of  pro-inflammatory  cytokines  such  as  IL-1  and  tumor  necrosis  factor  (TNF)  by 
peripheral  blood  mononuclear  cells  (PBMC)  from  healthy  volunteers  (Meydani  et  al,  1993). 
Studies  of  weight-losing  pancreatic  cancer  patients  receiving  high-purity  EPA  have 
demonstrated  suppression  of  PBMC  IL-6  production  (Wigmore  et  al,  1997d).  EPA  has  also  been 
shown  to  have  inhibitory  effects  on  the  growth  of  human  pancreatic  cancer  cell  lines  in  vitro 
(Falconer  et  al,  1994b)  and  to  have  anti-tumour  and  anti-cachectic  effects  in  the  chemoresistant 
murine  MAC  16  colon  adenocarcinoma  model  (Beck  et  al,  1991).  The  cachexia  seen  in  this 
animal  model  has  been  attributed  to  the  production  of  a  proteolysis  inducing  factor  by  tumour 
cells  and  such  a  factor  is  also  found  in  tumour-bearing  humans  with  cachexia  (Todorov  et  al, 
1996).  It  has  been  suggested  that  EPA  may  act  by  inhibiting  the  end  organ  effects  of  this  factor 
(Tisdale,  1996). 
It  has  previously  been  reported  that  administration  of  a  mixed  fish  oil  preparation 
(providing  around  2.2g  EPA  and  1.4g  DHA  daily)  and  a  pure  EPA  preparation  (providing  6g 
EPA  daily)  will  stabilise  weight  in  patients  with  unresectable  pancreatic  cancer  (Wigmore  et  al, 
1996,  Barber  et  al,  1997).  Clearly,  in  order  to  lay  down  new  tissue  and  thereby  increase  body 
weight  additional  macronutrients  need  to  be  consumed. 
The  present  study  aimed  to  assess  whether  the  provision  of  additional  oral  nutrients 
together  with  fish  oil  could  reverse  weight-loss  in  patients  with  advanced  pancreatic  cancer. Chapter  6 
Materials  and  methods 
Patients 
Patients  enrolled  were  men  or  non-pregnant,  non-lactating  women  between  18  and  80 
years  with  histological  confirmation  or  unequivocal  operative  or  radiological  diagnosis  of 
unresectable  adenocarcinoma  of  the  pancreas  with  evidence  of  ongoing  weight-loss.  Patients 
had  a  life  expectancy  of  over  two  months  and  a  WHO  performance  status  "2  at  enrolment. 
Written,  informed  consent  was  obtained  from  all  patients.  Patients  were  excluded  if  they  had 
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received  surgery  or  endoscopic  stenting  during  the  previous  four  weeks,  had  other  active  medical 
conditions,  another  malignancy  or  were  receiving  medication  which  could  profoundly  modulate 
metabolism  or  weight.  No  patients  had  received  radiotherapy  or  chemotherapy.  A  total  of 
twenty  patients  were  recruited  to  the  study.  Confirmation  of  unresectable  pancreatic 
adenocarcinoma  was  by  histology  (16/20)  or  unequivocal  operative  or  radiological  findings 
(4/20).  17  patients  had  cancers  of  the  head  of  pancreas  and  three  of  the  body.  On  enrolment 
none  of  the  patients  were  jaundiced,  pyrexial,  ascitic,  severely  anaemic  or  had  clinical  or 
radiological  evidence  of  infection  and  none  were  taking  steroid  drugs.  All  patients  had  adequate 
pain  control  at  the  time  of  study.  Pancreatic  enzyme  supplements  were  administered  if  patients 
had  or  developed  clinical  evidence  of  steatorrhoea. 
Patients  were  studied  formally  at  baseline,  3  and  7  weeks  although  patients  were  assessed 
approximately  monthly  until  death,  withdrawal  from  the  study  or  until  their  condition 
deteriorated  such  that  further  assessment  was  not  possible.  Trial  results  were  monitored 
independently. 
Fish  oil-enriched  nutritional  supplement 
The  fish  oil-enriched  nutritional  supplement  was  provided  by  Ross  Products  Division, 
Abbott  Laboratories,  Columbus,  Ohio,  USA.  The  composition  of  this  product  is  shown  in 
appendix  2.  Patients  were  requested  to  store  product  in  the  refrigerator. 
Patients  were  asked  to  consume  two  cans  per  day  (providing  610kcal,  32.2g  protein,  2.2g 
EPA  and  0.96g  DHA).  Compliance  was  assessed  by  a  diary  of  consumption,  return  of  labels 
from  empty  cans  and  by  plasma  fatty  acid  analysis  at  baseline  and  after  3  weeks  consumption  of 
the  supplement. 
Toxicity  assessment 
Blood  was  drawn  for  full  blood  count,  electrolytes,  urea,  glucose  and  liver  function  tests. 
These  were  measured  using  standard  automated  techniques  in  the  haematology  and  clinical 
chemistry  laboratories  of  the  Royal  Infirmary,  Edinburgh,  UK.  A  history  and  full  clinical 
examinaton  was  performed  at  each  of  these  visits.  Toxicity  reported  to  general  practitioners  or 
observed  on  clinical  examination  was  documented. Chapter  6 
Nutritional  and  metabolic  assessment 
At  the  initial  assessment,  height,  pre-illness  stable  weight  and  duration  of  weight-loss 
were  recorded.  At  each  review  subjects  were  weighed,  and  mid-arm  muscle  circumference 
(MAMC)  and  triceps  skinfold  thickness  (TSF)  measured.  Body  composition  was  measured  by 
bioelectrical  impedence. 
The  daily  caloric  intake  and  resting  energy  expenditure  of  patients  were  measured  at 
baseline  and  after  three  weeks  of  supplement  administration. 
The  daily  nitrogen  intake  of  patients  was  measured  at  baseline  and  after  three  weeks  of 
supplement  administration.  Values  were  based  on  the  mean  dietary  intake. 
Nitrogen  loss  was  determined  by  measurement  of  urinary  nitrogen.  A  further  2g  per  day 
was  added  for  faecal  losses. 
Acute  phase  protein  response 
The  APPR  was  documented  by  assaying  serum  C-reactive  protein. 
Fatty  acid  analysis 
Plasma  phospholipid  fatty  acid  analysis  was  performed  before  commencement  of  the 
supplement  and  3  weeks  thereafter. 
Performance  status  and  appetite 
Karnofsky  performance  status  was  noted  before  commencement  of  the  supplement,  at 
three  weeks  and  at  monthly  intervals  thereafter. 
Appetite  was  measured  on  a  numerical  rating  scale  between  0  and  10,  where  0  indicated 
absolutely  no  appetite  and  10  indicated  an  extremely  good  appetite  (Simons  et  al,  1996). 
Survival 
Survival  was  recorded  from  the  time  of  diagnosis  and  study  baseline  to  the  time  of  death. 
Diagnosis  was  defined  as  the  date  of  confirmation  of  adenocarcinoma  of  the  pancreas  by 
histological  examination  or  of  unequivocal  operative  or  radiological  findings  in  patients  in 
whom  definitive  pathological  confirmation  of  diagnosis  was  lacking. 
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Further  details  of  methods  are  found  in  Chapter  2. Chapter  6  87 
Results 
Patient  characteristics 
Patients  comprised  10  males  and  10  females  of  median  age  62  years  (range  51-75). 
Tumour  stages  were  as  follows:  stage  2,8  patients;  stage  3,3  patients  and  stage  4,9  patients.  No 
patients  underwent  prior  chemotherapy  or  radiotherapy.  Eight  patients  underwent  non- 
resectional  palliative  surgical  procedures  and  eight  patients  had  endobiliary  stenting  prior  to  the 
study.  Patients  had  tumours  of  the  pancreatic  head  in  17  cases  and  the  pancreatic  body  in  the 
remainder.  Baseline  characteristics  of  patients  is  shown  in  table  6.1.  No  patients  on  whom  data 
was  available  over  the  7  week  study  period  developed  clinically  detectable  ascites  or  oedema. 
Table  6.1.  Baseline  characteristics  of  study  patients  with  advanced  pancreatic  cancer  (n=20). 
Weight  (kg)  55.2  (48.8-61.2) 
Body  mass  index  (kg/m2)  19.8  (17.8-21.8) 
Rate  of  weight  change  per  month  (kg)  -2.9  (-4.4--2.2) 
Percentage  weight  loss  17.9  (15.9-22.8) 
Mid  arm  muscle  circumference  (cm)  20.8  (18.4-22.4) 
Triceps  skinfold  thickness  (mm)  11.1  (7.8-15.9) 
Percentage  total  body  water  52.9  (51.2-56.1) 
Lean  body  mass  (kg)  41.5  (38.1-44.8) 
Fat  mass  (kg)  14.5  (12.3-16.7) 
C-reactive  protein  (mg/i)  10  (<10-27) 
Karnofsky  performance  status  85  (80-90) 
(10  (moribund)  to  100  (normal)) 
Appetite  5  (3-7) 
(0  (none)  to  10  (excellent)) 
Figures  are  median  (interquartile  range) Chapter  6 
Tolerance/toxicity 
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Patients  consumed  a  median  of  1.9  cans  of  the  fish  oil-enriched  supplement  per  day  (range 
1.2-2). 
Full  blood  count,  electrolytes,  urea,  glucose  and  liver  function  tests  were  assessed  at  each 
review.  Values  did  not  change  significantly  over  the  course  of  the  study. 
Two  patients  developed  and  one  patient  had  worsening  of  pre-existing  steatorrhoea  with 
administration  of  the  supplement.  This  was  successfully  treated  by  pancreatic  enzyme 
supplementation.  Otherwise  no  patient  developed  an  adverse  event  outwith  the  expected 
progression  of  advanced  pancreatic  cancer. 
At  3  weeks,  two  patients  were  unavailable  for  analysis  due  to  disease  progression.  At  7 
weeks  a  further  5  patients  were  unavailable  due  to  disease  progression.  Reasons  for  stopping  the 
supplement  during  the  7  week  study  period  were  temporary  interruption  in  supply  in  one  patient 
(after  3  weeks),  excessive  weight  gain  in  one  patient  (after  3  weeks),  dislike  of  taste  in  two 
patients  (after  3  weeks)  and  progression  of  disease  in  the  remainder.  Data  were  only  available 
for  one  patient  not  taking  the  supplement  at  7  weeks.  Thus  all  18  patients  assessed  at  3  weeks 
and  12  of  13  patients  assessed  at  7  weeks  were  consuming  the  supplement. 
Body  weight 
Changes  in  body  weight  for  individual  patients  are  depicted  graphically  in  figure  6.1. 
Weight  change  at  3  (n=  18)  and  7  (n=  13)  weeks  is  shown  in  table  6.2.  Patients  had  statistically 
significant  weight  gain  at  3  and  7  weeks  of  median  1  and  2kg  respectively.  The  patient  who  had 
discontinued  the  supplement  at  3  weeks  but  on  whom  data  was  available  at  7  weeks  gained  0.5kg 
over  the  first  3  weeks  on  the  supplement  and  lost  0.9kg  in  the  subsequent  4  weeks  off  the 
supplement.  Excluding  this  patient,  median  weight  gain  at  7  weeks  was  2.5kg  (0.2-4.6). 
Anthropometry  and  body  composition  analysis 
Values  for  MAMC  and  TSF  recorded  before  commencement  of  the  supplement  and 
changes  after  3  and  7  weeks  are  shown  in  tables  6.1  and  6.2.  There  was  no  significant  change  in 
either  MAMC  or  TSF  over  this  period. 
Values  for  total  body  water  expressed  as  a  percentage  of  total  body  weight  are  also 
presented  in  tables  6.1  and  6.2.  There  was  no  significant  change  in  this  factor  in  patients 
remaining  in  the  trial  at  3  and  7  weeks. 
Values  for  calculated  lean  body  mass  and  fat  mass  are  presented  in  tables  6.1  and  6.2. 
There  was  a  statistically  significant  rise  in  calculated  lean  body  mass  at  three  and  seven  weeks 
(of  median  1.0kg  and  1.9kg  respectively)  but  no  change  in  fat  mass  at  either  time  point. Chapter  6 
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Figure  6.1.  Weight  change  of  20  patients  with  advanced  pancreatic  cancer  administered  a  fish 
oil-enriched  nutritional  supplement  after  3  and  7  weeks.  Median  rate  of  weight  loss  prior  to 
intervention  was  2.9kg  per  month.  Median  weight  gain  at  3  weeks  was  1.0kg  (p=0.028  vs 
baseline  Wilcoxon  signed  rank  test).  Median  weight  gain  at  7  weeks  was  2.0kg  (p=0.033). Chapter  6  90 
Table  6.2.  Change  in  characteristics  of  patients  with  advanced  pancreatic  cancer  after  3  and  7 
weeks  administration  of  a  fish  oil-enriched  nutritional  supplement. 
Duration  of  supplement  3  weeks  7  weeks 
administration 
Number  of  patients  18  13 
p  p 
Weight  change  (kg)  +1.0  0.024  +2.0  0.033 
(-0.1-+2.0)  (-0.4-+4.6) 
Change  in  mid  arm  muscle  0  NS  +0.4  NS 
circumference  (cm)  (-0.2-+0.5)  (-0.7-+  1.1) 
Change  in  triceps  skinfold  0  NS  +0.2  NS 
thickness  (mm)  (-0.2-+0.4)  (-0.5-+0.6) 
Change  in  percentage  total  body  +0.1  NS  -0.1  NS 
water  (-0.3-+1.9)  (-0.4-+1.5) 
Change  in  lean  body  mass  (kg)  +1.0  0.0064  +1.9  0.0047 
(+0.6-+1.4)  (+1.0-+3.0) 
Change  in  fat  mass  (kg)  -0.2  NS  +0.2  NS 
(-0.8-+0.9)  (-0.8-+2) 
Change  in  C-reactive  protein  0  NS  0  NS 
(mg/1)  (0-+3)  (-5-+22) 
Change  in  Karnofsky  +10  0.0047  +10  0.046 
performance  status  (0-+  10)  (0-+  10) 
(10  (moribund)  to  100  (normal)) 
Change  in  appetite  +1  0.001  +1  NS 
(0  (none)  to  10  (excellent))  (0-+1)  (0-+1) 
Figures  are  median  (interquartile  range). 
Paired  comparison  with  baseline  by  Wilcoxon  signed  rank  test 
Nutritional  intake 
The  daily  caloric  intake  of  patients  before  commencement  of  supplement  and  after  3  weeks 
(n=18)  are  presented  in  table  6.3.  There  was  a  statistically  significant  increase  in  caloric  intake 
after  3  weeks  (p=0.0016).  The  median  increase  for  each  patient  was  372kca1  per  day. 
Energy  expenditure 
REE  and  ZEE  expressed  per  kg  body  weight  and  per  kg  lean  body  mass  as  measured  at 
baseline  and  after  3  weeks  are  presented  in  table  6.3.  While  there  was  no  change  in  overall  REE 
(p=©.  18),  REE  kg  per  body  weight  and  REE  kg  per  lean  body  mass  both  fell  significantly 
(p=0.025  and  0.018  respectively). Chapter  6  91 
Table  6.3.  Caloric  intake  and  resting  energy  expenditure  of  18  patients  with  advanced 
pancreatic  cancer  at  baseline  and  after  3  weeks  administration  of  a  fish  oil-enriched  nutritional 
supplement. 
Duration  of  Caloric  intake  REE  REE/kg  body  REE/kg  lean  Nitrogen 
supplement  (kcal/day)  (kcal/day)  weight  body  mass  balance 
administration  (kcal/kg/day)  (kcal/kg/day)  (g) 
0  1450  1339  24.2  34.0  -0.8 
(1048-2043)  (1159-1448)  (23.1-27.7)  (29.6-35.6)  (-4.9-+1.3) 
3  weeks  1798  a  1303  b  24.0  c  31.8  d  +1.9  e 
(1355-2474)  (1186-1470)  (20.2-25.8)  (27.7-33.9)  (-1.  ]-+2.8) 
Figures  are  median  (interquartile  range). 
Paired  comparison  of  value  at  3  weeks  versus  baseline  using  Wilcoxon  signed  rank  test 
REE  -  Resting  energy  expenditure. 
a  p=0.0016  d  p=0.018 
b  p=0.18  e  p=0.016 
c  p=0.025 
Nitrogen  balance 
Patients  had  a  significant  improvement  in  their  nitrogen  balance  from  -0.8g/day  at  baseline 
to  +1.9g/day  after  3  weeks  (p=0.016)  (table  6.3). 
Acute  phase  protein  response 
Values  for  serum  CRP  concentration  before  commencement  of  the  supplement  and 
changes  after  3  and  7  weeks  are  shown  in  tables  6.1  and  6.2.  There  was  also  no  change  in  the 
percentage  of  patients  exhibiting  an  APPR  as  defined  by  a  CRP  "1  0mg/l  throughout  the  study 
period. 
Fatty  acid  analysis 
Fatty  acid  content  of  plasma  phospholipids  of  patients  before  commencement  of 
supplement  and  after  3  weeks  are  presented  in  table  6.4.  There  was  a  statistically  significant 
increase  in  both  EPA  and  DHA  in  plasma  phospholipids  after  3  weeks. 
Performance  status  and  appetite 
Scores  for  Karnofsky  performance  status  before  administration  of  the  supplement  and 
change  after  3  and  7  weeks  are  shown  in  tables  6.1  and  6.2.  There  was  a  statistically  significant 
improvement  in  Karnofsky  performance  status  compared  with  baseline  after  3  and  7  weeks 
administration  of  the  supplement  (p=0.0047  and  0.046  respectively). 
Appetite  scores  before  administration  of  the  supplement  and  change  after  3  and  7  weeks 
are  shown  in  tables  6.1  and  6.2.  There  was  a  statistically  significant  improvement  in  appetite  at 
3  weeks  (p=0.0095). Chapter  6  92 
Table  6.4.  Percentage  of  fatty  acids  in  plasma  phospholipid  profile  of  18  patients  with  advanced 
pancreatic  cancer  at  baseline  and  after  3  weeks  administration  a  fish  oil-enriched  nutritional 
supplement. 
Fatty  acid  Percentage  at 
baseline 
Percentage  after  3 
weeks  supplement 
p  value 
EPA  20:  5n-3  0.5  5.2  0.0003 
(0.2-1.6)  (2.6-6.7) 
DHA  22:  6n-3  2.9  4.8  0.0086 
(1.6-3.9)  (3.3-5.3) 
ALA  18:  3n-3  0.7  1.1  0.11 
(0-1.1)  (0.6-1.8) 
AA  20:  4n-6  6.4  5.1  0.33 
(4.1-7.5)  (4.3-6.4) 
LA  18:  2n-6  18.6  15.8  0.040 
(16.2-20.2)  (12.5-18.3) 
OA  18:  l  n-9  25.8  21.8  0.11 
(19.8-30.7)  (19.1-24.4) 
POA16:  In-7  3.7  3.1  0.28 
(2.9-4.6)  (2.1-3.9) 
SA  18:  0  9.4  10.6  0.62 
(8.5-11.3)  (9.4-11.7) 
PA  16:  0  32.0  33.2  0.79 
(29.3-33.2)  (29.8-35.0) 
Figures  are  median  (interquartile  range). 
Paired  comparison  of  value  at  3  weeks  versus  baseline  using  Wilcoxon  signed  rank  test 
EPA  -  eicosapentaenoic  acid 
DHA  -  docosahexaenoic  acid 
ALA  -  alpha  linolenic  acid 
AA  -  arachidonic  acid 
LA  -  linoleic  acid 
OA  -  Oleic  acid 
POA  -  Palmitoleic  acid 
SA  -  Stearic  acid 
PA  -  Palmitic  acid 
See  appendix  1 Chapter  6  93 
Survival 
Nineteen  of  the  patients  have  died.  One  patient  remained  alive  at  14  months  from  the  time 
of  diagnosis.  The  survivor  has  histological  confirmation  of  the  diagnosis  of  pancreatic 
adenocarcinoma.  The  censored  median  survival  from  the  time  of  diagnosis  for  all  patients  was 
254  days  (124-311).  The  censored  median  survival  from  the  time  of  commencing  the  supplement 
was  170  days  (90-270).  Survival  is  shown  in  figure  6.2. 
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Figure  6.2.  Duration  of  survival  of  20  patients  with  advanced  pancreatic  cancer  from  time  of 
commencement  offish  oil-enriched  nutritional  supplement. Chapter  6 
Discussion 
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In  the  present  chapter,  the  administration  of  a  nutritional  supplement  enriched  with  fish  oil 
resulted  in  weight  gain  in  a  group  of  patients  with  advanced  pancreatic  cancer  who  had 
previously  been  losing  weight  at  a  median  rate  of  2.9kg  per  month. 
Not  all  of  the  patients  who  entered  the  present  study  completed  the  7  week  study  period. 
This  is  a  reflection  of  the  advanced  stage  at  presentation  and  subsequent  poor  survival  of  patients 
with  pancreatic  cancer.  By  observing  weight  change  in  those  survivors  who  remained  on  study 
at  3  (n=  18/20)  and  7  (n=13/20)  weeks  there  might  be  a  bias  to  overestimate  the  overall  efficacy 
of  EPA  as  an  anti-cachectic  agent.  Nevertheless,  the  finding  of  weight  gain  in  the  majority  of 
patients  at  both  time  points  contrasts  markedly  with  previous  study  of  patients  receiving 
supportive  care  alone  which  demonstrated  near  uniform  progressive  weight  loss  in  patients  with 
this  disease  (Wigmore  et  al,  1997a  and  Chapter  3).  In  addition,  previous  controlled  trials  of  oral 
nutritional  supplementation  in  patients  with  advanced  cancer  have  succeeded  in  increasing 
nutritional  intake  but  have  not  been  able  to  show  any  change  in  weight  change  compared  with 
controls  (Evans  et  al,  1987,  Ovesen  et  al,  1993b).  There  was  a  variation  in  response  of  patients 
in  the  present  study  with  some  continuing  to  lose  weight.  The  factors  determining  response  are 
not  clear  as  there  was  no  relationship  between  weight  change  and  disease  stage,  previous  surgery 
or  the  acute  phase  response.  Such  analysis  is  complicated  by  the  fact  that  even  patients  who 
continued  to  lose  weight  experienced  a  slowing  of  their  rate  of  weight  loss  with  the 
administration  of  the  trial  supplement. 
It  has  been  reported  that  increased  body  weight  following  parenteral  and  enteral  nutritional 
support  in  cancer  patients  is  largely  due  to  the  accumulation  of  body  water  (Cohn  et  al,  1982). 
However,  in  the  present  study  there  was  no  change  in  hydration  as  total  body  water  as  a 
percentage  of  body  weight  remained  stable.  Values  for  lean  body  mass  and  fat  mass  were 
derived  from  bioimpedence  measurements.  Overall  there  was  a  small  but  statistically  significant 
increase  in  lean  body  mass  with  administration  of  the  supplement  while  fat  mass  remained 
stable.  The  coefficient  of  variation  for  the  estimate  of  lean  body  mass  has  been  estimated  to  be 
around  2kg  (Jensen  et  al,  1997).  Most  of  the  changes  documented  in  this  study  were  around  this 
value  and  therefore  the  interpretation  of  data  on  individual  patients  is  difficult.  Nevertheless,  the 
changes  for  the  group  as  a  whole  suggest  that  patients  were  laying  down  lean  tissue  rather  than 
fat  to  account  for  weight  gain  and  this  may  have  contributed  to  the  observed  rise  in  Karnofsky 
performance  status.  This  contrasts  with  studies  of  synthetic  progestogens  such  as 
medroxyprogesterone  acetate  and  megestrol  acetate  in  similar  patients  in  whom  weight  gain  is 
due  to  the  accumulation  of  fat  (Loprinzi  et  al,  1993,  Simons  et  al,  1998).  Measurements  of 
MAMC  and  TSF  demonstrated  no  significant  change  from  baseline  levels  but  this  is  not Chapter  6  95 
surprising  given  the  small  changes  in  bioimpedence  derived  body  composition  seen.  However, 
they  do  provide  supporting  evidence  that  protein  and  fat  reserves  were  at  least  stabilised  with 
administration  of  the  fish  oil-enriched  supplement.  These  findings  are  in  contrast  to  the 
continuing  decline  in  MAMC  and  TSF  (Wigmore  et  al,  1997a)  and  Karnofsky  performance 
status  (Chapter  3)  seen  in  similar  patients  who  undergo  no  specific  intervention. 
Patients  in  this  study  achieved  a  significant  increase  in  nutritional  intake  and  a  relative  fall 
in  resting  energy  expenditure.  Patients  did  not  simply  replace  normal  food  intake  with  the 
supplement  provided.  Overall,  patients  had  an  improvement  in  energy  balance  of  around 
500kcal  per  day.  This  is  entirely  compatible  with  the  weight  gain  seen  and  may  have  provided 
additional  energy  for  activities  of  daily  living,  reflected  in  the  observed  improvements  in 
Karnofsky  performance  status.  Appetite  appeared  to  increase  over  the  early  part  of  the  study 
period  and  may  account  for  the  overall  increase  in  food  intake.  The  improvement  in  nitrogen 
balance  of  around  2g  per  day  is  also  compatible  with  the  gain  in  lean  body  mass  suggested  by 
body  composition  analysis. 
The  fish  oil-enriched  nutritional  supplement  was  well  tolerated  with  all  patients  able  to 
consume  over  one  can  (237m1)  per  day  and  15  of  18  managing  over  1.75  cans  per  day.  The  only 
adverse  event  attributable  to  the  trial  preparation  was  steatorrhoea  in  two  patients.  A  further 
patient  described  worsening  of  their  pre-existing  steatorrhoea.  Steatorrhoea  is  common  in 
patients  with  advanced  pancreatic  cancer  (Perez  et  al,  1983). 
There  was  a  marked  rise  in  levels  of  EPA  and  DHA  in  plasma  phospholipids  representing 
5.2%  and  4.8%  respectively  of  fatty  acids  after  3  weeks  of  receiving  the  supplement.  This  also 
provided  an  objective  measure  of  patient  compliance.  Such  a  pattern  of  change  is  similar  to  that 
previously  reported  following  fish  oil  supplementation  (Leaf  and  Weber,  1988,  Wigmore  et  al, 
1996).  The  percentage  of  EPA  incorporation  achieved  is  similar  to  that  seen  after 
supplementation  with  crude  fish  oil  capsules  in  pancreatic  cancer  patients  given  a  similar  final 
dose  equivalent  to  2g  EPA  per  day  after  a  dose  escalation  period  (Wigmore  et  al,  1996). 
Down-regulation  of  pro-inflammatory  cytokine  release  and  C-reactive  protein 
concentrations  have  been  demonstrated  in  pancreatic  cancer  patients  following  the 
administration  of  EPA  for  one  month  (Wigmore  et  al,  1997d).  CRP  may  be  used  as  a  marker  for 
pro-inflammatory  cytokine  activity  in  vivo.  In  the  present  cohort  of  patients,  the  proportion  with 
an  elevated  CRP  remained  stable  throughout  the  study  period.  In  patients  with  advanced 
pancreatic  cancer  receiving  no  specific  intervention,  CRP  tends  to  rise  with  disease  progression 
(Falconer  et  al,  1994a  and  Chapter  3).  The  provision  of  fish  oil  supplementation  provided  by  the 
trial  supplement  in  the  current  study  may  have  prevented  this  progressive  rise  in  CRP.  A  more 
detailed  analysis  of  the  full  spectrum  of  acute  phase  proteins  and  their  modulation  in  this  group 
of  patients  is  presented  in  Chapter  8. Chapter  6  96 
Polyunsaturated  fatty  acids  such  as  EPA  have  been  shown  to  have  an  inhibitory  effect  on 
human  pancreatic  carcinoma  cell  lines  in  vitro  (Falconer  et  al,  1994b).  These  effects  may  occur 
via  cell  cycle  arrest  and  the  induction  of  apoptosis  (Lai  et  al,  1996).  EPA  will  also  slow  the 
growth  of  experimental  tumors  in  mice  (Beck  et  al,  1991)  and  it  is  possible  that  part  of  the  effect 
upon  cachexia  seen  in  the  present  study  was  secondary  to  inhibition  of  tumor  growth.  However, 
serial  tumor  imaging  in  pancreatic  cancer  is  difficult  to  interpret  and  expensive  and  was  thus  not 
performed. 
Overall  survival  of  patients  with  pancreatic  cancer  is  very  poor  with  a  median  of  4.1 
months  (Ahlgren,  1996).  Median  survival  from  diagnosis  in  the  present  study  was  over  8 
months  although  a  condition  of  enrolment  was  that  survival  was  expected  to  be  over  2  months. 
Similar  conditions  apply  to  most  chemotherapy  trials  where  median  survival  of  untreated 
patients  has  been  noted  to  be  between  63  and  122  days  and  overall  median  survival  of  treated 
patients  to  be  between  160-170  days  (Fearon  et  al,  1996).  Clearly,  overall  survival  in  this  study 
is  at  the  upper  end  of  that  seen  in  chemotherapy  trials  but  without  the  side-effects  associated  with 
chemotherapy.  A  recent  randomised,  controlled  study  of  a  mixed  fish  oil  preparation  (providing 
around  3g  of  EPA  and  2g  of  DHA  daily)  in  a  group  of  patients  with  advanced  cancer  has 
suggested  a  modest  survival  benefit  for  those  patients  receiving  fish  oil  (Gogos  et  al,  1998). 
The  study  presented  in  this  chapter  suggests  that  a  fish  oil-enriched  nutritional  supplement 
has  the  potential  to  be  a  safe,  effective  anti-cachectic  agent,  in  contrast  to  conventional 
nutritional  supplements.  A  randomised,  controlled  trial  would  be  required  to  confirm  the 
observed  anti-cachectic  effect,  evaluate  any  effect  on  survival  and  reveal  any  as  yet  undetected 
side-effects.  Such  a  study  is  currently  under  way. 
The  next  chapter  examines  the  effects  of  the  fish  oil-enriched  nutritional  supplement  on 
potential  mediators  of  cachexia. Chapter  6 
Appendix  to  Chapter  6 
Changes  in  functional  and  quality  of  life  measurements  in  weight  losing 
pancreatic  cancer  patients  after  the  provision  of  fish  oil-enriched  nutritional 
supplement 
As  a  prelude  to  a  planned  randomised  trial  a  number  of  functional  and  quality  of  life 
measures  were  studied  in  subgroups  of  the  patients  in  this  study. 
Methods 
Patients  and  interventions  were  as  previously  described. 
Fatigue  score 
Subjects  were  asked  to  describe  their  fatigue  on  a  10  point  linear  analogue  scale  from  10  (most 
fatigued)  to  0  (least  fatigued)  (Christensen  et  al,  1982).  This  was  assessed  in  7  patients. 
Grip  strength 
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Subjects'  grip  strength  was  measured  in  the  seated  position  with  the  nondominant  hand  using  a 
hand  grip  dynamometer  (Grip-A,  Takai,  Japan).  The  best  of  three  attempt  was  taken  with  a  rest 
of  around  2  minutes  between  attempts  (Schroeder  &  Hill,  1991).  This  was  assessed  in  7  patients. 
Peak  expiratory  flow  rate 
Peak  expiratory  flow  rate  was  measured  with  a  peak  flow  meter  (Vitalograph).  The  best  of  three 
attempt  was  taken  with  a  rest  of  around  2  minutes  between  attempts.  This  was  assessed  in  7 
patients. 
Quality  of  life  measures 
Four  different  questionnaires  were  used  to  assess  quality  of  life  in  various  patients.  The  Hospital 
Anxiety  Depression  scale  (Zigmond  &  Snaith,  1983)  and  the  Rotterdam  Symptom  Checklist  (de 
Haes  et  al,  1990,  Watson  et  al,  1992)  were  assessed  in  12  patients  and  the  European  Organisation 
for  Research  and  Treatment  of  Cancer  Quality  of  Life  Questionnaire  C30  (Aaronson  et  al,  1993) 
and  the  EuroQOL  group  5D  questionnaire  were  assessed  in  7  patients.  Copies  of  the 
questionnaires  are  included  in  appendix  3. Chapter  6 
Statistics 
Results  are  presented  as  median  and  range. 
Results  and  discussion 
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The  performance  of  patients  in  the  functional  and  quality  of  life  assessments  are  presented 
in  table  6.5.  The  presentation  of  quality  of  life  data  is  controversial  but  in  this  instance  we  have 
chosen  to  present  data  by  domain.  Numbers  were  too  small  to  make  meaningful  comparisons 
with  changes  in  weight  or  performance  status.  In  general,  however,  the  majority  of  patients 
showed  stable  or  improved  function  and  quality  of  life.  The  EQ-5D  score  and  Rotterdam 
Symptom  Checklist  appeared  less  able  to  demonstrate  a  change  with  many  patients  remaining 
unchanged  or  with  small  changes  in  absolute  values. 
Key  for  Table  6.5 
Fatigue  scale  -  0-10  -  higher  score  =  worse  function 
PEFR  -  peak  expiratory  flow  rate 
HAD  -  Hospital  Anxiety  Depression  scale  -  Score  of  8-11  or  more  suggests  high 
likelihood  of  anxiety  or  depression 
RSC  -  Rotterdam  Symptom  Checklist  - 
Physical,  psychological  -  high  score  =  more  symptoms 
Activity  -  high  score  =  poor  activity 
Overall  -  high  score  =  poor  quality  of  life 
QLQ-C30  -  function  -  high  score  =  good  function 
global  -  high  score  =  good  quality  of  life 
symptoms  -  high  score  =  more  symptoms 
EQ-5D  -  Score  and  thermometer  -  higher  score  =  better  quality  of  life Chapter  6  99 
Table  6.5.  Performance  of  patients  in  the  functional  and  quality  of  life  assessments  at  baseline 
and  after  3  weeks  offish  oil-enriched  nutritional  supplement. 
Baseline  3  weeks  Proportion  p  value 
improving 
or  stable 
Fatigue  4  4  6/7  0.085 
(0-10)  (2-6)  (2-5) 
Grip  strength  36  37  6/7  0.047 
(kg)  (25-45)  (26-48) 
PEFR  360  380  5/7  0.67 
(1/min)  (270-510)  (310-520) 
HAD  5  4  5/12  0.93 
Anxiety  (0-21)  (0-13)  (0-17) 
HAD  4  6  6/12  0.39 
Depression  (1-10)  W(1-11) 
RSC  25  27  6/12  0.93 
Physical  (%)  (12-65)  (6-56) 
RSC  26  25  6/12  0.89 
Psychological  (0-62)  (0-71) 
RSC  12  9  11/12  0.18 
Activity  (0-62)  (0-62) 
RSC  38  38  9/12  0.74 
Overall  (0-75)  (0-75) 
QLQ-C30  77  83  6/7  0.075 
Function  (%)  (44-86)  (53-97) 
QLQ-C30  24  18  5/7  0.67 
Symptom  (13-53)  (8-47) 
QLQ-C30  58  67  5/7  0.29 
Global  (25-67)  (33-75) 
EQ-5D  0.76  0.73  5/7  1.0 
Score  (0-1)  (0.36-0.80)  (0.29-1.0) 
EQ-5D  60  70  6/7  0.074 
Thermometer  (%)  (34-70)  (28-80) 
Figures  presented  are  median  (range). 
Comparison  by  Wilcoxon  signed  rank  test. Chapter  7  100 
Metabolic  mediators  in  cancer  patients  and  the  effects  of  a  fish  oil- 
enriched  nutritional  supplement. 
Summary 
Weight  loss  in  cancer  is  often  refractory  to  conventional  nutritional  supplementation 
perhaps  due  to  a  variety  of  metabolic  changes.  Such  metabolic  abnormalities  may  be  mediated 
in  part  by  pro-inflammatory  cytokines,  hormones  and  tumour  derived  products.  In  Chapter  6  it 
was  demonstrated  that  a  fish  oil-enriched  nutritional  supplement  could  reverse  the  loss  of  lean 
tissue  in  cachectic  cancer  patients  and  thus  may  overcome  the  aforementioned  metabolic 
changes.  This  chapter  examines  a  number  of  potential  mediators  of  cachexia  in  the  same  group 
of  advanced  pancreatic  cancer  patients  before  and  after  receiving  the  fish  oil-enriched 
supplement  and  compares  them  with  a  group  of  healthy  controls. 
Serum  concentration  of  interleukin-6  and  its  soluble  receptor,  tumour  necrosis  factor 
receptor  55  and  75  and  leptin,  peripheral  blood  mononuclear  cell  production  of  interleukin-1  ß, 
interleukin-6  and  tumour  necrosis  factor  and  urinary  excretion  of  proteolysis  inducing  factor 
(PIP)  were  measured  in  20  weight-losing  patients  with  pancreatic  cancer  and  6  healthy 
subjects.  Leptin  was  only  measured  in  the  cancer  patients.  Cancer  patients  were  asked  to 
consume  2  cans  per  day  of  a  nutritional  supplement  providing  a  total  of  over  600kcal  and  2g 
eicosapentaenoic  acid  per  day.  Samples  were  repeated  after  3  weeks  of  consuming  the 
supplement. 
Serum  concentrations  of  IL-6,  TNF-R55  and  TNF-R75  were  significantly  higher  in 
cancer  patients  than  controls.  There  was  a  significant  correlation  between  concentrations  of 
these  cytokines  and  the  level  of  the  acute  phase  response  measured  as  the  C-reactive  protein 
concentration.  There  was  no  significant  difference  in  production  of  the  measured  cytokines 
between  cancer  patients  and  controls.  However,  there  was  a  significant  correlation  between  IL- 
6  production  and  the  acute  phase  response.  PIF  was  excreted  by  89%  of  the  weight  losing 
cancer  patients  and  none  of  the  controls  (p=0.0002). 
After  3  weeks  of  consumption  of  the  fish  oil-enriched  nutritional  supplement  there  was 
no  change  in  serum  cytokine  or  leptin  concentrations.  However,  there  was  a  significant  fall  in 
the  production  of  interleukin-6  and  a  fall  in  the  proportion  of  patients  excreting  PIP. 
Modulation  of  production  of  IL-6  and  other  mediators  of  cachexia  by  the  fish  oil- 
enriched  nutritional  supplement  examined  in  the  present  study  may  explain  the  beneficial 
nutritional  effects  seen  in  Chapter  6. Chapter  7 
Introduction 
Chapter  6  described  the  reversal  of  weight  loss  in  a  group  of  patients  with  advanced 
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pancreatic  cancer  given  a  nutritional  supplement  enriched  with  fish  oil.  A  significant  increase 
in  nutritional  intake  was  also  noted.  However,  previous  studies  of  nutritional  intervention  in 
patients  with  advanced  cancer  have  failed  to  show  any  nutritional  benefit  despite  an  increase  in 
caloric  intake  (Evans  et  al,  1987,  Ovesen  et  al,  1993b).  This  thesis  has  been  exploring  the 
hypothesis  that  the  failure  of  nutritional  intervention  alone  to  affect  weight  loss  in  advanced 
cancer  is  due  to  a  combination  of  metabolic  changes  which  prevent  the  efficient  use  of  these 
nutrients.  Mediators  of  these  changes  are  thought  to  include  pro-inflammatory  cytokines  (as 
described  in  Chapters  4  and  5),  hormones  and  tumour  specific  products.  Weight  losing  patients 
with  cancer  have  been  observed  to  have  upregulation  of  interleukin  (IL)-6  and  tumour  necrosis 
factor  (TNF)  production  (Falconer  et  al,  1994a),  to  have  an  elevated  cortisol/insulin  ratio 
(Fearon  et  al,  1998)  and  to  excrete  in  their  urine  proteolysis  inducing  factor  (PIF),  a  newly 
described  glycoprotein  which  causes  muscle  protein  breakdown  when  administered  to  animals 
(Todorov  et  al,  1996a).  Leptin  is  a  hormone  produced  by  fat  which  affects  energy  expenditure 
and  appetite  (Zhang  et  al,  1994).  It  has  been  suggested  that  in  inflammatory  models  leptin 
concentrations  are  inappropriately  high,  perhaps  contributing  to  hypermetabolism  (Grunfeld  et 
al,  1996a) 
Fish  oil  is  rich  in  the  n-3  polyunsaturated  fatty  acid  eicosapentaenoic  acid  (EPA).  EPA 
and  fish  oil  have  been  shown  to  reduce  production  of  pro-inflammatory  cytokines  by  isolated 
peripheral  blood  mononuclear  cells  in  both  healthy  volunteers  (Endres  et  al,  1989,  Meydani  et 
al,  1993)  and  pancreatic  cancer  patients  (Wigmore  et  al,  1997).  It  has  also  been  suggested  that 
EPA  may  modulate  the  activity  of  PIF  on  muscle  in  vitro  (Tisdale,  1996). 
The  present  chapter  examines  the  effects  of  a  fish  oil-enriched  nutritional  supplement 
upon  a  variety  of  cytokine  and  hormonal  mediators  and  other  metabolic  indicators  in  an  attempt 
to  explain  the  mechanisms  whereby  addition  of  fish  oil  to  a  conventional  nutritional 
supplement  may  alter  the  metabolic  milieu  and  allow  some  restoration  of  body  composition. Chapter  7  102 
Methods 
Patients  and  fish  oil-enriched  nutritional  supplement 
Enrolment  criteria  and  patients  studied  and  the  fish  oil-enriched  nutritional  supplement 
administered  are  described  in  Chapter  6. 
6  weight  stable  healthy  controls  were  also  studied. 
Venous  blood  samples  were  collected  at  Bam  after  an  overnight  fast.  After  baseline 
sampling  cancer  patients  were  administered  2  cans  per  day  of  the  fish  oil-enriched  nutritional 
supplement  and  underwent  repeat  blood  sampling  after  3  weeks. 
Blood  samples  were  assessed  for  concentrations  of  IL-6,  soluble  IL-6  receptor  (sIL-6R), 
soluble  TNF  receptor  (sTNF-R)  55  and  75,  C-reactive  protein  and  leptin.  Peripheral  blood 
mononuclear  cells  (PBMC)  isolated  from  blood  samples  were  assessed  for  their  production  of 
IL-1,  TNFa  and  IL-10. 
24  hour  urine  collections  from  before  and  after  intervention  were  assessed  for  the 
presence  of  PIF. 
Further  details  of  methods  are  found  in  Chapter  2. Chapter  7 
Results 
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Baseline  mediator  status 
Serum  concentrations  of  IL-6,  sIL-6R,  TNF-R55  and  TNF-R75  are  shown  in  table  7.1. 
Concentrations  of  IL-6  and  the  TNFa  receptors  were  significantly  higher  in  the  cancer  patients 
than  controls  (p<0.006).  sIL-6R  concentrations  were  not  significantly  different  between  the 
two  groups  (p=0.10). 
There  was  no  significant  difference  in  PBMC  production  of  IL-1  13,  IL-6  or  TNFa 
between  cancer  patients  and  controls  (p>0.33)  (table  7.1). 
17  of  19  weight  losing  cancer  patients  had  detectable  PIF  in  urine  at  baseline  while  it 
was  detected  in  the  urine  of  none  of  the  6  control  subjects  (p=0.0002)  (figure  7.4). 
Table  7.1.  Serum  cytokine  concentration  and  peripheral  blood  mononuclear  cell  cytokine 
(PBMC)  production  of  18  weight  losing  pancreatic  cancer  patients  and  6  healthy  controls. 
Cancer  patients  Healthy  controls  p  value 
Serum  IL-6  6.0  1.75  0.0055 
(pg/ml)  (2.5-7.9)  (1.5-2.75) 
Serum  slL-6R  107.6  85.5  0.10 
(ng/ml)  (80.0-127.8)  (48.8-100.0) 
Serum  TNF-R55  1.71  1.09  0.0051 
(ng/ml)  (1.23-1.88)  (0.92-1.17) 
Serum  TNF-R75  3.46  2.22  0.0051 
(ng/ml)  (2.78-4.26)  (1.52-2.59) 
PBMC  IL-1  0  production  2.33  3.80  0.33 
(ng/ml)  (1.64-3.60)  (2.19-4.93) 
PBMC  IL-6  production  16.5  12.5  0.44 
(ng/ml)  (10.5-28.4)  (9.4-21.8) 
PBMC  TNFa  production  0.77  0.84  0.67 
(ng/ml)  (0.62-1.69)  (0.43-1.25) 
Figures  are  median  and  interquartile  range. 
Comparison  by  Mann  Whitney  U  test. Chapter  7  104 
Mediator  status  after  3  weeks  fish  oil-enriched  nutritional  supplement 
As  described  previously,  patients  tolerated  the  supplement  well,  consuming  a  median  of 
1.9  cans/day  (range  1.25-2.0).  The  18  evaluable  patients  had  a  median  prestudy  weight  loss  of 
17.9%  (interquartile  range  15.9-20.7)  and  a  rate  of  weight  loss  of  2.9kg/month  (-3.9--2.1). 
After  3  weeks  of  consumption  of  the  fish  oil-enriched  supplement  patients  had  a  median  weight 
gain  of  1.0kg  (interquartile  range  -0.1-+2.0)  (p=0.024  versus  baseline). 
There  was  no  significant  change  in  the  serum  concentration  of  IL-6,  sTNF-RI,  sTNF- 
RII  or  slL-6R  over  the  3  week  supplementation  period  (figure  7.1). 
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Figure  7.1.  Serum  concentrations  of  interleukin-6  (IL-6)  (filled  square),  soluble  tumour 
necrosis  factor  I  (sTNF-RI)  (triangle)  and  II  (sTNF-RII)  (circle)  and  soluble  interleukin-6 
receptor  (sIL-6R)  (open  square)  in  18  patients  with  advanced  pancreatic  cancer  at  baseline 
and  after  3  weeks  consumption  of  a  fish  oil-enriched  nutritional  supplement.  Graphs  show 
median  and  interquartile  range.  Comparison  by  Wilcoxon  signed  rank  test. Chapter  7  105 
There  was  a  significant  fall  in  IL-6  production  by  peripheral  blood  mononuclear  cells 
stimulated  with  lipopolysaccharide  and  cultured  in  fetal  calf  serum  (p=0.015)  after  3  weeks  of 
the  trial  supplement.  There  was  a  trend  to  reduced  production  of  IL-1  ß  in  cells  cultured  under 
these  conditions  (p=0.068)  but  no  change  in  TNF  production  (p=0.55)  (figure  7.2).  There  was 
no  significant  change  in  PBMC  production  of  the  measured  cytokines  when  cells  were  cultured 
without  lipopolysaccharide  or  in  autologous  plasma. 
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Figure  7.2.  Peripheral  blood  mononuclear  cell  production  of  interleukin-6  (IL-6)  (square), 
tumour  necrosis  factor  (TNFa)  (triangle)  and  interleukin-1  ß  (IL-1  f3)  (circle)  in  18  patients 
with  advanced  pancreatic  cancer  at  baseline  and  after  3  weeks  consumption  of  a  fish  oil- 
enriched  nutritional  supplement.  Graphs  show  median  and  interquartile  range.  Comparison 
by  Wilcoxon  signed  rank  test. Chapter  7 
There  was  no  significant  change  in  the  serum  concentration  of  leptin  over  the 
supplementation  period  (p=0.38)  (figure  7.3). 
There  was  a  significant  fall  in  the  proportion  of  patients  with  detectable  excretion  of 
PIF  in  urine  from  89%  at  baseline  to  40%  after  3  weeks  of  the  fish  oil-enriched  nutritional 
supplement  (p=0.0022)  (figure  7.4). 
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Figure  7.3.  Serum  concentration  of  leptin  in  18  patients  with  advanced  pancreatic  cancer  at 
baseline  and  after  3  weeks  consumption  of  a  fish  oil-enriched  nutritional  supplement.  Graph 
shows  median  and  interquartile  range.  Comparison  by  Wilcoxon  signed  rank  test. 
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Figure  7.4.  Proportion  of  healthy  control  subjects  and  patients  with  advanced  pancreatic 
cancer  excreting  proteolysis  inducing  factor  in  urine  at  baseline  and  after  3  weeks 
consumption  of  a  fish  oil-enriched  nutritional  supplement.  Comparison  by  Chi  squared  test. 
Healthy  controls Chapter  7  107 
Relationship  between  serum  cytokines  or  cytokine  production  and  the  acute  phase  response 
There  was  a  statistically  significant  relationship  between  the  concentration  of  a  number 
of  cytokines  and  the  concentration  of  C-reactive  protein  in  the  cancer  patients  (IL-6  -  r=0.50, 
p=0.0023,  TNF-R55  -  r=0.59,  p=0.0004,  TNF-R75  -  r=0.57,  p=0.0005).  There  was  also  a 
marginal  but  statistically  significant  relationship  between  PBMC  IL-6  production  and  C- 
reactive  protein  (r=0.39,  p=0.025). 
Further  details  of  the  acute  phase  response  in  the  control  and  patient  groups  are  found  in 
Chapter  8. Chapter  7 
Discussion 
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The  study  presented  in  this  chapter  has  demonstrated  that  there  are  increases  in  serum 
pro-inflammatory  cytokine  concentrations  and  PIF  excretion  in  weight  losing  pancreatic  cancer 
patients  when  compared  with  healthy  controls.  Similar  differences  in  the  concentrations  of  IL- 
6  and  the  TNF  receptors  were  described  in  an  overlapping  group  of  pancreatic  cancer  patients 
using  different  ELISA  kits  described  in  Chapter  4.  However,  the  present  chapter  did  not 
demonstrate  any  upregulation  of  cytokine  production  by  PBMCs  isolated  from  the  cancer 
patients  compared  with  controls  (despite  increased  circulating  concentrations  of  IL-6  and  TNF 
receptors  in  the  cancer  patients'  serum).  It  has  previously  been  assumed  that  ex  vivo  cytokine 
production  is  a  better  measure  of  the  true  in  vivo  situation  than  circulating  serum 
concentrations  (Falconer  et  al,  1994a)  and  higher  cytokine  production  has  previously  been 
shown  in  pancreatic  cancer  patients  (Falconer  et  al,  1994a,  Wigmore  et  al,  1997d).  Cytokine 
production  in  the  healthy  controls  was  variable  in  the  present  study  and  it  may  be  that  this, 
combined  with  the  small  number  of  control  subjects  obscured  any  difference.  The  use  of 
different  batches  of  fetal  calf  serum  or  endotoxin  may  also  have  affected  culture  conditions  and 
therefore  cytokine  production.  Patients  in  the  present  study  were  recruited  at  a  relatively  early 
stage  in  their  disease  in  an  attempt  to  ensure  survival  for  follow  up  after  intervention  and  this 
may  also  have  contributed  to  the  difference  between  the  present  study  and  previous  studies  of 
apparently  similar  patients. 
PIF  was  initially  found  to  be  produced  by  an  experimental  murine  cancer  cell  line  and 
shown  to  induse  protein  breakdown  in  vitro  (Todorov  et  al,  1996a).  An  identical  glycoprotein 
has  been  isolated  from  the  urine  of  weight-losing  cancer  patients  but  not  those  losing  weight 
for  other  reasons  (Todorov  et  al,  1996b,  Cariuk  et  al,  1997).  In  the  present  study  no  PIF 
excretion  was  observed  in  healthy  controls  while  the  majority  of  the  weight-losing  cancer 
patients  did  have  detectable  PIF  in  urine  (in  line  with  previous  observations). 
With  regard  to  the  changes  observed  after  the  administration  of  a  fish  oil-enriched 
nutritional  supplement  the  present  study  has  shown  that  in  a  group  of  cachectic  pancreatic 
cancer  patients  the  weight  gain  described  in  Chapter  6  is  associated  with  a  significant  fall  in 
peripheral  blood  mononuclear  cell  IL-6  production  and  a  fall  in  the  proportion  of  patients 
excreting  PIF. 
Fish  oil  and  EPA  have  been  shown  to  reduce  production  of  IL-1,  IL-6  and  TNFa  from 
stimulated  peripheral  blood  mononuclear  cells  isolated  from  healthy  volunteers  after 
consuming  1-3g  EPA  per  day  for  16-24  weeks  (Endres  et  al,  1989,  Meydani  et  al,  1993)  and  of Chapter  7  109 
IL-6  in  pancreatic  cancer  patients  given  6g  EPA  daily  for  4  weeks  (Wigmore  et  al,  1997d). 
Although  not  observed  in  the  present  study,  perhaps  due  to  reasons  discussed  above, 
production  of  IL-6  and  TNFa  may  be  elevated  in  weight-losing  patients  with  pancreatic  cancer 
(Falconer  et  al,  1994a,  Wigmore  et  al,  1997d).  The  present  study  has  shown  a  significant 
reduction  in  IL-6  production  and  a  trend  to  a  reduction  in  IL-11  after  3  weeks  of  fish  oil 
supplementation  in  pancreatic  cancer  patients  receiving  the  equivalent  of  2g  EPA  per  day. 
There  was  no  change  in  TNFa  production.  The  significance  of  these  findings  is  unclear  in  the 
light  of  the  similarity  in  cytokine  production  between  patients  and  controls.  However,  the 
observation  that  there  was  a  weak  correlation  between  the  ex  vivo  production  of  IL-6  and 
serum  CRP  concentration  from  the  cancer  patients  suggests  that  this  mediator  is  of  importance 
in  determining  the  APPR.  In  addition,  Chapter  3  demonstrated  a  tendency  for  progression  of 
the  acute  phase  response  (stimulated  by  pro-inflammatory  cytokines)  with  time.  This  stability 
of  acute  phase  protein  production  and  circulating  concentrations  may  represent  a  change  from 
the  progressive  upregulation  in  patients  without  intervention. 
TNFa  is  frequently  not  detected  in  the  serum  of  cachectic  cancer  patients  (Socher  et  al, 
1988)  and  it  has  been  suggested  that  circulating  concentrations  of  the  soluble  TNF  receptors 
may  give  a  better  estimate  of  tissue  TNFot  production  (Olsson  et  al,  1993).  The  role  of  soluble 
IL-6  receptors  in  the  inflammatory  state  remains  unclear,  although  it  has  been  suggested  that  it 
may  help  to  mediate  the  IL-6  signal  in  cells  lacking  membrane  receptors  (Taga  et  al,  1989). 
However,  the  present  study  did  not  reveal  any  reduction  in  the  concentrations  of  1L-6,  sIL-6R 
or  TNF  receptors  in  pancreatic  cancer  patients  administered  a  fish  oil-enriched  nutritional 
supplement  despite  these  cytokines  being  found  in  elevated  concentrations  in  the  cancer 
patients.  IL-1  ß  was  only  detectable  in  the  serum  of  two  of  the  patients  in  the  present  study. 
The  relationship  of  serum  IL-6  and  the  TNF  receptors  with  CRP  concentration  observed  in  the 
present  study  is  similar  to  that  described  in  Chapter  4. 
The  present  study  found  no  change  in  the  concentration  of  leptin  after  3  weeks 
receiving  the  trial  supplement.  Leptin  is  a  hormone  produced  by  fat  which  decreases  food 
intake  and  increases  energy  expenditure  (Zhang  et  al,  1994).  It  has  been  suggested  that  leptin 
concentrations  are  increased  in  inflammatory  states,  thus  contributing  to  weight  loss  in  animal 
models  (Grunfeld  et  al,  1996,  Sarraf  et  al,  1997).  However,  leptin  concentrations  would  appear 
to  be  appropriately  low  in  human  cancer  cachexia  (Simons  et  al,  1997).  Body  composition 
analysis  of  patients  in  the  present  study  suggested  that  the  weight  gained  was  largely  lean  tissue 
with  no  change  observed  in  fat  mass  (see  chapter  6).  Thus  no  great  change  in  leptin 
concentrations  would  have  been  expected. Chapter  7  110 
EPA  has  been  shown  to  inhibit  muscle  protein  breakdown  by  PIF  in  vitro  (Tisdale  et  al, 
1996).  The  present  study  has  shown  that  the  administration  of  a  fish  oil-enriched  nutritional 
supplement  results  in  a  reduction  in  the  proportion  of  patients  excreting  PIF  in  the  urine 
perhaps  suggesting  that  EPA  will  not  only  inhibit  the  end-organ  effects  of  PIF  but  also  reduce 
its  production. 
The  present  chapter  has  demonstrated  that  the  positive  changes  in  weight  and  body 
composition  produced  by  the  fish  oil-enriched  nutritional  supplement  in  cachectic  cancer 
patients  are  associated  with  down-regulation  of  some  mediators  of  the  metabolic  response  to 
cancer  which  have  previously  been  suggested  to  prevent  weight  gain  in  such  patients. 
Modulation  of  these  mediators  by  the  fish  oil  component  of  the  supplement  may  explain  this 
beneficial  effect. 
The  next  chapter  describes  details  of  the  acute  phase  protein  response  in  pancreatic 
cancer  patients  without  intervention  and  after  receiving  the  fish  oil-enriched  nutritional 
supplement. Chapter  8  111 
Progression  of  the  acute  phase  response  in  cancer  patients  and  the 
effects  of  a  fish  oil-enriched  nutritional  supplement 
Summary 
The  presence  of  an  acute  phase  protein  response  (APPR)  has  been  suggested  to  shorten 
survival  and  contribute  to  weight-loss  in  patients  with  pancreatic  cancer.  Fatty  acids  derived 
from  fish  oil  have  been  shown  to  alter  pro-inflammatory  cytokine  production  and  acute  phase 
protein  synthesis  in  vitro.  The  study  presented  in  this  chapter  was  designed  to  determine  the 
effects  of  a  fish  oil-enriched  nutritional  supplement  upon  the  concentrations  of  a  range  of 
individual  acute  phase  proteins  in  patients  with  advanced  pancreatic  cancer.  18  patients  with 
pancreatic  cancer  received  the  supplement  (providing  2g  eicosapentaenoic  acid  and  1g 
docosahexaenoic  acid  per  day)  for  3  weeks  while  another  18  received  full  supportive  care 
alone.  Six  healthy  subjects  served  as  additional  controls.  Acute  phase  proteins  were  measured 
before  and  after  the  3  week  intervention  period  in  cancer  patients.  At  baseline  albumin, 
transferrin  and  pre-albumin  were  significantly  reduced  and  fibrinogen,  haptoglobin,  (x-  I  -acid 
glycoprotein,  a  -1-antitrypsin,  ceruloplasmin  and  C-reactive  protein  (CRP)  were  significantly 
elevated  in  the  cancer  patients  compared  with  healthy  controls  (reflecting  their  roles  as 
negative  and  positive  acute  phase  proteins  respectively).  In  the  supplemented  cancer  group  the 
only  significant  change  in  acute  phase  protein  concentrations  over  the  3  week  study  period  was 
an  increase  in  transferrin.  In  the  control  cancer  group  there  were  further  significant  reductions 
in  albumin,  transferrin  and  pre-albumin  and  a  significant  increase  in  CRP  concentration.  These 
results  suggest  that  many  positive  and  negative  acute  phase  proteins  are  altered  in  advanced 
pancreatic  cancer.  The  APPR  tends  to  progress  in  untreated  patients  but  may  be  stabilized  by 
the  administration  of  a  fish  oil-enriched  nutritional  supplement.  This  may  have  implications 
upon  the  progress  of  wasting  in  such  patients  and  may  help  explain  the  nutritional  benefits  of 
the  fish  oil-enriched  supplement  described  in  Chapter  6. Chapter  8 
Introduction 
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The  previous  chapter  described  a  reduction  in  IL-6  production  (known  to  stimulate  the 
acute  phase  protein  response)  with  the  administration  of  a  fish  oil-enriched  nutritional 
supplement.  However,  in  Chapter  6,  although  a  reversal  of  weight  loss  with  this  supplement 
was  demonstrated,  there  was  no  significant  change  in  the  concentration  of  the  positive  acute 
phase  protein,  C-reactive  protein  (CRP).  This  would  appear  counter  to  the  hypothesis  that  if 
the  inflammatory  state  and  acute  phase  protein  response  were  key  metabolic  processes 
preventing  weight  gain  with  conventional  nutrition  in  cancer  then  the  arrest  of  weight  loss 
would  be  associated  with  an  attenuation  of  the  acute  phase  response.  However,  Chapter  3 
suggested  that  there  is  a  progressive  rise  in  CRP  in  untreated  cachectic  cancer  patients.  This 
progressive  rise  was  not  observed  in  the  Chapter  6  and  thus  may  have  reflected  a  change  from 
the  expected  progression  of  the  APPR,  modulated  by  the  supplement. 
The  acute  phase  protein  response  (APPR)  is  seen  following  a  wide  variety  of  insults  to 
the  body  including  trauma,  infection,  inflammation  and  cancer.  C-reactive  protein  (CRP)  is 
the  archetypal  positive  acute  phase  protein  in  humans  (Baumann  &  Gauldie,  1994)  and  is 
widely  used  as  a  marker  for  the  acute  phase  response  in  clinical  practice.  Previous  studies 
have  shown  that  at  diagnosis  about  40%  of  patients  with  pancreatic  cancer  exhibit  an  elevated 
serum  level  of  C-reactive  protein.  This  proportion  increases  until  about  80%  have  an  elevated 
CRP  level  close  to  the  time  of  death  (Falconer  et  al,  1994a).  Similar  findings  were  described 
in  Chapter  3.  An  elevated  CRP  level  has  been  found  to  be  an  independent  and  robust  predictor 
of  poor  survival  in  pancreatic  cancer  (Falconer  et  al,  1995)  and  this  was  confirmed  in  Chapter 
5. 
In  the  human  hepatocyte  the  production  of  acute  phase  proteins  is  regulated  by 
interleukin  (IL)-6  and  other  pro-inflammatory  cytokines  (Castell  et  al,  1990).  Thus  the  level  of 
the  acute  phase  response  in  vivo  may  be  taken  as  indirect  evidence  of  pro-inflammatory 
cytokine  production.  The  work  presented  in  Chapter  4  supports  this  assumption.  From  studies 
in  animal  models  a  variety  of  pro-inflammatory  cytokines  have  been  strongly  implicated  in 
both  the  anorexia  and  altered  metabolism  thought  to  contribute  to  cancer  cachexia  (Tracey  et 
al,  1988,  Yasumoto  et  al,  1995).  However,  it  is  not  known  whether  the  loss  of  lean  tissue  in 
cachexia  is  due  to  a  direct  effect  of  cytokines  at  the  level  of  skeletal  muscle  or  whether  net  loss 
of  muscle  protein  is  due  to  indirect  effects  of  altered  metabolism  elsewhere  or  a  combination  of 
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It  has  been  suggested  that  with  the  induction  of  the  acute  phase  response  in  the  face  of 
an  inadequate  dietary  intake,  the  imbalance  in  amino  acid  composition  between  skeletal  muscle 
and  acute  phase  proteins  may  contribute  to  increased  loss  of  muscle  (Reeds  et  al,  1994). 
Clearly  for  this  mechanism  to  be  important  there  would  have  to  be  a  uniform  upregulation  of 
the  positive  acute  phase  proteins  whose  serum  concentrations  are  measured  in  gram  quantities 
and  that  have  a  high  turnover  rate.  However,  there  is  little  information  on  the  range  of  acute 
phase  proteins  that  are  upregulated  in  cachectic  cancer  patients. 
Cancer  cachexia  has  proven  resistant  to  intervention  with  supplemental  enteral  or 
parenteral  nutrition  (Nixon  et  al,  1981,  Ovesen  et  al,  1993).  This  may  be  due  to  metabolic 
changes,  including  the  APPR,  which  are,  at  least  in  part,  stimulated  by  increased  tumour  or 
host  production  of  pro-inflammatory  cytokines  (Castell  et  al,  1990,  Falconer  et  al,  1994, 
Strassmann  et  al,  1993,  Yasumoto  et  al,  1995).  We  have  previously  shown  that  fish  oil  or 
eicosapentaenoic  acid  (EPA),  a  polyunsaturated  fatty  acid  derived  from  fish  oil,  administered 
to  patients  with  advanced  pancreatic  cancer  may  attenuate  weight-loss  whilst  down-regulating 
production  of  IL-6  and  serum  levels  of  CRP  (Wigmore  et  al,  1996,  Wigmore  et  al,  1997d).  In 
vitro  work  has  suggested  that  EPA  may  have  differential  effects  on  a  spectrum  of  acute  phase 
proteins  produced  in  response  to  IL-6  (Wigmore  et  al,  1997e). 
The  present  chapter  was  designed  to  explore  the  effect  of  the  administration  of  a 
nutritional  supplement  enriched  with  fish  oil,  rich  in  EPA,  upon  progress  of  the  acute  phase 
protein  response  in  patients  with  advanced  pancreatic  cancer  in  comparison  with  patients 
receiving  full  supportive  care  alone,  looking  at  the  levels  of  several  individual  acute  phase 
proteins. Chapter  8 
Methods 
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After  informed  consent  and  local  ethical  committee  approval,  36  weight-losing  patients 
with  a  diagnosis  of  advanced  pancreatic  cancer  based  on  histological  or  unequivocal 
radiological  or  operative  findings  were  studied  and  compared  with  6  healthy  individuals. 
Weight  was  measured  with  subject  in  light  clothing  without  shoes  using  a  beam  scale.  No 
subjects  had  clinically  evident  oedema  or  ascites. 
All  subjects  underwent  venous  blood  sampling  at  least  three  weeks  after  surgery  or  bile 
duct  stenting.  The  initial  18  patients  received  full  supportive  care  alone  and  underwent  a 
further  venous  blood  sample  after  a  median  of  28  days.  The  subsequent  18  patients  received  2 
cans  per  day  of  a  nutritional  supplement  enriched  with  fish  oil  providing  a  total  of  2.6  MJ,  32.2 
g  protein,  99.4  g  carbohydrate,  13  g  fat,  2.18  g  EPA  and  0.92  g  docosahexaenoic  acid  (DHA) 
in  a  volume  of  480  mL  as  described  previously.  After  a  median  of  24  days  a  second  venous 
blood  sample  was  taken.  (The  two  patients  who  were  unable  to  be  reassessed  after 
consumption  of  the  supplement  as  described  in  Chapter  6  were  not  considered  in  the  current 
chapter). 
Samples  were  assessed  for  the  concentration  of  the  positive  APP  C-reactive  protein, 
a-1-antitrypsin,  a-1-acid  glycoprotein,  haptoglobin  and  ceruloplasmin  and  the  negative  APP, 
albumin,  prealbumin  and  transferrin,  at  both  timepoints.  The  positive  APP  fibrinogen  was 
measured  at  baseline  only. Chapter  8 
Results 
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Subject  characteristics 
Characteristics  of  the  patient  groups  and  controls  are  shown  in  table  8.1.  Patients  were 
well  matched  for  age  and  disease  stage.  Cancer  patients  were  slightly  older  than  healthy 
controls. 
Table  8.1.  Characteristics  of  cancer  patients  and  healthy  controls. 
UICC  disease 
Prestudy  stage 
n  Age  weight  loss  234 
(%) 
Cancer  patients  receiving  fish  18  64  17.9  828 
oil-enriched  supplement  (56-66)  (15.9-20.7) 
Cancer  patients  receiving  18  60  11.8  10  26 
supportive  care  (54-70)  (5.6-23.5) 
Healthy  controls  6  54*  0 
(50-56) 
Values  are  median  (interquartile  range) 
*p=0.017  between  all  cancer  patients  and  healthy  controls  by  Mann  Whitney  U  test Chapter  8  116 
Acute  phase  protein  concentrations  in  cancer  patients  compared  with  healthy  controls 
Serum  concentrations  of  the  negative  acute  phase  proteins,  albumin,  prealbumin  and 
transferrin  were  significantly  lower  in  cancer  patients  than  healthy  controls  (figure  8.1). 
Concentrations  of  the  positive  acute  phase  proteins,  CRP,  fibrinogen,  a-1-antitrypsin,  a-1-acid 
glycoprotein,  haptoglobin  and  ceruloplasmin  were  significantly  higher  in  cancer  patients  than 
healthy  controls. 
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Figure  8.1.  Concentrations  of  a  cute  phase  proteins  in  36  patients  with  advanced  pancreatic 
cancer  and  6  healthy  controls.  Graphs  show  median  and  interquartile  range.  Comparison  by 
Mann-Whitney  U  test. Chapter  8 
Effect  of  feeding  nutritional  supplement  enriched  with  fish  oil  on  acute  phase  protein 
concentrations  and  nutritional  status  in  cancer  patients 
Patient  groups  were  well  matched  for  baseline  serum  levels  of  acute  phase  proteins 
117 
although  ceruloplasmin  concentration  was  significantly  higher  in  patients  receiving  supportive 
care  alone  (table  8.2). 
Table  8.2.  Baseline  serum  levels  of  acute  phase  proteins  from  patients  with  advanced 
pancreatic  cancer  who  subsequently  received  nutritional  supplement  enriched  with  fish  oil  and 
those  who  went  on  to  receive  full  supportive  care  alone. 
Cancer  patients  receiving  Cancer  patients  receiving 
supplement  supportive  care 
C-reactive  protein  (mg/L)  <5  11 
[<5]  (<5-21)  (<5-30) 
a-1-acid  glycoprotein  1.12  1.33 
(g/L)  (0.89-1.39)  (0.94-2.10) 
[0.55-1.4] 
a-l-antitrypsin  (g/L)  2.07  2.22 
[1.1-2.3]  (1.62-2.33)  (1.76-2.73) 
Haptoglobin  (g/L)  2.01  2.26 
[0.5-2.0]  (1.45-2.21)  (1.75-2.63) 
Ceruloplasmin  (g/L)  0.30  0.38* 
[0.15-0.3]  (0.27-0.35)  (0.32-0.44) 
Albumin  (g/L)  41  41 
[36-47]  (38-43)  (35-44) 
Prealbumin  (g/L)  0.20  0.22 
[0.15-0.4]  (0.14-0.22)  (0.13-0.30) 
Transferrin  (g/L)  2.17  2.38 
[2.2-4.0]  (1.89-2.61)  (2.01-2.75) 
Total  positive  APP  5.53  6.28 
(g/L)  (4.74-6.38)  (5.10-7.40) 
Total  negative  APP  43.6  43.7 
(gIL)  (40.2-45.4)  (36.4-46.8) 
Normal  range  in  squared  brackets  Values  are  median  (interquartile  range) 
*p=0.035  comparison  between  patient  groups  by  Mann  Whitney  U  test Chapter  8  118 
There  was  a  significant  difference  in  the  pattern  of  weight  loss  between  the  two  groups 
with  those  receiving  the  supplement  gaining  a  median  of  lkg  (as  shown  in  chapter  6)  while 
those  receiving  supportive  care  lost  a  median  of  2.8kg  (table  8.3). 
Table  8.3.  Baseline  weight  and  change  in  weight  in  patients  with  advanced  pancreatic  cancer 
receiving  nutritional  supplement  enriched  with  fish  oil  and  those  receiving  full  supportive  care 
only. 
Initial  weight  Change  in  weight 
(kg)  (kg) 
Cancer  patients  receiving  supplement  1  55.0  +1.0 
(46.5-60.5)  (-0.1-+2.0) 
Cancer  patients  receiving  supportive  care  58.5  -2.8* 
(47.8-70.7)  (-3.7--1.7) 
Values  are  median  (interquartile  range) 
*p=0.0001  comparison  between  patient  groups  by  Mann  Whitney  U  test Chapter  8  119 
There  were  significant  differences  in  the  changes  observed  in  the  serum  concentrations 
of  CRP,  albumin,  prealbumin  and  transferrin  between  supplemented  and  unsupplemented 
cancer  patients  over  the  study  period  (figure  8.2). 
A=  Cancer  patients  receiving  fish  oil-enriched  supplement,  n=18 
=  Cancer  patients  receiving  supportive  care  alone,  n=18 
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Figure  8.2.  Percentage  changes  in  concentrations  of  acute  phase  proteins  in  weight  losing 
patients  with  advanced  pancreatic  cancer  given  either  nutritional  supplement  enriched  with 
fish  oil  or  full  supportive  care.  Graphs  show  median  and  interquartile  range.  Comparison 
between  groups  by  Mann-Whitney  U  test. Chapter  8 
In  patients  receiving  the  nutritional  supplement  enriched  with  fish  oil,  there  were  no 
significant  changes  from  baseline  in  serum  acute  phase  protein  levels  over  the  assessment 
period  apart  from  a  rise  in  the  concentration  of  the  negative  acute  phase  protein  transferrin 
(p=0.031).  In  patients  receiving  full  supportive  care,  there  was  a  further  increase  in  the 
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concentration  of  the  positive  acute  phase  protein  CRP  (p=0.0013)  and  a  further  reduction  in  the 
concentration  of  the  negative  acute  phase  proteins  albumin,  prealbumin  and  transferrin 
(p=0.012,0.0048  and  0.038  respectively). 
Overall  changes  in  concentration  of  acute  phase  proteins  in  cancer  patients 
Total  measured  positive  acute  phase  proteins  did  not  change  significantly  in  each  group 
although  there  was  a  trend  towards  an  increase  in  the  cancer  patients  who  received  supportive 
care  alone  (p=0.07).  However,  there  was  a  marked  difference  in  the  pattern  of  total  production 
of  negative  acute  phase  proteins  between  the  two  patient  groups  with  a  significant  increase  in 
those  receiving  the  nutritional  supplement  enriched  with  fish  oil  (p=0.048)  and  a  significant 
decrease  in  those  receiving  supportive  treatment  (p=0.016).  Thus,  the  difference  between  the 
groups  was  highly  significant  (p=0.0012)  (table  8.4). 
Table  8.4.  Changes  in  total  production  of  positive  and  negative  acute  phase  proteins  in 
patients  with  advanced  pancreatic  cancer  receiving  nutritional  supplement  enriched  with  fish 
oil  and  those  receiving  full  supportive  care  only  over  the  4  week  study  period. 
Change  in  total  positive  Change  in  total  negative 
acute  phase  proteins  (g/L)  acute  phase  proteins  (g/L) 
Cancer  patients  receiving  -0.02  +1.32 
supplement  (-0.19-+0.53)  (-1.07-+2.95) 
Cancer  patients  receiving  +0.42  -2.44* 
supportive  care  (-0.30-+1.24)  (-5.72-+0.28) 
Measured  positive  acute  phase  proteins  were  C-reactive  protein,  a-l-antitrypsin,  a-1-acid 
glycoprotein,  haptoglobin  and  ceruloplasmin.  Measured  negative  acute  phase  proteins  were 
albumin,  prealbumin  and  transferrin. 
Values  are  median  (interquartile  range) 
*p=0.0012  comparison  between  patient  groups  by  Mann  Whitney  U  test Chapter  8  121 
Discussion 
In  the  present  study  the  concentrations  of  CRP,  fibrinogen,  a-  I  -antitrypsin,  a-1-acid 
glycoprotein,  haptoglobin  and  ceruloplasmin  were  significantly  higher  in  cancer  patients  than 
healthy  controls  whilst  albumin,  prealbumin  and  transferrin  were  significantly  lower.  This 
finding  reflects  the  role  of  these  proteins  as  positive  and  negative  acute  phase  proteins 
respectively  (Baumann  &  Gauldie,  1994)  and  confirms  the  tendency  for  patients  with  advanced 
cancer  to  exhibit  an  APPR  as  observed  previously  in  pancreatic  and  other  malignancies 
(Falconer  et  al,  1994,  Staal-van  den  Brekel  et  al,  1995,  Wayman  et  al,  1997). 
It  is  possible  that  the  so-called  negative  acute  phase  reactants  (Albumin,  prealbumin 
and  transferrin)  might  also  have  been  reduced  as  a  result  of  the  relative  protein-calorie 
malnutrition  observed  in  the  cancer  patients.  Indeed,  following  administration  of  the  fish  oil 
enriched-supplement  the  weight  of  patients  increased  as  did  transferrin  concentration  and  this 
may  reflect  the  role  of  the  latter  as  a  fast-turnover  hepatic  protein  sensitive  to  short-term 
improvements  in  nutritional  status. 
Although  hepatocyte  albumin  secretion  may  be  reduced  in  vitro  by  pro-inflammatory 
cytokines  (Castell  et  al,  1990)  it  has  been  demonstrated  recently  that  in  cachectic  cancer 
patients  with  hypoalbuminaemia  and  an  ongoing  APPR,  albumin  synthesis  rates  are  unaltered 
(Fearon  et  al,  1998  and  see  also  chapter  10).  Thus  the  low  serum  albumin  concentration 
observed  in  the  present  study  is  likely  to  reflect  either  an  increased  transcapillary  escape  rate, 
an  increased  degradation  rate  or  a  combination  of  the  two.  Transcapillary  escape  has  been 
shown  to  occur  at  an  elevated  rate  in  weight-losing  cancer  patients  and  has  been  suggested  to 
contribute  to  the  hypoalbuminemia  of  the  acute  phase  response  (Fleck  et  al,  1985).  However, 
lymphatic  return  must  be  similarly  increased  as  there  is  no  relationship  between  transcapillary 
escape  and  albumin  concentration  (Ballmer  et  al,  1994)  and  no  change  in  the  intravascular 
albumin  pool  with  elevated  transcapillary  escape  (Ballmer-Weber  et  al,  1995). 
The  demand  for  specific  amino  acids  to  manufacture  positive  acute  phase  proteins  in 
patients  with  an  inadequate  nutritional  intake  has  been  suggested  to  contribute  to  ongoing 
muscle  protein  breakdown  (Reeds  et  al,  1994)  and  in  a  prolonged  APPR  this  may  lead  to 
accelerated  weight-loss  and  a  shortened  survival.  Although  the  present  study  was  not  a  formal 
randomized  trial,  cancer  patients  who  received  the  fish  oil-enriched  nutritional  supplement  had 
no  change  in  the  concentration  of  total  positive  acute  phase  proteins  but  total  negative  acute 
phase  proteins  increased  compared  with  patients  receiving  supportive  care  alone.  This 
suggests  either  an  attenuation  of  the  APPR,  an  improvement  in  nutritional  status  or,  more Chapter  8  122 
likely,  a  combination  of  the  two.  The  patients  receiving  supportive  care  alone  had  no 
significant  change  in  total  positive  acute  phase  proteins  but  sustained  a  further  fall  in  negative 
acute  phase  proteins.  This  suggests  either  progression  of  the  APPR,  a  further  reduction  in 
nutritional  status  or,  again,  a  combination  of  the  two.  It  has  been  suggested,  however,  that  the 
negative  acute  phase  proteins  are  not  good  indicators  of  nutritional  status  in  the  presence  of  an 
acute  phase  response  (Fleck,  1989). 
The  supplement  used  in  this  study  contained  appreciable  amounts  of  the  DHA  in 
addition  to  EPA.  DHA  is  a  closely  related  polyunsaturated  fatty  acid,  also  of  the  n-3  class, 
which  is  metabolised  to  EPA  in  vivo  (von  Schacky  &  Weber,  1985).  The  relative  contribution 
of  these  two  agents  to  the  effects  observed  in  the  present  study  is  not  clear.  In  addition,  it  is 
likely  that  the  patients  receiving  the  supplement  consumed  more  calories  and  protein  than 
those  receiving  supportive  care  so  it  is  not  possible  to  discriminate  an  effect  of  EPA  on  the 
APPR  and  hence  nutritional  status  from  a  direct  effect  of  the  calories  and  protein  supplied. 
However,  previous  studies  of  conventional  oral  supplements  in  cancer  patients  have 
demonstrated  no  effect  on  either  serum  albumin  concentration  or  body  weight  (Evans  et  al, 
1987,  Ovesen  et  al,  1993)  suggesting  that  the  effects  observed  in  the  present  study  are  at  least 
in  part  due  to  the  fish  oil  component  of  the  supplement.  EPA  at  a  dose  of  6g  daily  has  been 
shown  to  reduce  CRP  concentrations  in  pancreatic  cancer  patients  over  4  weeks  (Wigmore  et 
al,  1997).  Fish  oil  preparations  providing  between  1  and  4g  EPA  daily  have  also  been  shown 
to  reduce  plasma  fibrinogen  concentrations  in  healthy  and  hyperlipidaemic  subjects  after  as 
little  as  3  weeks  (Hostmark  et  al,  1988,  Radack  et  al,  1989,  Saynor  &  Gillott,  1992). 
The  link  between  the  concentration  of  various  plasma  proteins  and  changes  in  whole 
body  nitrogen  kinetics  is  complex.  Under  normal  circumstances  hepatic  protein  synthesis  is 
thought  to  contribute  about  15-20%  of  whole  body  protein  turnover.  During  an  APPR  the 
contribution  of  hepatic  protein  synthesis  is  thought  to  rise,  with  the  synthesis  of  individual 
acute  phase  reactants  such  as  fibrinogen  increasing  markedly  (Preston  et  al,  1998  and  see  also 
chapter  10).  The  measured  concentration  of  a  plasma  protein  is  the  end  result  of  a  variety  of 
processes  including  synthesis,  degradation  and  distribution  between  the  extravascular  and 
intravascular  pools.  Thus  although  synthesis  might  increase,  if  degradation  also  increases  the 
net  effect  may  be  no  change  in  the  plasma  concentration  but  a  significant  alteration  in  overall 
protein  turnover.  If  the  latter  process  is  not  100%  efficient,  this  would  result  in  net  protein  loss 
from  the  body  and  accelerated  wasting.  It  has  been  previously  demonstrated  that  in  fasting 
cancer  patients  with  an  ongoing  APPR,  fibrinogen  synthesis  is  increased  by  around  200% 
while  the  plasma  concentration  is  increased  by  some  50%  (Preston  et  al,  1998).  However, Chapter  8  123 
while  the  rate  of  albumin  synthesis  is  unchanged  plasma  concentrations  are  may  be  decreased 
by  around  25%  (Fearon  et  al,  1998).  Thus  further  interpretation  of  the  changes  in  acute  phase 
protein  concentrations  in  the  present  study  requires  further  evaluation  with  kinetic  studies  in 
order  to  determine  their  true  relation  to  nutritional  status  in  general  and  nitrogen  economy  in 
particular.  Unfortunately,  examination  of  synthesis  and,  more  so,  degradation  of  many  acute 
phase  proteins  is  methodologically  extremely  difficult  due  to  their  relatively  low  circulating 
concentrations.  Further  studies  of  the  synthesis  of  albumin  and  fibrinogen  in  cancer  patients 
are  found  in  Chapter  10. 
Several  explanations  exist  for  the  mechanism  of  the  apparent  stabilisation  of  the  APPR 
in  patients  receiving  the  fish  oil-enriched  supplement  observed  in  the  present  study.  In  vitro, 
the  APPR  is  largely  regulated  by  IL-6  (Castell  et  al,  1990).  It  has  been  shown  previously  that 
patients  with  advanced  pancreatic  cancer  exhibiting  an  APPR  have  elevated  production  of  IL-6 
by  isolated  peripheral  blood  mononuclear  cells  (Falconer  et  al,  1994a)  (although  this  was  not 
observed  in  chapter  7)  and  that  the  administration  of  a  pure  preparation  of  EPA  will  reduce  this 
production  of  IL-6  to  control  levels  (Wigmore  et  al,  1997d).  The  previous  chapter 
demonstrated  a  decrease  in  IL-6  production  in  the  intervention  group  in  the  present  study.  The 
production  of  pro-inflammatory  cytokines  and  APPs  is  controlled  to  some  extent  by  the 
transcription  factor  NF-KB  (Beauparlant  and  Hiscott  1996).  Polyunsaturated  fatty  acids  have 
been  shown  to  activate  NF-KB  but  initial  work  suggests  that  EPA  has  little  effect  on  this 
pathway  in  vitro  (Camandola  et  al,  1996).  The  administration  of  polyunsaturated  fatty  acids  to 
hepatocytes  in  culture  has  suggested  that  EPA  may  have  direct  effects  on  the  modulation  of 
APP  production  (Wigmore  et  al,  1997e).  Additional  elucidation  of  the  mechanism  of  action  of 
the  fish  oil-enriched  supplement  used  in  the  present  study  and  the  relative  contributions  of  its 
components  requires  further  study. 
A  randomised  study  would  have  been  preferable.  A  sequential  design  was  used  as  the 
trial  preparation  was  not  available  initially,  thus  patients  who  would  have  been  recruited  for 
interventional  studies  were  studied  with  best  supportive  care  in  the  meantime. 
In  summary,  the  present  study  suggests  that  the  improvements  in  nutritional  status  and 
the  modulation  of  metabolic  mediators  produced  by  a  fish  oil-enriched  nutritional  supplement 
in  weight  losing  patients  with  advanced  cancer  (described  in  Chapters  6  and  7),  occurs  in 
association  with  the  prevention  of  progression  of  the  APPR. 
The  next  chapter  examines  the  metabolic  response  to  feeding  in  cachectic  cancer 
patients  and  the  effects  of  the  fish  oil-enriched  supplement  on  the  response  to  feeding. Chapter  9  124 
The  metabolic  response  to  feeding  in  cancer  patients  and  the  effects  of 
a  fish  oil-enriched  nutritional  supplement 
Summary 
Cachectic  patients  with  advanced  cancer  often  fail  to  gain  weight  even  when  additional 
nutrients  are  supplied.  Increased  energy  expenditure  has  been  reported  in  cancer  patients  and  an 
increased  metabolic  response  to  feeding  may  prevent  the  effective  use  of  additional  nutrients 
supplied.  However,  the  work  presented  in  Chapters  6,7  and  8  has  suggested  that  eicosapentaenoic 
acid  (EPA)  -based  preparations  may  elements  of  the  metabolic  changes  of  cancer  cachexia.  This 
hypothesis  is  examined  further  in  the  present  chapter. 
Sixteen  weight-losing,  non-diabetic  patients  with  unresectable  pancreatic  adenocarcinoma 
were  compared  with  six  healthy,  weight-stable  controls.  After  baseline  indirect  calorimetry, 
subjects  received  four  hourly  meals  of  a  liquid  feed,  each  providing  a  twelfth  of  the  estimated  total 
daily  energy  requirement.  Indirect  calorimetry  and  measurement  of  serum  insulin  and  glucose 
concentrations  were  performed  regularly  over  the  four  hour  feeding  period.  Body  composition 
was  estimated  by  bioimpedence  analysis  and  urine  collection  allowed  calculation  of  urinary 
nitrogen  excretion.  Cancer  patients  were  then  given  a  fish  oil-enriched  nutritional  supplement 
providing  2g  of  EPA  and  600kcal  daily  and  underwent  repeat  metabolic  study  after  3  weeks. 
At  baseline,  overall  resting  energy  expenditure  was  not  significantly  different  between 
patients  and  controls.  However,  energy  expenditure  per  kg  body  weight,  lean  body  mass  or  body 
cell  mass  was  significantly  greater  in  the  cancer  patients.  Changes  in  insulin  and  glucose 
concentrations  in  the  cancer  patients  over  the  feeding  period  suggested  relative  glucose 
intolerance.  The  percentage  change  in  the  area  under  the  curve  of  energy  expenditure  was 
significantly  lower  in  the  cancer  patients  (median  7.9%  (interquartile  range  3.4-9.0))  than  controls 
(12.6%  (9.9-15.1),  p=0.0051).  Fat  oxidation  was  significantly  higher  in  the  fasting  state  in  the 
cancer  patients  (median  1.26g/kg/min  (interquartile  range  0.95-1.38)  than  controls  (0.76g/kg/min 
(0.62-0.92),  p=0.020). 
After  3  weeks  of  consuming  the  fish  oil-enriched  supplement  the  weight  of  the  cancer 
patients  increased  and  there  was  a  statistically  significant  increase  in  the  energy  expenditure  in Chapter  9  125 
response  to  feeding  (9.6%  (6.3-12.4))  such  that  it  was  no  longer  different  from  baseine  values  in 
healthy  controls  (p=0.073).  Similarly,  fasting  fat  oxidation  fell  to  1.02g/kg/min  (0.8-1.18),  no 
longer  significantly  different  from  baseline  healthy  control  values  (p=0.1). 
Thus,  while  it  would  appear  that  weight-losing  patients  with  advanced  pancreatic  cancer 
have  an  increased  resting  energy  expenditure  they  do  not  exhibit  any  increase  in  the  metabolic  cost 
of  feeding  (to  account  for  their  lack  of  anabolic  response  to  feeding)  but  in  fact  show  a  reduction 
appropriate  to  their  wasted  state.  In  addition,  provision  of  a  fish  oil-enriched  nutritional 
supplement  resulted  in  some  normalisation  of  the  metabolic  state.  This  work  also  emphasises  the 
importance  of  considering  the  fed  state  when  examining  metabolic  changes  in  disease. Chapter  9 
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As  discussed  in  Chapters  l  and  3,  weight  loss  is  a  major  cause  of  morbidity  and  mortality 
in  patients  with  advanced  cancer  (Warren  et  al,  1935,  Ovesen  et  al,  1993a).  Such  cancer  patients 
often  have  a  reduced  dietary  intake.  However,  while  it  is  possible  to  increase  energy  intake  by 
enteral  or  parenteral  means,  this  seems  to  have  no  impact  on  patients'  progressive  weight  loss 
(Nixon  et  al,  1981,  Evans  et  al,  1987,  American  College  of  Physicians,  1989,  Veterans 
Administration,  1991,  Ovesen  et  al,  1993b).  This  has  led  to  the  suggestion  that  there  is  a 
metabolic  block  to  the  accretion  of  lean  tissue  in  patients  with  cancer  (Nixon  et  al,  1981, 
Moldawer  and  Copeland,  1997).  The  role  of  mediators  of  this  metabolic  block  such  as  pro- 
inflammatory  cytokines,  alterations  in  the  balance  of  neuroendocrine  hormones  and  specific, 
tumour-derived  proteolytic  and  lipid  mobilising  factors  have  been  discussed  in  Chapters  1  and  7. 
It  has  been  reported  that  weight-losing  patients  with  advanced  cancer  may  have  an  increased 
resting  energy  expenditure,  particularly  those  with  an  acute  phase  protein  response  (Falconer  et  al, 
1994,  Staal-van  den  Brekel  et  al,  1994).  This  has  been  suggested  to  be  due  to  an  increase  in  futile 
metabolic  cycles  such  as  the  Cori  cycle  (Eden  et  al,  1984)  or  mitochondrial  uncoupling  proteins 
which  produce  heat  and  are  stimulated  in  inflammatory  models  with  similar  mediators  to  cancer 
(Faggioni  et  al,  1998).  However,  another  component  of  energy  expenditure  is  that  associated  with 
the  digestion  of  food  and  to  date  there  has  been  little  attempt  to  study  the  metabolic  response  to 
feeding  in  cachectic  patients.  An  exaggerated  response  to  feeding  may  to  some  extent  explain  the 
lack  of  an  anabolic  response  of  such  patients  to  the  provision  of  additional  food. 
In  Chapters  6,7  and  8  it  was  shown  that  a  nutritional  supplement  containig 
eicosapentaenoic  acid  (EPA),  an  n-3  polyunsaturated  fatty  derived  from  fish  oil,  will  reverse 
weight  loss  and  reduce  energy  expenditure  in  a  group  of  pancreatic  cancer  patients  and  will  affect 
the  production  and  action  of  a  number  of  mediators  of  cachexia  such  as  interleukin-6  and 
proteolysis  inducing  factor,  and  also  stabilise  the  acute  phase  protein  response.  It  is  possible, 
therefore,  that  such  a  preparation  will  modulate  the  metabolic  response  to  feeding. 
The  present  chapter  examines  the  metabolic  response  to  feeding  in  cachectic  cancer 
patients  (excluding  those  with  diabetes)  compared  with  healthy  controls  and  also  determines  the 
effect  on  the  response  to  feeding  of  the  administration  of  a  nutritional  supplement  containing 
eicosapentaenoic  acid  for  three  weeks  in  the  same  cancer  patients. Chapter  9  127 
Materials  and  methods 
Subjects 
Sixteen  patients  with  an  unequivocal  diagnosis  of  pancreatic  cancer  who  were  losing 
weight  with  no  clinical  evidence  of  ascites,  peripheral  oedema,  diabetes  mellitus  or  malabsorption 
were  examined  in  the  present  study  (two  patients  with  diabetes  mellitus  studied  in  previous 
chapters  were  excluded).  Six  weight-stable  healthy  individuals  served  as  controls.  None  of  the 
patients  received  chemotherapy  or  radiotherapy  and  none  had  undergone  surgery  in  the  preceding 
4  weeks.  No  patients  had  clinical  or  radiological  evidence  of  infection,  were  jaundiced  or  severely 
anemic,  or  were  receiving  steroids.  The  study  was  approved  by  the  local  ethical  committee  and  all 
subjects  gave  written  informed  consent. 
Metabolic  study  protocol 
The  study  protocol  is  presented  diagramatically  in  figure  9.1.  Subjects  attended  at  Bam  on 
two  consecutive  days.  On  the  first  day,  following  an  overnight  fast,  the  subject  rested  in  a  supine 
position  for  at  least  30  minutes  and  underwent  indirect  calorimetry  using  a  ventilated  hood 
technique  to  allow  measurement  of  energy  expenditure  and  substrate  utilisation.  A  venous  catheter 
was  inserted  into  the  subject's  antecubital  fossa  and  baseline  blood  samples  were  collected  for 
assessment  of  insulin,  cortisol  and  glucose.  C-reactive  protein  was  also  measured  to  determine  the 
presence  or  absence  of  an  acute  phase  protein  response  which  was  taken  to  be  present  if  C-reactive 
protein  concentration  was  10mg/l  or  greater. 
Subjects  were  weighed  on  spring  balance  scales  without  shoes  and  wearing  light  clothing. 
Body  composition  was  measured  by  bioelectrical  impedence  analysis. 
Energy  expenditure  was  measured  by  indirect  calorimetry  every  40  minutes  over  the 
subsequent  4  hours  for  20  minutes.  The  second  10  minute  period  of  each  measurement  was  used 
to  calculate  energy  expenditure.  Subjects  underwent  blood  sampling  for  measurement  of  serum 
insulin  and  glucose  every  60  minutes  during  this  4  hour  period. 
On  the  second  day,  following  an  overnight  fast  subjects  a  venous  catheter  was  again 
inserted  into  the  antecubital  fossa  for  blood  sampling.  Subjects  then  received  hourly  meals  for 
four  hours  of  a  balanced  whole  protein  liquid  nutritional  supplement  (Fortisip,  Nutricia, 
Zoetermeer,  Holland)  providing  a  twelfth  of  the  subjects  estimated  energy  requirement  (measured 
resting  energy  expenditure  *  1.4)  (Hunter  et  al,  1995).  The  supplement  provided  13%  of  energy 
from  protein,  48%  from  carbohydrate  and  39%  from  fat,  similar  to  a  "typical"  British  diet.  The Chapter  9  128 
subject  continued  to  rest  in  the  supine  position  during  the  feeding  period.  Energy  expenditure  was 
measured  by  indirect  calorimetry  every  40  minutes  as  on  the  previous  day  and  subjects  underwent 
blood  sampling  for  measurement  of  serum  insulin  and  glucose  every  30  minutes  during  the  feeding 
period. 
Patients  collected  urine  for  the  24  hours  prior  to  attendence.  After  emptying  their  bladders 
on  arrival,  subjects  provided  a  urine  sample  over  the  four  hour  study  period  on  each  day  to  provide 
estimation  of  fasting  and  fed  urinary  nitrogen  excretion. 
The  daily  dietary  intake  of  subjects  was  measured  based  on  the  mean  dietary  intake 
recorded  in  a3  day  food  diary. 
Fish  oil-enriched  nutritional  supplement 
After  baseline  metabolic  study,  patients  were  asked  to  consume  a  nutritional  supplement 
enriched  with  fish  oil  (providing  610kcal,  32.2g  protein,  2.2g  EPA  and  0.96g  docosahexaenoic 
acid  (DHA)  per  day)  for  3  weeks.  The  composition  of  this  product  is  shown  in  appendix  2.  After 
the  3  week  supplementation  period  patients  attended  for  repeat  metabolic  assessment. 
Baseline  metabolic  study 
(16  cancer  patients,  6  controls) 
4 
3  weeks  fish  oil-enriched  nutritional  supplementation 
4 
Repeat  metabolic  study 
(16  cancer  patients) 
Metabolic  study  protocol 
Day  1  (fasting) 
Blood  sampling  ***** 
Indirect  calorimetry  ****** 
Feed 
Urine  collection  ie 
0800  0900  1000  1100  1200 
Time 
Day  2  (fed) 
overnight 
0800  0900  1000  1100  1200 
Time 
Figure  9.1.  Study  protocol. Chapter  9 
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Subject  characteristics  are  shown  in  table  9.1.  Cancer  patients  were  older  than  the  controls 
but  groups  were  of  equal  sex  distribution.  Cancer  patients  were  significantly  lighter  than  controls 
having  lost  around  18%  of  their  preillness  stable  weight. 
Table  9.1.  Characteristics  of  weight  losing  cancer  patients  and  healthy  controls. 
Cancer  patients  (n=16)  Healthy  controls  (n=6)  p 
Age  63  54  0.014 
(years)  (56-66)  (50-62) 
Sex  7  male  3  male  1.0 
9  female  3  female 
Weight  55.2  77.2  0.0015 
(kg)  (48.8-61.2)  (70.3-96.0) 
Percentage  weight  loss  17.7  0  0.0002 
(15.3-21.4) 
Median  (interquartile  range). 
Comparison  by  Mann  Whitney  U  test  or  Chi  squared  test. 
Baseline  metabolic  study 
Baseline  fasting  metabolic  characteristics  are  shown  in  table  9.2.  There  was  no  difference 
in  overall  resting  energy  expenditure  between  the  cancer  and  control  groups.  However,  as  the 
cancer  patients  were  significantly  lighter,  energy  expenditure  expressed  per  kilogram  body  weight, 
lean  body  mass  or  body  cell  mass  was  significantly  greater  in  cancer  patients  than  controls.  There 
was  no  difference  in  energy  expenditure  between  those  cancer  patients  with  or  without  an  acute 
phase  protein  response.  However,  dietary  intake  expressed  as  a  proportion  of  resting  energy 
expenditure  was  significantly  lower  in  patients  with  an  acute  phase  protein  response  as  defined  by 
an  elevated  C-reactive  protein  concentration  (C-reactive  protein  elevated  1.0  (0.87-1.27)  versus  C- 
reactive  protein  normal  1.42  (1.11-1.62),  p=0.049). 
Fasting  serum  insulin  was  significantly  lower  in  cancer  patients  than  controls.  There  was 
no  significant  difference  between  fasting  cortisol  concentrations  between  the  two  groups. 
However,  the  cortisol  :  insulin  ratio  was  significantly  higher  in  cancer  patients.  There  was  no 
difference  in  fasting  glucose  concentrations  between  the  two  groups. O 
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In  the  fasting  state  there  was  little  change  in  metabolic  measurements  over  a4  hour  period. 
The  area  under  the  curve  of  energy  expenditure  increased  from  baseline  by  2.1%  (1.0-3.5)  in 
cancer  patients  and  by  1.1  %  (0.7-1.3)  in  controls.  This  difference  between  these  groups  was, 
however,  not  statistically  significant  (p=0.09).  There  was  a  decline  in  insulin  concentration  as  the 
fasting  period  continued  such  that  the  area  under  the  curve  decreased  from  baseline  by  13.9%  (2.9- 
40.7)  in  cancer  patients  and  27.1%  (20.2-33.0)  in  controls.  Again  there  was  no  significant 
difference  between  the  two  groups  (p=0.81). 
The  change  in  serum  insulin  concentrations  of  the  cancer  and  control  subjects  over  the 
study  feeding  period  are  shown  in  figure  9.2.  There  was  a  prompt  and  substantial  increase  in 
insulin  concentration  in  control  subjects.  Cancer  patients  had  a  slower  increase  in  insulin 
concentrations.  Insulin  concentrations  were  significantly  lower  in  cancer  patients  at  0,30,60  and 
90  minutes  (p<0.05,  Mann  Whitney  U  test).  Thereafter  there  was  no  significant  difference 
between  insulin  concentrations  between  cancer  patients  and  controls.  In  absolute  terms,  the 
change  in  insulin  concentration  over  the  study  period  in  cancer  patients  was  about  two  thirds  of 
that  in  healthy  controls  although  this  difference  did  not  reach  statistical  significance  (cancer 
patients  2195u/240mins  (954-3823)  versus  controls  3234u/240mins  (2948-5810),  p=0.11).  Due  to 
the  lower  fasting  concentration  in  cancer  patients  the  percentage  change  in  the  area  under  the  curve 
of  insulin  concentration  from  baseline  was  very  similar  between  the  two  groups  (cancer  patients 
256%  (114-371)  versus  control  subjects  216%  (163-261),  p=0.80). 
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Figure  9.2.  Change  in  serum  insulin  concentration  over  4  hour  feeding  period  in  weight  losing 
cancer  patients  (solid  line)  and  healthy  controls  (dotted  line). 
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The  change  in  glucose  concentrations  of  cancer  and  control  subjects  over  the  feeding 
period  are  shown  in  figure  9.3.  There  was  no  change  in  glucose  concentration  in  control  subjects 
over  the  feeding  period.  Cancer  patients  exhibited  an  increase  in  glucose  concentrations  over  the 
study  period  and  had  a  significantly  greater  area  under  the  curve  of  glucose  concentration  (cancer 
patients  30.7%  (24.4-48.9)  versus  control  subjects  3.4%  (-11.7-+11.6),  p=0.0064). 
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Figure  9.3.  Change  in  serum  glucose  concentration  over  4  hour  feeding  period  in  weight  losing 
cancer  patients  (solid  line)  and  healthy  controls  (dotted  line).  Median  and  interquartile  range  are 
shown.  Absolute  change  -  cancer  patients  426  mmol/240mins  (260-598)  versus  control  subjects 
38mmol/240mins  (-156-+140),  p=0.0040  Mann  Whitney  U  test. 
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The  change  in  energy  expenditure  of  cancer  and  control  subjects  over  the  study  feeding 
period  are  shown  in  figure  9.4.  Both  groups  had  a  rise  in  energy  expenditure  with  feeding.  This 
increase  was  significantly  greater  in  control  subjects  than  cancer  patients  (cancer  patients  7.9% 
(3.4-9.0)  versus  control  subjects  12.6%  (9.9-15.1),  p=0.0051).  In  absolute  terms  this  difference 
was  more  marked  (cancer  patients  14.  Okcal/200mins  (6.2-18.8)  versus  control  subjects 
25.2kcal/200mins  (21.5-33.1),  p=0.0025). 
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Figure  9.4.  Change  in  energy  expenditure  over  4  hour  feeding  period  in  weight  losing  cancer 
patients  (solid  line)  and  healthy  controls  (dotted  line).  Median  and  interquartile  range  are  shown. 
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Substrate  utilisation  rates  are  shown  in  table  9.3.  Rates  of  protein  oxidation  were  similar  in 
both  groups  in  the  fasting  state.  There  was  a  small  and  non-significant  rise  in  protein  oxidation 
with  feeding  in  both  cancer  patients  and  controls  . 
Carbohydrate  oxidation  doubled  in  controls  on 
feeding  and  tripled  in  cancer  patients,  a  statistically  significant  rise  in  both  groups.  Levels  of 
carbohydrate  oxidation  tended  to  be  higher  in  controls  compared  with  cancer  patients  but  this 
difference  was  not  statistically  significant  (Figure  9.5).  Fat  oxidation  was  significantly  higher  in 
the  fasting  state  in  cancer  patients  (median  1.26g/kg/min  (interquartile  range  0.95-1.38)  than 
controls  (0.76g/kg/min  (0.62-0.92),  p=0.020)  (Figure  9.6).  This  fell  by  26%  in  cancer  patients 
(P=0.001)  and  by  22%  in  controls  (p=0.17)  on  feeding.  In  the  fed  state  the  difference  in  fat 
oxidation  rates  was  no  longer  significantly  different  between  patients  and  controls. Chapter  9 
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Figure  9.5.  Carbohydrate  oxidation  rate  in  the  fed  and  fasting  state  in  weight  losing  cancer 
patients  and  healthy  controls.  Comparison  between  fasting  and  fed  values  by  Wilcoxon  signed 
rank  test  -  Cancer  patients  p=0.0010,  controls  -  p=0.046. 
1.5 
Fat  1.0 
oxidation  per  kg 
body  weight 
(g/kg/min) 
0.5 
0 
p=0.020 
p=0.14 
Fasting 
(Baseline) 
Fed 
(+200mins) 
   Controls 
"  Patients 
Figure  9.6.  Fat  oxidation  rate  in  the  fed  and  fasting  state  in  weight  losing  cancer  patients  and 
healthy  controls.  Comparison  between  fasting  and  fed  values  by  Wilcoxon  signed  rank  test  - 
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Cancer  patients  p=0.0010,  controls  -  p=0.17. L 
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Metabolic  study  after  3  weeks  fish  oil-enriched  nutritional  supplement 
After  3  weeks  of  the  fish  oil-enriched  nutritional  supplement  patients  had  a  median  weight 
gain  of  1.0kg  (interquartile  range  -0.25-+1.75)  (p=0.049  versus  baseline).  Prior  to  enrolment 
patients  had  a  rate  of  weight  loss  of  2.9kg/month  (-3.8--1.9).  Patients  tolerated  the  supplement 
well,  consuming  a  median  of  1.9  cans/day  (range  1.25-2.0). 
Changes  in  baseline  fasting  metabolic  characteristics  are  shown  in  table  9.2.  Resting 
energy  expenditure  did  not  change  after  the  3  week  supplementation  period  (p=0.12).  However, 
because  of  the  weight  gain  observed,  resting  energy  expenditure  per  kg  body  weight  and  per  kg 
lean  body  mass  both  fell  by  a  small  but  statistically  significant  amount  (p=0.025  and  0.0  18 
respectively). 
Serum  fasting  insulin  concentrations  rose  significantly  (p=0.0064)  over  the  3  week 
supplementation  period  and  were  no  longer  significantly  different  from  controls.  Fasting  serum 
concenrations  of  cortisol  did  not  change  after  the  supplementation  period.  However,  there  was  a 
significant  fall  in  the  cortisol:  insulin  ratio  (p=0.0084).  There  was  no  change  in  fasting  glucose 
concentration  (p=0.29). Chapter  9  138 
The  change  in  insulin  concentrations  with  feeding  after  the  3  week  supplementation  period 
is  shown  in  figure  9.7.  The  pattern  observed  was  similar  to  that  before  intervention  with 
significantly  lower  insulin  concentrations  at  30,60  and  90  minutes  but  no  difference  in  values 
thereafter.  Absolute  and  percentage  change  from  baseline  were  again  not  significantly  different 
between  patients  and  controls  studied  at  baseline.  Change  in  glucose  concentration  with  feeding 
was  no  different  after  the  3  week  supplementation  period,  with  an  increase  of  31.8%  (23.7-43.9) 
being  observed  in  the  area  under  the  curve  from  baseline. 
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Figure  9.7.  Change  in  serum  insulin  concentration  over  4  hour  feeding  period  in  weight  losing 
cancer  patients  (solid  line)  after  3  weeks  fish  oil-enriched  nutritional  supplementation.  Values  for 
healthy  controls  are  also  shown  (dotted  line).  Percentage  change  in  area  under  curve  -  cancer 
patients  202%  (135-343)  versus  control  subjects  216%  (163-261),  p=0.97  Mann  Whitney  U  test. 
Paired  comparison  with  baseline  by  Wilcoxon  signed  rank  test,  p=0.90.  Absolute  change  - 
1694u/240mins  (1160-3964)  -  p=0.18  versus  baseline,  p=0.18  versus  control. 
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The  percentage  change  in  the  area  under  the  curve  of  energy  expenditure  from  baseline  was 
9.6%  (6.3-12.4)  in  cancer  patients  after  the  3  week  supplementation  period  (figure  9.8).  This  was 
significantly  greater  than  for  the  same  subjects  at  baseline  (p=0.041)  and  was  no  longer 
significantly  different  from  healthy  controls  (p=0.073).  The  absolute  change  in  energy  expenditure 
also  increased  significantly  in  cancer  patients  to  18.8kcal/200mins  (12.3-23.0)  (p<0.033). 
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Figure  9.8.  Change  in  energy  expenditure  over  4  hour  feeding  period  in  weight  losing  cancer 
patients  (solid  line)  after  3  weeks  fish  oil-enriched  nutritional  supplementation.  Values  for  healthy 
controls  are  also  shown  (dotted  line).  Median  and  interquartile  range  are  shown.  Percentage 
change  in  area  under  curve  -  cancer  patients  9.6%  (6.3-12.4)  versus  control  subjects  12.6%  (9.9- 
15.1),  p=0.073  Mann  Whitney  U  test.  Paired  comparison  with  baseline  by  Wilcoxon  signed  rank 
test,  p=0.041.  Absolute  change  -  18.8  kcal/200mins  (12.3-23.0)  -  p=0.033  versus  baseline, 
p=0.018  versus  control. 
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Changes  in  substrate  utilisation  after  3  weeks  administration  of  the  fish  oil-enriched 
nutritional  supplement  are  shown  in  table  9.3.  Rates  of  protein  and  carbohydrate  oxidation  both 
rose  slightly  in  the  fed  and  fasting  state  in  cancer  patients  becoming  similar  to  values  observed  in 
control  subjects.  Fasting  fat  oxidation  fell  to  1.02g/kg/min  (0.8-1.18),  no  longer  significantly 
different  from  baseline  healthy  control  values  (p=0.10)  (Figure  9.9).  This  again  fell  promptly  on 
feeding  as  seen  in  control  subjects.  Median  percentage  substrate  utilisation  is  shown  in  figure 
9.10.  At  baseline  there  was  a  significant  difference  in  fat  oxidation  rate  in  the  fasting  state  between 
patients  and  controls  (figure  9.10).  However,  after  3  weeks  of  fish  oil-enriched  nutritional 
supplement  consumption  there  were  no  significant  differences  between  the  percentage  nutrient 
utilisation  of  patients  and  baseline  control  values  (figure  9.10). 
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Figure  9.9.  Fat  oxidation  rate  in  the  fed  and  fasting  state  in  weight  losing  cancer  patients  after  3 
weeks  fish  oil-enriched  nutritional  supplementation  and  healthy  controls.  Comparison  between 
fasting  and  fed  values  by  Wilcoxon  signed  rank  test  -  Cancer  patients  p=0.0045.  Paired 
comparison  with  before  supplementation  -  fasting  p=0.16,  fed  p=0.24. Chapter  9 
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Figure  9.10.  Percentage  substrate  oxidation  in  weight  losing  pancreatic  cancer  patients  (n=16) 
and  healthy  controls  (n=6)  and  the  same  cancer  patient  group  after  3  weeks  fish  oil-enriched 
nutritional  supplementation.  Median  is  shown.  Fasting  fat  oxidation  -  patients  versus  controls 
p=0.032,  Mann  Whitney  U  test.  Otherwise  p>0.1. Chapter  9 
Discussion 
142 
This  chapter  has  examined  the  metabolic  state  during  fasting  and  in  response  to  feeding  in 
weight-losing,  pancreatic  cancer  patients  compared  with  healthy,  weight  stable  controls.  Cancer 
patients  had  an  elevated  resting  energy  expenditure  per  unit  weight  and  an  increased  rate  of  fat 
oxidation  in  the  fasting  state  and  a  lower  serum  insulin  concentration.  Dietary  intake  was  lower  in 
patients  with  an  acute  phase  protein  response.  In  response  to  feeding  cancer  patients  exhibited 
relative  glucose  intolerance  but  a  reduction  in  the  metabolic  cost  of  feeding  compared  with 
controls. 
The  present  study  also  demonstrated  that  the  administration  of  a  fish  oil-enriched 
nutritional  supplement  containing  EPA  for  3  weeks  resulted  in  weight  gain  in  this  previously 
weight-losing  group  (as  described  previously),  an  increase  in  fasting  insulin  concentrations  and  a 
normalisation  of  energy  expenditure  with  a  fall  in  resting  energy  expenditure  per  unit  weight  and  a 
rise  in  the  apparent  metabolic  cost  of  feeding.  Substate  utilisation  also  normalised. 
Elevated  resting  energy  expenditure  has  been  demonstrated  in  the  fasting  state  in  weight- 
losing  patients  with  advanced  pancreatic  cancer  (Falconer  et  al,  1994)  and  lung  cancer  (Staal-van 
den  Brekel  et  al,  1994).  These  studies  were  also  able  to  demonstrate  a  relationship  between  the 
acute  phase  protein  response  and  energy  expenditure.  No  such  clear  relationship  was  seen  in  the 
present  study,  however,  energy  intake  was  lower  in  patients  with  an  acute  phase  protein  response. 
A  similar  relative  reduction  in  energy  intake  in  association  with  an  acute  phase  protein  response 
has  been  reported  previously  in  patients  with  advanced  pancreatic  cancer  (Wigmore  et  al,  1997b). 
The  pro-inflammatory  cytokines  which  stimulate  the  acute  phase  protein  response  will  also 
produce  anorexia  in  animal  models  (Moldawer  et  al,  1988).  It  is  not  clear  why  no  relationship 
between  resting  energy  expenditure  and  the  acute  phase  protein  response  was  seen  in  the  present 
study  although  it  may  be  that  C-reactive  protein  alone  may  be  an  imprecise  measure  and  that  other 
proteins  or  a  combination  may  give  a  better  impression  of  the  inflammatory  state  as  discussed  in 
chapter  8.  In  addition,  the  patients  examined  in  the  present  study  may  have  been  at  an  earlier  stage 
in  their  disease  than  those  examined  previously. 
An  elevated  cortisol  :  insulin  ratio  compared  to  controls  has  previously  been  noted  in 
patients  with  advanced  pancreatic  cancer  (Fearon  et  al,  1998).  This  would  imply  a  catabolic 
hormonal  environment  consistent  with  the  continuing  weight  loss  seen  in  these  patients. 
Relative  glucose  intolerance  has  been  noted  in  cancer  patients  for  many  years  (Rohdenberg 
et  al,  1919).  A  blunted  insulin  secretory  response  to  oral  glucose  administration  in  association Chapter  9  143 
with  delayed  clearance  of  glucose  has  been  reported  in  cachectic  colorectal  cancer  patients 
(although  fasting  insulin  concentrations  did  not  differ  between  patients  and  controls  in  this  study) 
(Holroyde  et  al,  1984).  Another  study  of  colorectal  cancer  patients  suggested  normal  insulin 
sensitivity  but  impaired  insulin  responsiveness  implying  a  postreceptor  defect  in  insulin  action 
(Copeland  et  al,  1987).  In  the  present  study  there  was  a  relative  blunting  of  the  insulin  response  in 
the  cancer  patients  with  lower  insulin  concentrations  over  the  early  part  of  the  feeding  period.  Over 
the  whole  time  course  there  was,  however,  no  statistically  significant  difference  between  absolute 
change  in  insulin  concentration  or  percentage  change  between  cancer  patients  and  controls.  This 
may  reflect  relatively  small  patient  numbers  combined  with  substantial  inter-individual  variation. 
If  anything,  the  present  results  only  suggest  a  delay  in  the  insulin  response  rather  than  a  major 
difference  in  its  overall  magnitude.  It  has  been  suggested  that  islet  amyloid  polypeptide  (amylin) 
produced  by  normal  pancreatic  tissue  in  patients  with  pancreatic  cancer  may  contribute  to  insulin 
resistance  (Permert  et  al,  1993,  Permert  et  al,  1994). 
Although  non-cancer-bearing  subjects  who  have  lost  weight  have  been  reported  to  have 
lower  resting  energy  expenditure  in  the  fasted  state,  there  is  little  evidence  in  normal  subjects  of 
energy  conservation  through  a  change  in  the  energy  cost  of  feeding  (Piers  et  al,  1992,  Leibel  et  al, 
1995).  This  chapter  has  examined  the  hypothesis  that  in  cancer  patients  in  whom  there  appears  to 
be  an  increase  in  resting  energy  expenditure  and  a  failure  to  gain  weight  there  may  be  an  increased 
cost  of  feeding.  However,  in  the  present  study  we  found  that  the  increase  in  energy  expenditure 
with  feeding  was  less  than  that  seen  in  controls.  Moreover,  the  size  of  the  feeding  stimulus 
provided  was  based  on  resting  energy  expenditure  and  this  was  relatively  larger  in  cancer  patients. 
Thus  the  observed  reduction  in  the  metabolic  response  to  oral  feeding  in  the  cancer  patients  was 
even  greater  in  relation  to  the  quantity  of  feed  provided. 
It  has  previously  been  shown  that  non-weight  losing  cancer  patients  have  no  difference  in 
their  response  to  feeding  compared  with  healthy  controls  (Melville  et  al,  1990).  Intravenous 
nutrition  has  been  shown  to  produce  a  similar  metabolic  response  in  malnourished  cancer  patients 
and  malnourished  controls  (Lindmark  et  al,  1986).  Although  no  normally  nourished  control  group 
was  examined  in  the  latter  study,  it  was  suggested  that  while  cachectic  cancer  patients  may  exhibit 
metabolic  changes  in  the  fasting  state,  these  patients  were  able  to  conserve  energy  normally  upon 
intravenous  feeding.  The  present  study  suggests  this  may  also  be  true  to  some  degree  with  oral 
feeding,  although  the  absolute  magnitude  of  the  reduction  in  the  cost  of  feeding  observed  in  cancer 
patients  in  the  present  study  is  small. Chapter  9  144 
Due  to  a  lack  of  pancreatic  lipase,  pancreatic  cancer  patients  frequently  have  problems  with 
malabsorption,  particularly  of  fat,  (Perez  et  al,  1983).  None  of  the  subjects  in  the  present  study 
had  symptomatic  malabsorption  but  clearly  if  there  was  a  reduction  in  the  proportion  of  feed 
absorbed  or  the  rate  of  absorption  this  may  have  accounted  for  some  of  the  observed  differences. 
However,  the  prompt  rise  in  blood  glucose  concentrations  and  the  rise  in  insulin  concentration  of 
equal  proportion  to  controls  seen  in  the  cancer  patients  does  not  suggest  a  substantial  difference  in 
absorption  between  the  two  groups.  Moreover,  the  cancer  patients  were  able  to  gain  weight  over 
the  three  week  study  period  again  suggesting  reasonable  absorption. 
As  in  the  present  study,  an  increase  in  the  proportion  of  fat  oxidation  has  previously  been 
observed  in  fasting  gastrointestinal  cancer  patients  when  compared  with  controls  (Hansell  et  al, 
1986,  Chen  &  Chung,  1994).  A  corresponding  significant  reduction  in  carbohydrate  oxidation  has 
also  been  reported  in  weight-losing  cancer  patients  (Hansell  et  al,  1986).  In  the  latter  study  these 
changes  were  more  pronounced  in  advanced  disease.  Although  there  was  a  trend  towards  a 
reduction  in  carbohydrate  oxidation  in  the  present  study  this  was  not  statistically  significant.  A 
similar  pattern  of  nutrient  oxidation  changes  has  been  observed  in  septic  patients  (Askenazi  et  al, 
1980).  However,  no  such  differences  were  seen  in  a  small  group  of  lung  cancer  patients  who  had 
lost  little  weight  (Melville  et  al,  1990).  The  equations  used  for  the  calculation  of  substrate 
utilisation  are  not  ideal  in  the  fed  state  (Garlick,  1986).  Within  these  limitations,  the  cancer 
patients  in  the  present  study  demonstrated  a  marked  increase  in  carbohydrate  oxidation  in  the  fed 
state.  Such  a  change  in  substrate  oxidation  is  observed  in  healthy  individuals  and  has  been 
documented  in  other  groups  of  cancer  patients  (Lindmark  et  al,  1986,  Melville  et  al,  1990).  Thus, 
it  appears  that  in  the  fasting  state  weight-losing  cancer  patients  preferentially  oxidise  fat,  perhaps 
due  to  depletion  of  glycogen  stores.  In  the  fed  state  a  switch  to  normal  substrate  oxidation  patterns 
is  seen. 
The  administration  of  an  EPA  containing  nutritional  supplement  to  patients  with  pancreatic 
cancer  resulted  in  an  increase  in  weight,  an  increase  in  fasting  insulin  concentration,  a  decrease  in 
resting  energy  expenditure  and  a  normalisation  of  the  metabolic  cost  of  feeding  and  substrate 
utilisation.  It  has  previously  been  shown  that  EPA  will  reduce  pro-inflammatory  cytokine 
production  in  cancer  patients  (Wigmore  et  al,  1997d  and  Chapter  7).  These  cytokines  increase 
energy  expenditure,  reduce  insulin  levels,  increase  cortisol  concentrations  and  induce  insulin 
resistance,  stimulate  the  acute  phase  response  and  cause  protein  and  fat  breakdown  (McNamara  et 
al,  1992).  Modulation  of  these  and  other  factors  by  the  EPA  containing  supplement  may  explain Chapter  9  145 
the  relative  normalisation  of  the  metabolic  state  observed.  EPA  also  modulates  the  activity  of 
other  factors  implicated  in  weight  loss  in  cancer  patients  such  as  proteolysis  inducing  factor 
(Tisdale,  1986  and  Chapter  7)  and  the  present  study  has  also  shown  changes  in  the  neuroendocrine 
state  with  a  rise  in  fasting  insulin  concentrations. 
Fish  oil  supplementation  has  been  suggested  to  adversely  affect  glucose  metabolism  in 
otherwise  well  patients  with  non-insulin-dependent  diabetes  mellitus  (Glauber  et  al,  1988, 
Borkman  et  al,  1989).  However,  a  study  of  patients  with  hypertension  given  4g  fish  oil  or  placebo 
daily  for  16  weeks  specifically  addressed  this  issue  and  showed  no  change  in  response  to  glucose 
tolerance  test,  insulin  release  or  insulin  sensitivity  in  those  given  fish  oil  and  no  difference 
between  groups  (Toft  et  al,  1995).  The  present  study  did  not  demonstrate  any  adverse  effect  on 
glucose  tolerance  with  the  administration  of  the  fish  oil-enriched  supplement. 
The  apparent  improvement  in  the  nutritional  state  of  the  cancer  patients  in  the  present  study 
may  have  contributed  to  the  metabolic  changes  observed  over  the  three  week  study  period. 
Patient's  caloric  intake  increased  by  around  400kcal.  Previous  studies  of  conventional  nutritional 
supplements  in  cancer  patients  in  which  a  similar  increment  in  protein  and  energy  intake  was 
achieved  failed  to  produce  nutritional  benefit  (Evans  et  al,  1987,  Ovesen  et  al,  1993b).  Thus  it  is 
conceivable  that  it  was  the  EPA  component  of  the  supplement  which  resulted  in  modulation  of  the 
weight-losing  state  and  allowed  the  protein  and  calories  supplied  to  be  used  with  more  benefit.  To 
compare  the  metabolic  changes  associated  with  the  fish  oil-enriched  supplement  we  performed  a 
paired  comparison  with  subjects  prior  to  consumption  of  the  supplement  and  a  comparison  with 
the  data  for  the  patients  who  were  only  studied  at  baseline  and  who  did  not  receive  the  fish  oil- 
enriched  supplement.  The  ideal  study  design  would  have  been  to  also  observe  the  effects  of  the 
supplement  on  control  subjects.  However,  the  present  study  design  avoided  the  ethical  issue  of 
administering  an  unnecessary  intervention  to  a  healthy  group  and  allowed  the  assessment  of 
whether  the  supplement  restored  metabolic  function  towards  that  observed  in  health. 
The  present  chapter  suggests  that  the  energy  cost  of  feeding  contributes  little  to  the  loss  of 
weight  in  cancer  patients,  however,  with  their  reduced  food  intake  the  increased  resting  energy 
expenditure  in  the  fasting  state  may  become  more  important.  The  increase  in  the  cost  of  feeding 
after  EPA  supplementation  in  association  with  weight  gain  implies  a  normalisation  of  the 
metabolic  state  and  less  need  to  conserve  energy  in  the  presence  of  weight  gain. 
The  next  chapter  examines  further  the  metabolic  effects  of  the  fish  oil-enriched  supplement 
in  terms  of  the  protein  kinetics  associated  with  the  acute  phase  protein  response. Chapter  10  146 
Acute  phase  protein  synthesis  in  the  fasted  and  fed  state  in  cancer 
patients  and  the  effects  of  a  fish  oil-enriched  nutritional 
supplement 
Summary 
The  presence  of  an  acute  phase  protein  response  may  be  an  important  determinant  of 
survival  in  advanced  cancer  perhaps  because  it  may  accelerate  breakdown  of  lean  tissue  to 
provide  amino  acids  for  acute  phase  protein  synthesis.  In  the  fasting  state  albumin  synthesis 
rates  are  not  different  in  cancer  patients  compared  with  healthy  controls  despite  lower 
circulating  concentrations  in  cancer  patients.  Fibrinogen  concentrations  are  elevated  in  the 
fasting  state  in  cancer  patients  in  association  with  higher  synthesis  rates.  The  present  chapter 
examines  the  effect  of  feeding  on  albumin  and  fibrinogen  synthesis  to  determine  whether  an 
abnormal  response  to  feeding  would  explain  the  lower  albumin  concentrations  of  cancer 
patients.  A  fish  oil-enriched  nutritional  supplement  has  been  shown  to  reverse  aspects  of 
cachexia  in  cancer  patients  (Chapters  6-9).  The  present  study  also  examined  the  effect  of  this 
supplement  on  hepatic  export  protein  synthesis  . 
Albumin  and  fibrinogen  synthesis  were  measured  in  the  fed  and  fasting  state  in  8 
weight-losing  patients  with  advanced  pancreatic  cancer.  6  healthy  controls  were  also  studied 
at  baseline.  Protein  synthesis  was  measured  by  an  intravenous  flooding  dose  of  labelled 
phenylalanine.  Tracer  incorporation  into  albumin  was  measured  by  gas  chromatography/mass 
spectrometry.  Nitrogen  balance  was  also  measured.  Patients  were  then  studied  again  after  the 
provision  of  a  nutritional  supplement  enriched  with  fish  oil  providing  600kcal  and  2g 
eicosapentaenoic  acid  per  day  for  three  weeks. 
At  baseline  all  patients  were  losing  weight  at  a  median  rate  of  2.4kg  per  month  and 
had  lost  a  median  of  19%  of  their  preillness  stable  weight.  Cancer  patients  had  a  significantly 
lower  serum  albumin  concentration  and  a  significantly  higher  plasma  fibrinogen  concentration 
than  controls  (p<0.01).  Cancer  patients  exhibited  a  29%  rise  in  albumin  synthesis  on  feeding 
from  a  median  of  11.3g/day  to  14.2g/day.  Healthy  controls  had  a  very  similar  (p=0.7) 
increase  of  24%  on  feeding  from  13.5g/ay  to  16.4g/day.  Fasting  fibrinogen  total  synthetic 
rate  was  significantly  higher  in  cancer  patients  than  controls  at  3.3g/day  versus  1.  Og/day 
(p<0.005).  In  cancer  patients  in  the  fed  state  fibrinogen  synthetic  rate  rose  significantly  by Chapter  10  147 
38%  to  4.5g/day  while  in  controls  there  was  no  significant  change  in  fibrinogen  synthesis. 
After  3  weeks  of  consumption  of  the  fish  oil-enriched  nutritional  supplement  patients 
had  a  significant  stabilisation  of  weight  (p=0.012)  with  a  median  weight  gain  of  lkg  (range 
+6--1.5).  Albumin  concentration  was  stable  with  a  median  change  of  Og/l  (range  +3--3) 
(p=0.67).  Fibrinogen  concentration  was  also  stable  with  a  median  change  of  -0.4g/l  (range  - 
1.78-+0.81).  Nitrogen  balance  significantly  improved  with  a  median  change  of  +2.6g/day 
(range  +8.3--0.7)  (p=0.025).  Fasting  albumin  synthesis  rate  was  unchanged  at  10.5g/day  but 
with  feeding  there  was  no  significant  change  (median  increase  3%  (p=0.29)).  Fasting 
fibrinogen  synthesis  was  also  unchanged  (median  2.9g/day)  and  this  increased  by  only  17% 
on  feeding  to  3.7g/day. 
Thus  cancer  patients  went  from  an  statistically  significant  initial  overall  33%  rise  in 
albumin  and  fibrinogen  synthesis  (from  14.7  to  18.7g/day  on  feeding  at  baseline)  to  a  situation 
where  the  change  was  not  significant  (from  12.3  to  14.6g/day  after  intervention).  This  was 
associated  with  a  stabilisation  in  weight  and  acute  phase  protein  concentrations  and  a  reversal 
of  nitrogen  balance  suggesting  that  modulation  of  liver  export  protein  synthesis  may  have  a 
clinically  significant  effect  on  protein  distribution.  Thus  the  targeting  of  the  inflammatory 
response  and  its  associated  metabolic  changes  (including  the  acute  phase  protein  response) 
may  be  an  avenue  for  further  therapeutic  intervention  in  cancer  cachexia. Chapter  10 
Introduction 
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Chapter  3  demonstrated  a  progressive  deterioration  in  nutritional  and  functional  status 
in  association  with  exacerbation  of  the  acute  phase  protein  response  (APPR)  in  patients  with 
cancer  cachexia.  The  APPR  is  thought  to  be  stimulated  by  pro-inflammatory  cytokines  such 
as  interleukin-6  (IL-6)  (Castell  et  al,  1990).  Chapter  4  described  an  association  between 
concentrations  of  IL-6  and  the  acute  phase  protein,  C-reactive  protein.  In  Chapter  5  an 
association  between  both  increased  pro-inflammatory  cytokine  production  and  the  presence  of 
an  APPR  and  poor  survival  was  demonstrated.  One  mechanism  by  which  the  APPR  may 
influence  survival  may  be  that,  with  inadequate  nutritional  intake,  the  demand  for  amino  acids 
to  manufacture  acute  phase  proteins  accelerates  loss  of  lean  tissue  resulting  in  cachexia. 
It  has  previously  been  shown  that  in  the  fasting  state  the  total  albumin  synthesis  rate  is 
unchanged  in  patients  with  advanced  cancer  compared  with  controls  despite  much  lower 
albumin  concentrations  (Fearon  et  al,  1998).  By  contrast,  the  total  synthesis  rate  of  fibrinogen 
is  significantly  increased  in  the  fasting  state  in  cancer  patients  accompanied  by  higher 
circulating  concentrations  compared  with  controls  (Preston  et  al,  1998).  This  would  suggest 
that  in  the  fasting  state  for  albumin  at  least,  a  reduced  synthesis  rate  does  not  explain  the 
hypoalbuminemia  observed.  In  contrast,  plasma  fibrinogen  concentrations  reflect,  at  least  in 
part,  an  increased  rate  of  synthesis  by  the  liver. 
It  has  been  suggested  that  synthesis  of  albumin  is  stimulated  by  feeding  in  healthy 
subjects  (de  Feo  et  al,  1992,  Hunter  et  al,  1995)  while  fibrinogen  synthesis  remains  unchanged 
(de  Feo  et  al,  1992).  If  there  was  a  reduced  albumin  synthetic  response  to  feeding  in  cancer 
this  might  contribute  to  hypoalbuminaemia.  Alternatively,  if  there  was  an  increased 
fibrinogen  synthetic  response  to  feeding  in  cancer  (and  this  process  affected  other  positive 
acute  phase  proteins)  then  this  might  contribute  to  the  metabolic  demands  on  the  nitrogen 
economy  of  such  patients  and  might  ultimately  contribute  to  loss  of  lean  tissue,  particularly  if 
dietary  protein  intake  was  restricted. 
The  failure  of  conventional  nutritional  supplementation  to  prevent  weight  loss  in 
advanced  cancer  patients  has  been  attributed  to  metabolic  changes  including  the  APPR  (Nixon 
et  al,  1981,  Evans  et  al,  1987,  Ovesen  et  al,  1993b).  Chapters  6,7,8  and  9  have  demonstrated 
improvement  in  nutritional  status,  modulation  of  metabolic  mediators  and  stabilisation  of 
acute  phase  protein  concentrations  with  the  administration  of  a  fish  oil-enriched  nutritional 
supplement  in  cachectic  pancreatic  cancer  patients. Chapter  10  149 
The  aim  of  the  present  study  was  to  quantify  the  level  of  hepatic  export  protein 
synthesis  in  cachectic  cancer  patients  in  the  fasted  and  fed  state  in  comparison  with  healthy 
controls.  This  study  also  examined  the  effect  of  the  fish  oil-enriched  nutritional  supplement 
on  albumin  and  fibrinogen  synthesis. Chapter  10  150 
Methods 
Subjects 
Eight  patients  with  an  unequivocal  diagnosis  of  pancreatic  cancer  who  were  losing 
weight  with  no  clinical  evidence  of  ascites  or  peripheral  oedema  were  examined.  Six  weight- 
stable  healthy  individuals  served  as  controls.  None  of  the  patients  received  chemotherapy  or 
radiotherapy  and  none  had  undergone  surgery  in  the  preceding  4  weeks.  No  patients  had 
clinical  or  radiological  evidence  of  infection,  were  jaundiced  or  severely  anaemic,  or  were 
receiving  steroids.  The  study  was  approved  by  the  local  ethical  committee  and  all  subjects 
gave  written  informed  consent. 
Study  protocol 
The  study  protocol  is  presented  diagrammatically  in  figure  10.1.  Subjects  attended  at 
Bam  on  two  consecutive  days.  On  the  first  day  following  an  overnight  fast,  a  venous  catheter 
was  inserted  into  the  subject's  antecubital  fossa.  The  patient  rested  in  a  supine  position  for  at 
least  30  minutes  and  underwent  measurement  of  resting  energy  expenditure  by  indirect 
calorimetry.  At  10am  subjects  received  an  intravenous  bolus  labelled  phenylalanine.  Blood 
samples  were  obtained  over  120  minutes  after  the  tracer  infusion.  The  blood  samples  were 
analysed  for  baseline  albumin  and  fibrinogen  concentrations,  labelled  phenylalanine 
enrichment  in  plasma  albumin  and  fibrinogen  and  in  the  plasma  free  phenylalanine  pool. 
Subjects  remained  fasting  throughout  this  period. 
On  the  second  day,  again  following  an  overnight  fast  a  venous  catheter  was  inserted 
into  the  subject's  antecubital  fossa  and  subjects  received  a  meal  of  a  balanced  whole  protein 
liquid  nutritional  supplement  (Fortisip,  Nutricia,  Zoetermeer,  Holland)  providing  a  twelfth  of 
the  subjects  estimated  energy  requirement  (measured  resting  energy  expenditure  *  1.4) 
(Hunter  et  al,  1995).  The  supplement  provided  13%  of  energy  from  protein,  48%  from 
carbohydrate  and  39%  from  fat,  similar  to  a  "typical"  British  diet.  Subjects  received  such  a 
feed  on  an  hourly  basis  until  the  end  of  the  study  period.  At  10am  a  similar  flooding  dose  of 
phenylalanine  was  given  as  described  above  and  blood  samples  collected  similarly. Chapter  10 
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Figure  10.1.  Study  protocol. 
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Fish  oil-enriched  nutritional  supplement 
The  cancer  patients  were  then  asked  to  consume  2  cans  per  day  of  a  fish  oil-enriched 
nutritional  supplement  providing  600kcal,  32g  protein  and  2g  eicosapentaenoic  acid  per  day 
in  a  volume  of  480m1.  After  3  weeks  the  cancer  patients  underwent  repeat  measurement  of 
protein  synthesis  as  described  above. 
Statistics 
Data  are  presented  as  median  and  range. Chapter  10 
Results 
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Baseline  study 
Subject  characteristics  are  shown  in  table  10.1.  Cancer  patients  weighed  substantially 
less  than  controls  having  lost  around  20%  of  their  pre-illness  stable  weight.  Cancer  patients 
had  significantly  lower  serum  albumin  concentrations  and  significantly  higher  plasma 
fibrinogen  concentrations  compared  with  controls. 
Table  10.1.  Characteristics  of  cancer  patients  and  healthy  controls  examined. 
Cancer  patients  Healthy  controls  p  value 
Age  (years)  65  54  0.0054 
(56-70)  (50-62) 
Sex  2  female  3  male  0.33 
6  male  3  female 
Weight  (kg)  56.2  77.2  0.0098 
(44.0-70.5)  (58.0-100.0) 
Percentage  weight  loss  18.9  0  0.0013 
(12.7-37.5) 
Rate  of  weight  loss  2.4  0  0.0013 
(kg/month)  (0.8-4.9) 
Albumin  (g/1)  42  45  0.0033 
(37-44)  (43-47) 
Fibrinogen  (g1l)  4.86  2.72  0.0019 
(3.72-6.02)  (1.87-3.19) 
Values  presented  are  median  and  range 
Comparison  by  Mann  Whitney  U  test  or  Chi  squared  test Chapter  10 
Insulin  concentration  change  with  time  is  shown  in  while  fasting  in  figure  10.2  and 
while  feeding  in  figure  10.3.  There  was  no  obvious  change  in  insulin  concentration 
attributable  to  the  flooding  dose  of  phenylalanine. 
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Figure  10.2.  Insulin  concentration  in  8  patients  with  advanced  pancreatic  cancer  in  the 
fasted  state.  Median  and  range  presented. 
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Figure  10.3.  Insulin  concentration  in  8  patients  with  advanced  pancreatic  cancer  with 
feeding.  Median  and  range  presented. 
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Albumin  synthesis  rates  are  shown  in  table  10.2.  Changes  in  albumin  synthesis 
between  the  fasted  and  fed  state  are  presented  in  figure  10.4.  There  was  no  difference  between 
albumin  synthesis  rates  between  weight-losing  cancer  patients  and  healthy  controls  in  the 
fasted  (median  14.2g/day  versus  15.7g/day  (p=0.30))  or  fed  (total  synthetic  rate  median 
11.3g/day  versus  13.9g/day  (p=0.70))  state.  Both  cancer  patients  and  controls  showed  an 
identical  pattern  of  significant  stimulation  of  albumin  synthesis  in  the  fed  state  of  median  29 
and  24%  respectively. 
Fibrinogen  synthesis  rates  are  shown  in  table  10.3.  Changes  in  fibrinogen  synthesis 
between  the  fed  and  fasted  state  are  presented  in  figure  10.5.  Cancer  patients  had 
substantially  and  significantly  elevated  rates  of  fibrinogen  synthesis  in  both  the  fasting 
(median  3.3g/day  versus  1.1g/day  (p=0.0019)  and  fed  (median  4.5g/day  versus  1.3g/day 
(p=0.0019)  state  compared  with  controls.  There  was  no  significant  change  in  fibrinogen 
synthesis  with  feeding  in  control  patients  (median  14%,  p=0.12).  By  contrast  there  was  a 
statistically  significant  stimulation  of  fibrinogen  synthesis  with  feeding  in  the  cancer  patients 
(median  38%,  p=0.012). `ý 
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Study  after  3  weeks  fish  oil-enriched  nutritional  supplement 
After  3  weeks  administration  of  the  fish  oil-enriched  nutritional  supplement  to  the  eight 
pancreatic  cancer  patients  weight  stabilised  (median  +1.0kg  (range  -1.5-+6.5),  p=0.23  versus 
baseline,  p=0.012  versus  prestudy  rate  of  weight  loss.  Albumin  and  fibrinogen  concentrations 
did  not  change  (0  (-3-+3),  p=0.67  and  -0.4  (-1.78-+0.81),  p=0.16  respectively). 
Albumin  synthesis  rates  are  shown  in  table  10.2.  Changes  in  albumin  synthesis 
between  the  fasted  and  fed  state  are  presented  in  figure  10.2.  At  baseline  there  was  a 
significant  rise  in  albumin  synthesis  in  the  fed  state  of  median  29%  (p=0.012).  However,  after 
administration  of  the  fish  oil-enriched  nutritional  supplement  for  three  weeks  cancer  patients 
no  longer  had  significant  stimulation  of  albumin  synthesis  on  feeding  (median  rise  3%, 
p=0.21). 
Fibrinogen  synthesis  rates  are  shown  in  table  10.3.  Changes  in  fibrinogen  synthesis 
between  the  fed  and  fasted  state  are  presented  in  figure  10.3.  At  baseline  there  was  a 
substantial  rise  in  fibrinogen  synthesis  in  the  fed  state  of  median  38%  (p=0.012).  After 
administration  of  the  fish  oil-enriched  nutritional  supplement  for  three  weeks  the  scale  of 
stimulation  of  fibrinogen  synthesis  in  the  fed  state  was  substantially  reduced  (median  17%) 
although  this  difference  did  not  reach  statistical  significance  (p=0.26). Chapter  10 
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Figure  10.2.  Albumin  total  synthesis  rate  in  the  fasted  and  fed  state  in  6  healthy  controls  and 
8  weight  losing  cancer  patients  at  baseline  and  after  3  weeks  consumption  of  a  fish  oil- 
enriched  nutritional  supplement.  Graph  presents  median  and  range.  Comparison  between 
fasting  and  fed  values  by  Wilcoxon  signed  rank  test. 
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Figure  10.3.  Fibrinogen  total  synthesis  rate  in  the  fasted  and  fed  state  in  healthy  controls  and 
weight  losing  cancer  patients  at  baseline  and  after  3  weeks  consumption  of  a  fish  oil-enriched 
nutritional  supplement.  Graph  presents  median  and  range.  Comparison  between  fasting  and 
fed  values  by  Wilcoxon  signed  rank  test. Chapter  10  159 
When  the  synthetic  rates  of  albumin  and  fibrinogen  were  combined  (table  10.4  and 
figure  10.4)  there  was  no  difference  in  synthetic  rates  of  patients  in  the  fasting  state  before  and 
after  3  weeks  consumption  of  the  fish  oil-enriched  nutritional  supplement.  Whereas,  at 
baseline,  there  had  been  a  substantial  stimulation  of  hepatic  export  protein  synthesis  of 
median  33%,  after  administration  of  the  fish  oil-enriched  nutritional  supplement  there  was 
now  no  significant  change,  with  a  significant  reduction  in  synthetic  rate  (p=0.012). 
Table  10.4.  Combined  albumin  plus  fibrinogen  total  synthetic  rates  in  cancer  patients  before 
and  after  administration  offish  oil-enriched  nutritional  supplement  for  3  weeks. 
Baseline  After  p  value 
(n=8)  intervention 
period 
TSR  14.7  12.3  0.093 
Fasting  (9.5-25.3)  (9.1-18.4) 
(g/day) 
TSR  18.7  14.6  0.012 
Fed  (15.2-34.2)  (11.0-25.2) 
(g/day) 
Percentage  3  3.5  10.2  0.12 
difference  (9.6-112.4)  (-0.6-+77.6) 
fasted  to  fed 
p  value 
fasting 
versus  fed 
0.012  0.093 
Values  are  median  (range). 
Comparison  by  Wilcoxon  signed  rank  test. 
FSR  -  Fractional  synthesis  rate 
ASR  -  Absolute  synthesis  rate 
TSR  -  Total  synthesis  rate Chapter  10 
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Figure  10.4.  Combined  albumin  and  fibrinogen  total  synthesis  rate  in  the  fasted  and  fed  state 
in  6  healthy  controls  and  8  pancreatic  cancer  patients  at  baseline  and  after  3  weeks 
consumption  of  a  fish  oil-enriched  nutritional  supplement.  Graph  presents  median  and  range. 
Comparison  between  fasting  and  fed  values  by  Wilcoxon  signed  rank  test.  Comparison  of 
fasting  synthesis  rate  at  baseline  and  after  supplement  p=0.093.  Comparison  of  fed  synthesis 
rate  at  baseline  and  after  supplement  p=0.012. Chapter  10  161 
Discussion 
This  chapter  has  shown  that  weight-losing  patients  with  pancreatic  cancer  undergo 
stimulation  of  albumin  synthesis  with  feeding  and  that  this  is  similar  to  healthy  controls 
despite  significantly  lower  circulating  albumin  concentrations  and  the  presence  of  an  APPR  in 
the  cancer  patients.  Circulating  fibrinogen  concentrations  were  significantly  elevated  in  the 
cancer  patients  and  their  fibrinogen  synthesis  was  elevated  significantly  in  both  the  fasting 
and  fed  state.  While  controls  show  no  change  in  fibrinogen  synthesis  in  the  fed  state  there 
was  a  significant  increase  with  feeding  in  cancer  patients. 
In  addition  the  present  chapter  has  shown  that  the  administration  of  this  supplement 
results  a  significant  reduction  in  the  combined  synthetic  rate  of  the  hepatic  export  proteins 
albumin  and  fibrinogen  in  the  fed  state  in  cachectic  pancreatic  cancer  patients  in  association 
with  beneficial  nutritional  effects,  modulation  of  metabolic  mediators  and  stabilisation  of 
acute  phase  protein  concentrations  as  described  in  Chapters  6-9. 
The  acute  phase  response  is  observed  following  a  variety  of  insults  including  trauma, 
infection  and  malignancy.  The  APPR  is  thought  to  be  stimulated  by  pro-inflammatory 
cytokines  such  as  interleukin-6  (Castell  et  al,  1990).  The  synthesis  of  acute  phase  proteins  by 
hepatocytes  is  also  known  to  be  influenced  by  endocrine  hormones  such  as  insulin  and 
cortisol  (O'Riordain  et  al,  1995).  Increased  production  of  interleukin-6  is  observed  in  patients 
with  advanced  pancreatic  cancer  (Falconer  et  al,  1994a)  and  Chapter  4  demonstrated  elevated 
circulating  IL-6  concentrations  in  such  patients.  Alterations  in  the  balance  of  neuroendocrine 
hormones  have  been  shown  previously  (Fearon  et  al,  1998  and  Chapter  9). 
In  the  present  chapter,  despite  evidence  of  an  acute  phase  protein  response  and  reduced 
circulating  albumin  concentrations  in  the  cancer  patients,  there  was  no  evidence  of  a  reduction 
in  albumin  synthesis  in  the  fasting  state.  These  findings  are  in  keeping  with  other  studies  in 
cancer  (Fearon  et  al,  1998),  during  surgery  (van  Acker  et  al,  1998,  Barle  et  al,  1998),  after 
vaccination  (Cayol  et  al,  1995),  acutely  after  stress  hormone  infusion  (McNurlan  et  al,  1996) 
or  in  sepsis  (Dahn  et  al,  1995).  Thus  the  mechanisms  controlling  hepatic  albumin  synthesis 
are  complex  and  the  importance  of  the  role  of  pro-inflammatory  cytokines  in  suppressing 
synthesis  ex  vivo  must  be  called  into  question. 
Albumin  synthesis  has  been  shown  to  be  stimulated  significantly  by  feeding  in  healthy 
individuals  (De  Feo  et  al,  1992,  Hunter  et  al,  1995).  The  administration  of  protein  appears  to 
provide  a  significantly  greater  stimulus  to  albumin  synthesis  than  a  protein-free  feed  (Cayol  et 
al,  1996,  Cayol  et  al,  1997),  suggesting  that  dietary  amino  acids  are  readily  used  to  synthesise Chapter  10  162 
hepatic  export  proteins.  Different  methods  of  measurement  of  protein  synthesis  and  different 
routes  of  feeding  have  been  used  in  the  above  studies.  Using  a  primed  constant  infusion 
method  and  intraduodenal  feeding  an  increase  of  around  90%  in  albumin  synthesis  in  the  fed 
state  was  found  (De  Feo  et  al,  1992),  while  a  flooding  dose  protocol  and  oral  feeding 
produced  an  increase  of  around  20%  (Hunter  et  al,  1995).  The  present  study  utilised  the 
flooding  dose  protocol  for  measurement  of  protein  synthesis  (Garlick  et  al,  1989,  Ballmer  et 
al,  1990,  Garlick  et  al,  1994).  This  technique  is  convenient  for  both  staff  and  experimental 
subjects,  allowing  the  present  study  to  be  performed  on  an  outpatient  basis.  It  also  allows 
more  certainty  of  enrichment  of  the  appropriate  precursor  pool  for  protein  synthesis  (Preston 
et  al,  1998).  The  flooding  dose  technique  for  measuring  protein  synthesis  has  been  criticised 
as  it  has  been  suggested  that  the  rapid  infusion  of  amino  acids,  particularly  essential  amino 
acids,  stimulates  insulin  secretion  and  therefore  protein  synthesis  (Rennie  et  al,  1994).  The 
present  study  suggests  that  any  stimulus  of  protein  synthesis  due  to  tracer  infusion  does  not 
disguise  the  stimulus  provided  by  feeding.  In  addition,  measurement  of  circulating  insulin 
concentrations  revealed  no  obvious  increase  after  the  infusion  of  labelled  phenylalanine.  This 
is  particularly  clear  in  the  fasted  state  (figure  2).  Similarly  there  is  no  difference  in  insulin 
concentrations  between  subjects  receiving  amino  acid  infusion  and  those  not  in  the  results 
presented  in  Chapter  9.  Insulin  samples  were  taken  every  20  minutes  and  so  a  transient  rise  in 
insulin  cannot  be  ruled  out. 
Albumin  synthesis  has  not  previously  been  studied  in  the  fed  state  in  cancer  patients 
but  the  present  study  using  a  flooding  dose  method  and  oral  feeding  suggests  that  synthesis  is 
stimulated  to  a  similar  degree  to  control  subjects  by  around  25%.  Thus,  an  abnormally  low 
albumin  synthetic  response  to  feeding  is  unlikely  to  explain  the  low  circulating  concentrations 
in  these  patients.  Head-injured  patients  with  an  acute  phase  response  also  have  higher 
albumin  synthesis  rates  than  controls  in  the  fed  state  (Mansoor  et  al,  1997).  In  the  present 
study  the  size  of  the  feeding  stimulus  was  determined  by  measured  resting  energy 
expenditure.  As  in  previous  studies  (Hunter  et  al,  1995)  the  size  of  the  feeding  stimulus  in  the 
present  study  was  determined  by  measured  resting  energy  expenditure.  As  the  cancer  patients 
had  a  significantly  lower  body  weight  than  controls  with  a  similar  resting  energy  expenditure, 
the  feeding  stimulus  was  larger  per  unit  body  weight  in  the  cancer  patients  (cancer  patients 
median  3.15kcal/kg  (range  2.73-3.37)  versus  controls  2.36kg/kcal  (1.92-2.71),  p=0.0019).  It 
is  possible  that  this  may  have  led  to  a  relative  increase  in  the  stimulation  of  protein  synthesis 
by  feeding  in  the  cancer  patients. Chapter  10  163 
Circulating  fibrinogen  concentrations  are  increased  during  an  acute  phase  response. 
Synthesis  of  fibrinogen  has  been  shown  to  be  elevated  approximately  2-fold  in  the  fasting 
state  in  cancer  patients  compared  with  controls  (Preston  et  al,  1998).  Fibrinogen  fractional 
synthesis  rates  of  around  26%  (Stein  et  al,  1978)  and  around  39%  (Preston  et  al,  1998),  with 
similar  ranges  to  that  in  the  present  study,  have  been  shown  in  fasting  cancer  patients.  A 
similar  degree  of  elevation  of  fibrinogen  synthesis  has  also  been  demonstrated  in  trauma  and 
burns  patients  (Thompson  et  al,  1989).  In  healthy  subjects,  feeding  has  been  shown  to  have 
either  no  effect  (De  Feo  et  al,  1992,  Cayol  et  al,  1996)  or  a  small  (around  20%)  stimulatory 
effect  (Boirie  et  al,  1998)  on  fibrinogen  synthesis  similar  to  the  findings  in  the  healthy 
controls  in  the  present  study.  In  contrast,  feeding  caused  a  marked  further  increase  in 
fibrinogen  synthesis  in  the  cancer  patients  in  the  present  study.  A  similar  observation  has 
been  made  in  head-injured  patients  although  the  synthesis  rate  in  controls  was  rather  lower 
than  that  seen  in  other  studies  and  the  effect  of  feeding  was  not  discriminated  from  that  of 
disease  (Mansoor  et  al,  1997).  The  present  study,  therefore,  suggests  that  in  cancer  patients 
the  synthesis  of  both  positive  and  negative  acute  phase  proteins  is  stimulated  by  feeding. 
There  was  no  obvious  relationship  between  circulating  protein  concentrations  and 
rates  of  synthesis  of  the  relevant  protein  with  the  numbers  in  the  present  study.  In  addition 
there  was  no  significant  change  in  concentration  of  albumin  or  fibrinogen  over  the  4  hour 
study  period.  With  a  fasting  fibrinogen  fractional  synthesis  rate  of  around  1%  per  hour,  a  fed 
rate  of  around  1.25%  per  hour  and  a  fractional  breakdown  rate  of  at  least  1%  one  would  not 
expect  an  increase  in  fibrinogen  concentration  within  the  precision  of  the  assay.  With  its 
larger  pool  and  slower  turnover  any  change  in  albumin  concentration  would  be  even  smaller. 
Patients  with  advanced  cancer  exhibit  marked  loss  of  weight,  a  large  component  of 
which  is  skeletal  muscle  (Fearon  &  Preston,  1990).  This  weight  loss  is  particularly  marked  in 
the  presence  of  an  acute  phase  protein  response  (Falconer  et  al,  1994a,  Staal-van  den  Brekel  et 
al,  1995,  Wigmore  et  al,  1997b)  and  appears  to  contribute  to  worsened  survival  (Blay  et  al, 
1992,  Falconer  et  al,  1995).  If  the  synthesis  of  negative  acute  phase  proteins  such  as  albumin 
is  not  changed  during  the  acute  phase  response  and  the  synthesis  of  positive  acute  phase 
proteins  is  markedly  elevated  (when  patients  are  in  the  fasted  or  fed  state)  then  the  demand  for 
amino  acids  in  order  to  manufacture  these  proteins  may  accelerate  the  breakdown  of  skeletal 
muscle  especially  if  nutritional  intake  is  inadequate.  It  has  been  suggested  that  the  differences 
in  the  amino  acid  composition  of  acute  phase  proteins  and  skeletal  muscle  may  further 
increase  the  need  for  muscle  breakdown  to  supply  particularly  aromatic  amino  acids  (Reeds  et Chapter  10  164 
al,  1994).  To  represent  a  continuing  drain  on  amino  acid  resources  recycling  of  amino  acids 
from  acute  phase  proteins  would  have  to  be  inefficient.  There  has  been  no  measure  of  amino 
acid  return  from  acute  phase  protein  breakdown.  In  any  event  the  synthesis  and  recycling  of 
this  protein  requires  energy  and  may  contribute  to  the  hypermetabolism  previously  observed 
in  association  with  the  acute  phase  response  (Falconer  et  al,  1994,  Staal-van  den  Brekel  et  al, 
1995,  Wigmore  et  al,  1997b). 
Albumin  may  account  for  5-7%  of  whole  body  protein  synthesis  in  the  fasted  state  in 
healthy  subjects  (De  Feo  et  al,  1992).  This  may  increase  to  over  10%  in  the  fed  state  (De  Feo 
et  al,  1992,  Cayol  et  al,  1997).  It  has  been  estimated  that  synthesis  of  all  acute  phase  proteins 
may  account  for  30%  of  total  protein  synthesis  during  infection  in  the  fasted  state  (Waterlow, 
1991).  While  this  total  may  be  less  in  the  chronic  inflammatory  state  such  as  cancer,  with  the 
stimulation  of  both  positive  and  negative  acute  phase  protein  synthesis  by  feeding,  acute 
phase  protein  synthesis  may  represent  a  substantial  proportion  of  total  body  protein  synthesis. 
The  present  study  suggests  that  a  proportion  of  dietary  amino  acids  may  be  used  for 
accelerated  acute  phase  protein  synthesis  and  thus  not  be  available  for  peripheral  tissue 
anabolism.  In  addition,  the  supply  of  additional  dietary  amino  acids  delivered  first  to  the  liver 
via  the  portal  system  and  used  for  acute  phase  protein  production  will  result  in  consumption 
of  particular  amino  acids.  The  remaining  amino  acid  mixture  may  thus  be  unbalanced  further 
inhibiting  efficient  skeletal  muscle  anabolism. 
Protein  synthesis  rates  are  only  one  factor  in  determining  plasma  protein 
concentrations  but  at  present  there  is  limited  information  on  acute  phase  protein  breakdown 
and  transcapillary  escape.  There  is  indirect  evidence  of  increased  fibrinogen  breakdown  in 
cancer  with  elevated  concentrations  of  fibrin  degradation  products  (Dvorak  et  al,  1987, 
McMillan  et  al,  1994),  however,  the  role  of  fibrinogen  in  coagulation  complicates  the 
relevance  of  this  finding.  Transcapillary  escape  has  been  shown  to  occur  at  an  elevated  rate  in 
weight-losing  cancer  patients  and  been  suggested  to  contribute  to  the  hypoalbuminemia  of  the 
acute  phase  response  (Fleck  et  al,  1985).  However,  lymphatic  return  must  be  similarly 
increased  as  there  is  no  relationship  between  transcapillary  escape  and  albumin  concentration 
(Ballmer  et  al,  1994)  and  no  change  in  the  intravascular  albumin  pool  with  elevated 
transcapillary  escape  (Ballmer-Weber  et  al,  1995).  Limited  work  has  suggested  a  moderate 
increase  in  albumin  breakdown  in  cancer  patients  although  it  is  not  clear  whether  the  patients 
studied  were  losing  weight  (Rossing,  1968).  It  has  also  been  suggested  that  the  tumour  itself 
may  consume  albumin  (Stehle  et  al,  1997)  although  the  significance  of  this  phenomenon  in Chapter  10  165 
human  disease  remains  unclear.  Further  study  of  acute  phase  protein  breakdown  in  weight- 
losing  cancer  patients  is  required. 
The  present  study  also  demonstrated  a  difference  in  the  pattern  of  stimulation  of 
protein  synthesis  by  feeding  in  pancreatic  cancer  patients  after  the  consumption  of  a  fish  oil- 
enriched  nutritional  supplement  for  three  weeks.  There  was  a  loss  of  stimulation  of  albumin 
synthesis  with  feeding  and  a  halving  of  the  magnitude  of  the  stimulation  of  fibrinogen 
synthesis.  This  meant  that  there  was  now  no  significant  stimulation  by  feeding  of  synthesis  of 
the  two  proteins  combined  and  that  there  was  a  significant  reduction  in  the  combined  protein 
synthesis  in  the  fed  state. 
The  magnitude  of  the  changes  in  protein  synthetic  rate  are  small  in  terms  of  whole 
body  protein  kinetics,  but  may  be  larger  if  all  positive  and  negative  acute  phase  proteins 
behave  in  a  similar  manner. 
Thus  the  stimulation  of  the  synthesis  of  hepatic  export  proteins  by  feeding  in  cancer 
patients  provides  one  new  mechanism  which  may  contribute  to  the  suboptimal  response  to 
conventional  nutritional  supplementation  observed  in  some  patients  with  cancer.  In  addition, 
the  demonstration  that  the  provision  of  a  fish  oil-enriched  nutritional  supplement  will  abolish 
this  provides  a  potential  mechanism  to  explain  in  part  the  beneficial  effects  seen  on  weight 
and  lean  body  mass  seen  in  Chapter  6.  Other  potential  actions  of  eicosapentaenoic  acid  may, 
of  course,  have  contributed  to  the  conservation  of  lean  tissue  observed  such  as  a  reduction  in 
the  activity  of  proteolysis  inducing  factor  (PIF)  at  the  skeletal  muscle  level  (Tisdale,  1996) 
and  a  reduction  in  resting  energy  expenditure  (Chapter  6). Chapter  11 
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In  contrast  to  those  otherwise  well  individuals  who  have  lost  weight  due  to  inadequate 
dietary  intake,  patients  with  cancer  cachexia  frequently  do  not  regain  weight  and  functional 
ability  when  supplied  with  additional  nutrients  (Roubenoff  et  al,  1.997).  This  thesis  has 
attempted  to  explore  some  of  the  possible  mechanisms  for  this  phenomenon  together  with 
studying  some  of  the  mediators  responsible  and  the  importance  of  cachexia  to  patients'  survival 
and  performance.  In  addition  an  attempt  has  been  made  to  modulate  the  mechanisms  and 
mediators  responsible  for  cachexia  to  allow  patients  to  regain  weight  with  the  provision  of  a 
fish  oil-enriched  nutritional  supplement. 
The  importance  of  cancer  cachexia  to  patient  well-being 
It  was  demonstrated  in  Chapter  3  that  patients  with  pancreatic  cancer  progressively  lose 
weight  and  associated  with  this  is  a  deterioration  in  performance  status.  Others  have  previously 
reported  that  cancer  patients  with  weight  loss  have  an  inferior  performance  status  and  quality  of 
life  compared  with  weight  stable  cancer  patients  (DeWys  et  al,  1980,  Ovesen  et  al,  1993a, 
O'Gorman  et  al,  1998). 
It  has  been  shown  that  advanced  cancer  patients  have  a  marked  deficit  in  lean  tissue 
compared  with  healthy  controls  (Heymsfield  &  McManus,  1985,  Fearon  &  Preston,  1990). 
Longitudinal  studies  using  total  body  potassium  measurement  have  demonstrated  that  a  major 
proportion  of  the  weight  lost  by  cancer  patients  is  accounted  for  by  loss  of  lean  tissue 
(McMillan  et  al,  1998).  The  data  presented  in  Chapter  3  is  consistent  with  this  finding, 
although  the  bioelectrical  impedence  technique  of  body  composition  analysis  used  in  the 
studies  presented  in  this  thesis  is  not  as  precise. 
Loss  of  protein  in  cancer  patients  has  been  associated  with  reduced  muscle  strength  and 
an  increased  frequency  of  infective  episodes  and  shortened  survival  (Nixon  et  al,  1980, 
Windsor  &  Hill,  1988a,  Windsor  &  Hill,  1988b).  The  ongoing  loss  of  lean  tissue  is,  therefore, 
a  crucial  step  in  the  progression  of  cachexia  and  a  vital  target  for  intervention  in  cachexia. 
While  some  agents  used  in  the  treatment  of  cachexia  such  as  steroids  will  transiently  improve  a 
few  measures  of  quality  of  life  (Robustelli  della  Cuna  et  al,  1989,  Popiella  et  al,  1989),  they 
probably  act  by  a  direct  central  effect  and  no  intervention  studied  previously  has  been  shown  to 
influence  loss  of  lean  tissue  in  cachexia. Chapter  11  167 
Pro-inflammatory  cytokines  and  their  role  in  cachexia 
When  considering  intervention  in  cachexia  it  is  important  to  try  to  understand  the 
mediator  pathways  involved  which  are  absent  in  benign  weight  loss  and  may  therefore  be 
responsible  for  the  relative  lack  of  response  to  refeeding  in  cachexia.  Elevated  ex  vivo 
peripheral  blood  mononuclear  cell  production  of  the  pro-inflammatory  cytokines  interleukin-6 
and  tumour  necrosis  factor  a  has  previously  been  demonstrated  in  advanced  pancreatic  cancer 
(Falconer  et  al,  1994a)  although  the  present  study  has  failed  to  confirm  this  (Chapter  7). 
Elevating  circulating  concentrations  of  interleukin-6  have  previously  been  shown  in  solid  adult 
tumours  (Fearon  et  al,  1991,  Scott  et  al,  1996)  and  this  has  now  been  demonstrated  in 
pancreatic  cancer  in  Chapter  7.  Concentrations  of  interleukin-6  have  also  been  found  to  be 
associated  with  the  acute  phase  response  (Fearon  et  al,  1991,  Scott  et  al,  1996  and  Chapters  4 
and  7)  and  with  weight  loss  in  cancer  patients.  Chapter  4  has  also  demonstrated  an  association 
between  tumour  necrosis  factor  receptor  concentrations  (suggested  to  reflect  tumour  necrosis 
factor  activity)  and  the  acute  phase  protein  response. 
It  is  not  clear  why  no  obvious  difference  was  demonstrated  between  peripheral  blood 
mononuclear  cell  cytokine  production  in  cancer  patients  and  healthy  controls  when  increased 
circulating  concentrations  of  interleukin-6  and  tumour  necrosis  factor  receptors  were  found  in 
cancer  patients  (Chapter  7).  Previous  studies  in  pancreatic  cancer  patients  have  shown 
increased  pro-inflammatory  cytokine  production  but  not  circulating  concentrations  (Falconer  et 
al,  1994a,  Wigmore  et  al,  1997d).  Similar  techniques  were  used  for  measuring  cytokine 
production  and  concentrations  in  the  previous  and  present  studies,  the  only  diffeence  being  the 
ELISA  kit  used.  The  different  kits  may  have  had  differing  sensitivity  for  the  cytokines  from 
serum  and  cell  culture  medium.  The  patients  examined  for  the  current  thesis  were  recruited  at  a 
relatively  early  stage  in  their  disease  compared  with  previous  studies  and  it  is  possible  that  this 
may  have  affected  the  results  obtained.  Further  study  of  cytokine  production  and  circulating 
concentrations  in  advanced  cancer  patients  is  required  to  clarify  the  significance  of  these 
conflicting  observations. 
The  data  presented  in  Chapter  5  suggests  that  production  of  interleukin-  1ß  is  associated 
with  the  acute  phase  protein  response,  that  interleukin-  1ß  production  is  genetically  determined 
in  pancreatic  cancer  and  that  these  factors  both  influence  survival.  This  raises  the  question  of 
whether  we  can  ascribe  effects  observed  to  a  single  cytokine  acting  alone  and  whether  the  loss 
of  weight  observed  in  cancer  is  a  direct  action  of  such  cytokines  or  whether  they  represent  a 
small  corner  of  a  much  larger  network  of  mediators  culminating  in  the  cachectic  syndrome. 
The  observations  in  Chapters  4,5  and  7  that  concentrations  of  interleukin-6,  markers  of  tumour Chapter  11  168 
necrosis  factor  activity  (tumour  necrosis  factor  receptor  concentrations)  and  production  of 
interleukin-1(3  all  seem  to  related  to  each  other,  to  the  inflammatory  response,  and,  by 
extension,  to  the  progression  of  cachexia  makes  it  unlikely  that  any  one  cytokine  acts  alone  in 
this  condition.  Experimental  work  also  seems  to  support  this  with  antibody  blockade  of  single 
cytokines  having  only  a  very  limited  effect  on  cachexia  in  animal  models  (Gershenwald  et  al, 
1990,  Gelin  et  al,  1991,  Strassmann  et  al,  1992,  Smith  &  Kluger,  1993).  Administration  of 
antibodies  against  single  cytokines  will  also  affect  concentrations  of  others  (Gershenwald  et  al, 
1990)  and  injection  of  single  cytokines  into  human  and  animal  subjects  will  induce  the 
production  of  others  (Yasumoto  et  al,  1995,  Mori  et  al,  1996).  Thus  it  seems  that  pro- 
inflammatory  cytokines  form  a  complicated  web  of  overlapping  effects,  mutual  stimulation  and 
redundancy  in  their  action.  An  important  result  of  this  is  that  pharmacological  agents  aimed  at 
downregulating  only  one  or  a  few  cytokines  are  unlikely  to  be  of  benefit  in  cachexia. 
While  cytokines  may  have  direct  effects  in  the  hypothalamus  to  decrease  appetite  and 
increase  resting  energy  expenditure  (Mahony  &  Tisdale,  1988,  Moldawer  et  al,  1988, 
Hellerstein  et  al,  1989,  Langstein  et  al,  1991,  Matthys  et  al,  1991,  Smith  &  Kluger,  1993)  and 
they  may  also  act  at  this  site  via  effects  on  neurotransmitters  such  as  serotonin,  neuropeptide  Y 
and  corticotrophin  releasing  hormone  (Cangiano  et  al,  1994,  Schwarz  et  al,  1995)  there  is  no 
evidence  that  cytokines  alone  in  culture  with  muscle  will  cause  protein  breakdown  (Goodman, 
1990,  Tisdale,  1997).  Thus,  while  pro-inflammatory  cytokines  may  be  a  significant  part  of  the 
inflammatory  cascade  ultimately  resulting  in  cachexia  and  protein  breakdown,  it  is  important  to 
examine  the  other  mediators  and  mechanisms  influenced  by  cytokines. 
Other  mediators  and  their  interaction  with  pro-inflammatory  cytokines 
The  data  presented  in  Chapter  9  demonstrated  that  weight-losing  patients  with  advanced 
pancreatic  cancer  have  a  reduced  fasting  concentration  of  the  anabolic  hormone  insulin 
compared  with  healthy  controls.  The  concentration  of  the  catabolic  hormone  cortisol  was  not 
different  in  cancer  patients  and  controls.  Such  findings  have  been  noted  previously  in  a  similar 
group  of  patients  (Fearon  et  al,  1998).  It  has  been  suggested  that  the  ratio  of  these  hormones 
may  give  an  impression  of  the  anabolic  /  catabolic  balance  and  in  the  present  study  the  cortisol 
/  insulin  ratio  was  substantially  increased  in  cancer  patients  compared  with  controls  suggesting 
a  catabolic  picture.  In  response  to  feeding  at  baseline,  the  concentration  of  insulin  rose  by  a 
similar  proportion  and  absolute  amount  to  that  seen  in  healthy  subjects  suggesting  that  it  is  not 
an  absolute  lack  of  insulin  in  the  fed  state  which  prevents  anabolism  with  feeding. 
Administration  of  supraphysiological  doses  of  pro-inflammatory  cytokines  will  influence  the Chapter  11  169 
concentrations  of  conventional  endocrine  hormones,  with  increases  in  cortisol  and  glucagon 
and  a  decrease  in  insulin  concentrations  (Selby  et  al,  1987,  Warren  et  al,  1987,  Michie  et  al, 
1988,  Starnes  et  al,  1988,  Stouthard  et  al,  1996).  It  is  not  clear  from  the  data  available  at 
present  whether  the  changes  observed  in  cancer  patients  are  a  response  to  cytokine  stimulation 
or  whether  both  are  reflections  of  the  wider  inflammatory  and  catabolic  state. 
Another  suggested  mediator  of  weight  loss  in  advanced  cancr  is  proteolysis  inducing 
factor  (PIF),  a  glycoprotein  identified  in  a  cachectic  mouse  model  which  causes  protein 
breakdown  (Todorov  et  al,  1996a).  Clinical  measurement  of  PIF  is  in  its  infancy.  Circulating 
concentrations  are  not  readily  measurable  but  assessments  are  made  of  urinary  excretion 
(Todorov  et  al,  1996a).  These  measurements  are  not  quantitative  but  excretion  has  so  far  only 
been  found  in  weight-losing  cancer  patients  but  not  in  weight-stable  cancer  patients,  those 
losing  weight  with  benign  disease  or  in  healthy  subjects  (Todorov  et  al,  1996a,  Todorov  et  al, 
1996b,  Cariuk  et  al,  1997).  It  was  shown  in  Chapter  7  that  proteolysis  inducing  factor  was 
found  in  the  urine  of  89%  of  the  weight  losing  pancreatic  cancer  patients  examined  and  not  in 
healthy  controls.  It  has  been  suggested  that  proteolysis  inducing  factor  may  work  in  concert 
with  pro-inflammatory  cytokines  to  produce  weight  loss  in  cancer  (Fujiki  et  al,  1997). 
The  role  of  energy  balance  in  cancer  cachexia 
It  has  previously  been  suggested  that  increased  resting  energy  expenditure  may 
contribute  to  weight  loss  in  advanced  cancer  (Fredrix  et  al,  1991,  Staal-van  den  Breckel  et  al, 
1994,  Falconer  et  al,  1994a).  This  is  perhaps  due  to  small  daily  energy  costs  of  increased 
protein  and  carbohydrate  turnover  (Eden  et  al,  1984,  Fearon  et  al,  1988).  The  data  presented  in 
Chapter  9  suggests  that  resting  energy  expenditure  per  unit  weight  was  elevated  in  the  group  of 
pancreatic  cancer  patients  studied.  However,  Chapter  9  also  demonstrated  that  there  was  no 
increased  energy  cost  of  feeding  in  these  patients.  The  physical  activity  component  of  energy 
expenditure  was  not  examined  in  the  present  study  but  it  has  been  suggested  that  this  may  be 
reduced  in  advanced  cancer  patients  (Gibney  et  al,  1997).  Those  examined  in  the  present  study 
did  have  limitations  to  their  functional  activity  brought  about  by  their  disease  reflected  in 
reduced  performance  status  (Chapter  3)  and  thus  the  present  study  provides  no  evidence  that 
overall  energy  expenditure  was  increased.  While  the  small  increase  in  relative  resting  energy 
expenditure  may  reflect  futile  metabolic  cycles  known  to  be  occuring  it  would  appear  that  the 
reduction  in  the  energy  cost  of  feeding  observed  in  Chapter  9  is  appropriate  to  the  weight- 
losing  state  of  these  patients. Chapter  11  170 
Before  intervention  only  a  few  patients  had  an  apparently  inadequate  dietary  intake  that 
would  result  in  a  marked  negative  energy  balance  based  on  estimated  total  energy  expenditure 
(Chapter  9).  While  previous  studies  have  shown  an  inadequate  dietary  intake  in  pancreatic 
cancer  patients,  differences  tend  to  be  small  or  limited  to  a  few  patients  (Wigmore  et  a1, 
1997b).  This  means  that  for  many  patients,  particularly  the  group  examined  in  the  present 
study  who  were  relatively  heterogeneous  in  terms  of  energy  balance,  a  large  increase  in  energy 
expenditure  (in  the  fasted  and  fed  state)  or  a  major  decrease  in  energy  intake  was  not  observed 
and  large  energy  imbalances  do  not  explain  the  weight  loss  observed.  Indeed  the  small 
reduction  in  the  energy  cost  of  feeding  would  appear  to  be  an  appropriate  adaptation  to  the 
weight-losing  state.  Thus  it  is  possible  that  specific  metabolic  pathways  may  drive  the 
progressive  loss  of  lean  tissue  in  cancer  patients  and  prevent  anabolism  with  feeding  rather  than 
a  particularly  marked  energy  imbalance  exacerbated  by  feeding. 
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It  is  increasingly  being  recognised  that  associated  with  loss  of  weight  and  progress  of 
disease  in  many  advanced  malignancies  is  an  inflammatory  response  characterised  by  changes 
in  plasma  protein  concentrations  (Falconer  et  al,  1994a,  Staal-van  den  Breckel  et  al,  1995, 
Wigmore  et  al,  1997b,  O'Gorman  et  al,  1998,  McMillan  et  al,  1998)  while  no  such  changes  are 
observed  in  simple  starvation.  This  acute  phase  protein  response,  with  increases  in  the 
concentrations  of  positive  acute  phase  proteins  such  as  C-reactive  protein  and  fibrinogen  and 
decreases  in  negative  acute  phase  proteins  such  as  albumin,  has  been  associated  with  poor 
survival  in  advanced  pancreatic  cancer  (Falconer  et  al,  1995)  and  this  association  has  also  been 
demonstrated  in  Chapter  5.  The  data  presented  in  Chapter  8  confirms  marked  changes  in  the 
concentrations  of  a  broad  spectrum  of  acute  phase  proteins  in  advanced  pancreatic  cancer 
patients  compared  with  healthy  controls  while  both  Chapter  3  and  Chapter  8  suggest  that  the 
relevant  positive  and  negative  changes  become  more  marked  with  progress  of  disease. 
The  acute  phase  protein  response  has  been  shown  to  be  stimulated  in  cultured 
hepatocytes  by  pro-inflammatory  cytokines  (Castell  et  al,  1990).  The  administration  of  pro- 
inflammatory  cytokines  also  stimulates  an  acute  phase  protein  response  in  human  subjects 
(Selby  et  al,  1987,  Warren  et  al,  1987,  Michie  et  al,  1988,  Starnes  et  al,  1988,  Stouthard  et  al, 
1996).  In  Chapters  4  and  7  data  was  presented  demonstrating  an  association  between 
circulating  concentrations  of  interleukin-6  and  tumour  necrosis  factor  receptors  and  the 
concentration  of  the  acute  phase  reactant  C-reactive  protein  and  of  interleukin-6  production  and 
C-reactive  protein  concentrations  in  pancreatic  cancer  patients.  In  Chapter  5  production  of 
interleukin-1  ß  was  shown  to  be  associated  with  C-reactive  protein  concentrations. 
Previous  studies  in  pancreatic  cancer  patients  have  associated  the  acute  phase  protein 
response  as  determined  by  an  elevated  C-reactive  protein  concentration  with  increased  resting 
energy  expenditure  and  reduced  nutritional  intake  (Falconer  et  al,  1994a,  Wigmore  et  al, 
1997b).  Using  C-reactive  protein  to  define  the  acute  phase  protein  response,  the  present  study 
demonstrated  a  reduced  nutritional  intake  in  such  patients  but  little  in  the  way  of  other 
metabolic  differences  (Chapter  9).  The  variety  of  abnormalities  in  acute  phase  protein 
concentrations  shown  in  Chapter  8  suggest  that  using  C-reactive  protein  alone  to  define  this 
condition  may  be  simplistic.  Hepatic  production  of  fibrinogen  and  circulating  concentrations 
were  markedly  elevated  in  cancer  patients  with  normal  C-reactive  protein  concentrations 
(Chapter  10),  thus  an  acute  phase  protein  response  may  apparently  be  present  without  changes 
in  the  concentrations  of  all  acute  phase  proteins.  Further  longitudinal  studies  would  be  required 
to  determine  how  the  various  acute  phase  protein  concentrations  change  quantitatively  and Chapter  11  172 
temporally  with  the  progress  of  disease.  However,  Chapter  8  also  suggests  a  progressive 
increase  in  the  concentration  of  positive  acute  phase  proteins  and  a  progressive  decrease  in  the 
concentration  of  negative  acute  phase  proteins  with  time. 
From  in  vitro  studies  which  demonstrated  increased  production  of  positive  acute  phase 
proteins  in  parallel  with  decreased  production  of  negative  acute  phase  proteins  it  has  been 
assumed  that  the  process  did  not  greatly  affect  overall  nitrogen  balance  (Castell  et  al,  1990). 
However,  it  has  recently  been  shown  that  although  the  albumin  concentration  may  be  reduced 
in  advanced  cancer  its  production  remains  unchanged  compared  with  controls  in  the  fasting 
state  (Fearon  et  al,  1998).  Fibrinogen  concentrations  are  elevated  in  cancer  patients  and  in  the 
fasting  state  its  synthesis  is  substantially  increased  compared  with  controls  (Preston  et  al, 
1998).  It  has  been  shown  in  Chapter  10  that  in  the  fed  state  there  is  a  very  similar  increase  in 
albumin  synthesis  in  both  cancer  patients  and  controls  and  that  while  controls  have  no  change 
in  fibrinogen  synthesis  with  feeding  there  is  a  substantial  stimulation  of  the  already  elevated 
fibrinogen  synthesis  in  cancer  patients.  Thus  if  these  results  apply  to  the  other  positive  and 
negative  acute  phase  proteins  there  is  no  apparent  nitrogen  saving  from  decreased  synthesis  of 
negative  acute  phase  proteins.  In  addition,  feeding  serves  to  stimulate  positive  (and  negative) 
acute  phase  protein  synthesis.  In  cachectic  cancer  patients  this  may  thus  represent  a  potential 
mechanism  for  continued  amino  acid  demand  which  must  be  supplied  from  lean  tissue  stores  in 
the  fasting  state.  In  addition  it  may  contribute  to  the  lack  of  anabolic  response  to  feeding  in 
cancer  patients  if  a  proportion  of  supplied  nutritents  are  diverted  to  acute  phase  protein 
synthesis. 
Despite  the  imbalance  in  skeletal  muscle  and  acute  phase  protein  amino  acid 
composition  (Reeds  et  al,  1994)  the  overall  quantity  of  protein  involved  is  small  and  factors 
such  as  amino  acid  recycling  have  not  been  examined,  however,  there  appears  to  be  strong 
evidence  to  link  the  acute  phase  protein  response  to  the  ongoing  process  of  cachexia  and 
potentially  to  the  lack  of  anabolic  response  to  feeding. Chapter  11 
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Curative  treatment  of  patients  with  advanced  cancer  remains  rare  thus  it  is  left  to  try  to 
treat  the  symptoms  suffered  by  patients  in  an  attempt  to  improve  their  quality  and  length  of  life. 
The  treatment  of  cachexia  would  seem  a  legitimate  target  for  treatment  as  it  has  a  substantial 
influence  on  patients  well-being  and  survival.  The  supply  of  additional  nutrients  does  not 
appear  to  influence  the  progress  of  cachexia  for  the  reasons  outlined  above. 
Options  for  intervention  in  cancer  cachexia  and  other  pro-inflammatory  cytokine 
mediated  weight  losing  conditions  such  as  sepsis  have  included  direct  anticytokine  therapy 
with  specific  antibodies  (Wherry  et  al,  1993,  Smith,  1998),  general  anti-cytokine  agents  such 
as  pentoxyfylline  and  thalidomide  (Goldberg  et  al,  1995,  Haslett,  1998),  agents  acting  on 
specific  enzymes  in  carbohydrate  metabolism  such  as  hydrazine  sulphate  (Loprinzi  et  al,  1994a, 
Loprinzi  et  al,  1994b)  and  agents  affecting  hypothalamic  neurotransmitters  such  as 
cyproheptadine  (Kardinal  et  al,  1990).  Steroids  and  progestogenic  agents  may  also  act 
centrally  to  affect  appetite  and  well  being  (Robustelli  della  Cuna  et  al,  1989,  Popiela  et  al, 
1989,  Bruera  et  al,  1998).  Unfortunately  none  of  these  approaches  appears  to  be  wholly 
successful  in  reversing  the  metabolic  changes  responsible  for  weight  loss  and  some,  such  as 
steroids,  may  exacerbate  them.  It  is  likely  that  these  agents  are  either  too  specific,  acting  only Chapter  11  174 
on  a  small  corner  of  the  huge  network  of  mediators  of  cachexia,  or  act  too  far  down  the  chain  of 
events  to  effect  an  overall  change. 
The  interventions  which  have  shown  some  promise  in  cachexia  have  been  suggested  to 
normalise  the  metabolic  state  of  cachectic  patients  to  some  degree.  The  non-steroidal  anti- 
inflammatory  ibuprofen  has  been  shown  to  reduce  concentrations  of  pro-inflammatory 
cytokines  and  acute  phase  proteins  and  to  normalise  whole  body  protein  kinetics  (McMillan  et 
al,  1995,  Preston  et  al,  1995,  Wigmore  et  al,  1995).  Indomethacin  may  stabilise  performance 
status  and  improve  survival.  The  n-3  fatty  acid  eicosapentaenoic  acid  and  fish  oil  rich  in 
eicosapentaenoic  acid  have  been  shown  to  reduce  pro-inflammatory  cytokine  production  and 
acute  phase  protein  concentrations  (Wigmore  et  al,  1996,  Wigmore  et  al,  1997d)  and  may 
stabilise  weight  and  prolong  survival  (Wigmore  et  al,  1996,  Barber  et  al,  1997,  Gogos  et  al, 
1998).  While  these  agents  have  shown  potential  in  manipulating  some  of  the  presumed 
mediators  of  cachexia  none  will  reverse  the  process  of  cachexia  itself  on  their  own. 
A  new  approach  has  been  the  combination  of  an  anti-inflammatory  agent  to  affect  the 
inflammatory  process  with  an  agent  to  increase  nutritional  intake.  The  only  trial  previously 
published  taking  this  approach  in  cancer  cachexia  examined  the  combination  of  ibuprofen  with 
the  appetite  stimulant  megestrol  acetate  compared  with  megestrol  acetate  alone  (McMillan  et 
al,  1999).  Seventy-three  patients  with  gastrointestinal  cancer  were  studied  over  12  weeks. 
Although  nutritional  intake  was  not  measured,  appetite  improved.  in  both  groups.  However,  in 
the  group  taking  megestrol  acetate  alone  weight  loss  continued  at  a  rate  of  around  lkg/month 
while  the  group  also  receiving  ibuprofen  had  a  significant  weight  gain  of  around  1kg  after  6 
weeks  and  2.3kg  after  12  weeks.  Quality  of  life  studies  also  suggested  some  benefits  to  the 
group  receiving  the  combination  treatment.  The  studies  presented  in  Chapters  6-10  took  a 
similar  approach  using  a  nutritional  supplement  to  increase  nutritional  intake  in  combination 
with  fish  oil,  rich  in  eicosapentaenoic  acid,  to  down-regulate  the  inflammatory  process. 
The  effect  of  a  fish  oil-enriched  nutritional  supplement  in  cancer  cachexia 
Previous  studies  have  suggested  that  fish  oil  or  eicosapentaenoic  acid  will  affect  various 
mediators  believed  to  have  a  role  in  cachexia.  Production  of  or  circulating  concentrations  of 
the  pro-inflammatory  cytokines  interleukin-1,  interleukin-6  and  tumour  necrosis  factor  have 
been  suggested  to  be  reduced  by  these  agents  in  humans  in  health  and  disease  (Endres  et  al, 
1989,  Meydani  et  al,  1991,  Meydani  et  al,  1993,  Cooper  et  al,  1993,  Purasiri  et  al,  1994, 
Caughey  et  al,  1996,  Wigmore  et  al,  1997d).  However,  another  group  using  apparently  similar 
techniques  and  n-3  fatty  acid  doses  have  found  prompt  rises  in  pro-inflammatory  cytokine Chapter  11  175 
production  (Demols  et  al,  1998).  The  present  study  demonstrated  that  there  was  a  significant 
reduction  in  the  production  of  interleukin-6  by  weight-losing  pancreatic  cancer  patients  after 
the  administration  of  a  fish  oil-enriched  nutritional  supplement  for  three  weeks  under  certain 
culture  conditions  while  there  was  no  change  in  the  concentration  of  circulating  cytokines  or 
their  receptors  (Chapter  7).  As  discussed  above  the  significance  of  this  finding  is  difficult  to 
guage  in  view  of  the  elevated  circulating  concentration  of  interleukin-6  observed  in  cancer 
patients  compared  with  controls  and  the  similar  ex  vivo  interleukin-6  production  in  the  two 
groups.  Further  study  in  this  area  is  required. 
It  has  previously  been  suggested  that  eicosapentaenoic  acid  may  inhibit  the  end  organ 
effects  of  PIF  in  vitro  (Tisdale  et  al,  1996).  The  effects  of  an  eicosapentaenoic  acid-based 
intervention  on  PIF  have  not  previously  been  studied  in  human  subjects.  The  present  study 
demonstrated  a  reduction  in  the  proportion  of  patients  with  detectable  PIP  in  urine  from  89%  to 
40%  after  provision  of  a  fish  oil  enriched  nutritional  supplement  for  3  weeks.  Measurement  of 
PIF  activity  in  vivo  is  not  yet  possible  and  it  is  not  yet  clear  in  any  detail  how  urinary  excretion 
of  PIP  relates  to  its  concentration  or  activity  in  circulation  but  the  observation  of  reduced 
urinary  excretion  may  suggest  that  the  concentration  of  this  mediator  in  circulation  may  be 
reduced  with  or  without  any  effect  on  end-organ  activity. 
Fasting  insulin  concentration  increased  significantly  in  the  weight-losing  cancer 
patients  after  intervention  to  a  level  similar  to  that  seen  in  healthy  controls  (Chapter  9).  The 
cortisol  /  insulin  ratio  also  fell  significantly  suggesting  a  change  to  a  more  anabolic  hormonal 
balance.  The  effect  of  a  fish  oil-derived  intervention  on  hormone  concentrations  has  not 
previously  been  studied.  However,  Chapter  9  also  demonstrated  that  the  insulin  response  to 
feeding  changed  little  after  supply  of  the  fish  oil-enriched  nutritional  supplement  suggesting 
that  it  is  not  an  increased  amount  of  insulin  in  the  fed  state  that  is  responsible  for  allowing 
anabolism.  This  observation  also  supports  the  supposition  made  above  that  it  is  not  a  lack  of 
insulin  in  the  fed  state  which  prevents  anabolism  in  cachexia.  It  therefore  seems  likely  that 
insulin  concentrations  appropriately  reflect  the  general  metabolic  state  rather  than  being  a 
major  causative  factor  of  the  cachexia. 
After  intervention  there  was  a  reduction  in  resting  energy  expenditure  but  an  increase  in 
the  energy  cost  of  feeding  (Chapter  9).  These  changes  were  seen  in  conjunction  with  a  relative 
normalisation  of  substrate  utilisation  and  suggest  patients  were  in  a  more  stable  metabolic  state 
similar  to  the  healthy  controls  examined.  This  again  suggests  that  these  factors  are  a  reflection 
of  the  metabolic  changes  of  these  patients  rather  than  a  cause. Chapter  11  176 
The  weight-losing  pancreatic  cancer  patients  achieved  a  significant  increase  in  their 
nutritional  intake  with  the  provision  of  the  fish  oil-enriched  nutritional  supplement  (Chapter  6). 
This  occured  despite  an  initially  poor  appetite  and  was  accompanied  by  an  improvement  in 
appetite.  Patients  had  a  substantial  ongoing  weight-loss  prior  to  intervention  with  all  patients 
losing  more  than  1.6kg/month.  Fourteen  of  the  eighteen  surviving  patients  began  regaining 
weight  after  receiving  the  fish  oil-enriched  nutritional  supplement  and  the  other  four  patients 
had  a  substantial  slowing  of  their  rate  of  weight-loss.  Previous  studies  in  cancer  patients  have 
succeeded  in  increasing  the  nutritional  intake  of  patients  to  a  similar  degree  to  that  which  was 
achieved  in  the  present  thesis  (Evans  et  al,  1987,  Ovesen  et  al,  1993b).  However,  the 
provision  of  additional  nutrients  in  these  studies  failed  to  affect  weight.  Similarly,  while  the 
administration  of  anti-inflammatory  agents  such  as  ibuprofen  and  fish  oil-based  preparations 
have  reduced  concentrations  of  inflammatory  mediators  and  stabilised  weight  none  have  been 
shown  to  reverse  weight  loss  in  cachectic  cancer  patients  (McMillan  et  all,  1995,  Preston  et  al, 
1995,  Wigmore  et  al,  1995,  Wigmore  et  al,  1996,  Barber  et  al,  1997).  Thus  it  appears  that  the 
combination  of  the  fish  oil  as  an  anti-inflammatory  agent  with  nutritional  supplementation  was 
responsible  for  the  effects  observed. 
Weight  gain  has  been  achieved  in  previous  studies  of  interventions  in  cachectic  cancer 
patients,  notably  megestrol  acetate,  however,  body  composition  analysis  has  revealed  this  to  be 
due  to  the  accumulation  of  water  or  fat  (Loprinzi  et  al,  1993b,  Simons  et  al,  1998).  As 
discussed  above,  it  would  appear  to  be  the  loss  of  lean  tissue  that  contributes  to  the  loss  of 
functional  ability  and  shortened  survival  of  cachectic  cancer  patients  and  thus  weight  gain 
alone  is  not  an  appropriate  endpoint  in  studies  of  intervention  in  cachexia.  In  the  present  thesis 
body  composition  was  assessed  by  bioelectrical  impedence  analysis  and  a  significant  increase 
in  lean  body  mass  was  observed  after  intervention  with  no  change  in  percentage  body  water  or 
fat  mass.  The  observed  body  composition  changes  may  be  questioned  due  to  the  relatively 
imprecise  nature  of  the  bioimpedence  method  used  (Kotler  et  al,  1996,  Jensen  et  al,  1997).  The 
method  relies  on  equations  (largely  based  on  weight  and  height)  to  derive  body  composition. 
Body  composition  changes  with  disease  (Fearon  &  Preston,  1990)  so  it  is  important  to  use 
equations  derived  from  study  of  a  similarly  diseased  group  such  as  was  used  in  the  present 
study  (Hannan  et  al,  1995).  There  are  a  number  of  potentially  more  precise  methods  of 
measuring  body  composition  such  as  hydrodensitometry,  measurement  of  total  body  potassium, 
isotope  dilution  and  dual  energy  X-ray  absorptiometry,  however,  these  are  much  more  costly 
and  less  convenient  than  bioimpedence  analysis  and  may  be  subject  to  their  own  inaccuracies 
(McMillan  et  al,  1994,  Paton  et  al,  1995).  However,  the  body  composition  findings  in  the Chapter  11  177 
present  study  were  reinforced  by  the  lack  of  change  in  serum  leptin  concentration  suggesting  a 
no  change  in  fat  mass  and  a  reversal  of  nitrogen  balance  from  -0.8g/day  to  +1.9g/day  consistent 
with  a  gain  in  lean  body  mass.  While  no  change  was  seen  in  anthropometric  measures  but  this 
may  represent  a  change  from  the  expected  pattern  of  a  progressive  fall  in  arm  muscle 
circumference  and  triceps  skinfold  thickness  previously  described  in  weight-losing  pancreatic 
cancer  patients  (Wigmore  et  al,  1997a).  The  improvement  in  lean  body  mass  with  an 
intervention  in  cancer  cachexia  has  not  previously  been  demonstrated  and  future  confirmation 
using  a  more  rigorous  technique  of  body  composition  analysis  would  be  valuable. 
While  detailed  studies  of  quality  of  life  were  not  performed  in  all  patients  in  the  present 
study,  Karnofsky  performance  status,  a  measure  of  functional  ability  was  recorded  and 
demonstrated  a  significant  improvement  (Chapter  6)  in  contrast  to  a  progressive  decline  in 
untreated  patients  (Chapter  3).  The  limited  quality  of  life  and  other  functional  studies 
performed  did,  however,  also  suggest  that  particularly  functional  aspects  of  quality  of  life  may 
have  been  improved.  Thus  it  seems  that  the  provision  of  a  nutritional  supplement  enriched 
with  fish  oil  to  weight-losing  advanced  pancreatic  cancer  patients  resulted  in  a  reversal  of 
weight-loss  with  a  gain  in  lean  tissue  resulting  in  functional  benefit  for  the  patients. 
Any  survival  benefit  produced  by  the  fish  oil-enriched  nutritional  supplement  could  not 
be  formally  addressed  in  the  present  study  although  survival  was  at  the  top  end  of  that  expected 
for  patients  with  advanced  pancreatic  cancer  (Ahlgren,  1996).  However,  it  is  conceivable  that 
if  deterioration  in  lean  body  mass  contributes  to  shortened  survival  then  a  reversal  of  this 
process  may  have  a  survival  benefit.  Lengthened  survival  in  patients  given  Maxepa,  providing 
3g  eicosapentaenoic  acid  daily,  has  been  shown  in  a  randomised  study  of  advanced  cancer 
patients  (Gogos  et  al,  1998).  These  patients  were  reported  as  not  showing  weight  change  over 
the  course  of  the  study  but  it  is  not  clear  whether  this  represents  a  change  from  the  expected 
course  in  this  group.  A  randomised  controlled  trial  in  circumstances  similar  to  those  of  the 
present  study  is  required  to  address  survival. 
In  association  with  the  beneficial  nutritional  effects  of  the  nutritional  supplement 
enriched  with  fish  oil,  a  stabilisation  of  acute  phase  protein  concentrations  was  shown  while 
progressive  increases  and  decreases  in  positive  and  negative  acute  phase  protein  concentrations 
respectively  were  seen  without  intervention  (Chapter  8).  The  stabilisation  in  the  concentrations 
of  negative  acute  phase  proteins  such  as  albumin  (Chapter  8)  despite  the  relative  reduction  in 
their  synthesis  (Chapter  10)  suggests  that  factors  such  as  plasma  protein  breakdown  and 
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protein  concentrations  alone  are  of  limited  value  for  studying  changes  in  amino  acid  balance 
without  knowledge  of  their  synthesis. 
Conventional  nutritional  supplementation  does  not  result  in  anabolism  in  cachectic 
cancer  patients  and  in  Chapter  10  it  has  been  observed  that  overall  synthesis  of  acute  phase 
proteins  may  be  stimulated  by  feeding  in  cancer  patients  but  not  in  controls.  A  hypothesis 
examined  in  this  thesis  was  that  this  stimulation  of  acute  phase  protein  synthesis  by  feeding 
may  contribute  to  the  lack  of  anabolic  effect  of  feeding  in  advanced  cancer  patients.  After 
consumption  of  the  fish  oil-enriched  nutritional  supplement  for  3  weeks,  stimulation  of 
albumin  synthesis  was  abolished  and  the  degree  of  stimulation  of  fibrinogen  synthesis  was 
halved  resulting  in  no  significant  overall  stimulation  of  acute  phase  protein  synthesis  with 
feeding  and  a  significant  reduction  in  acute  phase  protein  synthesis  in  the  fed  state.  This 
observation  in  association  with  the  reversal  of  weight  loss,  positive  nitrogen  balance,  and  gain 
in  lean  body  mass  (Chapter  6)  suggests  that  the  potential  amino  acid  sparing  effect  of  the 
reduction  in  acute  phase  protein  synthesis  may  allow  dietary  amino  acids  to  be  used  for  lean 
tissue  synthesis.  This  represents  a  substantial  change  in  the  metabolic  milieu  compared  with 
the  condition  before  intervention.  Fish  oil-derived  interventions  will  influence  pro- 
inflammatory  cytokine  production  (Endres  et  al,  1989,  Meydani  et  al,  1991,  Meydani  et  al, 
1993,  Cooper  et  al,  1993,  Purasiri  et  al,  1994,  Caughey  et  al,  1996,  Wigmore  et  al,  1997d  and 
Chapter  7)  which  may  effect  acute  phase  protein  synthesis.  However,  pro-inflammatory 
cytokine  synthesis  and  acute  phase  protein  synthesis  are  stimulated  by  the  same  nuclear 
transcription  factor  (Beauparlant  &  Hiscot,  1996)  and  it  is  not  clear  whether  fish  oil  is  acting 
via  suppression  of  the  pro-inflammatory  state  or  by  a  direct  effect  on  acute  phase  protein 
synthesis.  Either  way  the  present  study  provides  evidence  that  the  normally  irreversible 
weight-loss  of  advanced  cancer  may  be  at  least  partly  due  to  the  diversion  of  amino  acids  for 
acute  phase  protein  synthesis  and  that  the  reversal  of  weight-loss  by  the  fish  oil-enriched 
nutritional  supplement  may  be  at  least  partly  due  to  suppression  of  the  stimulation  of  acute 
phase  protein  synthesis  by  feeding. 
Limitations  of  the  present  studies 
There  were  some  disappointing  aspects  to  the  work  described  in  this  thesis.  The 
controls  recruited  were,  in  general,  younger  than  the  cancer  patients  studied.  It  was  decided  to 
try  to  recruit  controls  over  the  age  of  50  years  in  an  attempt  to  minimise  potential  physiological 
differences  between  cancer  patients  and  controls  on  the  basis  of  age  but  it  remains  possible  that 
age  may  have  influenced  results  to  some  extent. Chapter  11  179 
The  inability  to  demonstrate  elevated  cytokine  production  in  cancer  patients  compared 
with  controls,  despite  this  having  been  shown  previously  (Falconer  et  al,  1995,  Wigmore  et  al, 
1997d)  would  appear  to  threaten  the  hypothesis  that  such  increased  cytokine  production  is  of 
crucial  importance  to  driving  the  metabolic  changes  in  cancer.  As  discussed  above  this  may 
have  been  due  to  limitations  of  the  cell  culture  technique  or  an  earlier  disease  stage  in  the 
patients  examined  in  the  present  study.  However,  increased  circulating  concentrations, 
particularly  of  interleukin-6,  were  shown  and  the  relative  clinical  importance  of  ex  vivo 
cytokine  production  and  in  vivo  circulating  concentrations  of  cytokines  remains  to  be 
determined. 
The  design  of  the  present  study  did  not  allow  for  an  assessment  of  the  effects  of  the 
various  components  of  the  fish  oil-enriched  supplement.  It  is  assumed  from  previous  studies 
that  nutritional  intervention  alone  does  not  affect  weight  change  in  cachectic  cancer  patients 
(Evans  et  al,  1987,  Ovesen  et  al,  1993b).  The  relative  role  of  eicosapentaenoic  acid  and 
docosahexaenoic  acid  could  not  be  determined  and  no  dose  response  relationship  could  be 
ascertained. 
Other  problems  result  from  the  relative  success  of  the  study.  Because  changes  in 
mediators,  mechanisms  and  the  progress  of  cachexia  were  demonstrated  relatively 
unequivocally,  analysis  of  other  factors  in  more  detail  became  more  relevant.  Effective 
measures  of  quality  of  life  and  functional  ability  were  not  identified  until  well  into  the  study 
and  if  examined  in  all  patients  may  have  been  able  to  demonstrate  benefit  in  these,  arguably 
more  important,  factors.  The  technique  of  bioimpedence  analysis,  while  cheap,  quick,  easy  and 
well  tolerated,  has  many  critics  and  additional  or  alternative  measures  would  have  been  value. 
However,  these  factors  leave  several  opportunities  for  future  study  particularly  in  the  context  of 
a  randomised  controlled  trial. 
Potential  value  of  fish  oil-based  intervention  in  other  weight-losing  conditions 
The  non-toxic  nature  of  n-3  fatty  acids  and  their  widespread  availability  means  they 
have  enormous  potential  not  only  as  an  anti-cachectic  agent  in  cancer  but  also  in  other 
circumstances  where  an  inflammatory  metabolic  milieu  has  an  apparently  detrimental  effect, 
such  as  trauma  and  sepsis  and  after  surgery.  A  nutritional  supplement  enriched  with  n-3  fatty 
acids  in  addition  to  arginine,  glutamine  and  ribonucleotides  has  been  shown  to  reduce 
infectious  complications  and  hospital  stay  in  a  randomised  trial  of  severely  injured  patients 
compared  to  a  standard  supplement  (Kudsk  et  al,  1996).  A  study  of  a  similar  preparation 
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patients  had  fewer  complications  and  shorter  hospital  stay  compared  with  those  given  standard 
supplements  (Daly  et  al,  1995).  A  recent  meta-analysis  of  studies  comparing  nutritional 
supplements  enriched  with  n-3  fatty  acids,  arginine,  glutamine  and  ribonucleotides  with 
standard  supplements  has  also  suggested  a  shorter  hospital  stay  in  cancer  and  critically  ill 
patients  and  a  reduction  in  infective  complications  in  cancer  patients  (Heys  et  al,  1999). 
However,  a  study  in  postoperative  upper  gastrointestinal  cancer  patients  demonstrated  no 
difference  between  those  on  such  an  enriched  supplement  and  those  receiving  intravenous 
crystalloid  alone  (Heslin  et  al,  1997).  The  relative  contributions  of  the  substances  used  to 
enrich  such  supplements  is  unclear,  indeed  some  may  have  opposing  immunological  actions. 
Arginine,  glutamine  and  ribonucleotides  have  been  suggested  to  cause  relative  immune 
enhancement  while  n-3  fatty  acids  may  cause  immunosuppression  (Meydani  et  al,  1991, 
Brittenden  et  al,  1994,  O'Riordain  et  al,  1994,  Khan  et  al,  1995)  However,  it  is  likely  that  the 
effects  of  these  agents  is  to  produce  a  more  subtle  immunomodulation  damping  down  the 
catabolic  inflammatory  response  rather  than  a  straight  forward  immune  enhancement  or 
suppression  (Furukawa  et  al,  1999). 
Two  trials  of  eicosapentaenoic  acid  based  preparations  have  been  undertaken  in  patients 
with  AIDS,  a  condition  often  associated  with  weight  loss.  In  an  uncontrolled  study  of  20  HIV 
infected  weight-losing  men  administered  18g/day  of  Maxepa,  providing  around  3g 
eicosapentaenoic  acid  per  day,  for  10  weeks,  weight  was  unchanged  over  the  trial  period.  It  is 
not  clear  whether  this  represented  a  change  from  the  state  before  intervention  (Hellerstein  et  al, 
1996).  A  randomised  trial  of  64  HIV  infected  individuals  of  oral  nutritional  supplementation 
or  supplementation  enriched  with  n-3  fatty  acids  (1.7g/day)  and  arginine  for  6  months  produced 
weight  gain  in  both  groups.  An  increase  in  body  weight  of  around  2kg  and  of  fat  mass  of 
around  lkg  were  seen  over  6  months  with  a  trend  towards  greater  weight  gain  with  the  n-3  fatty 
acid  enriched  supplement.  However,  the  patients  examined  in  this  study  were  not  weight 
losing  at  baseline  (Pichard  et  al,  1998).  These  studies  in  AIDS  unfortunately  add  little  to  our 
understanding  of  the  role  of  eicosapentaenoic  acid  in  cachexia  due  to  limitations  of  the  studies. 
It  has  also  been  suggested  that  the  pattern  of  weight  loss  in  AIDS  differs  from  that  in  cancer. 
While  weight  loss  appears  to  proceed  in  a  fairly  constant  manner  in  cancer  in  association  with  a 
chronic  inflammatory  state,  in  AIDS  weight  loss  occurs  in  a  more  stepwise  fashion  associated 
with  acute  infections  (Grunfeld  et  a1,1992,  Mulligan  &  Bloch,  1998). 
Further  study  of  the  potential  effects  of  ei.  cosapentaenoic  acid-based  preparations  in 
cachexia  in  non-malignant  conditions  is  clearly  required. Chapter  11  181 
Potential  for  future  studies  of  fish  oil-based  preparations  in  cancer  cachexia 
There  is  much  further  work  to  be  carried  out  in  this  field  to  further  define  the  nature  of 
cachexia  and  the  role  of  n-3  polyunsaturated  fatty  acids  in  affecting  this  process. 
The  present  thesis  formed  a  pilot  study  for  planned  larger,  randomised,  controlled 
studies.  A  randomised  trial  of  the  effects  of  eicosapentaenoic  acid  in  cachexia  is  required  to 
consolidate  and  confirm  the  findings  of  the  present  work.  Ideally,  to  assess  the  effect  of 
nutritional  supplementation  and  eicosapentaenoic  acid,  a  randomised  trial  would  involve 
patients  receiving  placebo  alone,  eicosapentaenoic  acid  alone,  a  conventional  nutritional 
supplement  alone  and  a  nutritional  supplement  enriched  with  eicosapentaenoic  acid.  Such  a 
study  would  require  the  collaboration  of  several  centres  with  the  involvement  of  a  few  hundred 
patients.  Necessarily  such  a  study  would  not  be  able  to  examine  metabolic  factors  in  such 
detail  as  the  present  study  but  measures  of  functional  ability  and  quality  of  life  would  be  of 
great  interest.  For  this,  reliable  and  reproducible  measures  which  are  able  to  reflect  changes  in 
the  well  being  of  patients  are  essential. 
Such  clinical  studies  should  also  address  the  body  composition  of  patients,  perhaps 
using  more  sophisticated  measures  than  bioimpedence  analysis.  The  effect  of  cachexia  on  total 
energy  expenditure  is  of  interest  together  with  any  effect  of  intervention.  If  total  energy 
expenditure  increased  with  the  reversal  of  cachexia  it  may  represent  an  objective  measure  of 
improvement  in  quality  of  life  due  to  increased  physical  activity. 
Further  work  may  also  consider  fine  tuning  the  dosage  of  the  fish  oil  and  nutritional 
components  used  in  the  treatment  of  cachexia.  Previous  studies  have  revealed  no  obvious 
difference  in  the  metabolic  modulation  produced  by  2g  and  6g  of  eicosapentaenoic  acid  daily 
(Wigmore  et  al,  1997d,  Barber  et  al,  1997).  The  role  of  other  components  of  the  fish  oil  such 
as  docosahexaenoic  acid  also  require  further  elucidation. 
The  role  of  the  nuclear  transcription  factor  NF-KB,  in  driving  cachexia  and  the  agents 
responsible  for  its  activation  and  inhibition  deserve  further  investigation.  The  effects  of  n-3 
fatty  acids  on  activation  of  NF-KB  are  also  of  interest. 
The  present  thesis  examined  too  few  individuals  to  allow  assessment  of  which  patients 
may  gain  particular  benefit  from  this  form  of  therapy.  It  is  not  clear  whether  intervening  early 
in  the  course  of  the  disease,  before  substantial  weight  loss  and  a  measurable  inflammatory 
response  may  be  more  beneficial  than  trying  to  intervene  when  patients  are  already  severely 
catabolic.  It  is  also  not  clear  whether  measuring  factors  such  as  C-reactive  protein  and 
interleukin-10  polymorphism  genotype  may  allow  determination  of  patients  who  would  gain Chapter  11  182 
particular  benefit  or  who  would  continue  to  decline  even  with  intervention.  Hopefully  future 
studies  may  help  clarify  this. 
Conclusion 
Cancer  cachexia  is  of  profound  importance  to  the  deterioration  in  condition  of  many 
patients  with  advanced  cancer.  The  syndrome  produces  a  metabolic  state  in  which  patients  will 
not  regain  weight  even  with  the  supply  of  apparently  adequate  nutrition.  This  thesis  has 
described  several  components  of  the  inflammatory  reaction  culminating  in  cachexia  and  drawn 
particular  attention  to  the  acute  phase  protein  response.  The  demand  for  amino  acids  for  the 
synthesis  of  acute  phase  proteins  may  contribute  to  the  lean  tissue  breakdown  seen  in  cachectic 
cancer  patients  and  the  supply  of  additional  nutrients  may  be  diverted  due  to  stimulation  of 
acute  phase  protein  synthesis.  This  thesis  has  also  described  the  effects  of  a  nutritional 
supplement  enriched  with  fish  oil  and  shown  that  it  will  normalise  many  aspects  of  the 
metabolic  state.  Patients  receiving  the  supplement  regained  lean  tissue  with  an  apparent 
improvement  in  functional  ability  in  association  with  an  abolition  of  the  stimulation  of  acute 
phase  protein  synthesis  by  food.  This  approach,  combining  an  anti-inflammatory  agent  and 
additional  nutrients,  shows  considerable  potential  as  a  safe,  well  tolerated  treatment  for  patients 
suffering  from  cancer  cachexia. References 
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Appendix  1 
Fatty  acid  nomenclature 
1 
Fatty  acids  are  unbranched,  acyclic  monocarboxylic  acids  usually  with  an  even  number 
of  carbon  atoms.  They  are  designated  according  to  the  number  of  carbon  atoms  they  contain  by 
a  prefix,  eg  eicosa  (20),  docosa  (22).  They  are  also  classified  according  to  the  number  of  double 
bonds  as  saturated  (no  double  bonds),  monounsaturated  (one  double  bond),  and  polyunsaturated 
(two  or  more  double  bonds).  Depending  on  the  number  of  double  bonds  they  are  called  dienoic 
(2),  trienoic  (3),  tetraenic  (4),  pentaenoic  (5)  or  hexaenoic  (6)  (figure  A.  1). 
The  carbon  atoms  are  numbered  from  the  terminal  methyl  group  (the  omega  (n,  w  or  ") 
system)  and  the  abbreviated  term  uses  this  numbering  to  denote  the  position  of  the  first  double 
bond  from  the  methyl  end. 
Many  fatty  acids  retain  older  nonsystematic  names. 
Examples 
Palmitic  acid  (from  palm  oil)  with  16  carbon  and  no  double  bonds  -  16:  0 
Oleic  acid  (from  olive  oil)  with  18  carbon  atoms  and  one  double  bond  nine  carbons  from  the 
methyl  end  -  18:  ln-9 
Linoleic  acid  with  18  carbon  atoms  and  two  double  bonds,  the  first  6  carbons  from  the  methyl 
end  -  18:  2n-6 
Eicosapentaenoic  acid  with  20  carbon  atoms  and  5  double  bonds,  the  first  3  carbons  from  the 
methyl  end  -  20:  5n-3 
OH 
Palmitic  Acid  16:  0 
C 
off 
Oleic  Acid  18:  1  n-9 
r0  Linoleic  Acid  18:  2n-6 
0H 
111111111111  11111111111111  jjjlII::::::  IIII  OiO  Arachidonic  Acid  20:  4n-6 
III  OH 
0 
Linolenic  Acid  18:  3n-3 
off 
c0 
Eicosapentaenoic  Acid  20:  5n-3 
OH 
Figure  A.  1.  Structure  and  nomenclature  of  fatty  acids. Appendix 
Appendix  2 
Patient  details 
2 
The  patients  studied  were  all  diagnosed  with  unresectable  pancreatic  cancer  having  been 
referred  to  the  Royal  Infirmary  of  Edinburgh.  Data  was  collected  on  all  patients  referred  but 
advanced  stage  of  disease,  travel  distance  and  patient  choice  affected  the  studies  patients 
underwent.  The  core  group  of  20  patients  with  appropriate  diagnosis,  ongoing  weight-loss, 
performance  status,  life  expectancy  and  willingness  to  participate  were  studied  in  depth  for 
Chapters  6-9.  Two  patients  were  unfit  for  further  study  and  were  excluded  from  Chapters  7-9. 
Two  further  diabetic  patients  were  excluded  from  Chapter  9.  Eight  of  this  core  group 
underwent  study  of  protein  synthesis  mainly  due  to  lack  of  availability  of  the  labelled 
phenylalanine. 
This  appendix  describes  basic  characteristics  of  all  patients  studied. 
%  weight  loss  -  percentage  weight  loss  at  diagnosis 
Survival  -  from  diagnosis 
Surgery  -  stent  =  endoscopic  or  percutaneous  biliary  stenting 
bypass  =  Surgical  bypass  of  stomach  and  biliary  tree 
Histology  -  histological  confirmation  of  diagnosis  -y=  yes,  n=  no Appendix  3 
Age  Sex  %weight 
loss 
IUCC 
stage 
Survival 
(days) 
Surgery  Histolog  Chapter 
69  m  33  IV  168  none  y  3,4,5,6,7,8,9,10 
70  m  19  II  256  none  n  5 
77  f  6  IV  310  bypass  y  3,4,5 
58  f  6  IV  242  stent  y  3,5 
,8  58  m  18  11  82  bypass  y  3,5,6,7,8,9,10 
77  f  6  11  136  none  y  5 
58  m  19  111  115  stent  n  5,6,7,8,9,10 
69  f  11  IV  83  none  y  3,5 
58  f  18  11  277  stent  y  3,4,5,6,7,8,9 
59  f  9  IV  77  bypass  y  3,5 
64  f  29  11  15  none  y  5 
64  f  18  11  265  stent  n  5,6,7,8,9,10 
78  m  14  IV  256  stent  n  3,5 
61  m  16  II  223  none  y  3,5 
68  f  22  II  334  none  y  5 
60  f  13  II  281  bypass  y  3,4,5,6,7,8,9 
75  m  6  II  112  stent  n  5 
74  m  6  IV  280  none  y  5 
62  m  nk  II  768  bypass  y  5 
77  f  11  IV  333  bypass  y  4,5,6,7,8,9 
55  f  26  111  113  none  y  3,4,5,6,7,8,9 
77  f  13  II  246  stent  y  3,5,8 
69  f  6  II  >360  bypass  y  5 
42  f  5  IV  1696  bypass  y  5 
74  m  6  lI  112  stent  y  5,8 
73  m  10  IV  539  bypass  n  4,5 
61  f  19  II  165  bypass  y  3,5,8 
66  m  24  III  111  stent  y  3,5,6,8 
64  f  8  II  295  bypass  y  3,4,5,6,7,8,9 
37  m  17  IV  122  stent  y  5 
72  m  16  IV  465  stent  n  3,5,6,7,8,10 
52  in  14  IV  445  bypass  y  5 
59  m  12  IV  97  none  y  3,4,5,6 
61  m  12  III  441  bypass  y  5 
66  f  3  III  273  stent  y  5 
66  m  9  IV  221  bypass  n  5 
68  f  nk  IV  76  none  y  5 
29  m  33  111  106  none  y  5 
54  m  6  IV  42  none  y  3,5,8 
67  f  4  IV  221  stent  y  3,5,8 
69  f  31  III  144  bypass  y  5 
56  f  8  II  63  none  n  5 
67  f  12  IV  307  bypass  y  5,6,7,8,9,10 
81  m  8  II  496  bypass  n  5 
85  m  nk  II  57  stent  y  5 
66  m  14  IV  202  bypass  y  5,6,7,8,9,10 
76  f  6  I  214  stent  y  5 
60  m  nk  1V  65  stent  n  5 
62  m  18  11  185  stent  y  3,4,5,6,7,8,9 
59  m  17  II  >900  bypass  y  5 
56  f  15  II  243  bypass  y  3,4,5,6,7,8 
48  m  7  III  927  bypass  y  5 
67  m  12  IV  153  none  y  3,5,6,7,8,9,10 
47  f  20  IV  126  none  y  5 
74  m  25  II  227  stent  y  5 
68  f  2  Iv  38  none  y  5 
76  m  nk  II  181  stent  n  5 
78  m  nk  IV  50  none  n  5 
72  m  24  II  266  stent  n  3,4,5,6,7,8,9 
53  f  22  II  316  stent  y  3,4,5,6,7,8,9 
66  m  11  IV  94  bypass  y  3,5,8 
67  f  16  IV  >300  bypass  y  5,6,7,8,9 
56  m  19  II  559  stent  n  5 
65  f  30  II  67  none  5 Appendix  4 
Appendix  3 
Composition  of  the  trial  fish  oil-enriched  nutritional  supplement 
Between  batch  coefficients  of  variation  in  the  proportion  of  EPA  and  DHA  in  the  supplement 
were  <1%  and  <1.5%  respectively. 
Nutrient  Amount  per  can  (237ml) 
Energy  (kcal)  310 
Protein  (g)  16.1  (21%  of  calories) 
Carbohydrate  (g)  49.7  (61%  of  calories) 
Fat  (g)  6.5  (18%  of  calories) 
EPA  1.09 
DHA  0.46 
Vitamin  A  (IU)  1320 
Vitamin  D  (IU)  192 
Vitamin  E  (IU)  72 
Vitamin  K  (IU)  32 
Vitamin  C  (mg)  156 
Folic  acid  (mcg)  456 
Thiamin  (mg)  1.6 
Riboflavin  (mg)  1.2 
Vitamin  B6  (mg)  1.2 
Vitamin  B  12  (mcg)  4.32 
Niacin  (mg)  9.6 
Choline  (mg)  126 
Biotin  (mcg)  187 
Pantothenic  acid  (mg)  6 
Sodium  (mg)  360 
Potassium  (mg)  480 
Chloride  (mg)  365 
Calcium  (mg)  432 
Phosphorus  (mg)  300 
Magnesium  (mg)  108 
Iodine  (mcg)  42 
Copper  (mg)  1.5 
Manganese  (mg)  0.6 
Zinc  (mg)  7 
Iron  (mg)  5.3 
Selenium  (mg)  22 
Chromium  (mcg)  30 
Molybdenum  (mcg)  49.4 Appendix 
Appendix  4 
Quality  of  life  questionaires 
Hospital  Anxiety  and  Depression  Scale  (Zigmond  &  Snaith,  1983) 
Rotterdam  Symptom  Checklist  (de  Haes  et  al,  1990,  Watson  et  al,  1992) 
5 
European  Organisation  for  Research  and  Treatment  of  Cancer  OLQ-C30  (Aaronson  et  al,  1993) 
EuroQOL  EQ-5D Hospital  Anxiety  and  Depression  Scale 
wi 
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NAME:  DATE: 
Doctors  are  aware  that  emotions  play 
an  important  part  in  most  illnesses.  If 
your  doctor  knows  about  these  feelings 
he  will  be  able  to  help  you  more. 
This  questionnaire  is  designed  to 
help  your  doctor  to  know  how  you  feel. 
Ignore  the  numbers  printed  on  the  left 
of  the  questionnaire.  Read  each  item 
and  underline  the  reply  which  comes 
closest  to  how  you  have  been  feeling  in 
the  past  week. 
Don't  take  too  long  over  your 
replies;  your  immediate  reaction  to  each 
item  will  probably  be  more  accurate  than 
a  long  thought  out  response. 
I  feel  tense  or  'wound  up': 
Most  of  the  time 
A  lot  of  the  time 
From  time  to  time,  occasionally 
Not  at  all 
I  still  enjoy  the  things  I  used  to  enjoy: 
Definitely  as  much 
Not  quite  so  much 
Only  a  little 
Hardly  at  all 
I  get  a  sort  of  frightened  feeling  as 
if  something  awful  is  about  to  happen: 
Very  definitely  and  quite  badly 
yes,  but  not  too  badly 
A  little,  but  it  doesn't  worry  me 
Not  at  all 
I  can  laugh  and  see  the  funny  side  of  things: 
As  much  as  I  always  could 
Not  quite  so  much  now 
Definitely  not  so  much  now 
Not  at  all 
I A 
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2 
1 
0 
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1 
O 
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D 
3 
2 
1 
0 
A 
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2 
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,..  71 
0 
wl 
Worrying  thoughts  go  through  my  mind: 
A  great  deal  of  the  time 
A  lot  of  the  time 
From  time  to  time  but  not  too  often 
Only  occasionally 
I  feel  cheerful: 
Not  at  all 
Not  often 
Sometimes 
Most  of  the  time 
I  can  sit  at  ease  and  feel  relaxed: 
Definitely 
Usually 
Not  often 
Not  at  all 
I  feel  as  if  I  am  slowed  down: 
Nearly  all  the  time 
Very  often 
Sometimes 
Not  at  all 
I  get  a  sort  of  frightened  feeling  like 
'  butterflies'  in  the  stomach: 
Not  at  all 
Occasionally 
Quite  often 
Very  often 
I  have  lost  interest  in  my  appearance: 
Definitely 
I  don't  take  so  much  care  as  I  should 
I  may  not  take  quite  as  much  care 
I  take  just  as  much  care  as  ever 
(Continued  overleaf) 
2 A 
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I  feel  restless  as  if  I  have  to  be  on 
the  move: 
Very  much  indeed 
Quite  a  lot 
Not  very  much 
Not  at  all 
I  look  forward  with  enjoyment  to  things: 
As  much  as  ever  I  did 
Rather  less  than  I  used  to 
Definitely  less  than  I  used  to 
Hardly  at  all 
I  get  sudden  feelings  of  panic: 
Very  often  indeed 
Quite  often 
Not  very  often 
Not  at  all 
I  can  enjoy  a  good  book  or  radio 
or  TV  programme: 
Often 
Sometimes 
Not  often 
Very  seldom 
Now  check  you  have  answered  all  questions 
FOR  HOSPITAL  USE  ONLY 
D 
. 
(8  -  10)  -------------------------------- 
A  (8  -  10)  -------------------------------- Rotterdam  Symptom  Checklist  Confidential 
date  of  completion  19 
In  this  questionnaire  you  will  be  asked  about  your  symptoms.  Would  you  please,  for  all 
symptoms  mentioned,  indicate  to  what  extent  you  have  been  bothered  by  it,  by  circling 
the  answer  most  applicable  to  you.  The  questions  are  related  to  the  past  week. 
Example:  Have  you  been  bothered,  during  the  past  week,  by 
headaches  not  at  all  a  little  quite  a  bit  very  much 
Have  you,  during  the  past  week,  been  bothered  by 
lack  of  appetite  not  at  all  a  little  quite  a  bit  very  much 
irritability  not  at  all  a  little  quite  a  bit  very  much 
tiredness  not  at  all  a  little  quite  a  bit  very  much 
............... 
worrying 
......... 
not  at  all 
......... 
a  little 
......... 
quite  a  bit 
.......... 
very  much 
sore  muscles  not  at  all  a  little  quite  a  bit  very  much 
depressed  mood  not  at  all  a  little  quite  a  bit  very  much 
lack  of  energy  not  at  all  a  little  quite  a  bit  very  much 
low  back  pain  not  at  all  a  little  quite  a  bit  very  much 
nervousness  not  at  all  a  little  quite  a  bit  very  much 
nausea  not  at  all  a  little  quite  a  bit  very  much 
despairing  about  the  future  not  at  all  a  little  quite  a  bit  very  much 
difficulty  sleeping  not  at  all  a  little  quite  a  bit  very  much 
headaches  not  at  all  a  little  quite  a  bit  very  much 
vomiting  not  at  all  a  little  quite  a  bit  very  much 
dizziness  not  at  all  a  little  quite  a  bit  very  much 
decreased  sexual  interest  not  at  all  a  little  quite  a  bit  very  much 
tension  not  at  all  a  little  quite  a  bit  very  much 
abdominal  (stomach)  aches  not  at  all  a  little  quite  a  bit  very  much 
............... 
anxiety 
......... 
not  at  all 
........ 
a  little 
.......... 
quite  a  bit 
.......... 
very  much 
constipation  not  at  all  a  little  quite  a  bit  very  much diarrhoea  not  at  all  a  little  quite  a  bit  very  much 
acid  indigestion  not  at  all  a  little  quite  a  bit  very  much 
shivering  not  at  all  a  little  quite  a  bit  very  much 
........ 
tingling  hands  or  feet 
........ 
not  at  all 
........ 
a  little 
.......... 
quite  a  bit 
.......... 
very  much 
................ 
difficulty  concentrating 
........ 
not  at  all 
........ 
a  little 
.......... 
quite  a  bit 
.......... 
very  much 
................ 
sore  mouth/pain  when  swallowing 
........ 
not  at  all 
........ 
a  little 
.......... 
quite  a  bit 
.......... 
very  much 
................ 
loss  of  hair 
........ 
not  at  all 
........ 
a  little 
.......... 
quite  a  bit 
.......... 
very  much 
................ 
burning/sore  eyes 
........ 
not  at  all 
........ 
a  little 
.......... 
quite  a  bit 
.......... 
very  much 
................ 
shortness  of  breath 
........ 
not  at  all 
........ 
a  little 
.......... 
quite  a  bit 
.......... 
very  much 
................ 
dry  mouth 
................ 
........ 
not  at  all 
........ 
........ 
a  little 
........ 
.......... 
quite  a  bit 
.......... 
......... 
very  much 
.......... 
A  number  of  activities  is  listed  below.  We  do  not  want  to  know  whether  you 
actually  do  these,  but  only  whether  you  are  able  to  perform  them  presently. 
Would  you  please  mark  the  answer  that  applies  most  to  your  condition  of  the 
past  week. 
unable  only  with  without  help,  without  help 
help  with  difficulty 
care  for  myself  (wash  etc.  )  0  0  0  0 
walk  aboutthe  house  0  0  0  0 
................. 
light  housework/household  jobs 
......... 
0 
........ 
0 
......... 
0 
........ 
0 
................. 
climb  stairs 
......... 
0 
........ 
0 
.......... 
0 
........ 
0 
................. 
heavy  housework/household  jobs 
......... 
0 
........ 
0 
.......... 
0 
........ 
0 
walk  out  of  doors  0  0  0  0 
go  shopping  0  0  0  0 
go  to  work  0  0  0  0 
All  things  considered,  how  would  you  0  excellent 
describe  your  quality  of  life  during  0  good 
the  past  week?  0  moderately  good 
0  neither  good  nor  bad 
0  rather  poor 
0  poor 
0  extremely  poor 
Would  you  please  check  whether  you  answered  all  questions? 
Thank  you  for  your  help.  patient  number 0 
EORTC  QLQ-C30  (version  2.0.  ) 
We  are  interested  in  some  things  about  you  and  your  health.  Please  answer  all  of  the  questions 
yourself  by  circling  the  number  that  best  applies  to  you.  There  are  no  "right"  or  "wrong"  answers. 
The  information  that  you  provide  will  remain  strictly  confidential. 
Please  fill  in  your  inititals: 
Your  birthdate  (Day,  Month,  Year): 
Today's  date  (Day,  Month,  Year): 
No  Yes 
1.  Do  you  have  any  trouble  doing  strenuous  activities, 
like  carrying  a  heavy  shopping  bag  or  a  suitcase?  12 
2.  Do  you  have  any  trouble  taking  a  long  walk?  12 
3.  Do  you  have  any  trouble  taking  a  short  walk  outside  of  the  house?  12 
4.  Do  you  have  to  stay  in  a  bed  or  a  chair  for  most  of  the  day?  12 
5.  Do  you  need  help  with  eating,  dressing,  washing  yourself  or 
using  the  toilet?  12 
During  the  past  week: 
6.  Were  you  limited  in  doing  either  your  work  or  other 
daily  activities? 
7.  Were  you  limited  in  pursuing  your  hobbies  or  other 
leisure  time  activities? 
8.  Were  you  short  of  breath? 
9.  Have  you  had  pain? 
10.  Did  you  need  to  rest? 
11.  Have  you  had  trouble  sleeping? 
12.  Have  you  felt  weak? 
13.  Have  you  lacked  appetite? 
14.  Have  you  felt  nauseated? 
15.  Have  you  vomited? 
Not  at  A  Quite  Very 
All  Little  a  Bit  Much 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
Please  go  on  to  the  next  page During  the  past  week: 
16.  Have  you  been  constipated? 
17.  Have  you  had  diarrhea? 
18.  Were  you  tired? 
19.  Did  pain  interfere  with  your  daily  activities? 
20.  Have  you  had  difficulty  in  concentrating  on  things, 
like  reading  a  newspaper  or  watching  television? 
21.  Did  you  feel  tense? 
22.  Did  you  worry? 
23.  Did  you  feel  irritable? 
24.  Did  you  feel  depressed? 
25.  Have  you  had  difficulty  remembering  things? 
26.  Has  your  physical  condition  or  medical  treatment 
interfered  with  your  family  life? 
27.  Has  your  physical  condition  or  medical  treatment 
interfered  with  your  social  activities? 
28.  Has  your  physical  condition  or  medical  treatment 
caused  you  financial  difficulties? 
Not  at  A  Quite  Very 
All  Little  a  Bit  Much 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1  2  3  4 
1234 
1234 
1234 
For  the  following  questions  please  circle  the  number  between  1  and  7  that  best 
applies  to  you 
29.  How  would  you  rate  your  overall  health  during  the  past  week? 
1234567 
Very  poor  Excellent 
30.  How  would  you  rate  your  overall  quality  of  life  during  the  past  week? 
1234567 
Very  poor 
Excellent 
Copyright  1995  EORTC  Study  Group  on  Quality  of  Life.  All  rights  reserved. 
Version  2.0 EuroQOL  EQ-5D 
By  placing  a  tick  in  one  box  in  each  group  below,  please  indicate  which, 
statement  best  describes  your  own  health  state  today. 
Do  not  tick  more  than  one  box  in  each  group. 
Mobility 
I  have  no  problems  in  walking  about 
I  have  some  problems  in  walking  about 
I  am  confined  to  bed 
Self-Care 
I  have  no  problems  with  self-care 
I  have  some  problems  washing  or  dressing  myself 
I  am  unable  to  wash  or  dress  myself 
Usual  Activities  (eg.  work,  study,  housework,  family  or  leisure  activities) 
I  have  no  problems  with  performing  my  usual  activities 
I  have  some  problems  with  performing  my  usual  activities 
I  am  unable  to  perform  my  usual  activities 
Pain/Discomfort 
I  have  no  pain  or  discomfort 
I  have  moderate  pain  or  discomfort 
I  have  extreme  pain  or  discomfort 
Anxiety/Depression 
I  am  not  anxious  or  depressed 
I  am  moderately  anxious  or  depressed 
I  am  extremely  anxious  or  depressed 
0 
I To  help  people  say  how 
good  or  bad  a  health  state 
is,  we  have  drawn  a  scale 
(rather  like  a  thermometer) 
on  which  the  best  state  you 
can  imagine  is  marked  100 
and  the  worst  state  you  can 
imagine  is  marked  0. 
We  would  like  you  to  indi- 
cate  on  this  scale  how  good 
or  bad  your  own  health  is 
today,  in  your  opinion. 
Please  do  this  by  drawing  a 
line  from  the  box  below  to 
whichever  point  on  the  scale 
indicates  how  good  or  bad 
your  health  state  is. 
100 
900 
810 
7*0 
600 
500 
400 
3400 
200 
100 
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